BMP	B-PRGE
-	I-PRGE
6	E-PRGE
inhibits	O
growth	O
of	O
mature	O
human	O
B	O
cells	O
;	O
induction	O
of	O
Smad	O
phosphorylation	O
and	O
upregulation	O
of	O
Id1	S-PRGE

Background	O

Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
belong	O
to	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
superfamily	O
and	O
are	O
secreted	O
proteins	O
with	O
pleiotropic	O
roles	O
in	O
many	O
different	O
cell	O
types	O
.	O

A	O
potential	O
role	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
the	O
immune	O
system	O
has	O
been	O
implied	O
by	O
various	O
studies	O
of	O
malignant	O
and	O
rheumatoid	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
explored	O
the	O
role	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
normal	O
human	O
peripheral	O
blood	O
B	O
cells	O
.	O

Results	O

The	O
B	O
cells	O
were	O
found	O
to	O
express	O
BMP	O
type	O
I	O
and	O
type	O
II	O
receptors	O
and	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
rapidly	O
induced	O
phosphorylation	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
.	O

Furthermore	O
,	O
Smad	S-PRGE
-	O
phosphorylation	O
was	O
followed	O
by	O
upregulation	O
of	O
Id1	S-PRGE
mRNA	O
and	O
Id1	S-PRGE
protein	O
,	O
whereas	O
Id2	S-PRGE
and	O
Id3	S-PRGE
expression	O
was	O
not	O
affected	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
had	O
an	O
antiproliferative	O
effect	O
both	O
in	O
naive	O
(	O
CD19	S-PRGE
+	O
CD27	S-PRGE
-	O
)	O
and	O
memory	O
B	O
cells	O
(	O
CD19	S-PRGE
+	O
CD27	S-PRGE
+	O
)	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	S-PRGE
.	O

Additionally	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
.	O

Importantly	O
,	O
the	O
antiproliferative	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
B	O
-	O
cells	O
was	O
completely	O
neutralized	O
by	O
the	O
natural	O
antagonist	O
,	O
noggin	S-PRGE
.	O

Furthermore	O
,	O
B	O
cells	O
were	O
demonstrated	O
to	O
upregulate	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
upon	O
stimulation	O
with	O
anti	O
-	O
IgM	O
.	O

Conclusion	O

In	O
mature	O
human	O
B	O
cells	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
inhibited	O
cell	O
growth	O
,	O
and	O
rapidly	O
induced	O
phosphorylation	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
followed	O
by	O
an	O
upregulation	O
of	O
Id1	S-PRGE
.	O

Members	O
of	O
the	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
beta	E-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
)	O
superfamily	O
play	O
central	O
roles	O
in	O
controlling	O
cellular	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
[	O
1	O
]	O
.	O

These	O
cytokines	O
can	O
be	O
divided	O
into	O
three	O
subgroups	O
:	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
,	E-PRGE
the	O
activins	O
/	O
inhibins	O
,	O
and	O
the	O
bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
,	O
of	O
which	O
the	O
latter	O
constitute	O
the	O
largest	O
family	O
.	O

BMPs	O
are	O
30	O
-	O
38	O
kDa	O
hetero	O
-	O
or	O
homodimeric	O
proteins	O
originally	O
identified	O
by	O
their	O
ability	O
to	O
induce	O
ectopic	O
cartilage	O
and	O
bone	O
formation	O
[	O
2	O
,	O
3	O
]	O
.	O

Several	O
studies	O
have	O
demonstrated	O
an	O
essential	O
role	O
of	O
these	O
proteins	O
during	O
embryogenesis	O
,	O
and	O
more	O
recently	O
,	O
also	O
in	O
adult	O
tissues	O
[	O
1	O
]	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
has	O
been	O
intensively	O
studied	O
in	O
normal	O
and	O
malignant	O
haematopoietic	O
cells	O
and	O
is	O
one	O
of	O
the	O
most	O
potent	O
endogenous	O
negative	O
regulators	O
known	O
to	O
date	O
.	O

[	O
4	O
]	O
.	O

In	O
contrast	O
,	O
the	O
effect	O
of	O
BMPs	O
in	O
the	O
immune	O
system	O
has	O
not	O
been	O
widely	O
investigated	O
.	O

In	O
that	O
respect	O
,	O
BMP	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
-	B-PRGE
4	E-PRGE
and	O
-	B-PRGE
7	E-PRGE
have	O
been	O
found	O
to	O
control	O
differentiation	O
of	O
hematopoietic	O
stem	O
cells	O
[	O
5	O
]	O
and	O
early	O
T	O
cell	O
development	O
[	O
6	O
,	O
7	O
]	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
has	O
been	O
reported	O
to	O
reduce	O
the	O
number	O
of	O
cobblestone	O
-	O
area	O
-	O
forming	O
cells	O
of	O
normal	O
human	O
haematopoietic	O
cells	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
BMP	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
-	B-PRGE
4	E-PRGE
,	O
6	S-PRGE
and	O
-	B-PRGE
7	E-PRGE
had	O
an	O
antiproliferative	O
and	O
a	O
proapoptotic	O
effect	O
on	O
multiple	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

In	O
addition	O
,	O
by	O
gene	O
expression	O
profiling	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
significantly	O
increased	O
the	O
predictive	O
value	O
for	O
a	O
multi	O
-	O
gene	O
signature	O
test	O
and	O
was	O
associated	O
with	O
a	O
poor	O
outcome	O
in	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
(	O
DLBCL	O
)	O
[	O
12	O
]	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
like	O
the	O
other	O
BMP	O
members	O
,	O
signals	O
through	O
ligation	O
and	O
heterodimerzation	O
of	O
BMP	O
type	O
I	O
[	O
activin	O
-	O
like	O
-	O
kinase	O
(	O
ALK	O
)	O
]	O
and	O
type	O
II	O
serine	O
-	O
threonine	O
kinase	O
receptors	O
,	O
which	O
subsequently	O
propagates	O
the	O
signal	O
downstream	O
by	O
phosphorylating	O
Smad	O
proteins	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
can	O
signal	O
through	O
the	O
ligation	O
of	O
the	O
type	O
I	O
receptors	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
,	O
BMP	B-PRGE
-	I-PRGE
RIA	E-PRGE
,	O
and	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
and	O
the	O
type	O
II	O
receptors	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
,	O
Act	B-PRGE
-	I-PRGE
RIIA	E-PRGE
and	O
Act	B-PRGE
-	I-PRGE
RIIB	E-PRGE
,	O
which	O
lead	O
to	O
the	O
phosphorylation	O
of	O
the	O
receptor	O
Smads	O
(	O
Smad	B-PRGE
-	I-PRGE
1	E-PRGE
,	O
Smad	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
and	O
Smad	B-PRGE
-	I-PRGE
8	E-PRGE
)	O
.	O

The	O
R	O
-	O
Smads	O
then	O
form	O
complexes	O
with	O
the	O
co	O
-	O
Smad	O
(	O
Smad4	S-PRGE
)	O
and	O
are	O
translocated	O
into	O
the	O
nucleus	O
where	O
they	O
exert	O
gene	O
regulation	O
[	O
1	O
,	O
13	O
]	O
.	O

Given	O
the	O
reported	O
role	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
B	O
-	O
cell	O
malignancies	O
and	O
haematopoietic	O
progenitor	O
cells	O
,	O
we	O
wanted	O
to	O
explore	O
its	O
potential	O
role	O
in	O
normal	O
human	O
B	O
cells	O
.	O

We	O
studied	O
the	O
effects	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
proliferation	O
and	O
apoptosis	O
on	O
resting	O
and	O
stimulated	O
B	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
BMP	O
receptors	O
and	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
activation	O
of	O
the	O
Smad	O
signalling	O
pathway	O
with	O
subsequent	O
regulation	O
of	O
the	O
target	O
genes	O
Id1	S-PRGE
-	O
Id4	S-PRGE
,	O
were	O
resolved	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
B	O
cells	O
also	O
were	O
capable	O
of	O
producing	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
inhibits	O
anti	O
-	O
IgM	O
induced	O
proliferation	O
of	O
human	O
B	O
cells	O

The	O
effects	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
normal	O
and	O
neoplastic	O
hematopoietic	O
cells	O
prompted	O
us	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
normal	O
human	O
B	O
cells	O
.	O

All	O
experiments	O
in	O
this	O
study	O
were	O
performed	O
under	O
serum	O
-	O
free	O
conditions	O
as	O
FCS	O
has	O
been	O
shown	O
to	O
interfere	O
with	O
BMP	O
-	O
signalling	O
[	O
14	O
]	O
(	O
own	O
observations	O
)	O
.	O

To	O
study	O
the	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
proliferation	O
,	O
B	O
-	O
cells	O
from	O
healthy	O
volunteers	O
were	O
stimulated	O
with	O
anti	O
-	O
IgM	O
and	O
/	O
or	O
CD40L	S-PRGE
in	O
the	O
presence	O
or	O
absence	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
for	O
three	O
days	O
.	O

We	O
found	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
led	O
to	O
a	O
35	O
%	O
mean	O
reduction	O
of	O
anti	O
-	O
IgM	O
-	O
induced	O
DNA	O
synthesis	O
(	O
n	O
=	O
8	O
;	O
p	O
<	O
=	O
0	O
.	O
0002	O
,	O
Figure	O
1A	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
B	O
cells	O
treated	O
with	O
anti	O
-	O
IgM	O
and	O
CD40L	S-PRGE
(	O
26	O
%	O
mean	O
reduction	O
,	O
n	O
=	O
6	O
;	O
p	O
<	O
=	O
0	O
.	O
023	O
)	O
.	O

The	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
induced	O
inhibition	O
of	O
proliferation	O
was	O
dose	O
-	O
dependent	O
in	O
both	O
peripheral	O
B	O
cells	O
(	O
Figure	O
1B	O
)	O
and	O
the	O
Burkitt	O
lymphoma	O
cell	O
line	O
Ramos	O
(	O
40	O
%	O
reduction	O
of	O
DNA	O
synthesis	O
,	O
Figure	O
1C	O
)	O
.	O

The	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
effects	O
could	O
be	O
reversed	O
by	O
addition	O
of	O
the	O
extracellular	O
inhibitor	O
Noggin	S-PRGE
(	O
Figure	O
1D	O
)	O
.	O

Similarly	O
,	O
a	O
combination	O
of	O
the	O
soluble	O
BMP	O
receptors	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
-	O
Fc	O
and	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
-	O
Fc	O
also	O
neutralized	O
the	O
effects	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
test	O
whether	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
had	O
different	O
effect	O
on	O
naive	O
and	O
memory	O
B	O
cells	O
.	O

Naive	O
(	O
CD19	S-PRGE
+	O
CD27	S-PRGE
-	O
)	O
and	O
memory	O
(	O
CD19	S-PRGE
+	O
CD27	S-PRGE
+	O
)	O
B	O
cells	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
cell	O
sorting	O
of	O
immunobead	O
-	O
isolated	O
CD19	S-PRGE
+	O
B	O
cells	O
[	O
15	O
]	O
,	O
and	O
tested	O
for	O
their	O
capacity	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
.	O

However	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
inhibited	O
anti	O
-	O
IgM	O
induced	O
DNA	O
synthesis	O
in	O
the	O
two	O
subpopulations	O
to	O
a	O
similar	O
extent	O
,	O
with	O
a	O
mean	O
reduction	O
of	O
DNA	O
-	O
synthesis	O
of	O
45	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
004	O
)	O
for	O
naive	O
B	O
cells	O
and	O
48	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
001	O
)	O
for	O
memory	O
B	O
cells	O
(	O
Figure	O
1E	O
)	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induces	O
cell	O
death	O
in	O
human	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O

Next	O
,	O
we	O
wanted	O
to	O
establish	O
whether	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
also	O
could	O
affect	O
the	O
viability	O
of	O
normal	O
B	O
cells	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
propidium	O
iodide	O
(	O
PI	O
)	O
staining	O
after	O
culture	O
with	O
or	O
without	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
for	O
48	O
hours	O
.	O

Interestingly	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
showed	O
a	O
small	O
,	O
but	O
reproducible	O
mean	O
increase	O
of	O
cell	O
death	O
from	O
17	O
to	O
23	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
003	O
)	O
in	O
anti	O
-	O
IgM	O
stimulated	O
CD27	S-PRGE
+	O
memory	O
B	O
cells	O
.	O

Furthermore	O
,	O
Ramos	O
cells	O
showed	O
a	O
mean	O
increase	O
in	O
cell	O
death	O
from	O
20	O
to	O
50	O
%	O
(	O
n	O
=	O
3	O
,	O
p	O
<	O
0	O
,	O
001	O
,	O
figure	O
3	O
)	O
after	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
treatment	O
.	O

In	O
contrast	O
,	O
cell	O
death	O
of	O
total	O
CD19	S-PRGE
+	O
cells	O
(	O
n	O
=	O
6	O
;	O
p	O
<	O
=	O
0	O
,	O
32	O
;	O
data	O
not	O
shown	O
)	O
or	O
CD27	S-PRGE
-	O
IgG	O
-	O
naive	O
B	O
cells	O
was	O
not	O
significantly	O
affected	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
65	O
,	O
figure	O
2	O
)	O
.	O

Human	O
B	O
cells	O
express	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
receptors	O

Detailed	O
knowledge	O
regarding	O
expression	O
of	O
different	O
BMP	O
receptors	O
in	O
B	O
cells	O
is	O
currently	O
not	O
available	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
BMPs	O
in	O
human	O
B	O
cells	O
,	O
we	O
performed	O
western	O
blot	O
analysis	O
for	O
type	O
I	O
and	O
type	O
II	O
BMP	O
receptors	O
.	O

This	O
analysis	O
revealed	O
that	O
the	O
type	O
I	O
receptors	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
,	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
and	O
the	O
type	O
II	O
receptors	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
and	O
Act	B-PRGE
-	I-PRGE
RIIb	E-PRGE
are	O
expressed	O
on	O
resting	O
human	O
B	O
-	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

Ramos	O
cells	O
expressed	O
the	O
type	O
I	O
receptors	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
,	O
weakly	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
and	O
the	O
type	O
II	O
receptor	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
,	O
but	O
more	O
weakly	O
than	O
normal	O
B	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

HL60	O
cells	O
were	O
used	O
for	O
comparison	O
and	O
weakly	O
expressed	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
and	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
normal	O
human	O
B	O
cells	O
and	O
Ramos	O
cells	O
express	O
a	O
set	O
of	O
BMP	O
receptors	O
,	O
previously	O
shown	O
to	O
bind	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
[	O
16	O
]	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induces	O
phosphorylation	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE

Upon	O
ligand	O
binding	O
,	O
the	O
type	O
II	O
receptor	O
transphosphorylates	O
and	O
activates	O
the	O
type	O
I	O
receptor	O
.	O

Type	O
I	O
receptors	O
can	O
signal	O
via	O
several	O
pathways	O
.	O

We	O
examined	O
the	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
Smad	O
phosphorylation	O
,	O
as	O
the	O
activation	O
of	O
Smad	O
is	O
considered	O
to	O
be	O
a	O
major	O
signalling	O
pathway	O
for	O
BMPs	O
[	O
17	O
]	O
.	O

B	O
cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
media	O
over	O
night	O
and	O
then	O
treated	O
with	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
for	O
various	O
time	O
points	O
.	O

Total	O
protein	O
lysates	O
were	O
prepared	O
,	O
and	O
the	O
amounts	O
of	O
the	O
phosphorylated	O
forms	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
were	O
determined	O
by	O
western	O
blot	O
analysis	O
.	O

Interestingly	O
,	O
treatment	O
with	O
500	O
ng	O
/	O
ml	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
phosphorylation	O
of	O
Smad	O
.	O

The	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
phosphorylation	O
was	O
high	O
at	O
the	O
earliest	O
time	O
point	O
tested	O
(	O
15	O
minutes	O
)	O
,	O
and	O
remained	O
high	O
for	O
at	O
least	O
48	O
hours	O
(	O
Figure	O
5	O
)	O
.	O

A	O
similar	O
phosphorylation	O
was	O
observed	O
in	O
Ramos	O
cells	O
,	O
but	O
not	O
in	O
HL60	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

Furthermore	O
,	O
we	O
also	O
tested	O
whether	O
other	O
known	O
downstream	O
signalling	O
pathways	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
could	O
be	O
triggered	O
by	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
human	O
B	O
cells	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
significant	O
changes	O
in	O
the	O
level	O
of	O
phospho	O
-	O
STAT3	S-PRGE
or	O
phospho	O
-	O
p38	S-PRGE
upon	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
treatment	O
of	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induces	O
upregulation	O
of	O
Id1	S-PRGE

Next	O
,	O
we	O
wanted	O
to	O
explore	O
whether	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
phosphorylation	O
of	O
Smad	B-PRGE
1	E-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
also	O
could	O
induce	O
transcriptional	O
changes	O
of	O
target	O
genes	O
.	O

In	O
this	O
regard	O
,	O
the	O
inhibitors	O
of	O
DNA	O
binding	O
proteins	O
(	O
Ids	O
)	O
are	O
considered	O
to	O
be	O
some	O
of	O
the	O
major	O
target	O
genes	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

Thus	O
,	O
B	O
cells	O
were	O
pre	O
-	O
incubated	O
over	O
night	O
in	O
X	O
-	O
VIVO	O
15	O
,	O
and	O
then	O
cultured	O
in	O
medium	O
alone	O
or	O
in	O
the	O
presence	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
for	O
various	O
time	O
points	O
before	O
preparation	O
of	O
total	O
RNA	O
.	O

The	O
amount	O
of	O
Id1	S-PRGE
-	O
Id4	S-PRGE
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	O
of	O
Id1	S-PRGE
mRNA	O
in	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
treated	O
B	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
up	O
-	O
regulation	O
of	O
Id1	S-PRGE
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
inducible	O
gene	O
,	O
with	O
maximal	O
upregulation	O
two	O
hours	O
after	O
the	O
addition	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
and	O
returned	O
to	O
baseline	O
after	O
24	O
hours	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
for	O
Id2	S-PRGE
and	O
Id3	S-PRGE
mRNA	O
,	O
whereas	O
Id4	S-PRGE
-	O
transcripts	O
were	O
not	O
detectable	O
(	O
Figure	O
7	O
,	O
data	O
not	O
shown	O
)	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
induced	O
upregulation	O
of	O
Id1	S-PRGE
mRNA	O
also	O
was	O
correlated	O
with	O
upregulation	O
of	O
Id1	S-PRGE
protein	O
as	O
well	O
.	O

The	O
increase	O
in	O
Id1	S-PRGE
protein	O
level	O
was	O
detectable	O
after	O
one	O
hour	O
and	O
increased	O
until	O
24	O
hours	O
after	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
addition	O
,	O
showing	O
a	O
16	O
-	O
fold	O
upregulation	O
compared	O
with	O
t0	O
(	O
p	O
<	O
=	O
0	O
.	O
020	O
,	O
n	O
=	O
4	O
)	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

In	O
line	O
with	O
the	O
mRNA	O
data	O
,	O
no	O
consistent	O
change	O
in	O
the	O
amounts	O
of	O
Id2	S-PRGE
and	O
Id3	S-PRGE
protein	O
could	O
be	O
observed	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

We	O
were	O
able	O
to	O
block	O
the	O
Id1	S-PRGE
specific	O
band	O
with	O
a	O
blocking	O
peptide	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
Id1	S-PRGE
could	O
be	O
a	O
possible	O
target	O
gene	O
for	O
mediating	O
the	O
effects	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
human	O
B	O
cells	O
,	O
whereas	O
Id2	S-PRGE
and	O
Id3	S-PRGE
not	O
seem	O
to	O
be	O
involved	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
production	O
in	O
B	O
cells	O

The	O
fact	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
has	O
been	O
reported	O
to	O
act	O
as	O
an	O
autocrine	O
stimulator	O
in	O
chondrocytes	O
[	O
18	O
]	O
and	O
ovarium	O
[	O
19	O
]	O
,	O
prompted	O
us	O
to	O
investigate	O
whether	O
normal	O
human	O
B	O
cells	O
could	O
produce	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
upon	O
stimulation	O
.	O

Ramos	O
cells	O
,	O
which	O
have	O
been	O
described	O
to	O
express	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
endogenously	O
[	O
20	O
]	O
,	O
and	O
the	O
T	O
cell	O
line	O
Jurkat	O
,	O
served	O
as	O
positive	O
and	O
negative	O
controls	O
,	O
respectively	O
.	O

Endogenous	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
levels	O
in	O
normal	O
B	O
cells	O
were	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
after	O
stimulation	O
with	O
anti	O
-	O
IgM	O
for	O
different	O
time	O
points	O
.	O

Interestingly	O
,	O
the	O
up	O
-	O
regulation	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
-	O
to	O
intermediate	O
inducible	O
gene	O
with	O
maximal	O
upregulation	O
four	O
hours	O
after	O
the	O
addition	O
of	O
anti	O
-	O
IgM	O
.	O

The	O
level	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
was	O
back	O
to	O
baseline	O
after	O
24	O
hours	O
upon	O
stimulation	O
(	O
Figure	O
10	O
)	O
.	O

Furthermore	O
,	O
both	O
FCS	O
and	O
human	O
AB	O
-	O
serum	O
induced	O
significant	O
upregulation	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
(	O
Figure	O
11	O
)	O
.	O

Interestingly	O
,	O
in	O
a	O
separate	O
study	O
we	O
have	O
found	O
that	O
normal	O
human	O
T	O
cells	O
do	O
not	O
express	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
after	O
activation	O
(	O
Sivertsen	O
et	O
al	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
detect	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
protein	O
in	O
normal	O
B	O
-	O
cells	O
and	O
tested	O
various	O
commercially	O
available	O
antibodies	O
.	O

However	O
,	O
in	O
our	O
hands	O
these	O
anti	O
-	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
antibodies	O
did	O
only	O
recognize	O
the	O
recombinant	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
protein	O
and	O
not	O
the	O
native	O
protein	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
an	O
important	O
role	O
for	O
BMP	O
superfamily	O
members	O
in	O
hematopoietic	O
stem	O
cells	O
,	O
early	O
thymocytes	O
[	O
6	O
,	O
7	O
]	O
and	O
B	O
-	O
cell	O
malignancies	O
[	O
8	O
,	O
11	O
,	O
12	O
]	O
,	O
but	O
a	O
role	O
for	O
BMPs	O
in	O
normal	O
human	O
B	O
cells	O
has	O
previously	O
not	O
been	O
reported	O
.	O

The	O
present	O
study	O
demonstrated	O
a	O
significant	O
antiproliferative	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
peripheral	O
blood	O
CD19	S-PRGE
+	O
B	O
cells	O
.	O

Additionally	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
cell	O
death	O
in	O
CD27	S-PRGE
+	O
memory	O
B	O
cells	O
as	O
well	O
as	O
in	O
a	O
Burkitt	O
lymphoma	O
cell	O
line	O
(	O
Ramos	O
)	O
.	O

Importantly	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
a	O
rapid	O
and	O
marked	O
increase	O
in	O
Smad	B-PRGE
-	I-PRGE
1	E-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
phosphorylation	O
.	O

Furthermore	O
,	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
Smad	S-PRGE
phosphorylation	O
was	O
followed	O
by	O
a	O
selective	O
upregulation	O
of	O
Id1	S-PRGE
mRNA	O
and	O
subsequent	O
Id1	S-PRGE
protein	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
demonstrated	O
antiproliferative	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
anti	O
-	O
IgM	O
treated	O
B	O
cells	O
was	O
significant	O
and	O
dose	O
-	O
dependent	O
.	O

Importantly	O
,	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
could	O
be	O
completely	O
neutralized	O
by	O
the	O
use	O
of	O
a	O
natural	O
inhibitor	O
,	O
Noggin	S-PRGE
.	O

This	O
is	O
in	O
line	O
with	O
others	O
,	O
showing	O
that	O
Noggin	S-PRGE
can	O
function	O
as	O
a	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
antagonist	O
[	O
21	O
,	O
22	O
]	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
soluble	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
-	O
Fc	O
and	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
-	O
Fc	O
fusion	O
proteins	O
also	O
neutralized	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
human	O
B	O
cells	O
.	O

Interestingly	O
,	O
as	O
for	O
other	O
TGF	O
family	O
members	O
,	O
bifunctional	O
effects	O
have	O
also	O
been	O
demonstrated	O
for	O
BMPs	O
.	O

Whereas	O
several	O
of	O
the	O
BMPs	O
have	O
been	O
shown	O
to	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
including	O
condrocytes	O
[	O
23	O
]	O
,	O
liver	O
[	O
24	O
]	O
and	O
granulosa	O
cells	O
[	O
25	O
]	O
,	O
antiproliferative	O
effects	O
and	O
induction	O
of	O
apoptosis	O
has	O
been	O
reported	O
for	O
B	O
and	O
T	O
lineage	O
cells	O
.	O

Similar	O
effects	O
as	O
demonstrated	O
for	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
on	O
human	O
B	O
cells	O
in	O
the	O
present	O
study	O
,	O
were	O
demonstrated	O
for	O
BMP	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
4	S-PRGE
,	O
6	S-PRGE
and	O
-	B-PRGE
7	E-PRGE
in	O
human	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

Other	O
members	O
of	O
the	O
BMP	O
-	O
family	O
have	O
also	O
been	O
reported	O
to	O
induce	O
apoptosis	O
,	O
including	O
in	O
mouse	O
B	O
lineage	O
cells	O
[	O
26	O
]	O
.	O

Additionally	O
,	O
BMP	B-PRGE
-	I-PRGE
4	E-PRGE
inhibits	O
thymocyte	O
proliferation	O
[	O
6	O
]	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
role	O
of	O
BMPs	O
in	O
the	O
regulation	O
of	O
proliferation	O
and	O
apoptosis	O
is	O
highly	O
cell	O
type	O
dependent	O
.	O

To	O
examine	O
how	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
exerts	O
its	O
functional	O
effects	O
in	O
B	O
cells	O
,	O
we	O
analysed	O
BMP	O
receptor	O
expression	O
by	O
western	O
blot	O
analysis	O
.	O

Human	O
peripheral	O
B	O
cells	O
were	O
found	O
to	O
express	O
the	O
BMP	O
type	O
I	O
receptors	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
and	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
,	O
and	O
the	O
type	O
II	O
-	O
receptors	O
BMP	B-PRGE
-	I-PRGE
RII	E-PRGE
and	O
Act	B-PRGE
-	I-PRGE
RIIb	E-PRGE
,	O
which	O
signal	O
after	O
binding	O
of	O
several	O
BMPs	O
,	O
including	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
[	O
16	O
,	O
13	O
]	O
.	O

To	O
further	O
explore	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induced	O
signalling	O
,	O
activation	O
of	O
several	O
pathways	O
is	O
possible	O
.	O

The	O
major	O
signalling	O
pathway	O
known	O
to	O
date	O
,	O
is	O
activation	O
of	O
R	O
-	O
Smads	O
[	O
13	O
,	O
27	O
]	O
.	O

In	O
that	O
respect	O
,	O
BMPs	O
have	O
been	O
shown	O
to	O
exert	O
antiproliferative	O
effects	O
in	O
B	O
lineage	O
cells	O
via	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
[	O
11	O
,	O
28	O
]	O
.	O

Furthermore	O
,	O
BMP	B-PRGE
-	I-PRGE
2	E-PRGE
has	O
been	O
shown	O
to	O
induce	O
activation	O
of	O
STAT3	S-PRGE
in	O
myeloma	O
cells	O
[	O
9	O
]	O
.	O

However	O
,	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
was	O
not	O
investigated	O
in	O
that	O
study	O
.	O

BMP	B-PRGE
-	I-PRGE
2	E-PRGE
has	O
also	O
been	O
shown	O
to	O
induce	O
phosphorylation	O
of	O
p38	O
[	O
29	O
]	O
.	O

Thus	O
,	O
phosphorylation	O
of	O
p38	O
,	O
STAT3	S-PRGE
and	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
represent	O
important	O
BMP	O
-	O
signalling	O
pathways	O
that	O
mediated	O
the	O
effects	O
of	O
BMPs	O
and	O
even	O
cross	O
-	O
talk	O
between	O
these	O
pathways	O
has	O
been	O
reported	O
[	O
29	O
,	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
induced	O
changes	O
in	O
the	O
phosphorylation	O
status	O
of	O
STAT3	S-PRGE
or	O
p38	O
in	O
human	O
peripheral	O
B	O
cells	O
.	O

Instead	O
,	O
a	O
rapid	O
and	O
marked	O
phosphorylation	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
was	O
revealed	O
.	O

In	O
a	O
parallel	O
study	O
,	O
we	O
have	O
found	O
that	O
other	O
BMPs	O
also	O
induced	O
phosphorylation	O
of	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
in	O
peripheral	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
are	O
currently	O
pursuing	O
microarray	O
studies	O
to	O
identify	O
the	O
signalling	O
pathways	O
and	O
target	O
genes	O
that	O
are	O
differently	O
regulated	O
by	O
the	O
various	O
BMPs	O
in	O
human	O
B	O
cells	O
.	O

Upregulation	O
of	O
Id1	S-PRGE
via	O
Smad1	S-PRGE
/	O
5	S-PRGE
/	O
8	S-PRGE
phosphorylation	O
is	O
a	O
known	O
mechanism	O
for	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
signalling	O
in	O
other	O
cell	O
systems	O
[	O
31	O
,	O
32	O
]	O
and	O
regulation	O
of	O
Id	O
-	O
proteins	O
is	O
thought	O
to	O
be	O
an	O
important	O
mechanism	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
experiments	O
revealed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	O
for	O
Id1	S-PRGE
in	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
treated	O
B	O
cells	O
,	O
while	O
the	O
amount	O
of	O
Id2	S-PRGE
-	O
Id4	S-PRGE
remained	O
unchanged	O
.	O

In	O
agreement	O
with	O
this	O
,	O
western	O
blot	O
analysis	O
demonstrated	O
an	O
upregulation	O
of	O
Id1	S-PRGE
protein	O
,	O
while	O
the	O
amount	O
of	O
Id2	S-PRGE
and	O
Id3	S-PRGE
protein	O
levels	O
remained	O
unchanged	O
.	O

Previously	O
,	O
Id1	S-PRGE
has	O
been	O
considered	O
not	O
to	O
be	O
expressed	O
in	O
later	O
developmental	O
stages	O
than	O
pro	O
-	O
B	O
cells	O
[	O
33	O
,	O
34	O
]	O
,	O
and	O
its	O
constitutive	O
expression	O
has	O
been	O
reported	O
to	O
impair	O
mouse	O
B	O
cell	O
development	O
[	O
35	O
]	O
.	O

Therefore	O
,	O
our	O
demonstration	O
of	O
the	O
time	O
-	O
dependent	O
upregulation	O
of	O
Id1	S-PRGE
mRNA	O
and	O
protein	O
in	O
mature	O
normal	O
human	O
B	O
cells	O
is	O
of	O
particular	O
interest	O
.	O

In	O
that	O
respect	O
,	O
it	O
is	O
noteworthy	O
that	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signalling	O
in	O
early	O
and	O
mature	O
B	O
cells	O
induces	O
both	O
Id2	S-PRGE
and	O
Id3	S-PRGE
expression	O
[	O
36	O
,	O
37	O
]	O
,	O
but	O
not	O
Id1	S-PRGE
(	O
data	O
not	O
shown	O
)	O
.	O

Interestingly	O
,	O
these	O
results	O
show	O
that	O
various	O
members	O
of	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
family	O
regulate	O
Id	O
proteins	O
differently	O
.	O

Id2	S-PRGE
and	O
Id3	S-PRGE
are	O
considered	O
to	O
be	O
the	O
Id	O
proteins	O
mainly	O
expressed	O
in	O
mature	O
B	O
cells	O
[	O
38	O
]	O
.	O

The	O
present	O
study	O
also	O
found	O
Id2	S-PRGE
and	O
Id3	S-PRGE
protein	O
in	O
B	O
cells	O
to	O
be	O
more	O
highly	O
expressed	O
than	O
Id1	S-PRGE
in	O
resting	O
B	O
cells	O
.	O

However	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
did	O
not	O
induce	O
significant	O
changes	O
in	O
the	O
protein	O
expression	O
of	O
Id2	S-PRGE
and	O
Id3	S-PRGE
.	O

It	O
is	O
believed	O
that	O
Id	O
proteins	O
block	O
differentiation	O
and	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
[	O
39	O
,	O
33	O
]	O
.	O

Id	O
proteins	O
act	O
as	O
dominant	O
-	O
negative	O
inhibitors	O
of	O
E	O
-	O
proteins	O
and	O
Pax5	S-PRGE
function	O
by	O
forming	O
dimers	O
with	O
these	O
proteins	O
,	O
making	O
them	O
unable	O
to	O
bind	O
DNA	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
balance	O
among	O
E	O
-	O
proteins	O
,	O
Pax5	S-PRGE
and	O
Id	O
proteins	O
might	O
have	O
an	O
important	O
role	O
in	O
activated	O
B	O
cells	O
[	O
38	O
]	O
.	O

In	O
that	O
respect	O
,	O
E	O
-	O
proteins	O
have	O
been	O
implicated	O
in	O
both	O
the	O
promotion	O
and	O
inhibition	O
of	O
cell	O
survival	O
and	O
growth	O
at	O
different	O
points	O
in	O
lymphocyte	O
development	O
[	O
40	O
]	O
.	O

The	O
antiproliferative	O
and	O
death	O
inducing	O
effect	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
B	O
cells	O
with	O
concomitant	O
upregulation	O
of	O
Id1	S-PRGE
protein	O
is	O
therefore	O
in	O
line	O
with	O
the	O
view	O
that	O
Id	O
proteins	O
are	O
required	O
for	O
the	O
induction	O
of	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
-	O
lymphocyte	O
progenitors	O
by	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
[	O
40	O
]	O
.	O

Furthermore	O
,	O
Id	O
proteins	O
are	O
known	O
as	O
important	O
parts	O
of	O
signalling	O
pathways	O
involved	O
in	O
development	O
,	O
cell	O
cycle	O
and	O
tumorigenesis	O
[	O
32	O
]	O
.	O

It	O
is	O
well	O
established	O
that	O
various	O
members	O
of	O
the	O
Id	O
family	O
are	O
overexpressed	O
in	O
a	O
range	O
of	O
human	O
tumours	O
and	O
generally	O
,	O
Id1	S-PRGE
appears	O
to	O
be	O
the	O
family	O
member	O
most	O
widely	O
overexpressed	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
[	O
41	O
]	O
,	O
including	O
multiple	O
myeloma	O
[	O
42	O
,	O
32	O
]	O
.	O

Additionally	O
,	O
our	O
findings	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
activates	O
intracellular	O
signalling	O
pathways	O
in	O
human	O
B	O
cells	O
might	O
be	O
of	O
potential	O
pathophysiological	O
significance	O
in	O
lymphoma	O
and	O
inflammation	O
.	O

High	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
expression	O
in	O
DLBCL	O
has	O
been	O
shown	O
to	O
correlate	O
to	O
unfavourable	O
outcome	O
[	O
12	O
]	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
of	O
interest	O
that	O
targeted	O
expression	O
of	O
Id1	S-PRGE
to	O
B	O
-	O
lymphocytes	O
resulted	O
in	O
aberrant	O
B	O
cell	O
development	O
,	O
massive	O
apoptosis	O
,	O
and	O
subsequent	O
development	O
of	O
B	O
cell	O
lymphomas	O
[	O
35	O
]	O
.	O

Moreover	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
[	O
43	O
,	O
44	O
]	O
and	O
elevated	O
levels	O
of	O
Id1	S-PRGE
and	O
Id3	S-PRGE
have	O
been	O
found	O
in	O
the	O
synovia	O
of	O
RA	O
-	O
patients	O
[	O
45	O
]	O
.	O

Altogether	O
,	O
these	O
results	O
point	O
to	O
an	O
important	O
role	O
for	O
Id	O
proteins	O
in	O
the	O
regulation	O
of	O
normal	O
B	O
cell	O
homeostasis	O
and	O
in	O
diseases	O
,	O
where	O
B	O
cells	O
are	O
involved	O
.	O

It	O
will	O
therefore	O
be	O
important	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
Id	B-PRGE
-	I-PRGE
1	E-PRGE
in	O
human	O
B	O
cells	O
by	O
selective	O
over	O
expression	O
or	O
inhibition	O
of	O
Id	B-PRGE
-	I-PRGE
1	E-PRGE
gene	O
expression	O
.	O

Given	O
the	O
role	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
mature	O
human	O
B	O
cells	O
demonstrated	O
here	O
,	O
identification	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
producing	O
cells	O
in	O
vivo	O
with	O
possibility	O
of	O
interaction	O
with	O
naive	O
and	O
memory	O
B	O
cells	O
might	O
contribute	O
to	O
the	O
understanding	O
of	O
mature	O
B	O
cell	O
biology	O
.	O

High	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
expression	O
in	O
DLBCL	O
has	O
been	O
detected	O
by	O
gene	O
expression	O
profiling	O
[	O
12	O
]	O
.	O

Furthermore	O
,	O
production	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
transcripts	O
in	O
normal	O
activated	O
B	O
cells	O
was	O
detected	O
in	O
the	O
same	O
study	O
.	O

Of	O
note	O
,	O
an	O
autocrine	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
loop	O
has	O
been	O
reported	O
by	O
others	O
in	O
chondrocytes	O
and	O
in	O
the	O
ovarium	O
[	O
46	O
,	O
19	O
,	O
18	O
]	O
.	O

Therefore	O
,	O
we	O
wanted	O
to	O
explore	O
the	O
possibility	O
for	O
an	O
autocrine	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
loop	O
in	O
human	O
B	O
cells	O
.	O

We	O
analysed	O
the	O
expression	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
in	O
peripheral	O
blood	O
B	O
cells	O
by	O
real	O
-	O
time	O
PCR	O
,	O
and	O
report	O
here	O
the	O
upregulation	O
of	O
endogenous	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
transcripts	O
after	O
stimulation	O
with	O
FCS	O
,	O
human	O
AB	O
-	O
serum	O
and	O
,	O
most	O
importantly	O
,	O
anti	O
-	O
IgM	O
.	O

However	O
,	O
our	O
attempts	O
to	O
study	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
protein	O
levels	O
were	O
unsuccessful	O
due	O
to	O
problems	O
with	O
unspecific	O
binding	O
of	O
the	O
anti	O
-	O
BMP	O
-	O
6	O
antibodies	O
tested	O
,	O
and	O
lack	O
of	O
specific	O
staining	O
in	O
control	O
cells	O
known	O
to	O
express	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
.	O

In	O
contrast	O
,	O
the	O
recombinant	O
protein	O
was	O
readily	O
detected	O
.	O

In	O
that	O
respect	O
,	O
few	O
investigators	O
have	O
detected	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
protein	O
in	O
humans	O
,	O
especially	O
in	O
non	O
-	O
pathogenic	O
tissue	O
.	O

The	O
possibility	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
production	O
in	O
human	O
B	O
-	O
cells	O
is	O
in	O
line	O
with	O
a	O
recent	O
work	O
that	O
reported	O
the	O
production	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
mouse	O
B	O
cells	O
,	O
infiltrating	O
the	O
bone	O
marrow	O
of	O
mice	O
with	O
inflammatory	O
arthritis	O
[	O
43	O
]	O
.	O

In	O
this	O
study	O
,	O
a	O
role	O
for	O
BMPs	O
in	O
the	O
inflammatoric	O
process	O
of	O
arthritis	O
was	O
suggested	O
.	O

The	O
upregulation	O
of	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
transcripts	O
after	O
IgM	O
-	O
crosslinking	O
is	O
of	O
pathophysiologic	O
interest	O
[	O
12	O
]	O
.	O

A	O
loss	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
responsiveness	O
has	O
been	O
suggested	O
to	O
be	O
a	O
critical	O
contribution	O
to	O
malignant	O
transformation	O
[	O
47	O
,	O
48	O
]	O
and	O
similar	O
oncogenic	O
mechanisms	O
have	O
been	O
postulated	O
for	O
BMPs	O
.	O

Lines	O
of	O
evidence	O
suggest	O
[	O
49	O
]	O
that	O
at	O
early	O
stages	O
of	O
carcinogenesis	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
is	O
not	O
a	O
tumour	O
promoter	O
,	O
but	O
suppresses	O
benign	O
and	O
malignant	O
tumour	O
outgrowth	O
.	O

These	O
findings	O
are	O
in	O
good	O
agreement	O
with	O
previous	O
findings	O
for	O
other	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
family	O
members	O
,	O
including	O
TGF	B-PRGE
-	I-PRGE
beta1	E-PRGE
and	O
BMP	B-PRGE
-	I-PRGE
4	E-PRGE
[	O
50	O
]	O
,	O
indicating	O
that	O
cellular	O
context	O
of	O
the	O
BMP	O
target	O
cell	O
might	O
define	O
the	O
various	O
observed	O
effects	O
.	O

In	O
contrast	O
to	O
the	O
upregulation	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
transcript	O
in	O
B	O
cells	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
transcripts	O
in	O
human	O
peripheral	O
blood	O
CD4	S-PRGE
+	O
or	O
CD8	S-PRGE
+	O
T	O
cells	O
(	O
resting	O
or	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
and	O
anti	O
-	O
CD28	S-PRGE
;	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
findings	O
in	O
T	O
cell	O
lines	O
[	O
20	O
]	O
and	O
T	O
cells	O
in	O
mice	O
[	O
43	O
]	O
.	O

Other	O
potential	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
sources	O
for	O
mature	O
B	O
cells	O
in	O
vivo	O
might	O
be	O
other	O
cells	O
of	O
the	O
immune	O
system	O
or	O
tissue	O
with	O
contact	O
to	O
the	O
hematopoietic	O
system	O
.	O

One	O
well	O
recognized	O
source	O
for	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
production	O
is	O
the	O
human	O
bone	O
and	O
bone	O
marrow	O
stroma	O
[	O
51	O
,	O
8	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
noteworthy	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
highly	O
express	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
[	O
52	O
]	O
,	O
and	O
vascular	O
endothelium	O
has	O
been	O
reported	O
to	O
produce	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
[	O
53	O
]	O
.	O

These	O
studies	O
might	O
imply	O
a	O
role	O
for	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
in	O
transendothelial	O
migration	O
of	O
B	O
cells	O
.	O

BMP	B-PRGE
-	I-PRGE
6	E-PRGE
mRNA	O
has	O
been	O
demonstrated	O
in	O
murine	O
macrophage	O
cell	O
lines	O
,	O
but	O
not	O
in	O
humans	O
[	O
54	O
]	O
.	O

In	O
accordance	O
with	O
these	O
findings	O
,	O
other	O
human	O
cell	O
lines	O
of	O
neutrophil	O
and	O
monocytic	O
origin	O
have	O
been	O
described	O
to	O
be	O
negative	O
for	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
transcript	O
[	O
20	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
currently	O
no	O
report	O
about	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
production	O
of	O
human	O
dendritic	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induces	O
activation	O
of	O
intracellular	O
Smad	O
signalling	O
in	O
mature	O
human	O
B	O
-	O
cells	O
with	O
consecutive	O
production	O
of	O
Id1	S-PRGE
protein	O
.	O

Furthermore	O
,	O
we	O
report	O
that	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
has	O
an	O
antiproliferative	O
effect	O
in	O
B	O
cells	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	S-PRGE
.	O

Additionally	O
,	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
induces	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
rationale	O
to	O
further	O
examine	O
the	O
role	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
signalling	O
in	O
normal	O
B	O
cell	O
biology	O
as	O
well	O
as	O
in	O
pathologic	O
conditions	O
like	O
B	O
cell	O
malignancies	O
and	O
autoimmune	O
disorders	O
.	O

Cell	O
culture	O

If	O
not	O
specified	O
,	O
all	O
cells	O
were	O
cultured	O
in	O
X	O
-	O
VIVO	O
15	O
(	O
TM	O
)	O
(	O
BioWhittaker	O
,	O
Verviers	O
,	O
Belgium	O
)	O
serum	O
-	O
free	O
medium	O
at	O
37degreesC	O
and	O
5	O
%	O
CO2	O
in	O
air	O
.	O

Peripheral	O
blood	O
was	O
provided	O
by	O
the	O
Blood	O
Bank	O
at	O
Buskerud	O
Regional	O
Hospital	O
with	O
formal	O
agreement	O
by	O
the	O
patients	O
,	O
and	O
approval	O
by	O
the	O
regional	O
ethics	O
committee	O
.	O

Highly	O
purified	O
resting	O
human	O
B	O
-	O
lymphocytes	O
(	O
CD19	S-PRGE
+	O
cells	O
)	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
by	O
rosetting	O
with	O
immunomagnetic	O
beads	O
(	O
Dynabeads	O
M450	O
;	O
Dynal	O
,	O
Oslo	O
,	O
Norway	O
)	O
as	O
described	O
[	O
55	O
]	O
.	O

This	O
procedure	O
yields	O
less	O
than	O
0	O
.	O
5	O
%	O
T	O
cells	O
,	O
0	O
.	O
1	O
%	O
NK	O
cells	O
,	O
and	O
0	O
.	O
5	O
%	O
monocytes	O
as	O
judged	O
by	O
indirect	O
immunofluorescence	O
staining	O
.	O

The	O
following	O
cell	O
lines	O
from	O
human	O
lymphoid	O
malignancies	O
were	O
maintained	O
in	O
RPMI	O
1640	O
(	O
PAA	O
Laboratories	O
GmbH	O
,	O
Pasching	O
,	O
Austria	O
)	O
supplemented	O
with	O
10	O
%	O
foetal	O
bovine	O
serum	O
(	O
FCS	O
)	O
,	O
100	O
units	O
/	O
ml	O
penicillin	O
G	O
,	O
and	O
100	O
units	O
/	O
ml	O
of	O
streptomycin	O
sulphate	O
,	O
but	O
serum	O
-	O
starved	O
for	O
at	O
least	O
four	O
hours	O
and	O
cultured	O
in	O
X	O
-	O
VIVO	O
15	O
(	O
TM	O
)	O
when	O
included	O
in	O
experiments	O
:	O
EBV	O
-	O
negative	O
BL	O
cell	O
lines	O
Ramos	O
(	O
ECACC	O
85030802	O
)	O
,	O
HL60	O
(	O
JCRB0085	O
)	O
.	O

Growth	O
factors	O
/	O
supplements	O

The	O
following	O
reagents	O
were	O
used	O
at	O
indicated	O
concentrations	O
:	O
recombinant	O
human	O
(	O
rhu	O
)	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
1	O
mug	O
/	O
ml	O
,	O
if	O
not	O
specified	O
otherwise	O
)	O
,	O
rhu	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
/	O
ALK	B-PRGE
-	I-PRGE
6	E-PRGE
/	O
Fc	O
Chimera	O
(	O
5	O
mug	O
/	O
ml	O
)	O
,	O
rhu	O
BMPR	B-PRGE
-	I-PRGE
II	E-PRGE
/	O
Fc	O
Chimera	O
(	O
5	O
mug	O
/	O
ml	O
)	O
,	O
and	O
recombinant	O
mouse	O
Noggin	S-PRGE
(	O
5	O
mug	O
/	O
ml	O
)	O
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
;	O
Anti	O
-	O
IgM	O
F	O
(	O
ab	O
)	O
2	O
fragments	O
of	O
rabbit	O
polyclonal	O
antibodies	O
to	O
human	O
IgM	O
heavy	O
chain	O
(	O
37	O
.	O
5	O
mug	O
/	O
ml	O
)	O
was	O
obtained	O
from	O
Dako	O
,	O
Copenhagen	O
,	O
Denmark	O
and	O
rhu	O
CD40	B-PRGE
ligand	E-PRGE
(	O
CD40L	S-PRGE
,	O
10	O
ng	O
/	O
ml	O
)	O
was	O
a	O
gift	O
from	O
Immunex	O
Corp	O
.	O

(	O
Seattle	O
,	O
WA	O
)	O
.	O

Antibodies	O
used	O
for	O
flow	O
cytometric	O
analysis	O
and	O
immunoblot	O
analysis	O

Antibodies	O
against	O
the	O
human	O
BMP	O
-	O
receptors	O
Act	B-PRGE
-	I-PRGE
RIA	E-PRGE
,	O
BMP	B-PRGE
-	I-PRGE
RIB	E-PRGE
,	O
BMPR	B-PRGE
-	I-PRGE
II	E-PRGE
,	O
Act	B-PRGE
-	I-PRGE
RIIA	E-PRGE
and	O
Act	B-PRGE
-	I-PRGE
RIIb	E-PRGE
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
.	O

Detection	O
of	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
protein	O
has	O
been	O
tried	O
with	O
the	O
following	O
antibodies	O
:	O
goat	O
polyclonal	O
anti	O
-	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
,	O
monoclonal	O
mouse	O
anti	O
-	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
and	O
polyclonal	O
goat	O
anti	O
-	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
,	O
and	O
mouse	O
monoclonal	O
anti	O
-	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
Chemicon	O
International	O
Inc	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Characterisation	O
of	O
BMP	O
-	O
signalling	O
pathways	O
was	O
done	O
by	O
use	O
of	O
anti	O
-	O
phospho	O
-	O
Smad1	S-PRGE
,	O
-	B-PRGE
5	E-PRGE
,	O
-	O
and	O
8	S-PRGE
polyclonal	O
antibody	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Expression	O
levels	O
of	O
Id1	S-PRGE
-	O
3	S-PRGE
proteins	O
were	O
detected	O
with	O
polyclonal	O
rabbit	O
antibody	O
and	O
detection	O
was	O
blocked	O
with	O
blocking	O
peptide	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

As	O
secondary	O
antibodies	O
served	O
anti	O
-	O
mouse	O
,	O
anti	O
-	O
goat	O
or	O
anti	O
-	O
rabbit	O
IgG	O
-	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
from	O
Dakocytomation	O
AS	O
(	O
Copenhagen	O
,	O
Denmark	O
)	O
for	O
immunoblot	O
analysis	O
.	O

Anti	O
-	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
was	O
from	O
Santa	O
-	O
Cruz	O
.	O

From	O
Becton	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
)	O
,	O
we	O
purchased	O
anti	O
-	O
CD19	S-PRGE
-	O
PE	O
,	O
anti	O
-	O
CD19	S-PRGE
-	O
FITC	O
.	O

The	O
antibodies	O
used	O
for	O
cell	O
sorting	O
were	O
anti	O
-	O
CD19	S-PRGE
PC5	O
from	O
Immunotech	O
SA	O
(	O
Marseille	O
,	O
France	O
)	O
and	O
anti	O
-	O
CD27	S-PRGE
PE	O
from	O
Becton	O
Dickinson	O
,	O
Biosciences	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cell	O
sorting	O

Highly	O
purified	O
CD19	S-PRGE
+	O
CD27	S-PRGE
-	O
or	O
CD19	S-PRGE
+	O
CD27	S-PRGE
+	O
cells	O
were	O
obtained	O
by	O
staining	O
CD19	S-PRGE
+	O
cells	O
with	O
anti	O
-	O
CD27	S-PRGE
PE	O
and	O
CD19	S-PRGE
PC5	O
mAbs	O
for	O
30	O
minutes	O
at	O
4degreesC	O
,	O
followed	O
by	O
washing	O
with	O
PBS	O
and	O
sorting	O
on	O
FACS	O
DiVa	O
from	O
Becton	O
Dickinson	O
.	O

Western	O
-	O
blot	O
analysis	O

B	O
cells	O
from	O
peripheral	O
blood	O
or	O
cultured	O
cell	O
-	O
lines	O
were	O
lysed	O
in	O
lysis	O
buffer	O
(	O
glycerol	O
10	O
%	O
,	O
beta	O
-	O
mercaptoethanol	O
5	O
%	O
,	O
0	O
.	O
0625	O
M	O
Tris	O
-	O
HCL	O
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
sodium	O
dodecyl	O
sulphate	O
[	O
SDS	O
]	O
2	O
.	O
5	O
%	O
w	O
/	O
vol	O
)	O
.	O

Total	O
protein	O
(	O
30	O
-	O
100	O
mug	O
)	O
from	O
each	O
sample	O
was	O
run	O
on	O
10	O
%	O
or	O
12	O
%	O
SDS	O
/	O
polyacrylamide	O
(	O
SDS	O
/	O
PAGE	O
)	O
gels	O
and	O
blotted	O
onto	O
nitrocellulose	O
filters	O
(	O
Protran	O
;	O
Schleicher	O
&	O
Schuell	O
GmbH	O
,	O
Dassel	O
,	O
Germany	O
)	O
.	O

Blocking	O
,	O
washing	O
and	O
incubation	O
of	O
the	O
filters	O
with	O
primary	O
antibodies	O
were	O
done	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocols	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
.	O

After	O
washing	O
with	O
TBS	O
/	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
(	O
TBS	O
-	O
T	O
)	O
,	O
the	O
filters	O
were	O
incubated	O
with	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
coupled	O
to	O
relevant	O
secondary	O
antibodies	O
(	O
see	O
above	O
)	O
for	O
60	O
minutes	O
at	O
RT	O
.	O

Enzyme	O
activity	O
was	O
visualised	O
by	O
the	O
enhanced	O
chemiluminescence	O
system	O
,	O
ECL	O
+	O
PLUS	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Densitometric	O
analysis	O
was	O
performed	O
by	O
scanning	O
hyperfilms	O
on	O
a	O
Personal	O
Densitometer	O
SI	O
(	O
Molecular	O
Dynamics	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Quantification	O
of	O
Id1	S-PRGE
,	O
Id2	S-PRGE
and	O
Id3	S-PRGE
protein	O
was	O
calculated	O
by	O
normalizing	O
the	O
specific	O
protein	O
bands	O
to	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
using	O
Image	O
Quant	O
5	O
.	O
5	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Analysis	O
of	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O

Endogenous	O
expression	O
of	O
the	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
gene	O
was	O
examined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Absolutely	O
RNA	O
(	O
TM	O
)	O
RT	O
-	O
PCR	O
Miniprep	O
Kit	O
(	O
Stratagene	O
Europe	O
,	O
Amsterdam	O
,	O
Netherland	O
)	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Quantification	O
of	O
the	O
isolated	O
total	O
RNA	O
was	O
achieved	O
by	O
using	O
spectrophotometric	O
OD260	O
measurements	O
.	O

Equal	O
amounts	O
of	O
RNA	O
were	O
then	O
reverse	O
transcribed	O
to	O
cDNA	O
with	O
TaqMan	O
(	O
R	O
)	O
Reverse	O
Transcription	O
Reagents	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
U	O
.	O
S	O
.	O
A	O
)	O
.	O

To	O
measure	O
mRNA	O
expression	O
of	O
BMP6	S-PRGE
,	O
Id1	S-PRGE
-	O
Id4	S-PRGE
and	O
PGK1	S-PRGE
PCR	O
were	O
carried	O
out	O
with	O
TaqMan	O
(	O
R	O
)	O
universal	O
master	O
mix	O
.	O

Primers	O
and	O
probes	O
were	O
provided	O
by	O
Assay	O
-	O
on	O
-	O
Demand	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
final	O
volume	O
of	O
25	O
mul	O
(	O
BMP	B-PRGE
-	I-PRGE
6	E-PRGE
)	O
or	O
20	O
mul	O
(	O
ID1	O
)	O
.	O

The	O
cDNA	O
added	O
to	O
each	O
reaction	O
was	O
equivalent	O
to	O
the	O
input	O
of	O
20	O
ng	O
of	O
total	O
RNA	O
.	O

The	O
gene	O
expression	O
was	O
quantified	O
using	O
the	O
standard	O
curve	O
method	O
(	O
BMP6	S-PRGE
)	O
,	O
or	O
the	O
comparative	O
CT	O
method	O
(	O
Id1	S-PRGE
)	O
as	O
described	O
in	O
ABI7700	O
User	O
Bulletin	O
2	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
expression	O
was	O
then	O
normalized	O
to	O
the	O
expression	O
level	O
of	O
PGK1	S-PRGE
.	O

PGK1	S-PRGE
was	O
chosen	O
,	O
because	O
it	O
has	O
been	O
shown	O
to	O
have	O
low	O
expression	O
variability	O
among	O
lymphocyte	O
specimens	O
[	O
56	O
]	O
.	O

Expression	O
levels	O
in	O
B	O
cells	O
were	O
then	O
related	O
to	O
the	O
expression	O
levels	O
in	O
Ramos	O
cells	O
.	O

Cell	O
proliferation	O

For	O
estimation	O
of	O
DNA	O
synthesis	O
,	O
CD19	S-PRGE
+	O
cells	O
(	O
7	O
.	O
5	O
x	O
104	O
cells	O
/	O
0	O
.	O
2	O
ml	O
)	O
or	O
Ramos	O
cells	O
(	O
1	O
x	O
104	O
cells	O
/	O
0	O
.	O
2	O
ml	O
)	O
were	O
cultured	O
in	O
triplicate	O
in	O
microtiter	O
wells	O
.	O

The	O
cells	O
were	O
pulsed	O
with	O
3	O
.	O
7	O
x	O
104Bq	O
[	O
3H	O
]	O
thymidine	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
for	O
the	O
last	O
16	O
h	O
of	O
a	O
72	O
-	O
h	O
incubation	O
.	O

The	O
cells	O
were	O
harvested	O
using	O
an	O
automated	O
cell	O
harvester	O
(	O
Packard	O
Instrument	O
Company	O
,	O
Meriden	O
,	O
CT	O
,	O
USA	O
)	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
determined	O
in	O
a	O
scintillation	O
counter	O
(	O
TopCount	O
,	O
Packard	O
Instrument	O
Company	O
Inc	O
.	O
,	O
Meriden	O
,	O
CT	O
)	O
.	O

Determination	O
of	O
cell	O
death	O

Cell	O
death	O
was	O
measured	O
by	O
vital	O
dye	O
exclusion	O
test	O
by	O
staining	O
cells	O
with	O
5	O
mug	O
/	O
ml	O
propidium	O
iodide	O
(	O
[	O
PI	O
]	O
;	O
Calbiochem	O
Corp	O
.	O
;	O
La	O
Jolla	O
,	O
CA	O
;	O
5	O
mg	O
/	O
ml	O
)	O
for	O
one	O
minute	O
on	O
ice	O
.	O

At	O
least	O
1	O
,	O
000	O
cells	O
per	O
sample	O
were	O
run	O
on	O
a	O
BD	O
FACSCalibur	O
flow	O
cytometer	O
.	O

Statistical	O
analysis	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
groups	O
was	O
determined	O
using	O
the	O
paired	O
two	O
-	O
tailed	O
Wilcoxon	O
nonparametric	O
test	O
,	O
by	O
applying	O
SPSS10	O
.	O
1	O
software	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
regulate	O
basal	O
transcription	O
of	O
the	O
human	O
APOBEC3G	S-PRGE
gene	O

APOBEC3G	S-PRGE
(	O
A3G	S-PRGE
)	O
,	O
a	O
member	O
of	O
the	O
recently	O
discovered	O
family	O
of	O
human	O
cytidine	O
deaminases	O
,	O
is	O
expressed	O
in	O
peripheral	O
blood	O
lymphocytes	O
and	O
has	O
been	O
shown	O
to	O
be	O
active	O
against	O
HIV	O
-	O
1	O
and	O
other	O
retroviruses	O
.	O

To	O
gain	O
new	O
insights	O
into	O
the	O
transcriptional	O
regulation	O
of	O
this	O
restriction	O
factor	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
promoter	O
region	O
of	O
A3G	S-PRGE
.	O

Transcriptional	O
start	O
sites	O
were	O
identified	O
by	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
.	O

Luciferase	S-PRGE
reporter	O
assays	O
demonstrated	O
that	O
a	O
1025	O
bp	O
A3G	O
promoter	O
sequence	O
(	O
from	O
-	O
959	O
to	O
+	O
66	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
displayed	O
constitutive	O
promoter	O
activity	O
.	O

In	O
T	O
cells	O
,	O
the	O
A3G	S-PRGE
promoter	O
was	O
not	O
inducible	O
by	O
mitogenic	O
stimulation	O
,	O
interferon	O
treatment	O
or	O
expression	O
of	O
HIV	O
-	O
1	O
proteins	O
.	O

Using	O
a	O
series	O
of	O
5	O
'	O
deletion	O
promoter	O
constructs	O
in	O
luciferase	S-PRGE
reporter	O
assays	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
was	O
sufficient	O
for	O
full	O
promoter	O
activity	O
.	O

Transcriptional	O
activity	O
of	O
this	O
A3G	O
core	O
promoter	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
(	O
located	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
and	O
was	O
abolished	O
after	O
mutation	O
of	O
this	O
DNA	O
element	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
the	O
identified	O
GC	O
-	O
box	O
represented	O
a	O
binding	O
site	O
for	O
the	O
ubiquitous	O
transcription	O
factors	O
specificity	B-PRGE
protein	I-PRGE
(	I-PRGE
Sp	I-PRGE
)	I-PRGE
1	E-PRGE
and	O
Sp3	S-PRGE
.	O

The	O
recently	O
discovered	O
APOBEC3	O
family	O
of	O
cytidine	O
deaminases	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
antiviral	O
intrinsic	O
immunity	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
primates	O
,	O
the	O
seven	O
paralogs	O
APOBEC3A	S-PRGE
,	O
B	S-PRGE
,	O
C	S-PRGE
,	O
DE	S-PRGE
,	O
F	S-PRGE
,	O
G	S-PRGE
,	O
H	S-PRGE
(	O
A3A	O
-	O
H	O
)	O
have	O
been	O
described	O
(	O
3	O
)	O
,	O
and	O
they	O
appear	O
to	O
fulfill	O
individual	O
functions	O
.	O

Human	O
APOBEC3G	S-PRGE
(	O
A3G	S-PRGE
)	O
,	O
the	O
most	O
prominent	O
member	O
of	O
the	O
APOBEC3	O
family	O
has	O
been	O
identified	O
as	O
the	O
cellular	O
restriction	O
factor	O
that	O
is	O
responsible	O
for	O
inhibition	O
of	O
virion	B-PRGE
infectivity	I-PRGE
factor	E-PRGE
(	O
Vif	S-PRGE
)	O
-	O
deleted	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
non	O
-	O
permissive	O
cells	O
(	O
4	O
)	O
.	O

A3G	S-PRGE
is	O
packaged	O
into	O
HIV	O
-	O
1deltavif	S-PRGE
particles	O
and	O
causes	O
C	O
-	O
to	O
-	O
U	O
deaminations	O
on	O
the	O
single	O
-	O
stranded	O
viral	O
DNA	O
during	O
reverse	O
transcription	O
(	O
5	O
-	O
8	O
)	O
.	O

This	O
leads	O
to	O
degradation	O
of	O
the	O
uracile	O
-	O
containing	O
DNA	O
by	O
cellular	O
repair	O
mechanisms	O
or	O
to	O
hypermutation	O
of	O
the	O
viral	O
genome	O
(	O
5	O
,	O
6	O
)	O
.	O

As	O
a	O
result	O
,	O
only	O
a	O
marginal	O
fraction	O
of	O
the	O
A3G	S-PRGE
-	O
containing	O
HIV	O
-	O
1	O
particles	O
is	O
able	O
to	O
complete	O
the	O
replication	O
cycle	O
.	O

In	O
addition	O
to	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
,	O
A3G	S-PRGE
restricts	O
replication	O
of	O
other	O
lentiviruses	O
,	O
gammaretroviruses	O
,	O
deltaretroviruses	O
,	O
spumaviruses	O
,	O
long	O
-	O
terminal	O
-	O
repeat	O
(	O
LTR	O
)	O
-	O
retrotransposons	O
,	O
orthohepadnaviruses	O
and	O
avihepadnaviruses	O
(	O
9	O
-	O
21	O
)	O
.	O

Interestingly	O
,	O
deamination	O
seems	O
not	O
to	O
be	O
the	O
only	O
A3G	S-PRGE
-	O
mediated	O
antiviral	O
mechanism	O
;	O
in	O
the	O
case	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
,	O
A3G	S-PRGE
was	O
shown	O
to	O
restrict	O
virus	O
replication	O
by	O
deamination	O
-	O
independent	O
mechanisms	O
(	O
12	O
,	O
13	O
,	O
19	O
,	O
22	O
-	O
25	O
)	O
.	O

Another	O
member	O
of	O
the	O
APOBEC3	O
family	O
,	O
APOBEC3F	S-PRGE
(	O
A3F	S-PRGE
)	O
,	O
appears	O
to	O
have	O
similar	O
activities	O
like	O
A3G	S-PRGE
(	O
26	O
,	O
27	O
)	O
.	O

A3F	S-PRGE
is	O
also	O
packaged	O
into	O
HIV	O
-	O
1deltavif	S-PRGE
particles	O
and	O
induces	O
similar	O
C	O
-	O
to	O
-	O
U	O
deaminations	O
,	O
although	O
the	O
proteins	O
differ	O
in	O
their	O
target	O
sequences	O
specificity	O
(	O
26	O
,	O
28	O
)	O
.	O

Furthermore	O
,	O
A3F	S-PRGE
proteins	O
were	O
detected	O
in	O
many	O
tissues	O
that	O
express	O
A3G	S-PRGE
and	O
are	O
able	O
to	O
form	O
heteromultimers	O
with	O
A3G	S-PRGE
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

Both	O
proteins	O
localize	O
to	O
mRNA	O
processing	O
(	O
P	O
)	O
bodies	O
,	O
cytoplasmic	O
compartments	O
involved	O
in	O
the	O
degradation	O
and	O
storage	O
of	O
non	O
-	O
translating	O
mRNAs	O
(	O
30	O
,	O
31	O
)	O
.	O

A3G	S-PRGE
has	O
been	O
shown	O
to	O
be	O
expressed	O
in	O
T	O
cells	O
,	O
a	O
relevant	O
cell	O
target	O
for	O
HIV	O
-	O
1	O
in	O
vivo	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
regulation	O
(	O
4	O
,	O
29	O
,	O
32	O
)	O
.	O

There	O
is	O
a	O
report	O
describing	O
that	O
mitogenic	O
stimulation	O
of	O
T	O
cells	O
upregulates	O
A3G	S-PRGE
mRNA	O
levels	O
,	O
but	O
this	O
was	O
not	O
analyzed	O
on	O
the	O
transcriptional	O
level	O
(	O
33	O
)	O
.	O

Since	O
the	O
A3G	S-PRGE
promoter	O
has	O
not	O
been	O
systematically	O
analyzed	O
so	O
far	O
,	O
our	O
aim	O
was	O
to	O
clone	O
the	O
A3G	S-PRGE
promoter	O
and	O
characterize	O
its	O
regulation	O
in	O
T	O
cells	O
.	O

In	O
our	O
study	O
,	O
we	O
observed	O
that	O
A3G	S-PRGE
uses	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
of	O
the	O
A3G	S-PRGE
promoter	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
mediated	O
basal	O
transcription	O
.	O

In	O
T	O
cells	O
,	O
transcriptional	O
activity	O
of	O
this	O
core	O
promoter	O
was	O
not	O
inducible	O
by	O
mitogenic	O
stimulation	O
or	O
interferon	S-PRGE
treatment	O
,	O
but	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
which	O
was	O
recognized	O
by	O
Sp	B-PRGE
(	I-PRGE
specificity	I-PRGE
protein	I-PRGE
)	I-PRGE
1	E-PRGE
and	O
Sp3	S-PRGE
transcription	O
factors	O
.	O

Cell	O
culture	O

The	O
human	O
T	O
cell	O
lines	O
A3	O
.	O
01	O
and	O
PM1	O
(	O
NIBSC	O
,	O
UK	O
)	O
and	O
the	O
human	O
myeloid	O
cell	O
line	O
U937	O
(	O
NIBSC	O
,	O
UK	O
)	O
were	O
grown	O
in	O
complete	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U	O
/	O
ml	O
penicillin	O
-	O
streptomycin	O
.	O

The	O
human	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
kindly	O
provided	O
by	O
Dr	O
Thomas	O
Pietschmann	O
,	O
Department	O
of	O
Molecular	O
Virology	O
,	O
University	O
of	O
Heidelberg	O
)	O
as	O
well	O
as	O
HeLa	O
cells	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
high	O
glucose	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U	O
/	O
ml	O
penicillin	O
-	O
streptomycin	O
.	O

Cells	O
lines	O
were	O
incubated	O
at	O
37degreesC	O
with	O
100	O
%	O
humidity	O
in	O
5	O
-	O
7	O
%	O
CO2	O
and	O
passaged	O
using	O
standard	O
cell	O
culture	O
techniques	O
.	O

Plasmids	O

For	O
cloning	O
of	O
an	O
APOBEC3G	S-PRGE
promoter	O
-	O
driven	O
reporter	O
plasmid	O
,	O
genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
T	O
cell	O
line	O
PM1	O
using	O
the	O
DNeasy	O
Kit	O
(	O
Qiagen	O
)	O
.	O

The	O
DNA	O
sequence	O
ranging	O
from	O
positions	O
-	O
959	O
to	O
+	O
66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
was	O
amplified	O
via	O
PCR	O
using	O
the	O
primers	O
3Gprom1025	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTGCTGCAGGCCATCTGGATGTATATG	O
-	O
3	O
'	O
)	O
and	O
3Gpromreverse	O
(	O
5	O
'	O
-	O
ACAGCAGATCTAGGGACCTCTGATAAAGACAGG	O
-	O
3	O
'	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pwo	S-PRGE
DNA	O
Polymerase	O
(	O
Roche	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
58degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

The	O
amplicon	O
was	O
ligated	O
into	O
the	O
promoterless	O
luciferase	S-PRGE
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
,	O
which	O
were	O
introduced	O
by	O
the	O
primers	O
.	O

The	O
resulting	O
construct	O
contained	O
1025	O
bp	O
of	O
the	O
A3G	S-PRGE
promoter	O
and	O
was	O
designated	O
pGL3	O
-	O
APOprom1025	O
.	O

Reporter	O
plasmids	O
containing	O
shorter	O
fragments	O
of	O
the	O
APOBEC3G	S-PRGE
promoter	O
were	O
constructed	O
using	O
pGL3	O
-	O
APOprom1025	O
as	O
template	O
and	O
the	O
following	O
forward	O
primers	O
:	O
for	O
plasmid	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436	O
/	O
+	O
66	O
)	O
:	O
3Gprom502	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCCATAACATGGGGACAAGA	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159	O
/	O
+	O
66	O
)	O
:	O
3Gprom225	O
(	O
5	O
'	O
-	O
TGTGAACGCGTCGAGGGCAGGATCCGGGAGT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom180	O
(	O
containing	O
sequence	O
-	O
114	O
/	O
+	O
66	O
)	O
:	O
3Gprom180	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCTTGATGGTGGAGAGGAGG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom150	O
(	O
containing	O
sequence	O
-	O
84	O
/	O
+	O
66	O
)	O
:	O
3Gprom150	O
(	O
5	O
'	O
-	O
TGTGAACGCGTGCGGGACCACCAGGGGAGGGGCTT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom120	O
(	O
containing	O
sequence	O
-	O
54	O
/	O
+	O
66	O
)	O
:	O
3Gprom120	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTGCTGGCTCAGCCTGGTGTG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom60	O
(	O
containing	O
sequence	O
+	O
7	O
/	O
+	O
66	O
)	O
:	O
3Gprom60	O
(	O
5	O
'	O
-	O
TGTGAACGCGTCCCTTTGCAATTGCCTTG	O
-	O
3	O
'	O
)	O
;	O
each	O
in	O
combination	O
with	O
the	O
reverse	O
primer	O
3Gpromreverse	O
(	O
described	O
above	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pfu	S-PRGE
Ultra	O
Hotstart	O
(	O
Stratagene	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

As	O
for	O
pGL3	O
-	O
APOprom1025	O
,	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
and	O
PCR	O
products	O
were	O
ligated	O
into	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
these	O
restriction	O
sites	O
.	O

pGL3	O
-	O
APOprom180mut	O
carries	O
two	O
point	O
mutations	O
(	O
bold	O
)	O
and	O
was	O
generated	O
using	O
the	O
primer	O
3GProm180mut	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGTTCGGGACCACCAG	O
-	O
3	O
'	O
)	O
in	O
combination	O
with	O
primer	O
3Gpromreverse	O
.	O

This	O
PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
65degreesC	O
.	O

pGL3promE1	O
(	O
containing	O
nucleotides	O
-	O
114	O
/	O
-	O
85	O
)	O
and	O
pGL3promE2	O
(	O
containing	O
nucleotides	O
-	O
92	O
/	O
-	O
63	O
)	O
were	O
constructed	O
by	O
annealing	O
the	O
following	O
single	O
-	O
stranded	O
oligonucleotides	O
:	O
114	O
_	O
85Plus	O
(	O
5	O
'	O
-	O
CGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGGA	O
-	O
3	O
'	O
)	O
and	O
114	O
_	O
85Minus	O
(	O
5	O
'	O
-	O
GATCTCCAGCTGGAGCCTCCTCTCCACCATCAAGAA	O
-	O
3	O
'	O
)	O
or	O
92	O
-	O
63Plus	O
(	O
5	O
'	O
-	O
CGCGTCCAGCTGGGCGGGACCACCAGGGGAGGGGCA	O
-	O
3	O
'	O
)	O
and	O
92	O
_	O
63Minus	O
(	O
5	O
'	O
-	O
GATCTGCCCCTCCCCTGGTGGTCCCGCCCAGCTGGA	O
-	O
3	O
'	O
)	O
.	O

After	O
annealing	O
,	O
the	O
double	O
-	O
stranded	O
oligonucleotides	O
which	O
contained	O
the	O
respective	O
30	O
bp	O
of	O
the	O
APOBEC3G	S-PRGE
promoter	O
and	O
sticky	O
ends	O
compatible	O
with	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
ligated	O
into	O
the	O
pGL3	O
-	O
Promoter	O
(	O
Promega	O
)	O
vector	O
.	O

The	O
sequences	O
of	O
all	O
constructed	O
plasmids	O
were	O
verified	O
by	O
sequence	O
analysis	O
.	O

Nucleotide	O
-	O
219	O
of	O
the	O
cloned	O
APOBEC3G	S-PRGE
promoter	O
differs	O
from	O
the	O
sequence	O
in	O
the	O
database	O
(	O
GenBank	O
(	O
TM	O
)	O
accession	O
number	O
DQ147772	O
)	O
.	O

An	O
A	O
-	O
to	O
-	O
C	O
substitution	O
is	O
present	O
at	O
this	O
position	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
we	O
identified	O
.	O

The	O
reporter	O
plasmids	O
pGL3	O
-	O
Control	O
and	O
phRG	O
-	O
TK	O
were	O
purchased	O
from	O
Promega	O
.	O

pGL2	O
-	O
CVX	O
contains	O
two	O
repeats	O
of	O
the	O
IFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
(	O
GATCTGGATTTAGAGTAATATGAAACTGAAAGTACTTCG	O
)	O
of	O
the	O
guanylate	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	E-PRGE
(	O
GBP	S-PRGE
)	O
gene	O
in	O
front	O
of	O
a	O
CMV	O
minimal	O
promoter	O
and	O
was	O
kindly	O
provided	O
by	O
Ute	O
Pagelow	O
and	O
Mario	O
Koster	O
from	O
the	O
Helmholtz	O
-	O
Zentrum	O
fur	O
Infektionsforschung	O
.	O

Plasmid	O
pNL4	O
-	O
3	O
(	O
NIBSC	O
,	O
UK	O
)	O
contains	O
the	O
full	O
-	O
length	O
HIV	O
-	O
1NL4	O
-	O
3	O
genome	O
and	O
has	O
been	O
described	O
previously	O
(	O
34	O
)	O
.	O

pcDNA3	O
.	O
1Vif	O
was	O
generously	O
provided	O
by	O
Nathaniel	O
R	O
.	O
Landau	O
from	O
the	O
Salk	O
Institute	O
,	O
La	O
Jolla	O
.	O

It	O
was	O
generated	O
by	O
amplifying	O
the	O
Vif	S-PRGE
gene	O
from	O
pNL4	O
-	O
3	O
and	O
ligating	O
it	O
into	O
the	O
pcDNA3	O
.	O
1	O
vector	O
via	O
BamHI	O
and	O
XhoI	O
restriction	O
sites	O
.	O

A	O
3	O
'	O
-	O
WPRE	O
element	O
was	O
included	O
into	O
the	O
XhoI	O
site	O
.	O

pBS	O
-	O
kRSPA	O
-	O
TatHIV	S-PRGE
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
was	O
constructed	O
by	O
amplifying	O
the	O
two	O
exons	O
of	O
Tat	S-PRGE
via	O
PCR	O
reaction	O
using	O
the	O
molecular	O
clone	O
pNL4	O
-	O
3	O
as	O
template	O
and	O
the	O
following	O
primer	O
sets	O
:	O
exon1	O
,	O
5UXho1HIV	O
-	O
Tat1Plus	S-PRGE
(	O
5	O
'	O
-	O
GCATGCTCGAGATGGAGCCAGTAGATCCTAG	O
-	O
3	O
'	O
)	O
and	O
HIV	O
-	O
Tat1Minus	S-PRGE
(	O
5	O
'	O
-	O
TGCTTTGATAGAGAAGCTTGATG	O
-	O
3	O
'	O
)	O
;	O
exon2	O
,	O
15FHIV	O
-	O
Tat2Plus	S-PRGE
(	O
5	O
'	O
-	O
TTCTCTATCAAAGCAACCCACCTCCCAATCCCG	O
-	O
3	O
'	O
)	O
and	O
5USpe1HIV	O
-	O
Tat2Minus	S-PRGE
(	O
5	O
'	O
-	O
GACGTACTAGTCTATTCCTTCGGGCCTGTC	O
-	O
3	O
'	O
)	O
.	O

XhoI	O
and	O
SpeI	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
.	O

The	O
sense	O
-	O
primer	O
of	O
exon2	O
starts	O
with	O
a	O
15	O
-	O
mer	O
which	O
is	O
homologous	O
to	O
the	O
3	O
'	O
end	O
of	O
exon1	O
and	O
necessary	O
for	O
fusion	O
of	O
both	O
exons	O
.	O

PCRs	O
were	O
performed	O
with	O
Expand	O
High	O
Fidelity	O
PCR	O
System	O
(	O
Roche	O
)	O
using	O
the	O
following	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
55degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
45	O
s	O
;	O
one	O
cycle	O
68degreesC	O
for	O
7	O
min	O
.	O

For	O
fusion	O
of	O
both	O
exons	O
,	O
the	O
following	O
PCR	O
conditions	O
were	O
applied	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
60	O
s	O
.	O

After	O
10	O
cycles	O
without	O
primers	O
,	O
the	O
sense	O
-	O
primer	O
of	O
exon1	O
and	O
the	O
antisense	O
-	O
primer	O
of	O
exon2	O
were	O
added	O
for	O
the	O
remaining	O
cycles	O
.	O

The	O
resulting	O
amplicon	O
was	O
ligated	O
into	O
the	O
pBS	O
-	O
kRSPA	O
vector	O
(	O
35	O
)	O
via	O
XhoI	O
and	O
SpeI	O
restriction	O
sites	O
.	O

5	O
'	O
-	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O

Total	O
RNA	O
was	O
isolated	O
from	O
A3	O
.	O
01	O
T	O
cells	O
using	O
RNeasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
transcriptional	O
start	O
sites	O
of	O
A3G	S-PRGE
were	O
identified	O
using	O
the	O
5	O
'	O
/	O
3	O
'	O
RACE	O
Kit	O
,	O
2nd	O
Generation	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
following	O
primers	O
were	O
used	O
:	O
RACE	O
-	O
APO3G1	O
(	O
5	O
'	O
-	O
TATCCCTTGTACACTTTGT	O
-	O
3	O
'	O
)	O
for	O
cDNA	O
synthesis	O
,	O
RACE	O
-	O
APO3G2	O
(	O
5	O
'	O
-	O
CATACTCCTGGTCACGAT	O
-	O
3	O
'	O
)	O
for	O
the	O
first	O
PCR	O
and	O
RACE	O
-	O
APO3Gnest	O
(	O
5	O
'	O
-	O
GAATACACCTGGCCTCGAA	O
-	O
3	O
'	O
)	O
for	O
the	O
nested	O
PCR	O
.	O

Reaction	O
products	O
were	O
analyzed	O
by	O
agarose	O
gel	O
electrophoresis	O
,	O
purified	O
using	O
QIAquick	O
gel	O
extraction	O
kit	O
(	O
Qiagen	O
)	O
,	O
T	O
/	O
A	O
-	O
cloned	O
into	O
vector	O
pCR4	O
-	O
TOPO	O
(	O
Invitrogen	O
)	O
and	O
sequenced	O
.	O

Luciferase	S-PRGE
assay	O

For	O
transient	O
transfection	O
of	O
A3	O
.	O
01	O
and	O
U937	O
cells	O
,	O
DMRIE	O
-	O
C	O
transfection	O
reagent	O
(	O
Life	O
Technologies	O
)	O
was	O
used	O
(	O
36	O
)	O
.	O

Cells	O
were	O
seeded	O
in	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
(	O
5	O
x	O
105	O
cells	O
per	O
well	O
)	O
in	O
1	O
.	O
5	O
ml	O
Opti	O
-	O
MEM	O
(	O
Life	O
Technologies	O
)	O
containing	O
0	O
.	O
5	O
microg	O
firefly	O
luciferase	S-PRGE
reporter	O
plasmid	O
and	O
3	O
.	O
5	O
microl	O
DMRIE	O
-	O
C	O
.	O

After	O
4	O
-	O
5	O
h	O
of	O
incubation	O
,	O
1	O
.	O
5	O
ml	O
complete	O
RPMI	O
medium	O
were	O
added	O
.	O

HepG2	O
and	O
Huh7	O
cell	O
lines	O
were	O
transfected	O
using	O
LipofectAMINE	O
Plus	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Life	O
Technologies	O
)	O
.	O

Briefly	O
,	O
exponential	O
growing	O
cells	O
(	O
1	O
.	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
5	O
microl	O
LipofectAMINE	O
,	O
6	O
microl	O
PLUS	O
reagent	O
and	O
the	O
required	O
amount	O
of	O
plasmid	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
Opti	O
-	O
MEM	O
.	O

Following	O
4	O
h	O
of	O
incubation	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
and	O
3	O
ml	O
of	O
complete	O
DMEM	O
medium	O
were	O
added	O
.	O

For	O
cotransfection	O
of	O
reporter	O
plasmids	O
and	O
siRNA	O
into	O
HeLa	O
cells	O
,	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
cotransfection	O
of	O
adherent	O
cells	O
with	O
siRNA	O
and	O
plasmid	O
DNA	O
.	O

Two	O
days	O
after	O
transfection	O
of	O
the	O
respective	O
cell	O
lines	O
,	O
cells	O
were	O
harvested	O
in	O
100	O
microl	O
(	O
suspension	O
cells	O
)	O
or	O
300	O
microl	O
(	O
adherent	O
cells	O
)	O
of	O
Passive	O
Lysis	O
Buffer	O
(	O
Promega	O
)	O
and	O
luciferase	S-PRGE
assay	O
was	O
performed	O
using	O
the	O
Dual	O
Luciferase	O
Assay	O
System	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

As	O
an	O
internal	O
control	O
,	O
50	O
ng	O
(	O
adherent	O
cells	O
)	O
or	O
100	O
ng	O
(	O
suspension	O
cells	O
)	O
of	O
ph	O
-	O
RG	O
-	O
TK	O
plasmid	O
(	O
Promega	O
)	O
,	O
which	O
constitutively	O
expresses	O
renilla	O
luciferase	S-PRGE
was	O
cotransfected	O
in	O
every	O
sample	O
and	O
firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
in	O
the	O
figures	O
.	O

For	O
stimulation	O
of	O
cells	O
,	O
final	O
concentrations	O
of	O
20	O
ng	O
/	O
ml	O
TPA	O
(	O
Sigma	O
)	O
or	O
30	O
ng	O
/	O
ml	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
30	O
ng	O
/	O
ml	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
(	O
Tebu	O
-	O
Bio	O
)	O
were	O
applied	O
approximately	O
15	O
h	O
before	O
harvesting	O
for	O
luciferase	S-PRGE
assay	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O

For	O
preparation	O
of	O
nuclear	O
extracts	O
,	O
5	O
x	O
106	O
A3	O
.	O
01	O
T	O
cells	O
were	O
washed	O
in	O
cold	O
PBS	O
and	O
resuspended	O
in	O
500	O
microl	O
buffer	O
A	O
(	O
10	O
mM	O
HEPES	O
pH7	O
.	O
9	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
1	O
mM	O
EGTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
)	O
.	O

After	O
incubation	O
for	O
15	O
min	O
on	O
ice	O
,	O
swollen	O
cells	O
were	O
pressed	O
10	O
times	O
through	O
a	O
syringe	O
with	O
a	O
26G	O
needle	O
and	O
centrifuged	O
at	O
5000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
5	O
min	O
.	O

Pellets	O
contained	O
the	O
nuclei	O
and	O
were	O
washed	O
in	O
buffer	O
A	O
for	O
two	O
times	O
and	O
resuspended	O
in	O
50	O
microl	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
400	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
)	O
.	O

After	O
shaking	O
for	O
30	O
min	O
at	O
4degreesC	O
and	O
centrifugation	O
for	O
10	O
min	O
at	O
13	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
,	O
supernatants	O
were	O
used	O
as	O
nuclear	O
extracts	O
.	O

EMSA	O
probes	O
were	O
generated	O
by	O
annealing	O
the	O
following	O
complementary	O
oligonucleotides	O
:	O
APO	O
-	O
Sp1	S-PRGE
/	O
3	O
,	O
5	O
'	O
-	O
CCAGCTGGGCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCCCCTCCCCTGGTGGTCCCGCCCAGCTGG	O
-	O
3	O
'	O
;	O
APO	O
-	O
Sp1	S-PRGE
/	O
3mut	O
,	O
5	O
'	O
-	O
CCAGCTGTTCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCCCCTCCCCTGGTGGTCCCGAACAGCTGG	O
-	O
3	O
'	O
according	O
to	O
standard	O
procedures	O
.	O

Nucleotides	O
differing	O
from	O
the	O
original	O
promoter	O
sequence	O
are	O
shown	O
in	O
bold	O
type	O
.	O

A	O
commercially	O
available	O
Sp1	S-PRGE
probe	O
(	O
sc	O
-	O
2502	O
,	O
referred	O
to	O
as	O
Sp1cons	O
)	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

The	O
double	O
-	O
stranded	O
oligonucleotides	O
were	O
5	O
'	O
end	O
-	O
labeled	O
using	O
T4	B-PRGE
polynucleotide	I-PRGE
kinase	E-PRGE
(	O
New	O
England	O
Biolabs	O
)	O
and	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
(	O
3000	O
Ci	O
/	O
mmol	O
,	O
Amersham	O
)	O
and	O
purified	O
by	O
using	O
Nick	O
G50	O
columns	O
(	O
Amersham	O
)	O
.	O

For	O
EMSA	O
,	O
5	O
microg	O
of	O
nuclear	O
proteins	O
were	O
preincubated	O
on	O
ice	O
with	O
2	O
microg	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Roche	O
)	O
as	O
an	O
unspecific	O
competitor	O
and	O
1	O
microg	O
of	O
bovine	B-PRGE
serum	I-PRGE
albumin	E-PRGE
in	O
band	O
shift	O
buffer	O
(	O
50	O
mM	O
Tris	O
,	O
150	O
mM	O
KCl	O
,	O
5	O
mM	O
EDTA	O
,	O
2	O
.	O
5	O
mM	O
dithiothreitol	O
,	O
20	O
%	O
Ficoll	O
)	O
for	O
15	O
min	O
.	O

32P	O
-	O
labeled	O
oligonucleotides	O
(	O
50	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
)	O
were	O
added	O
in	O
a	O
total	O
volume	O
of	O
20	O
microl	O
,	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
5	O
%	O
native	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5xTris	O
-	O
borate	O
-	O
EDTA	O
buffer	O
.	O

Upon	O
fractionation	O
,	O
gels	O
were	O
dried	O
and	O
exposed	O
for	O
autoradiography	O
.	O

For	O
competition	O
experiments	O
,	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1	S-PRGE
/	O
3	O
or	O
APO	O
-	O
Sp1	S-PRGE
/	O
3mut	O
oligonucleotides	O
was	O
added	O
to	O
the	O
preincubation	O
mixture	O
.	O

For	O
supershift	O
experiments	O
,	O
2	O
microg	O
Sp1	S-PRGE
antibody	O
(	O
sc	O
-	O
59x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
Sp3	S-PRGE
antibody	O
(	O
sc	O
-	O
644x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
added	O
to	O
the	O
preincubation	O
mixture	O
and	O
preincubation	O
time	O
was	O
extended	O
to	O
30	O
min	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O

A3	O
.	O
01	O
cells	O
were	O
treated	O
with	O
RPMI	O
culture	O
medium	O
containing	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
.	O
at	O
37degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
incubated	O
for	O
10	O
min	O
.	O
on	O
ice	O
after	O
resuspension	O
in	O
SDS	O
lysis	O
buffer	O
(	O
ChIP	O
Assay	O
Kit	O
,	O
Upstate	O
)	O
.	O

After	O
centrifugation	O
,	O
pellets	O
were	O
resuspended	O
in	O
MNase	O
reaction	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
10	O
mM	O
NaCl	O
,	O
3	O
mM	O
MgCl2	O
,	O
1	O
mM	O
CaCl2	O
,	O
4	O
%	O
NP	O
-	O
40	O
)	O
.	O

DNA	O
digestion	O
was	O
performed	O
using	O
50	O
U	O
Micrococcal	B-PRGE
Nuclease	E-PRGE
(	O
Fermentas	O
)	O
and	O
1	O
x	O
107	O
cells	O
per	O
tube	O
in	O
a	O
volume	O
of	O
1	O
.	O
5	O
ml	O
.	O

After	O
2	O
min	O
,	O
reaction	O
was	O
stopped	O
by	O
adding	O
30	O
microl	O
200	O
mM	O
EGTA	O
.	O

Further	O
steps	O
were	O
performed	O
using	O
the	O
Chromatin	O
Immunoprecipitation	O
Assay	O
Kit	O
(	O
Upstate	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

1	O
x	O
107	O
cells	O
and	O
2	O
microg	O
antibody	O
(	O
Sp1	S-PRGE
(	O
Pep2	O
)	O
sc	O
-	O
59	O
,	O
Sp3	S-PRGE
(	O
D	O
-	O
20	O
)	O
sc	O
-	O
644	O
or	O
actin	S-PRGE
(	O
H	O
-	O
196	O
)	O
sc	O
-	O
7210	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
used	O
for	O
each	O
immunoprecipitation	O
.	O

All	O
buffers	O
were	O
freshly	O
supplied	O
with	O
protease	O
inhibitors	O
.	O

After	O
phenol	O
/	O
chloroform	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
DNA	O
was	O
resolved	O
in	O
16	O
microl	O
H2O	O
.	O

Immunoprecipitated	O
DNA	O
was	O
detected	O
by	O
nested	O
PCR	O
using	O
4	O
microl	O
of	O
the	O
resolved	O
DNA	O
in	O
the	O
first	O
PCR	O
,	O
and	O
1	O
microl	O
for	O
the	O
nested	O
PCR	O
.	O

For	O
amplification	O
of	O
the	O
A3G	S-PRGE
promoter	O
,	O
the	O
following	O
primers	O
were	O
used	O
:	O
ChIP3Gplus	O
5	O
'	O
-	O
ccacggtggcctccgagggtga	O
-	O
3	O
'	O
and	O
ChIP3Gminus	O
:	O
5	O
'	O
-	O
ctctccaccatcaagacagac	O
-	O
3	O
'	O
(	O
1	O
.	O
PCR	O
)	O
;	O
ChIP3G2plus	O
:	O
5	O
'	O
-	O
tactctccctccctgtcccca	O
-	O
3	O
'	O
and	O
ChIP3G	O
nested	O
minus	O
:	O
5	O
'	O
-	O
aggctgatgcctccgcag	O
-	O
3	O
'	O
(	O
nested	O
PCR	O
)	O
.	O

Taq	B-PRGE
polymerase	E-PRGE
(	O
Qiagen	O
)	O
was	O
used	O
together	O
with	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
60degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
2	O
min	O
;	O
one	O
cycle	O
72degreesC	O
for	O
10	O
min	O
.	O

As	O
a	O
negative	O
control	O
,	O
a	O
region	O
in	O
the	O
A3G	S-PRGE
gene	O
was	O
targeted	O
using	O
the	O
primers	O
ChIP3Gneg	O
_	O
plus	O
:	O
5	O
'	O
-	O
taagtaccacccagagatgag	O
-	O
3	O
'	O
and	O
ChIP3Gneg	O
_	O
minus	O
:	O
5	O
'	O
-	O
catgatcttcatggtggcacg	O
-	O
3	O
'	O
for	O
both	O
PCR	O
steps	O
.	O

PCR	O
conditions	O
were	O
the	O
same	O
as	O
for	O
the	O
A3G	S-PRGE
promoter	O
sequence	O
,	O
with	O
the	O
exception	O
that	O
annealing	O
temperature	O
was	O
decreased	O
to	O
55degreesC	O
.	O

RNA	O
interference	O
and	O
western	O
blot	O
analysis	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
translation	O
was	O
silenced	O
in	O
HeLa	O
cells	O
using	O
the	O
siRNA	O
duplexes	O
Hs	O
_	O
SP1	O
_	O
1	O
_	O
HP	O
and	O
Hs	O
_	O
SP3	O
_	O
1	O
_	O
HP	O
(	O
Qiagen	O
)	O
.	O

A	O
nonspecific	O
siRNA	O
(	O
Qiagen	O
)	O
was	O
used	O
as	O
control	O
.	O

HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
or	O
300	O
ng	O
siRNA	O
per	O
6	O
-	O
well	O
,	O
using	O
the	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
reverse	O
transfection	O
of	O
adherent	O
cells	O
in	O
6	O
-	O
well	O
plates	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
HeLa	O
cells	O
were	O
harvested	O
for	O
detection	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
proteins	O
.	O

Cells	O
were	O
washed	O
in	O
PBS	O
,	O
lysed	O
in	O
RIPA	O
(	O
25	O
mM	O
Tris	O
pH	O
8	O
.	O
0	O
,	O
137	O
mM	O
NaCl	O
,	O
1	O
%	O
Glycerol	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
2	O
mM	O
EDTA	O
pH	O
8	O
,	O
0	O
.	O
1	O
%	O
SDS	O
and	O
protease	O
inhibitors	O
)	O
and	O
lysates	O
were	O
cleared	O
by	O
centrifugation	O
.	O

After	O
boiling	O
with	O
Laemmli	O
'	O
s	O
buffer	O
,	O
samples	O
were	O
subjected	O
to	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
transfer	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
proteins	O
were	O
detected	O
using	O
alpha	O
-	O
Sp1	S-PRGE
(	O
Pep2	O
)	O
antibody	O
(	O
sc	O
-	O
59	O
,	O
Santa	O
Cruz	O
)	O
or	O
alpha	O
-	O
Sp3	S-PRGE
(	O
D	O
-	O
20	O
)	O
antibody	O
(	O
sc	O
-	O
644	O
,	O
Santa	O
Cruz	O
)	O
followed	O
by	O
incubation	O
with	O
alpha	O
-	O
rabbit	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

For	O
detection	O
of	O
tubulin	S-PRGE
,	O
alpha	O
-	O
tubulin	S-PRGE
(	O
B5	O
-	O
1	O
-	O
2	O
,	O
Sigma	O
)	O
and	O
alpha	O
-	O
mouse	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
antibodies	O
were	O
used	O
.	O

Signals	O
were	O
visualized	O
by	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
,	O
Amersham	O
Biosciences	O
)	O
.	O

Characterization	O
of	O
the	O
transcriptional	O
start	O
sites	O
of	O
APOBEC3G	S-PRGE
by	O
5	O
'	O
-	O
RACE	O

To	O
identify	O
the	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
of	O
APOBEC3G	S-PRGE
(	O
A3G	S-PRGE
)	O
in	O
A3	O
.	O
01	O
T	O
cells	O
,	O
we	O
performed	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O
with	O
A3G	S-PRGE
-	O
specific	O
primers	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Agarose	O
gel	O
electrophoresis	O
resolved	O
the	O
nested	O
PCR	O
products	O
into	O
three	O
bands	O
of	O
different	O
electrophoretic	O
mobility	O
with	O
a	O
dominant	O
middle	O
band	O
(	O
Figure	O
2	O
)	O
.	O

For	O
each	O
band	O
,	O
the	O
DNA	O
was	O
cloned	O
and	O
sequence	O
analysis	O
of	O
six	O
or	O
seven	O
individual	O
transformants	O
was	O
performed	O
.	O

We	O
observed	O
that	O
the	O
transcriptional	O
start	O
sites	O
of	O
the	O
A3G	S-PRGE
gene	O
were	O
located	O
between	O
58	O
and	O
361	O
nt	O
upstream	O
of	O
the	O
ATG	O
start	O
codon	O
(	O
Figure	O
1	O
)	O
.	O

Although	O
TSS	O
were	O
variable	O
and	O
most	O
sites	O
were	O
only	O
detected	O
once	O
among	O
the	O
19	O
clones	O
analyzed	O
,	O
one	O
TSS	O
was	O
identified	O
in	O
six	O
individual	O
clones	O
.	O

This	O
TSS	O
was	O
located	O
66	O
nt	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
A3G	S-PRGE
mRNA	O
sequence	O
(	O
GenBank	O
(	O
TM	O
)	O
accession	O
number	O
NM021822	O
)	O
and	O
we	O
defined	O
this	O
position	O
as	O
the	O
major	O
transcriptional	O
start	O
site	O
of	O
the	O
A3G	S-PRGE
gene	O
.	O

The	O
core	O
promoter	O
of	O
A3G	S-PRGE
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O

For	O
characterization	O
of	O
the	O
A3G	S-PRGE
promoter	O
,	O
we	O
cloned	O
the	O
1025	O
bp	O
located	O
at	O
position	O
-	O
959	O
/	O
+	O
66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
into	O
the	O
promoterless	O
pGL3	O
-	O
Basic	O
luciferase	S-PRGE
reporter	O
plasmid	O
and	O
designated	O
the	O
plasmid	O
pGL3	O
-	O
Basic	O
-	O
APOprom1025	O
.	O

Similarly	O
,	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436	O
/	O
+	O
66	O
)	O
,	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159	O
/	O
+	O
66	O
)	O
and	O
further	O
5	O
'	O
deletion	O
reporter	O
constructs	O
containing	O
180	O
,	O
150	O
,	O
120	O
or	O
60	O
bp	O
upstream	O
of	O
position	O
+	O
65	O
were	O
generated	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
order	O
to	O
analyze	O
transcriptional	O
activity	O
,	O
the	O
luciferase	S-PRGE
reporter	O
plasmids	O
were	O
transiently	O
transfected	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Luciferase	S-PRGE
assays	O
revealed	O
a	O
~	O
20	O
-	O
fold	O
increased	O
transcriptional	O
activity	O
of	O
the	O
1025	O
bp	O
sequence	O
as	O
compared	O
to	O
the	O
empty	O
vector	O
,	O
indicating	O
that	O
we	O
had	O
identified	O
an	O
active	O
A3G	S-PRGE
promoter	O
sequence	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
transcription	O
rate	O
was	O
not	O
significantly	O
altered	O
by	O
the	O
5	O
'	O
deletions	O
leading	O
to	O
the	O
502	O
,	O
225	O
and	O
180	O
bp	O
fragments	O
(	O
Figure	O
3B	O
)	O
.	O

In	O
contrast	O
,	O
a	O
drop	O
in	O
luciferase	S-PRGE
activity	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
150	O
bp	O
fragment	O
.	O

This	O
construct	O
only	O
retained	O
28	O
%	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
promoter	O
in	O
A3	O
.	O
01	O
T	O
cells	O
and	O
activity	O
of	O
the	O
120	O
bp	O
fragment	O
was	O
further	O
reduced	O
.	O

Comparable	O
reductions	O
relative	O
to	O
the	O
activity	O
of	O
180	O
bp	O
fragment	O
were	O
observed	O
in	O
the	O
myeloid	O
cell	O
line	O
U937	O
and	O
the	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
Figure	O
3C	O
)	O
,	O
indicating	O
that	O
the	O
core	O
promoter	O
of	O
A3G	S-PRGE
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

The	O
A3G	S-PRGE
promoter	O
is	O
not	O
inducible	O
in	O
T	O
cells	O

According	O
to	O
the	O
current	O
knowledge	O
,	O
APOBEC3G	S-PRGE
plays	O
a	O
role	O
in	O
the	O
innate	O
defence	O
against	O
pathogens	O
like	O
HIV	O
-	O
1	O
.	O

The	O
latter	O
has	O
evolved	O
a	O
mechanism	O
to	O
counteract	O
A3G	S-PRGE
activity	O
by	O
expressing	O
the	O
regulatory	O
protein	O
Vif	S-PRGE
(	O
4	O
)	O
.	O

Vif	S-PRGE
induces	O
proteasomal	O
degradation	O
of	O
A3G	S-PRGE
and	O
additionally	O
inhibits	O
A3G	S-PRGE
activity	O
by	O
further	O
mechanisms	O
(	O
8	O
,	O
37	O
-	O
43	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
overexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
also	O
influences	O
A3G	S-PRGE
promoter	O
activity	O
,	O
we	O
either	O
expressed	O
HIV	O
-	O
1	O
Vif	S-PRGE
or	O
the	O
HIV	O
-	O
1	O
Tat	S-PRGE
protein	O
,	O
the	O
latter	O
has	O
been	O
shown	O
to	O
activate	O
different	O
viral	O
and	O
cellular	O
promoters	O
(	O
44	O
,	O
45	O
)	O
.	O

In	O
addition	O
,	O
increasing	O
amounts	O
of	O
the	O
plasmid	O
pNL4	O
-	O
3	O
,	O
containing	O
the	O
full	O
-	O
length	O
genome	O
of	O
HIV	O
-	O
1	O
,	O
were	O
transfected	O
.	O

These	O
constructs	O
or	O
the	O
empty	O
vector	O
pcDNA3	O
.	O
1	O
were	O
cotransfected	O
with	O
the	O
1025	O
bp	O
construct	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Luciferase	S-PRGE
assays	O
showed	O
that	O
the	O
transcriptional	O
activity	O
of	O
the	O
A3G	S-PRGE
promoter	O
was	O
not	O
significantly	O
altered	O
in	O
the	O
presence	O
of	O
Vif	S-PRGE
,	O
Tat	S-PRGE
or	O
HIV	O
-	O
1NL4	O
-	O
3	O
(	O
Figure	O
4A	O
)	O
,	O
suggesting	O
that	O
HIV	O
-	O
1	O
is	O
not	O
modulating	O
A3G	S-PRGE
expression	O
on	O
the	O
transcriptional	O
level	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
amount	O
of	O
A3G	S-PRGE
mRNA	O
in	O
T	O
cells	O
is	O
increased	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phorbol	O
ester	O
(	O
46	O
-	O
48	O
)	O
.	O

In	O
addition	O
,	O
interferons	O
have	O
been	O
described	O
to	O
upregulate	O
A3G	S-PRGE
expression	O
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
,	O
48	O
)	O
.	O

To	O
investigate	O
whether	O
these	O
stimuli	O
interfere	O
with	O
A3G	S-PRGE
promoter	O
activity	O
in	O
T	O
cells	O
,	O
we	O
transfected	O
A3	O
.	O
01	O
T	O
cells	O
with	O
the	O
1025	O
bp	O
promoter	O
or	O
the	O
empty	O
vector	O
pGL3	O
-	O
Basic	O
(	O
vector	O
)	O
and	O
treated	O
the	O
cells	O
with	O
phorbol	O
ester	O
(	O
TPA	O
)	O
.	O

The	O
luciferase	S-PRGE
assay	O
showed	O
that	O
the	O
~	O
15	O
-	O
fold	O
increased	O
transcriptional	O
activity	O
of	O
the	O
1025	O
bp	O
promoter	O
relative	O
to	O
the	O
empty	O
vector	O
was	O
not	O
further	O
enhanced	O
by	O
TPA	O
treatment	O
(	O
Figure	O
4B	O
)	O
,	O
although	O
the	O
functional	O
activity	O
of	O
TPA	O
was	O
confirmed	O
by	O
induction	O
of	O
the	O
SV40	O
promoter	O
-	O
containing	O
reporter	O
plasmid	O
pGL3	O
-	O
Control	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similarly	O
,	O
treatment	O
of	O
A3	O
.	O
01	O
T	O
cells	O
transfected	O
with	O
the	O
A3G	S-PRGE
promoter	O
deletion	O
constructs	O
with	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
showed	O
no	O
effect	O
(	O
Figure	O
4C	O
)	O
.	O

Interestingly	O
,	O
a	O
control	O
plasmid	O
(	O
pGL2	O
-	O
CVX	O
)	O
containing	O
two	O
IFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
upstream	O
of	O
the	O
luciferase	S-PRGE
reporter	O
gene	O
was	O
only	O
induced	O
by	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
in	O
these	O
cells	O
(	O
Figure	O
4C	O
)	O
.	O

Since	O
two	O
reports	O
describe	O
A3G	S-PRGE
upregulation	O
by	O
interferons	O
in	O
hepatocytes	O
(	O
47	O
,	O
48	O
)	O
,	O
we	O
additionally	O
performed	O
the	O
experiment	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
.	O

In	O
line	O
with	O
these	O
publications	O
,	O
we	O
observed	O
an	O
induction	O
of	O
the	O
A3G	S-PRGE
promoter	O
by	O
approximately	O
2	O
-	O
fold	O
after	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
stimulation	O
(	O
Figure	O
4D	O
)	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
being	O
slightly	O
more	O
potent	O
.	O

For	O
both	O
interferon	O
types	O
,	O
induction	O
of	O
A3G	S-PRGE
promoter	O
activity	O
was	O
observed	O
for	O
all	O
deletion	O
constructs	O
except	O
for	O
the	O
60	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
responsible	O
region	O
is	O
located	O
within	O
the	O
60	O
nt	O
present	O
in	O
the	O
120	O
bp	O
,	O
but	O
not	O
in	O
the	O
60	O
bp	O
fragment	O
.	O

A	O
GC	O
-	O
box	O
located	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	S-PRGE
promoter	O
is	O
important	O
for	O
transcriptional	O
activity	O

The	O
reporter	O
studies	O
shown	O
in	O
Figure	O
3	O
had	O
demonstrated	O
a	O
drop	O
in	O
luciferase	S-PRGE
activity	O
after	O
deletion	O
of	O
the	O
30	O
nt	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

We	O
therefore	O
inspected	O
the	O
30	O
bp	O
sequence	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
and	O
identified	O
a	O
GC	O
-	O
box	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
(	O
see	O
Figure	O
1	O
)	O
.	O

The	O
sequence	O
TGGGCGGGAC	O
,	O
which	O
is	O
interrupted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
represents	O
a	O
variant	O
of	O
the	O
(	O
G	O
/	O
T	O
)	O
GGGCGG	O
(	O
G	O
/	O
A	O
)	O
(	O
G	O
/	O
A	O
)	O
(	O
C	O
/	O
T	O
)	O
consensus	O
motif	O
recognized	O
by	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
transcription	O
factors	O
.	O

To	O
analyze	O
whether	O
this	O
putative	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
site	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
,	O
we	O
introduced	O
two	O
point	O
mutations	O
which	O
changed	O
the	O
sequence	O
from	O
TGGGCGGGAC	O
to	O
TGTTCGGGAC	O
(	O
mutations	O
shown	O
in	O
bold	O
)	O
.	O

This	O
resulted	O
in	O
a	O
71	O
%	O
reduction	O
of	O
the	O
transcriptional	O
activity	O
compared	O
to	O
the	O
unmodified	O
180	O
bp	O
promoter	O
(	O
Figure	O
5A	O
)	O
and	O
this	O
value	O
was	O
only	O
marginally	O
higher	O
than	O
the	O
luciferase	S-PRGE
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
identified	O
motif	O
is	O
essential	O
for	O
basal	O
activity	O
of	O
the	O
A3G	S-PRGE
core	O
promoter	O
.	O

To	O
further	O
examine	O
the	O
transcriptional	O
potency	O
of	O
the	O
30	O
nt	O
present	O
in	O
the	O
180	O
bp	O
promoter	O
,	O
we	O
cloned	O
the	O
region	O
-	O
114	O
/	O
-	O
85	O
(	O
containing	O
all	O
nucleotides	O
which	O
are	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
designated	O
E1	O
)	O
or	O
the	O
region	O
-	O
92	O
/	O
-	O
63	O
(	O
containing	O
the	O
putative	O
Sp1	O
/	O
Sp3	O
motif	O
,	O
designated	O
E2	O
)	O
into	O
the	O
vector	O
pGL3	O
-	O
Promoter	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
vector	O
contains	O
a	O
luciferase	S-PRGE
reporter	O
gene	O
under	O
the	O
control	O
of	O
an	O
SV40	O
promoter	O
without	O
enhancer	O
sequences	O
,	O
and	O
putative	O
transcriptionally	O
active	O
sequences	O
can	O
be	O
cloned	O
upstream	O
of	O
the	O
SV40	O
promoter	O
.	O

Luciferase	S-PRGE
assays	O
showed	O
that	O
the	O
E1	O
element	O
increased	O
SV40	O
promoter	O
activity	O
only	O
by	O
~	O
2	O
-	O
fold	O
(	O
Figure	O
5B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
30	O
nt	O
of	O
E2	O
enhanced	O
the	O
transcriptional	O
activity	O
of	O
the	O
SV40	O
promoter	O
by	O
~	O
4	O
.	O
3	O
-	O
fold	O
,	O
indicating	O
that	O
the	O
intact	O
GC	O
-	O
box	O
present	O
in	O
the	O
E2	O
element	O
was	O
responsible	O
for	O
the	O
strongly	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
SV40	O
promoter	O
.	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
transcription	O
factors	O
bind	O
to	O
the	O
GC	O
-	O
box	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	S-PRGE
promoter	O

To	O
investigate	O
whether	O
the	O
GC	O
-	O
box	O
represents	O
a	O
binding	O
site	O
for	O
the	O
transcription	O
factors	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
,	O
we	O
performed	O
EMSA	O
analyses	O
with	O
nuclear	O
extracts	O
isolated	O
from	O
A3	O
.	O
01	O
T	O
cells	O
.	O

As	O
probes	O
,	O
we	O
radioactively	O
labeled	O
the	O
unmodified	O
E2	O
sequence	O
(	O
nucleotides	O
-	O
92	O
/	O
-	O
63	O
of	O
the	O
A3G	S-PRGE
promoter	O
,	O
probe	O
designated	O
APO	O
-	O
Sp1	O
/	O
3	O
)	O
or	O
the	O
same	O
region	O
carrying	O
the	O
two	O
point	O
mutations	O
described	O
above	O
(	O
probe	O
designated	O
APO	O
-	O
Sp1	O
/	O
3mut	O
)	O
.	O

As	O
control	O
,	O
we	O
used	O
a	O
commercially	O
available	O
Sp1	O
consensus	O
oligonucleotide	O
(	O
Sp1cons	O
)	O
,	O
which	O
is	O
known	O
to	O
be	O
recognized	O
by	O
Sp1	S-PRGE
transcription	O
factors	O
.	O

Four	O
DNA	O
-	O
protein	O
complexes	O
were	O
observed	O
in	O
the	O
presence	O
of	O
the	O
APO	O
-	O
Sp1	O
/	O
3	O
probe	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
upper	O
two	O
complexes	O
were	O
specific	O
since	O
they	O
disappeared	O
in	O
the	O
presence	O
of	O
a	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1	O
/	O
3	O
probe	O
(	O
Figure	O
6A	O
,	O
lane	O
7	O
)	O
.	O

Further	O
confirmation	O
of	O
the	O
specificity	O
of	O
these	O
DNA	O
-	O
protein	O
complexes	O
was	O
demonstrated	O
by	O
the	O
inability	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1	O
/	O
3mut	O
probe	O
to	O
abolish	O
binding	O
(	O
Figure	O
6A	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

As	O
expected	O
,	O
the	O
two	O
specific	O
complexes	O
were	O
also	O
present	O
in	O
the	O
case	O
of	O
the	O
Sp1cons	O
control	O
probe	O
(	O
Figure	O
6A	O
,	O
lanes	O
2	O
and	O
3	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
these	O
specific	O
complexes	O
was	O
observed	O
when	O
the	O
mutated	O
probe	O
was	O
used	O
(	O
Figure	O
6A	O
,	O
lanes	O
10	O
and	O
11	O
)	O
,	O
confirming	O
that	O
protein	O
binding	O
was	O
dependent	O
on	O
the	O
identified	O
GC	O
-	O
box	O
.	O

In	O
order	O
to	O
characterize	O
the	O
complexes	O
,	O
we	O
performed	O
supershift	O
experiments	O
using	O
Sp1	S-PRGE
-	O
and	O
Sp3	S-PRGE
-	O
specific	O
antibodies	O
.	O

The	O
upper	O
of	O
the	O
complexes	O
that	O
appeared	O
in	O
combination	O
with	O
the	O
Sp1cons	O
or	O
APO	O
-	O
Sp1	O
/	O
3	O
probes	O
,	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp1	S-PRGE
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
3	O
and	O
7	O
)	O
,	O
whereas	O
the	O
lower	O
complex	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp3	S-PRGE
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
4	O
and	O
8	O
)	O
.	O

Taken	O
together	O
,	O
the	O
EMSA	O
demonstrated	O
that	O
the	O
GC	O
-	O
box	O
located	O
on	O
the	O
A3G	S-PRGE
core	O
promoter	O
serves	O
as	O
a	O
binding	O
site	O
for	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
.	O

To	O
show	O
binding	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
factors	O
also	O
in	O
the	O
context	O
of	O
the	O
endogenous	O
A3G	S-PRGE
promoter	O
,	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
was	O
performed	O
.	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
antibodies	O
,	O
but	O
not	O
an	O
actin	S-PRGE
antibody	O
,	O
immunoprecipitated	O
the	O
A3G	S-PRGE
promoter	O
in	O
A3	O
.	O
01	O
T	O
cells	O
(	O
Figure	O
6C	O
,	O
upper	O
panel	O
)	O
.	O

In	O
contrast	O
,	O
no	O
PCR	O
signal	O
was	O
received	O
with	O
a	O
primer	O
pair	O
recognizing	O
a	O
region	O
in	O
the	O
A3G	S-PRGE
gene	O
~	O
4000	O
bp	O
downstream	O
of	O
the	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
site	O
(	O
Figure	O
6C	O
,	O
lower	O
panel	O
)	O
.	O

Only	O
the	O
positive	O
controls	O
showed	O
a	O
DNA	O
band	O
,	O
with	O
an	O
A3G	S-PRGE
expression	O
plasmid	O
or	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
input	O
DNA	O
used	O
as	O
template	O
.	O

This	O
demonstrates	O
the	O
binding	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
transcription	O
factors	O
to	O
the	O
endogenous	O
A3G	S-PRGE
promoter	O
.	O

Silencing	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
reduces	O
A3G	S-PRGE
promoter	O
activity	O

To	O
confirm	O
the	O
role	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
in	O
regulation	O
of	O
A3G	S-PRGE
promoter	O
activity	O
,	O
we	O
silenced	O
their	O
translation	O
via	O
RNA	O
interference	O
.	O

Functionality	O
of	O
the	O
siRNAs	O
directed	O
against	O
Sp1	S-PRGE
or	O
Sp3	S-PRGE
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
:	O
protein	O
levels	O
of	O
Sp1	S-PRGE
as	O
well	O
as	O
the	O
long	O
and	O
short	O
isoforms	O
of	O
Sp3	S-PRGE
were	O
strongly	O
reduced	O
in	O
the	O
presence	O
of	O
150	O
or	O
300	O
ng	O
specific	O
siRNA	O
(	O
Figure	O
7A	O
)	O
.	O

An	O
unspecific	O
control	O
siRNA	O
had	O
no	O
influence	O
(	O
Figure	O
7A	O
)	O
.	O

We	O
then	O
cotransfected	O
the	O
luciferase	B-PRGE
reporter	I-PRGE
plasmid	I-PRGE
containing	I-PRGE
the	I-PRGE
180	I-PRGE
bp	I-PRGE
A3G	I-PRGE
promoter	E-PRGE
together	O
with	O
100	O
ng	O
siRNA	O
using	O
an	O
optimized	O
protocol	O
for	O
the	O
cotransfection	O
of	O
plasmid	O
plus	O
siRNA	O
.	O

This	O
resulted	O
in	O
a	O
31	O
-	O
43	O
%	O
reduction	O
of	O
luciferase	O
activity	O
in	O
the	O
presence	O
of	O
Sp1	S-PRGE
-	O
or	O
Sp3	S-PRGE
-	O
specific	O
siRNA	O
compared	O
to	O
the	O
control	O
siRNA	O
.	O

In	O
contrast	O
,	O
no	O
influence	O
on	O
transcriptional	O
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
which	O
does	O
not	O
contain	O
the	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
motif	O
,	O
was	O
observed	O
.	O

Thus	O
,	O
both	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
factors	O
are	O
mediating	O
transcriptional	O
activity	O
of	O
the	O
A3G	S-PRGE
promoter	O
.	O

Shortly	O
after	O
the	O
discovery	O
of	O
APOBEC3G	S-PRGE
,	O
it	O
became	O
clear	O
that	O
this	O
human	O
gene	O
plays	O
an	O
important	O
role	O
in	O
antiretroviral	O
defense	O
(	O
4	O
)	O
.	O

Originally	O
identified	O
as	O
a	O
restriction	O
factor	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
expression	O
of	O
APOBEC3G	S-PRGE
was	O
found	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
,	O
which	O
represent	O
the	O
main	O
target	O
cells	O
for	O
HIV	O
-	O
1	O
(	O
32	O
)	O
.	O

In	O
addition	O
,	O
the	O
protein	O
was	O
detected	O
in	O
lung	O
,	O
liver	O
,	O
spleen	O
,	O
testis	O
and	O
ovary	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
transcriptional	O
regulation	O
(	O
29	O
,	O
32	O
,	O
47	O
)	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
cloned	O
the	O
human	O
APOBEC3G	S-PRGE
promoter	O
and	O
analyzed	O
its	O
regulation	O
in	O
T	O
cells	O
.	O

Applying	O
5	O
'	O
-	O
RACE	O
,	O
we	O
identified	O
multiple	O
start	O
sites	O
for	O
transcription	O
of	O
the	O
A3G	S-PRGE
gene	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
gene	O
appears	O
to	O
lack	O
canonical	O
CCAAT	O
and	O
TATA	O
boxes	O
(	O
32	O
)	O
,	O
a	O
condition	O
often	O
associated	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
49	O
-	O
51	O
)	O
.	O

However	O
,	O
one	O
single	O
start	O
site	O
was	O
detected	O
in	O
6	O
of	O
19	O
clones	O
and	O
was	O
designated	O
as	O
+	O
1	O
.	O

This	O
TSS	O
is	O
located	O
66	O
bp	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
mRNA	O
sequence	O
(	O
GenBank	O
(	O
TM	O
)	O
NM021822	O
)	O
.	O

We	O
cloned	O
a	O
1025	O
bp	O
promoter	O
,	O
which	O
ranges	O
from	O
position	O
-	O
959	O
/	O
+	O
66	O
relative	O
to	O
the	O
identified	O
TSS	O
.	O

Luciferase	S-PRGE
reporter	O
assays	O
showed	O
that	O
this	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Treatment	O
with	O
the	O
phorbol	O
ester	O
TPA	O
did	O
not	O
further	O
enhance	O
transcriptional	O
activity	O
,	O
although	O
upregulation	O
of	O
A3G	S-PRGE
mRNA	O
levels	O
in	O
T	O
cells	O
by	O
TPA	O
has	O
been	O
described	O
(	O
33	O
)	O
.	O

Rose	O
et	O
al	O
.	O
used	O
actinomycin	O
D	O
to	O
block	O
further	O
transcription	O
and	O
did	O
not	O
find	O
evidence	O
for	O
enhanced	O
mRNA	O
stability	O
.	O

Therefore	O
,	O
the	O
authors	O
suggested	O
that	O
an	O
enhanced	O
transcription	O
rate	O
could	O
be	O
responsible	O
for	O
the	O
increased	O
amount	O
of	O
A3G	S-PRGE
mRNA	O
after	O
TPA	O
treatment	O
.	O

However	O
,	O
the	O
promoter	O
analysis	O
we	O
performed	O
indicates	O
a	O
different	O
mechanism	O
that	O
is	O
independent	O
of	O
transcriptional	O
regulation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
A3G	S-PRGE
promoter	O
was	O
not	O
inducible	O
by	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
in	O
A3	O
.	O
01	O
T	O
cells	O
,	O
whereas	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
,	O
a	O
moderate	O
induction	O
was	O
measured	O
.	O

It	O
has	O
been	O
described	O
previously	O
that	O
A3G	S-PRGE
gene	O
expression	O
is	O
upregulated	O
by	O
interferons	O
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
-	O
48	O
,	O
52	O
)	O
.	O

In	O
this	O
context	O
,	O
two	O
interferon	O
-	O
responsive	O
elements	O
have	O
been	O
identified	O
at	O
the	O
positions	O
-	O
6	O
/	O
+	O
9	O
and	O
+	O
1	O
/	O
+	O
15	O
relative	O
to	O
the	O
TSS	O
(	O
48	O
)	O
.	O

Consistent	O
with	O
this	O
data	O
,	O
we	O
observed	O
an	O
interferon	O
induction	O
in	O
hepatocytes	O
for	O
the	O
fragments	O
ranging	O
between	O
1025	O
and	O
120	O
bp	O
length	O
.	O

The	O
activity	O
of	O
the	O
60	O
bp	O
fragment	O
that	O
does	O
not	O
contain	O
these	O
motifs	O
was	O
not	O
affected	O
.	O

Thus	O
,	O
the	O
induction	O
we	O
observed	O
was	O
most	O
likely	O
mediated	O
by	O
the	O
described	O
interferon	O
-	O
responsive	O
elements	O
.	O

However	O
,	O
according	O
to	O
our	O
results	O
,	O
these	O
motifs	O
can	O
enhance	O
transcription	O
in	O
hepatic	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

This	O
is	O
surprising	O
,	O
since	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
-	O
inducible	O
signaling	O
cascades	O
are	O
present	O
in	O
A3	O
.	O
01	O
T	O
cells	O
:	O
we	O
showed	O
that	O
the	O
control	O
plasmid	O
harboring	O
interferon	O
-	O
responsive	O
GAS	O
elements	O
was	O
markedly	O
induced	O
by	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
treatment	O
.	O

In	O
contrast	O
,	O
the	O
GAS	O
element	O
was	O
not	O
responsive	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
treatment	O
in	O
these	O
cells	O
,	O
suggesting	O
that	O
our	O
T	O
cell	O
line	O
was	O
not	O
able	O
to	O
mediate	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
-	O
induced	O
signals	O
.	O

So	O
far	O
,	O
enhanced	O
A3G	S-PRGE
promoter	O
activity	O
by	O
interferons	O
is	O
clearly	O
described	O
in	O
hepatocytes	O
and	O
macrophages	O
,	O
whereas	O
the	O
situation	O
in	O
T	O
cells	O
is	O
still	O
unclear	O
.	O

A	O
recent	O
study	O
found	O
no	O
influence	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
on	O
A3G	S-PRGE
expression	O
in	O
resting	O
primary	O
blood	O
lymphocytes	O
(	O
52	O
)	O
.	O

Another	O
publication	O
describes	O
an	O
enhanced	O
expression	O
of	O
A3G	S-PRGE
after	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
treatment	O
in	O
resting	O
primary	O
CD4	S-PRGE
T	O
cells	O
,	O
but	O
not	O
in	O
activated	O
T	O
cells	O
(	O
53	O
)	O
.	O

This	O
observation	O
is	O
not	O
contradictory	O
to	O
our	O
results	O
since	O
T	O
cell	O
lines	O
are	O
mitotically	O
active	O
and	O
therefore	O
rather	O
in	O
an	O
activated	O
than	O
in	O
a	O
resting	O
state	O
.	O

In	O
conclusion	O
,	O
the	O
current	O
data	O
suggests	O
that	O
regulation	O
of	O
the	O
A3G	S-PRGE
promoter	O
activity	O
by	O
interferons	O
is	O
dependent	O
on	O
the	O
cell	O
type	O
and	O
possibly	O
also	O
from	O
the	O
cellular	O
activation	O
status	O
.	O

We	O
additionally	O
analyzed	O
the	O
influence	O
of	O
HIV	O
-	O
1	O
proteins	O
on	O
A3G	S-PRGE
promoter	O
activity	O
.	O

The	O
HIV	O
-	O
1	O
Vif	S-PRGE
protein	O
is	O
neutralizing	O
the	O
antiviral	O
function	O
of	O
A3G	S-PRGE
by	O
a	O
multitude	O
of	O
ways	O
.	O

Targeting	O
the	O
A3G	S-PRGE
protein	O
for	O
proteasomal	O
degradation	O
is	O
considered	O
to	O
be	O
the	O
main	O
mode	O
of	O
action	O
(	O
37	O
-	O
41	O
)	O
,	O
but	O
it	O
becomes	O
more	O
and	O
more	O
clear	O
that	O
other	O
mechanisms	O
are	O
also	O
involved	O
.	O

There	O
is	O
evidence	O
that	O
Vif	S-PRGE
also	O
promotes	O
exclusion	O
of	O
A3G	S-PRGE
from	O
the	O
virus	O
particles	O
and	O
an	O
influence	O
on	O
the	O
A3G	S-PRGE
translation	O
process	O
is	O
discussed	O
(	O
8	O
,	O
42	O
,	O
43	O
)	O
.	O

The	O
question	O
whether	O
Vif	S-PRGE
alters	O
transcription	O
controlled	O
by	O
the	O
A3G	S-PRGE
promoter	O
has	O
not	O
been	O
analyzed	O
so	O
far	O
.	O

Our	O
analysis	O
indicates	O
that	O
transcription	O
from	O
the	O
A3G	S-PRGE
promoter	O
is	O
unaffected	O
by	O
Vif	S-PRGE
or	O
other	O
HIV	O
-	O
1	O
proteins	O
.	O

Taken	O
together	O
,	O
in	O
T	O
cell	O
lines	O
,	O
the	O
A3G	S-PRGE
promoter	O
appears	O
constitutively	O
active	O
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
,	O
we	O
showed	O
that	O
the	O
core	O
promoter	O
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

This	O
180	O
bp	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
the	O
lymphoid	O
,	O
myeloid	O
and	O
hepatic	O
cell	O
lines	O
we	O
tested	O
,	O
indicating	O
that	O
ubiquitous	O
transcription	O
factors	O
are	O
involved	O
in	O
regulation	O
of	O
A3G	S-PRGE
gene	O
transcription	O
.	O

A	O
GC	O
-	O
box	O
with	O
the	O
sequence	O
TGGGCGGGAC	O
was	O
identified	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	S-PRGE
promoter	O
.	O

This	O
GC	O
-	O
box	O
is	O
essential	O
for	O
basal	O
promoter	O
activity	O
,	O
since	O
changing	O
the	O
motif	O
to	O
TGTTCGGGAC	S-PRGE
by	O
introducing	O
two	O
point	O
mutations	O
strongly	O
reduced	O
A3G	S-PRGE
promoter	O
activity	O
.	O

The	O
transcriptional	O
potency	O
of	O
the	O
GC	O
-	O
box	O
was	O
further	O
demonstrated	O
by	O
cloning	O
it	O
upstream	O
of	O
an	O
SV40	O
promoter	O
.	O

This	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
enhanced	O
transcription	O
rate	O
.	O

The	O
hypothesis	O
that	O
a	O
general	O
transcription	O
factor	O
is	O
involved	O
in	O
regulation	O
of	O
A3G	S-PRGE
transcription	O
was	O
confirmed	O
by	O
EMSA	O
.	O

Supershift	O
analysis	O
showed	O
that	O
the	O
transcription	O
factors	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
which	O
are	O
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
,	O
bind	O
specifically	O
to	O
the	O
identified	O
motif	O
.	O

In	O
addition	O
,	O
the	O
binding	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
to	O
the	O
endogenous	O
A3G	S-PRGE
promoter	O
was	O
demonstrated	O
by	O
a	O
chromatin	O
immunoprecipitation	O
assay	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
the	O
5	O
'	O
-	O
RACE	O
,	O
since	O
Sp1	S-PRGE
is	O
known	O
to	O
play	O
an	O
important	O
role	O
for	O
RNA	B-PRGE
polymerase	I-PRGE
II	E-PRGE
to	O
bind	O
to	O
the	O
transcription	O
initiation	O
site	O
in	O
TATA	O
-	O
boxless	O
promoters	O
and	O
is	O
associated	O
with	O
multiple	O
transcription	O
initiation	O
sites	O
(	O
54	O
-	O
56	O
)	O
.	O

We	O
also	O
tested	O
whether	O
overexpression	O
of	O
Sp1	S-PRGE
or	O
Sp3	S-PRGE
proteins	O
had	O
an	O
influence	O
on	O
A3G	S-PRGE
promoter	O
activity	O
.	O

Luciferase	S-PRGE
assays	O
revealed	O
that	O
A3G	S-PRGE
promoter	O
activities	O
remained	O
unchanged	O
(	O
data	O
not	O
shown	O
)	O
,	O
most	O
probably	O
due	O
to	O
the	O
high	O
basal	O
expression	O
level	O
of	O
the	O
endogenous	O
Sp1	S-PRGE
and	O
/	O
or	O
Sp3	S-PRGE
proteins	O
.	O

The	O
Sp	O
family	O
of	O
transcription	O
factors	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
many	O
housekeeping	O
,	O
tissue	O
-	O
specific	O
,	O
viral	O
and	O
inducible	O
genes	O
(	O
57	O
)	O
.	O

Whereas	O
Sp1	S-PRGE
typically	O
acts	O
as	O
an	O
activator	O
,	O
Sp3	S-PRGE
can	O
serve	O
as	O
a	O
repressor	O
or	O
activator	O
(	O
57	O
)	O
.	O

However	O
,	O
in	O
the	O
context	O
of	O
the	O
A3G	S-PRGE
promoter	O
,	O
both	O
transcription	O
factors	O
serve	O
as	O
activators	O
,	O
as	O
shown	O
by	O
siRNA	O
-	O
mediated	O
silencing	O
of	O
the	O
single	O
factors	O
.	O

Although	O
siRNAs	O
directed	O
against	O
Sp1	S-PRGE
or	O
Sp3	S-PRGE
significantly	O
reduced	O
transcription	O
controlled	O
by	O
the	O
180	O
bp	O
promoter	O
,	O
transcriptional	O
activity	O
was	O
not	O
reduced	O
to	O
the	O
level	O
of	O
the	O
150	O
bp	O
fragment	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
remaining	O
low	O
amounts	O
of	O
Sp1	S-PRGE
/	O
Sp3	S-PRGE
proteins	O
which	O
can	O
be	O
seen	O
in	O
the	O
western	O
blot	O
analysis	O
.	O

Alternatively	O
,	O
other	O
transcription	O
factors	O
could	O
be	O
involved	O
in	O
A3G	S-PRGE
regulation	O
.	O

Our	O
results	O
also	O
provide	O
information	O
about	O
the	O
regulation	O
of	O
APOBEC3F	S-PRGE
(	O
A3F	S-PRGE
)	O
,	O
another	O
member	O
of	O
the	O
human	O
APOBEC3	O
family	O
.	O

A3F	S-PRGE
is	O
expressed	O
in	O
many	O
human	O
tissues	O
that	O
also	O
express	O
A3G	S-PRGE
and	O
both	O
proteins	O
have	O
been	O
shown	O
to	O
form	O
heteromultimers	O
,	O
which	O
are	O
most	O
likely	O
generated	O
through	O
binding	O
to	O
an	O
RNA	O
intermediate	O
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

A3F	S-PRGE
only	O
differs	O
in	O
16	O
nt	O
from	O
the	O
560	O
nt	O
upstream	O
of	O
the	O
TSS	O
of	O
A3G	S-PRGE
(	O
GenBank	O
(	O
TM	O
)	O
DQ146365	O
and	O
DQ147772	O
)	O
.	O

The	O
180	O
-	O
bp	O
core	O
promoter	O
region	O
,	O
which	O
we	O
identified	O
for	O
A3G	S-PRGE
has	O
100	O
%	O
identity	O
with	O
the	O
A3F	S-PRGE
sequence	O
.	O

Therefore	O
,	O
Sp1	S-PRGE
/	O
Sp3	S-PRGE
transcription	O
factors	O
are	O
most	O
likely	O
also	O
mediating	O
basal	O
transcription	O
of	O
the	O
A3F	S-PRGE
gene	O
.	O

Our	O
study	O
revealed	O
that	O
the	O
human	O
A3G	S-PRGE
gene	O
is	O
controlled	O
by	O
a	O
promoter	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
.	O

In	O
A3	O
.	O
01	O
T	O
cells	O
,	O
the	O
A3G	S-PRGE
promoter	O
appears	O
constitutively	O
active	O
and	O
is	O
not	O
inducible	O
by	O
TPA	O
,	O
type	O
I	O
or	O
II	O
interferons	O
or	O
by	O
HIV	O
-	O
1	O
proteins	O
.	O

The	O
core	O
promoter	O
is	O
located	O
within	O
a	O
region	O
of	O
180	O
bp	O
at	O
position	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

A	O
GC	O
-	O
box	O
is	O
crucial	O
to	O
the	O
function	O
of	O
the	O
core	O
promoter	O
and	O
represents	O
a	O
binding	O
site	O
for	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
transcription	O
factors	O
.	O

Our	O
results	O
can	O
serve	O
as	O
a	O
basis	O
for	O
future	O
studies	O
aimed	O
at	O
understanding	O
how	O
A3G	S-PRGE
and	O
A3F	S-PRGE
expression	O
is	O
controlled	O
in	O
different	O
tissues	O
and	O
how	O
these	O
restriction	O
factors	O
can	O
be	O
used	O
to	O
develop	O
novel	O
therapeutic	O
strategies	O
against	O
HIV	O
-	O
1	O
infection	O
.	O

Sequence	O
of	O
the	O
A3G	S-PRGE
promoter	O
and	O
the	O
downstream	O
region	O
.	O

The	O
first	O
1000	O
bp	O
upstream	O
of	O
the	O
major	O
TSS	O
are	O
shown	O
in	O
lower	O
case	O
,	O
the	O
first	O
800	O
bp	O
of	O
the	O
transcribed	O
sequence	O
are	O
shown	O
in	O
upper	O
case	O
.	O

Introns	O
are	O
removed	O
,	O
but	O
their	O
positions	O
are	O
indicated	O
.	O

Arrows	O
refer	O
to	O
transcriptional	B-PRGE
start	I-PRGE
sites	E-PRGE
and	O
their	O
observed	O
frequency	O
is	O
given	O
by	O
the	O
numbers	O
above	O
.	O

The	O
primer	O
binding	O
sites	O
for	O
5	O
'	O
-	O
RACE	O
analysis	O
and	O
cloning	O
of	O
the	O
luciferase	S-PRGE
reporter	O
constructs	O
are	O
underlined	O
and	O
the	O
names	O
of	O
the	O
primers	O
are	O
annotated	O
.	O

Gray	O
and	O
black	O
arrowheads	O
define	O
the	O
regions	O
designated	O
E1	O
and	O
E2	O
which	O
were	O
cloned	O
into	O
vector	O
pGL3	O
-	O
Promoter	O
and	O
used	O
as	O
EMSA	O
probes	O
.	O

The	O
ATG	O
start	O
codon	O
and	O
the	O
identified	O
Sp1	O
/	O
Sp3	O
transcription	O
factor	O
binding	O
site	O
are	O
shown	O
in	O
bold	O
.	O

5	O
'	O
-	O
RACE	O
analysis	O
of	O
the	O
A3G	S-PRGE
cDNA	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
size	O
marker	O
and	O
A3G	S-PRGE
5	O
'	O
-	O
RACE	O
products	O
after	O
nested	O
PCR	O
with	O
primer	O
RACE	O
-	O
APO3Gnest	O
(	O
see	O
Figure	O
1	O
for	O
primer	O
details	O
)	O
.	O

Arrowheads	O
indicate	O
the	O
three	O
resulting	O
DNA	O
bands	O
which	O
were	O
cloned	O
and	O
sequenced	O
.	O

Luciferase	S-PRGE
activities	O
of	O
A3G	S-PRGE
promoter	O
constructs	O
in	O
different	O
cell	O
lines	O
.	O

(	O
A	O
)	O
A3G	S-PRGE
promoter	O
5	O
'	O
deletion	O
constructs	O
of	O
different	O
sizes	O
were	O
cloned	O
into	O
pGL3	O
-	O
Basic	O
luciferase	S-PRGE
reporter	O
plasmids	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
TSS	O
.	O

A	O
putative	O
Sp1	O
/	O
Sp3	O
consensus	O
site	O
(	O
gray	O
square	O
)	O
is	O
depicted	O
.	O

(	O
B	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	S-PRGE
promoter	O
deletion	O
constructs	O
.	O

Numbers	O
on	O
the	O
x	O
-	O
axis	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	S-PRGE
promoter	O
fragments	O
in	O
bp	O
.	O

(	O
C	O
)	O
A3G	S-PRGE
promoter	O
plasmids	O
were	O
transfected	O
into	O
U937	O
,	O
HepG2	O
and	O
Huh7	O
cell	O
lines	O
.	O

Numbers	O
in	O
the	O
legends	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	S-PRGE
promoter	O
fragments	O
in	O
bp	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	S-PRGE
assay	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A3G	S-PRGE
promoter	O
activities	O
after	O
coexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
or	O
treatment	O
with	O
TPA	O
or	O
interferons	O
.	O

(	O
A	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
cotransfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	S-PRGE
promoter	O
and	O
1	O
microg	O
of	O
Vif	S-PRGE
expression	O
plasmid	O
,	O
1	O
microg	O
Tat	S-PRGE
expression	O
plasmid	O
or	O
increasing	O
amounts	O
of	O
HIV	O
-	O
1NL4	O
-	O
3	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
microg	O
)	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	S-PRGE
assay	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

(	O
B	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	S-PRGE
promoter	O
or	O
with	O
empty	O
vector	O
.	O

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	S-PRGE
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
20	O
ng	O
/	O
ml	O
TPA	O
.	O

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	S-PRGE
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
and	O
the	O
values	O
for	O
the	O
empty	O
vectors	O
(	O
untreated	O
and	O
TPA	O
-	O
stimulated	O
)	O
were	O
set	O
as	O
1	O
.	O

(	O
C	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	S-PRGE
promoter	O
constructs	O
or	O
with	O
the	O
interferon	S-PRGE
-	O
responsive	O
reporter	O
plasmid	O
pGL2	O
-	O
CVX	O
(	O
GAS	O
)	O
.	O

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	S-PRGE
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
30	O
ng	O
/	O
ml	O
IFN	B-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
.	O

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	S-PRGE
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

(	O
D	O
)	O
HepG2	O
cells	O
were	O
used	O
for	O
transfection	O
.	O

The	O
experiment	O
was	O
performed	O
as	O
described	O
in	O
(	O
C	O
)	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
representative	O
experiments	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A	O
GC	O
-	O
box	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

(	O
A	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
,	O
150	O
or	O
120	O
bp	O
of	O
the	O
A3G	S-PRGE
promoter	O
.	O

The	O
two	O
G	O
-	O
to	O
-	O
T	O
substitutions	O
introduced	O
into	O
the	O
GC	O
-	O
box	O
of	O
the	O
180	O
bp	O
fragment	O
(	O
180mut	O
)	O
are	O
specified	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	S-PRGE
assay	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

(	O
B	O
)	O
pGL3	O
-	O
Promoter	O
reporter	O
plasmids	O
containing	O
the	O
regions	O
E1	O
or	O
E2	O
(	O
see	O
Figure	O
1	O
)	O
upstream	O
of	O
the	O
SV40	O
promoter	O
were	O
transfected	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Sp1	S-PRGE
and	O
Sp3	S-PRGE
bind	O
to	O
the	O
GC	O
-	O
box	O
present	O
in	O
the	O
A3G	S-PRGE
promoter	O
.	O

(	O
A	O
)	O
Nuclear	O
extracts	O
of	O
A3	O
.	O
01	O
T	O
cells	O
were	O
incubated	O
with	O
a	O
32P	O
-	O
labeled	O
commercial	O
Sp1	S-PRGE
oligonucleotide	O
probe	O
(	O
Sp1cons	O
)	O
or	O
labeled	O
probes	O
homologous	O
to	O
the	O
unmodified	O
or	O
mutated	O
E2	O
region	O
(	O
see	O
Figure	O
1	O
)	O
of	O
the	O
A3G	S-PRGE
promoter	O
(	O
APO	O
-	O
Sp1	S-PRGE
/	O
3	S-PRGE
and	O
APO	O
-	O
Sp1	S-PRGE
/	O
3mut	S-PRGE
)	O
.	O

Protein	O
-	O
DNA	O
complexes	O
were	O
separated	O
by	O
polyacrylamide	O
electrophoresis	O
and	O
detected	O
by	O
autoradiography	O
.	O

EMSA	O
was	O
performed	O
with	O
a	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1	S-PRGE
/	O
3	S-PRGE
probe	O
(	O
competitor	O
,	O
lanes	O
6	O
and	O
7	O
)	O
or	O
APO	O
-	O
Sp1	S-PRGE
/	O
3mut	S-PRGE
probe	O
(	O
competitor	O
mut	O
.	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

(	O
B	O
)	O
Sp1	S-PRGE
-	O
and	O
Sp3	S-PRGE
-	O
specific	O
antibodies	O
were	O
added	O
to	O
the	O
EMSA	O
reactions	O
resulting	O
in	O
a	O
supershift	O
(	O
ss	O
)	O
of	O
the	O
respective	O
antibody	O
-	O
protein	O
-	O
oligo	O
complexes	O
(	O
lanes	O
3	O
,	O
4	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
12	O
)	O
.	O

(	O
C	O
)	O
ChIP	O
assay	O
was	O
performed	O
with	O
DNA	O
from	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Immunoprecipitation	O
was	O
performed	O
with	O
antibodies	O
against	O
Sp1	S-PRGE
,	O
Sp3	S-PRGE
or	O
actin	S-PRGE
.	O

PCR	O
primer	O
pairs	O
specific	O
for	O
the	O
A3G	S-PRGE
promoter	O
(	O
upper	O
panel	O
)	O
or	O
the	O
A3G	S-PRGE
gene	O
(	O
lower	O
panel	O
)	O
were	O
used	O
.	O

As	O
positive	O
controls	O
,	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
DNA	O
before	O
the	O
immunoprecipitation	O
step	O
(	O
input	O
)	O
or	O
a	O
plasmid	O
carrying	O
the	O
target	O
sequence	O
(	O
plasmid	O
)	O
was	O
used	O
as	O
template	O
.	O

Silencing	O
of	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
reduces	O
A3G	S-PRGE
promoter	O
activity	O
.	O

(	O
A	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
and	O
300	O
ng	O
of	O
unspecific	O
,	O
Sp1	S-PRGE
-	O
specific	O
or	O
Sp3	S-PRGE
-	O
specific	O
siRNA	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
and	O
Sp1	S-PRGE
and	O
Sp3	S-PRGE
proteins	O
were	O
detected	O
by	O
western	O
blot	O
analysis	O
.	O

As	O
loading	O
control	O
,	O
protein	O
levels	O
of	O
tubulin	S-PRGE
are	O
shown	O
.	O

(	O
B	O
)	O
HeLa	O
cells	O
were	O
cotransfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
or	O
150	O
bp	O
of	O
the	O
A3G	S-PRGE
promoter	O
and	O
siRNA	O
.	O

Hundred	O
nanogram	O
of	O
unspecific	O
siRNA	O
(	O
control	O
)	O
,	O
Sp1	S-PRGE
-	O
specific	O
siRNA	O
(	O
Sp1	S-PRGE
)	O
,	O
Sp3	S-PRGE
-	O
specific	O
siRNA	O
(	O
Sp3	S-PRGE
)	O
or	O
a	O
mixture	O
of	O
50	O
ng	O
Sp1	S-PRGE
-	O
specific	O
plus	O
50	O
ng	O
Sp3	S-PRGE
-	O
specific	O
siRNA	O
(	O
Sp1	S-PRGE
+	O
Sp3	S-PRGE
)	O
were	O
used	O
.	O

Firefly	O
luciferase	S-PRGE
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	S-PRGE
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Protein	O
kinase	O
D	O
enzymes	O
are	O
dispensable	O
for	O
proliferation	O
,	O
survival	O
and	O
antigen	O
receptor	O
-	O
regulated	O
NFkappaB	O
activity	O
in	O
vertebrate	O
B	O
-	O
cells	O

To	O
investigate	O
the	O
importance	O
of	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
enzymes	O
we	O
generated	O
a	O
PKD	O
-	O
null	O
DT40	O
B	O
-	O
lymphocyte	O
cell	O
line	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
PKDs	O
have	O
an	O
essential	O
role	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
in	O
DT40	O
B	O
-	O
cells	O
[	O
Matthews	O
,	O
S	O
.	O
A	O
.	O
,	O
Liu	O
,	O
P	O
.	O
,	O
Spitaler	O
,	O
M	O
.	O
,	O
Olson	O
,	O
E	O
.	O
N	O
.	O
,	O
McKinsey	O
,	O
T	O
.	O
A	O
.	O
,	O
Cantrell	O
,	O
D	O
.	O
A	O
.	O
and	O
Scharenberg	O
,	O
A	O
.	O
M	O
.	O
(	O
2006	O
)	O
Essential	O
role	O
for	O
protein	O
kinase	O
D	O
family	O
kinases	O
in	O
the	O
regulation	O
of	O
class	O
II	O
histone	O
deacetylases	O
in	O
B	O
lymphocytes	O
.	O
Mol	O
.	O
Cell	O
Biol	O
.	O
26	O
,	O
1569	O
-	O
1577	O
]	O
.	O

We	O
now	O
show	O
that	O
PKDs	O
are	O
also	O
required	O
to	O
regulate	O
HSP27	S-PRGE
phosphorylation	O
in	O
DT40	O
B	O
-	O
cells	O
.	O

However	O
,	O
in	O
contrast	O
to	O
previous	O
observations	O
in	O
other	O
cell	O
types	O
,	O
PKD	O
enzymes	O
do	O
not	O
regulate	O
basic	O
cellular	O
processes	O
such	O
as	O
proliferation	O
or	O
survival	O
responses	O
,	O
nor	O
NFkappaB	O
transcriptional	O
activity	O
downstream	O
of	O
the	O
B	O
cell	O
antigen	O
receptor	O
.	O

Thus	O
,	O
PKDs	O
have	O
a	O
selective	O
role	O
in	O
DT40	O
B	O
-	O
cell	O
biology	O
.	O

1The	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
serine	O
/	O
threonine	O
kinase	O
family	O
has	O
three	O
members	O
:	O
PKD1	S-PRGE
,	O
PKD2	S-PRGE
and	O
PKD3	S-PRGE
.	O

Most	O
cell	O
types	O
express	O
at	O
least	O
two	O
PKD	O
isoforms	O
but	O
PKD	O
enzymes	O
are	O
especially	O
highly	O
expressed	O
in	O
haematopoietic	O
cells	O
,	O
where	O
they	O
are	O
activated	O
in	O
response	O
to	O
antigen	O
receptors	O
stimulation	O
[	O
2	O
,	O
3	O
]	O
.	O

A	O
conserved	O
signalling	O
pathway	O
linking	O
antigen	O
receptors	O
to	O
PKDs	O
involves	O
the	O
activation	O
of	O
PLCgamma	O
and	O
the	O
subsequent	O
production	O
of	O
diacylglycerol	O
(	O
DAG	O
)	O
which	O
stimulates	O
classical	O
and	O
/	O
or	O
novel	O
protein	O
kinase	O
Cs	O
(	O
PKC	O
)	O
that	O
phosphorylate	O
two	O
key	O
regulatory	O
serine	O
residues	O
in	O
the	O
activation	O
loop	O
of	O
PKD	O
kinases	O
[	O
3	O
-	O
6	O
]	O
.	O

The	O
N	O
-	O
terminal	O
regulatory	O
region	O
of	O
PKD	O
enzymes	O
contains	O
a	O
DAG	O
binding	O
domain	O
and	O
direct	O
binding	O
of	O
DAG	O
also	O
contributes	O
to	O
PKD1	S-PRGE
activation	O
[	O
7	O
]	O
as	O
well	O
as	O
regulating	O
the	O
spatial	O
location	O
of	O
PKD	O
enzymes	O
within	O
cells	O
[	O
8	O
-	O
12	O
]	O
.	O

PKD	O
enzymes	O
have	O
been	O
proposed	O
to	O
regulate	O
numerous	O
cellular	O
functions	O
,	O
including	O
cell	O
proliferation	O
[	O
13	O
-	O
16	O
]	O
,	O
anti	O
-	O
apoptotic	O
signals	O
[	O
17	O
,	O
18	O
]	O
and	O
thymocyte	O
development	O
[	O
19	O
]	O
.	O

Expression	O
of	O
mutant	O
catalytically	O
inactive	O
and	O
constitutively	O
activated	O
PKDs	O
can	O
also	O
modify	O
Golgi	O
function	O
,	O
cell	O
adhesion	O
and	O
cell	O
motility	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

In	O
particular	O
,	O
PKDs	O
have	O
been	O
widely	O
linked	O
to	O
the	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
and	O
in	O
regulating	O
cell	O
survival	O
during	O
oxidative	O
stress	O
[	O
17	O
,	O
21	O
-	O
23	O
]	O
.	O

Another	O
recently	O
proposed	O
PKD1	S-PRGE
substrate	O
is	O
HSP27	S-PRGE
[	O
24	O
]	O
,	O
a	O
small	O
heat	O
shock	O
protein	O
involved	O
in	O
regulating	O
cell	O
migration	O
and	O
cell	O
survival	O
[	O
25	O
]	O
.	O

An	O
essential	O
role	O
for	O
PKD	O
enzymes	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
,	O
enzymes	O
that	O
repress	O
MEF2	S-PRGE
-	O
dependent	O
gene	O
transcription	O
,	O
has	O
also	O
been	O
demonstrated	O
[	O
1	O
,	O
26	O
-	O
28	O
]	O
.	O

To	O
investigate	O
the	O
biological	O
role	O
of	O
PKDs	O
we	O
have	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	O
expression	O
of	O
one	O
or	O
more	O
members	O
of	O
the	O
PKD	O
family	O
[	O
1	O
]	O
,	O
allowing	O
us	O
to	O
investigate	O
the	O
function	O
(	O
s	O
)	O
of	O
PKD	O
isoforms	O
following	O
B	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
stimulation	O
,	O
as	O
well	O
addressing	O
the	O
issue	O
of	O
functional	O
redundancy	O
between	O
the	O
different	O
PKD	O
family	O
members	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PKDs	O
are	O
indispensable	O
for	O
HDAC	O
regulation	O
in	O
B	O
cells	O
[	O
1	O
]	O
.	O

Herein	O
we	O
show	O
that	O
PKDs	O
are	O
also	O
indispensable	O
for	O
HSP27	S-PRGE
phosphorylation	O
in	O
B	O
cells	O
.	O

However	O
,	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O
are	O
viable	O
and	O
proliferate	O
normally	O
.	O

Moreover	O
,	O
loss	O
of	O
the	O
entire	O
cellular	O
pool	O
of	O
PKD	O
does	O
not	O
critically	O
affect	O
oxidative	O
stress	O
responses	O
in	O
B	O
cells	O
nor	O
do	O
PKD	O
kinases	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
NFkappaB	O
transcriptional	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
that	O
in	O
B	O
lymphocytes	O
,	O
PKD	O
kinases	O
are	O
not	O
critical	O
regulators	O
of	O
many	O
of	O
the	O
cellular	O
processes	O
previously	O
ascribed	O
to	O
them	O
in	O
other	O
cellular	O
systems	O
.	O

2	O
.	O
1Cell	O
culture	O
,	O
transient	O
transfections	O
and	O
cell	O
stimulation	O

The	O
generation	O
,	O
culture	O
and	O
activation	O
of	O
PKD1	S-PRGE
-	O
/	O
-	O
,	O
PKD3	S-PRGE
-	O
/	O
-	O
and	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
knockout	O
DT40	O
B	O
cell	O
lines	O
have	O
been	O
described	O
previously	O
[	O
1	O
]	O
.	O

Cells	O
were	O
lysed	O
and	O
protein	O
extracts	O
were	O
analysed	O
in	O
Western	O
blotting	O
experiments	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
assays	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O

2	O
.	O
2sIgM	O
staining	O

DT40	O
B	O
cells	O
(	O
2	O
x	O
106	O
cells	O
per	O
point	O
)	O
were	O
resuspended	O
in	O
200	O
mul	O
buffer	O
(	O
RPMI	O
1640	O
media	O
,	O
1	O
%	O
foetal	O
calf	O
serum	O
)	O
containing	O
anti	O
-	O
chicken	O
M1	O
monoclonal	O
antibody	O
conjugated	O
to	O
FITC	O
for	O
20	O
min	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
and	O
fluorescent	O
intensity	O
was	O
analysed	O
by	O
flow	O
cytometry	O
.	O

All	O
results	O
shown	O
are	O
representative	O
of	O
at	O
two	O
to	O
four	O
independent	O
experiments	O
unless	O
otherwise	O
indicated	O
.	O

3	O
.	O
1Loss	O
of	O
HSP27	S-PRGE
phosphorylation	O
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

DT40	O
B	O
cells	O
express	O
two	O
PKD	O
isoforms	O
,	O
PKD1	S-PRGE
and	O
PKD3	S-PRGE
,	O
and	O
as	O
previously	O
described	O
we	O
have	O
recently	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	O
expression	O
of	O
either	O
PKD1	S-PRGE
or	O
PKD3	S-PRGE
or	O
both	O
enzymes	O
[	O
1	O
]	O
.	O

In	O
generating	O
the	O
double	O
knockout	O
cell	O
lines	O
we	O
targeted	O
the	O
PKD1	S-PRGE
loci	O
in	O
a	O
PKD3	S-PRGE
-	O
/	O
-	O
cell	O
line	O
that	O
expressed	O
a	O
Flag	O
-	O
PKD3	S-PRGE
transgene	O
under	O
the	O
control	O
of	O
a	O
doxycycline	O
-	O
inducible	O
promoter	O
.	O

Hence	O
,	O
in	O
the	O
presence	O
of	O
doxycycline	O
,	O
Flag	O
-	O
PKD3	S-PRGE
expression	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
double	O
knockout	O
cells	O
is	O
comparable	O
to	O
endogenous	O
PKD3	S-PRGE
present	O
in	O
wild	O
-	O
type	O
DT40	O
cells	O
and	O
removal	O
of	O
doxycycline	O
from	O
the	O
culture	O
media	O
for	O
5	O
days	O
results	O
in	O
a	O
completely	O
null	O
PKD	O
phenotype	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
phosphorylation	O
and	O
nuclear	O
exclusion	O
of	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
during	O
BCR	O
engagement	O
is	O
defective	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
B	O
cells	O
and	O
can	O
restored	O
upon	O
re	O
-	O
expression	O
of	O
a	O
single	O
PKD	O
isoform	O
[	O
1	O
]	O
.	O

The	O
small	O
heat	O
shock	O
protein	O
HSP27	S-PRGE
has	O
recently	O
been	O
proposed	O
as	O
a	O
PKD1	S-PRGE
substrate	O
[	O
24	O
]	O
and	O
we	O
accordingly	O
assessed	O
whether	O
PKD	O
-	O
null	O
DT40	O
cells	O
have	O
defective	O
phosphorylation	O
of	O
HSP27	S-PRGE
on	O
serine	O
82	O
,	O
the	O
proposed	O
PKD1	S-PRGE
substrate	O
sequence	O
.	O

We	O
initially	O
investigated	O
the	O
regulation	O
of	O
HSP27	S-PRGE
phosphorylation	O
in	O
single	O
knockout	O
DT40	O
B	O
cells	O
lacking	O
either	O
PKD1	S-PRGE
or	O
PKD3	S-PRGE
.	O

As	O
shown	O
in	O
Fig	O
.	O

1B	O
,	O
activation	O
of	O
the	O
BCR	O
or	O
treatment	O
with	O
the	O
DAG	O
-	O
mimetic	O
PdBu	O
increased	O
the	O
levels	O
of	O
HSP27	S-PRGE
phosphorylation	O
at	O
S82	O
in	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
.	O

BCR	O
and	O
phorbol	O
ester	O
signals	O
were	O
also	O
able	O
to	O
increase	O
HSP27	S-PRGE
phosphorylation	O
in	O
PKD1	S-PRGE
or	O
PKD3	S-PRGE
single	O
knockout	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

However	O
,	O
BCR	O
-	O
and	O
phorbol	O
ester	O
-	O
induced	O
phosphorylation	O
of	O
HSP27	S-PRGE
on	O
S82	O
was	O
abolished	O
in	O
B	O
cells	O
that	O
lacked	O
both	O
PKD1	S-PRGE
and	O
PKD3	S-PRGE
(	O
Fig	O
.	O
1C	O
)	O
.	O

Significantly	O
,	O
doxycycline	O
-	O
induced	O
expression	O
of	O
the	O
Flag	O
-	O
PKD3	S-PRGE
transgene	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
sufficient	O
to	O
restore	O
normal	O
regulation	O
of	O
HSP27	S-PRGE
phosphorylation	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
a	O
kinase	O
-	O
deficient	O
PKD3	S-PRGE
mutant	O
protein	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
not	O
able	O
to	O
restore	O
BCR	O
-	O
or	O
phorbol	O
ester	O
-	O
induced	O
HSP27	S-PRGE
phosphorylation	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

Hence	O
,	O
PKD3	S-PRGE
as	O
well	O
as	O
PKD1	S-PRGE
can	O
regulate	O
HSP27	S-PRGE
phosphorylation	O
and	O
in	O
DT40	O
B	O
cells	O
they	O
are	O
functionally	O
redundant	O
as	O
HSP27	S-PRGE
kinases	O
.	O

3	O
.	O
2Cellular	O
proliferation	O
and	O
survival	O
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
survival	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

To	O
investigate	O
the	O
effect	O
that	O
loss	O
of	O
PKD	O
kinases	O
had	O
on	O
B	O
cell	O
survival	O
and	O
/	O
or	O
proliferation	O
we	O
cultured	O
wild	O
-	O
type	O
and	O
PKD	O
-	O
null	O
cells	O
in	O
the	O
presence	O
(	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
:	O
Flag	O
-	O
PKD3	S-PRGE
+	O
ve	O
)	O
or	O
absence	O
(	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
)	O
of	O
doxycycline	O
and	O
monitored	O
exponential	O
growth	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2A	O
,	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
cells	O
proliferated	O
exponentially	O
and	O
re	O
-	O
expression	O
of	O
Flag	O
-	O
PKD3	S-PRGE
in	O
these	O
cells	O
had	O
no	O
impact	O
on	O
the	O
rate	O
of	O
proliferation	O
.	O

Furthermore	O
,	O
the	O
viability	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
B	O
cells	O
during	O
routine	O
culturing	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
was	O
noted	O
that	O
the	O
population	O
doubling	O
time	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
cells	O
was	O
slightly	O
slower	O
than	O
that	O
of	O
wild	O
type	O
DT40	O
cells	O
(	O
12	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
8	O
h	O
versus	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
h	O
)	O
but	O
the	O
failure	O
of	O
PKD3	S-PRGE
re	O
-	O
expression	O
to	O
modify	O
the	O
proliferation	O
rate	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
cells	O
suggests	O
that	O
these	O
small	O
differences	O
were	O
most	O
likely	O
the	O
result	O
of	O
clonal	O
variation	O
and	O
were	O
not	O
caused	O
specifically	O
by	O
loss	O
of	O
PKD	O
enzymes	O
.	O

Thus	O
,	O
PKD	O
family	O
enzymes	O
are	O
not	O
essential	O
for	O
regulating	O
basal	O
survival	O
and	O
proliferation	O
of	O
DT40	O
B	O
cells	O
.	O

PKD	O
enzymes	O
,	O
specifically	O
PKD1	S-PRGE
and	O
PKD2	S-PRGE
,	O
have	O
previously	O
been	O
linked	O
to	O
a	O
protective	O
role	O
against	O
oxidative	O
stress	O
-	O
induced	O
injury	O
in	O
3T3	O
fibroblast	O
,	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
[	O
17	O
,	O
30	O
-	O
32	O
]	O
.	O

We	O
therefore	O
addressed	O
the	O
role	O
of	O
PKD	O
family	O
kinases	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
other	O
stress	O
stimuli	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2B	O
,	O
loss	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
expression	O
had	O
no	O
significant	O
impact	O
on	O
the	O
survival	O
of	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
mitochondrial	O
stress	O
stimuli	O
(	O
H2O2	O
or	O
serum	O
deprivation	O
)	O
;	O
DNA	O
damaging	O
agents	O
(	O
etoposide	O
or	O
doxorubicin	O
)	O
;	O
ER	O
pathway	O
stress	O
due	O
to	O
calcium	O
overload	O
(	O
thapsigargin	O
)	O
or	O
following	O
prolonged	O
treatment	O
with	O
phorbol	O
esters	O
or	O
Trichostatin	O
A	O
,	O
an	O
inhibitor	O
of	O
class	O
I	O
/	O
II	O
HDACs	O
.	O

Thus	O
,	O
PKD	O
kinases	O
do	O
not	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
a	O
range	O
of	O
different	O
stress	O
stimuli	O
.	O

3	O
.	O
3Antigen	O
receptor	O
regulated	O
signalling	O
pathways	O
in	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O

To	O
further	O
explore	O
the	O
contribution	O
of	O
PKD	O
kinases	O
to	O
DT40	O
B	O
cell	O
biology	O
we	O
investigated	O
whether	O
specific	O
BCR	O
-	O
regulated	O
signalling	O
events	O
were	O
defective	O
in	O
the	O
PKD	O
-	O
null	O
B	O
cells	O
.	O

Initial	O
experiments	O
revealed	O
that	O
surface	O
expression	O
of	O
the	O
BCR	O
was	O
reduced	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
(	O
and	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
:	O
Flag	O
-	O
PKD3	S-PRGE
+	O
ve	O
)	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
3A	O
and	O
data	O
not	O
shown	O
)	O
.	O

Nevertheless	O
,	O
BCR	O
-	O
crosslinking	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
cells	O
was	O
sufficient	O
to	O
induce	O
the	O
activation	O
of	O
a	O
number	O
of	O
signalling	O
cascades	O
,	O
similar	O
to	O
that	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Hence	O
,	O
BCR	O
-	O
induced	O
activation	O
of	O
the	O
Akt	S-PRGE
,	O
mTOR	S-PRGE
/	O
p70	O
S6	O
kinase	O
(	O
as	O
shown	O
by	O
S6	B-PRGE
ribosomal	I-PRGE
protein	E-PRGE
phosphorylation	O
)	O
and	O
MAPK	O
signalling	O
pathways	O
was	O
clearly	O
detectable	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
null	O
B	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Furthermore	O
,	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
cellular	O
proteins	O
as	O
well	O
as	O
an	O
increase	O
in	O
intracellular	O
calcium	O
levels	O
was	O
also	O
observed	O
following	O
BCR	O
stimulation	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
null	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
did	O
observe	O
that	O
the	O
strength	O
of	O
BCR	O
(	O
but	O
not	O
phorbol	O
ester	O
)	O
-	O
induced	O
regulation	O
of	O
the	O
Erk1	S-PRGE
-	O
RSK1	S-PRGE
signalling	O
pathway	O
was	O
reduced	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
B	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
B	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

One	O
interpretation	O
of	O
this	O
data	O
is	O
that	O
PKD	O
enzymes	O
may	O
modulate	O
Erk	O
activation	O
.	O

Indeed	O
,	O
PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
growth	O
factor	O
-	O
regulated	O
Erk	O
signalling	O
in	O
fibroblast	O
and	O
endothelial	O
cell	O
lines	O
[	O
33	O
-	O
35	O
]	O
.	O

However	O
,	O
BCR	O
-	O
induced	O
Erk	O
phosphorylation	O
was	O
also	O
reduced	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3	S-PRGE
+	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
suggesting	O
that	O
reduced	O
BCR	O
levels	O
on	O
the	O
surface	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
(	O
and	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3	S-PRGE
+	O
)	O
B	O
cells	O
may	O
itself	O
impact	O
on	O
the	O
strength	O
of	O
activation	O
of	O
this	O
specific	O
intracellular	O
signalling	O
pathway	O
.	O

To	O
search	O
for	O
other	O
potential	O
PKD	O
targets	O
that	O
may	O
show	O
defective	O
regulation	O
in	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
DT40	O
B	O
cells	O
,	O
we	O
used	O
a	O
PKD	O
substrate	O
phospho	O
-	O
antibody	O
that	O
recognises	O
consensus	O
phosphorylation	O
sequences	O
targeted	O
by	O
PKD	O
enzymes	O
(	O
LxRxxpS	O
/	O
T	O
)	O
[	O
36	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3C	O
,	O
phorbol	O
ester	O
-	O
and	O
BCR	O
-	O
induced	O
phosphorylation	O
of	O
cellular	O
substrates	O
detected	O
by	O
this	O
phospho	O
-	O
antibody	O
was	O
similar	O
in	O
wild	O
-	O
type	O
and	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
cells	O
and	O
is	O
therefore	O
independent	O
of	O
PKD	O
enzymes	O
.	O

However	O
,	O
pretreatment	O
of	O
both	O
wild	O
-	O
type	O
and	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
DT40	O
B	O
cells	O
with	O
GF109203X	O
,	O
a	O
bisindoylmaleimide	O
derivative	O
that	O
inhibits	O
PKCs	O
prevented	O
the	O
induction	O
of	O
proteins	O
that	O
contain	O
phosphorylated	O
LxRxxS	O
/	O
T	O
motifs	O
.	O

Thus	O
loss	O
of	O
PKD1	S-PRGE
/	O
3	S-PRGE
enzymes	O
does	O
not	O
globally	O
disrupt	O
the	O
phosphorylation	O
of	O
cellular	O
proteins	O
that	O
contain	O
LxRxxpS	O
/	O
T	O
motifs	O
.	O

This	O
result	O
is	O
perhaps	O
not	O
surprising	O
as	O
LxRxxS	O
/	O
T	O
motifs	O
also	O
act	O
as	O
good	O
substrates	O
for	O
other	O
serine	O
/	O
threonine	O
kinases	O
such	O
as	O
MAPKAPK2	S-PRGE
.	O

However	O
these	O
experiments	O
do	O
provide	O
further	O
evidence	O
that	O
phosphospecific	O
antisera	O
are	O
not	O
sufficiently	O
selective	O
to	O
be	O
designated	O
kinase	O
specific	O
substrate	O
antisera	O
.	O

BCR	O
-	O
induced	O
signalling	O
pathways	O
culminate	O
in	O
the	O
activation	O
of	O
gene	O
transcription	O
events	O
that	O
control	O
B	O
cell	O
survival	O
,	O
proliferation	O
and	O
function	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
proposed	O
that	O
PKD	O
family	O
members	O
control	O
of	O
gene	O
transcription	O
through	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
.	O

Thus	O
,	O
PKD	O
-	O
mediated	O
activation	O
of	O
NFkappaB	O
occurs	O
downstream	O
of	O
a	O
variety	O
of	O
different	O
signals	O
,	O
including	O
mROS	O
/	O
oxidative	O
stress	O
,	O
lysophosphatidic	O
acid	O
and	O
the	O
Bcr	B-PRGE
-	I-PRGE
Abl	I-PRGE
oncogene	E-PRGE
[	O
17	O
,	O
21	O
,	O
23	O
,	O
30	O
,	O
37	O
]	O
.	O

Furthermore	O
,	O
expression	O
of	O
an	O
activated	O
PKD1	S-PRGE
mutant	O
enhances	O
HPK1	S-PRGE
-	O
mediated	O
NFkappaB	O
activation	O
[	O
38	O
]	O
.	O

In	O
B	O
cells	O
,	O
NFkappaB	O
is	O
known	O
to	O
be	O
regulated	O
via	O
DAG	O
and	O
PKCbeta	S-PRGE
[	O
39	O
,	O
40	O
]	O
but	O
whether	O
PKDs	O
are	O
key	O
intermediaries	O
for	O
NFkappaB	O
regulation	O
has	O
not	O
been	O
explored	O
.	O

The	O
data	O
(	O
Fig	O
.	O
4A	O
)	O
show	O
that	O
NFkappaB	O
transcriptional	O
activity	O
was	O
strongly	O
induced	O
in	O
both	O
wild	O
-	O
type	O
and	O
PKD1	S-PRGE
/	O
3	S-PRGE
-	O
/	O
-	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
either	O
phorbol	O
ester	O
or	O
BCR	O
stimulation	O
.	O

In	O
contrast	O
,	O
BCR	O
and	O
phorbol	O
ester	O
-	O
induced	O
NFkappaB	O
transcriptional	O
activity	O
was	O
abolished	O
in	O
PKCbeta	S-PRGE
-	O
/	O
-	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
4A	O
)	O
,	O
although	O
strong	O
activation	O
of	O
PKD	O
kinases	O
(	O
as	O
assessed	O
by	O
autophosphorylation	O
of	O
PKD1	S-PRGE
at	O
S916	O
)	O
was	O
observed	O
in	O
the	O
PKCbeta	S-PRGE
-	O
/	O
-	O
cells	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Thus	O
,	O
PKD	O
kinases	O
are	O
neither	O
essential	O
nor	O
sufficient	O
to	O
mediate	O
BCR	O
-	O
induced	O
NFkappaB	O
activation	O
in	O
DT40	O
B	O
cells	O
and	O
hence	O
do	O
not	O
participate	O
in	O
DAG	O
/	O
PKC	O
mediated	O
control	O
of	O
NFkappaB	O
.	O

4Protein	O
kinase	O
D	O
serine	O
kinases	O
have	O
been	O
proposed	O
to	O
regulate	O
diverse	O
cellular	O
functions	O
including	O
the	O
phosphorylation	O
and	O
nuclear	O
localisation	O
of	O
class	O
II	O
HDACs	O
and	O
the	O
phosphorylation	O
of	O
HSP27	S-PRGE
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
PKDs	O
act	O
as	O
mitochondrial	O
sensors	O
for	O
oxidative	O
stress	O
and	O
play	O
a	O
role	O
in	O
regulating	O
NFkappaB	O
transcription	O
factors	O
[	O
41	O
]	O
.	O

Most	O
of	O
the	O
data	O
about	O
the	O
function	O
of	O
PKDs	O
has	O
come	O
from	O
experiments	O
that	O
ectopically	O
express	O
active	O
or	O
inhibitory	O
PKD	O
mutants	O
or	O
that	O
use	O
RNAi	O
to	O
reduce	O
PKD	O
expression	O
.	O

We	O
have	O
used	O
gene	O
targeting	O
to	O
specifically	O
delete	O
PKD	O
alleles	O
in	O
DT40	O
chicken	O
B	O
cells	O
and	O
can	O
thus	O
use	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
individual	O
PKD	O
isoforms	O
in	O
class	O
II	O
HDAC	O
control	O
versus	O
oxidative	O
stress	O
responses	O
and	O
NFkappaB	O
regulation	O
in	O
lymphocytes	O
.	O

We	O
have	O
previously	O
used	O
these	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
define	O
an	O
essential	O
role	O
for	O
PKDs	O
in	O
regulation	O
of	O
class	O
II	O
HDACs	O
,	O
the	O
present	O
report	O
now	O
describes	O
an	O
indispensable	O
role	O
for	O
PKDs	O
in	O
regulating	O
the	O
phosphorylation	O
of	O
HSP27	S-PRGE
on	O
serine	O
82	O
,	O
a	O
site	O
previously	O
identified	O
as	O
a	O
target	O
for	O
the	O
p38	O
-	O
MAPKAPK2	S-PRGE
signalling	O
cascade	O
[	O
42	O
]	O
.	O

However	O
,	O
studies	O
of	O
PKD	O
-	O
null	O
DT40	O
cells	O
reveal	O
that	O
PKD	O
family	O
kinases	O
are	O
not	O
essential	O
for	O
oxidative	O
stress	O
survival	O
responses	O
nor	O
are	O
they	O
required	O
for	O
activation	O
of	O
NFkappaB	O
transcription	O
factors	O
.	O

These	O
latter	O
findings	O
are	O
in	O
striking	O
contrast	O
to	O
previous	O
observations	O
in	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
where	O
overexpression	O
/	O
RNAi	O
approaches	O
have	O
implicated	O
PKD1	S-PRGE
/	O
2	S-PRGE
in	O
the	O
control	O
of	O
proliferation	O
,	O
survival	O
and	O
NFkappaB	O
activation	O
[	O
20	O
,	O
23	O
]	O
.	O

Hence	O
,	O
the	O
present	O
report	O
shows	O
that	O
the	O
proposed	O
roles	O
for	O
PKDs	O
as	O
key	O
sensors	O
that	O
modulate	O
survival	O
pathways	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
regulate	O
cell	O
survival	O
and	O
proliferation	O
are	O
not	O
ubiquitous	O
and	O
may	O
be	O
restricted	O
to	O
certain	O
cell	O
lineages	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
loss	O
of	O
expression	O
of	O
PKD	O
family	O
members	O
does	O
not	O
globally	O
impact	O
on	O
early	O
BCR	O
-	O
regulated	O
signalling	O
pathways	O
.	O

GATA3	S-PRGE
-	O
Driven	O
Th2	O
Responses	O
Inhibit	O
TGF	B-PRGE
-	I-PRGE
beta1	E-PRGE
-	O
Induced	O
FOXP3	S-PRGE
Expression	O
and	O
the	O
Formation	O
of	O
Regulatory	O
T	O
Cells	O

Transcription	O
factors	O
act	O
in	O
concert	O
to	O
induce	O
lineage	O
commitment	O
towards	O
Th1	O
,	O
Th2	O
,	O
or	O
T	O
regulatory	O
(	O
Treg	O
)	O
cells	O
,	O
and	O
their	O
counter	O
-	O
regulatory	O
mechanisms	O
were	O
shown	O
to	O
be	O
critical	O
for	O
polarization	O
between	O
Th1	O
and	O
Th2	O
phenotypes	O
.	O

FOXP3	S-PRGE
is	O
an	O
essential	O
transcription	O
factor	O
for	O
natural	O
,	O
thymus	O
-	O
derived	O
(	O
nTreg	O
)	O
and	O
inducible	O
Treg	O
(	O
iTreg	O
)	O
commitment	O
;	O
however	O
,	O
the	O
mechanisms	O
regulating	O
its	O
expression	O
are	O
as	O
yet	O
unknown	O
.	O

We	O
describe	O
a	O
mechanism	O
controlling	O
iTreg	O
polarization	O
,	O
which	O
is	O
overruled	O
by	O
the	O
Th2	O
differentiation	O
pathway	O
.	O

We	O
demonstrated	O
that	O
interleukin	B-PRGE
4	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
)	O
present	O
at	O
the	O
time	O
of	O
T	O
cell	O
priming	O
inhibits	O
FOXP3	S-PRGE
.	O

This	O
inhibitory	O
mechanism	O
was	O
also	O
confirmed	O
in	O
Th2	O
cells	O
and	O
in	O
T	O
cells	O
of	O
transgenic	O
mice	O
overexpressing	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
T	O
cells	O
,	O
which	O
are	O
shown	O
to	O
be	O
deficient	O
in	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	I-PRGE
TGF	I-PRGE
)	I-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
FOXP3	S-PRGE
induction	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
direct	O
binding	O
of	O
GATA3	S-PRGE
to	O
the	O
FOXP3	S-PRGE
promoter	O
,	O
which	O
represses	O
its	O
transactivation	O
process	O
.	O

Therefore	O
,	O
this	O
study	O
provides	O
a	O
new	O
understanding	O
of	O
tolerance	O
development	O
,	O
controlled	O
by	O
a	O
type	O
2	O
immune	O
response	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
treatment	O
in	O
mice	O
reduces	O
iTreg	O
cell	O
frequency	O
,	O
highlighting	O
that	O
therapeutic	O
approaches	O
that	O
target	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
or	O
GATA3	S-PRGE
might	O
provide	O
new	O
preventive	O
strategies	O
facilitating	O
tolerance	O
induction	O
particularly	O
in	O
Th2	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
allergy	O
.	O

Effective	O
immune	O
responses	O
are	O
characterized	O
by	O
T	O
cell	O
activation	O
,	O
which	O
directs	O
adaptive	O
and	O
innate	O
immune	O
responses	O
to	O
kill	O
pathogens	O
efficiently	O
.	O

Dependent	O
on	O
the	O
pathogen	O
,	O
T	O
cells	O
differentiate	O
into	O
different	O
subtypes	O
,	O
such	O
as	O
Th1	O
or	O
Th2	O
cells	O
,	O
which	O
are	O
most	O
efficient	O
in	O
defeating	O
microbial	O
or	O
parasitic	O
invaders	O
respectively	O
.	O

A	O
hallmark	O
of	O
Th1	O
and	O
Th2	O
differentiation	O
pathways	O
is	O
the	O
exclusiveness	O
of	O
the	O
individual	O
phenotype	O
leading	O
to	O
either	O
Th1	O
or	O
Th2	O
,	O
but	O
not	O
to	O
mixed	O
populations	O
.	O

The	O
exclusiveness	O
of	O
this	O
mechanism	O
is	O
provided	O
by	O
a	O
polarization	O
process	O
,	O
where	O
Th2	O
differentiation	O
inhibits	O
Th1	O
commitment	O
and	O
vice	O
versa	O
.	O

Specifically	O
interleukin	B-PRGE
4	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
)	O
-	O
induced	O
STAT6	S-PRGE
and	O
GATA3	S-PRGE
inhibit	O
differentiation	O
into	O
Th1	O
cells	O
in	O
the	O
early	O
phase	O
of	O
commitment	O
[	O
1	O
,	O
2	O
]	O
.	O

GATA3	S-PRGE
is	O
sufficient	O
to	O
induce	O
a	O
Th2	O
phenotype	O
[	O
3	O
]	O
and	O
acts	O
not	O
only	O
through	O
the	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
,	O
the	O
Th2	O
cytokines	O
,	O
but	O
also	O
through	O
the	O
inhibition	O
of	O
Th1	O
cell	O
-	O
specific	O
factors	O
[	O
3	O
]	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
directly	O
modulates	O
GATA3	S-PRGE
function	O
,	O
suggesting	O
that	O
transcription	O
factors	O
compete	O
in	O
the	O
early	O
differentiation	O
phase	O
of	O
T	O
cells	O
,	O
potentially	O
integrating	O
environmental	O
signals	O
to	O
finally	O
imprint	O
the	O
T	O
cell	O
phenotype	O
[	O
4	O
,	O
5	O
]	O
.	O

A	O
GATA3	S-PRGE
-	O
dominated	O
immune	O
response	O
has	O
been	O
shown	O
to	O
be	O
essential	O
in	O
airway	O
hyperresonsiveness	O
[	O
6	O
]	O
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
dominated	O
responses	O
can	O
break	O
antigen	O
-	O
specific	O
immune	O
tolerance	O
[	O
7	O
]	O
.	O

Overexpression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
GATA3	S-PRGE
[	O
8	O
]	O
or	O
treatment	O
with	O
antisense	O
-	O
mediated	O
GATA3	S-PRGE
blockade	O
[	O
9	O
]	O
decreased	O
the	O
severity	O
of	O
the	O
allergic	O
airway	O
hyper	O
-	O
responsiveness	O
.	O

The	O
discovery	O
of	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
highlights	O
another	O
phenotype	O
of	O
T	O
cells	O
,	O
which	O
is	O
essential	O
for	O
tolerance	O
against	O
self	O
-	O
antigens	O
.	O

Naturally	O
occurring	O
,	O
thymus	O
-	O
derived	O
Treg	O
(	O
nTreg	O
)	O
cells	O
are	O
generated	O
in	O
the	O
thymus	O
and	O
are	O
assumed	O
to	O
protect	O
against	O
the	O
activity	O
of	O
autoreactive	O
T	O
cells	O
in	O
the	O
periphery	O
.	O

These	O
cells	O
express	O
the	O
forkhead	O
transcription	O
factor	O
FOXP3	S-PRGE
and	O
constitutively	O
express	O
CD25	S-PRGE
on	O
their	O
surface	O
,	O
but	O
they	O
lack	O
expression	O
of	O
Th1	O
or	O
Th2	O
cytokines	O
.	O

Particularly	O
interesting	O
are	O
those	O
Treg	O
cells	O
that	O
are	O
generated	O
in	O
the	O
periphery	O
and	O
thus	O
are	O
potential	O
targets	O
for	O
therapeutic	O
interventions	O
.	O

These	O
induced	O
Treg	O
(	O
iTreg	O
)	O
cells	O
were	O
reported	O
to	O
express	O
FOXP3	S-PRGE
[	O
10	O
]	O
.	O

The	O
exact	O
mechanisms	O
of	O
iTreg	O
generation	O
are	O
unclear	O
,	O
but	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
triggering	O
has	O
been	O
shown	O
to	O
induce	O
FOXP3	S-PRGE
expression	O
and	O
suppressive	O
cells	O
in	O
human	O
[	O
11	O
,	O
12	O
]	O
,	O
however	O
the	O
phenotype	O
appears	O
to	O
be	O
of	O
transient	O
nature	O
[	O
13	O
,	O
14	O
]	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
has	O
been	O
demonstrated	O
to	O
be	O
important	O
for	O
the	O
persistent	O
induction	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
animals	O
lacking	O
the	O
TGF	B-PRGE
-	I-PRGE
betaRII	E-PRGE
on	O
T	O
cells	O
have	O
fewer	O
peripherally	O
iTreg	O
cells	O
[	O
15	O
]	O
and	O
suffer	O
from	O
a	O
T	O
cell	O
-	O
dependent	O
multiorgan	O
inflammatory	O
disease	O
[	O
16	O
]	O
.	O

Although	O
the	O
effect	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
on	O
natural	O
and	O
inducible	O
Treg	O
cell	O
induction	O
has	O
been	O
demonstrated	O
repeatedly	O
[	O
15	O
,	O
17	O
]	O
,	O
its	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
identified	O
.	O

The	O
current	O
study	O
provides	O
evidence	O
that	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
play	O
a	O
competitive	O
role	O
in	O
iTreg	O
cell	O
commitment	O
as	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
and	O
GATA3	S-PRGE
for	O
Th1	O
and	O
Th2	O
differentiation	O
,	O
respectively	O
.	O

We	O
show	O
that	O
GATA3	S-PRGE
inhibits	O
FOXP3	S-PRGE
induction	O
and	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
limits	O
FOXP3	S-PRGE
expression	O
in	O
a	O
GATA3	S-PRGE
-	O
mediated	O
way	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
show	O
that	O
GATA3	S-PRGE
directly	O
binds	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
and	O
thereby	O
prevents	O
the	O
induction	O
of	O
this	O
gene	O
,	O
demonstrating	O
that	O
Th2	O
differentiation	O
overrules	O
iTreg	O
induction	O
.	O

FOXP3	S-PRGE
Induction	O
in	O
T	O
Cell	O
Subsets	O

It	O
is	O
assumed	O
that	O
FOXP3	S-PRGE
expression	O
can	O
be	O
induced	O
in	O
nonregulatory	O
T	O
cells	O
,	O
which	O
is	O
an	O
important	O
step	O
in	O
iTreg	O
cell	O
differentiation	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
all	O
CD4	S-PRGE
+	O
T	O
cells	O
have	O
the	O
same	O
capacity	O
to	O
express	O
FOXP3	S-PRGE
.	O

To	O
investigate	O
whether	O
FOXP3	S-PRGE
can	O
be	O
expressed	O
by	O
any	O
T	O
cell	O
subset	O
or	O
if	O
expression	O
is	O
restricted	O
to	O
a	O
distinct	O
lineage	O
,	O
FOXP3	S-PRGE
mRNA	O
expression	O
was	O
analyzed	O
in	O
freshly	O
isolated	O
T	O
cells	O
such	O
as	O
CD25	S-PRGE
-	O
depleted	O
CD4	S-PRGE
+	O
cells	O
,	O
CD45RA	S-PRGE
+	O
naive	O
or	O
CD45RO	S-PRGE
+	O
memory	O
T	O
cells	O
(	O
Figure	O
1A	O
)	O
,	O
as	O
well	O
as	O
T	O
cells	O
driven	O
in	O
vitro	O
toward	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
phenotypes	O
(	O
Figure	O
1B	O
;	O
phenotype	O
on	O
Figure	O
S1	O
)	O
.	O

The	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
,	O
CD45RA	S-PRGE
+	O
,	O
CD45RO	S-PRGE
+	O
,	O
and	O
CD4	S-PRGE
+	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
-	O
were	O
able	O
to	O
significantly	O
induce	O
FOXP3	S-PRGE
mRNA	O
up	O
to	O
30	O
-	O
fold	O
upon	O
TCR	O
activation	O
and	O
addition	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

Th1	O
cells	O
showed	O
only	O
a	O
10	O
-	O
fold	O
increase	O
.	O

In	O
contrast	O
,	O
Th2	O
cells	O
stimulated	O
under	O
the	O
same	O
conditions	O
did	O
not	O
increase	O
FOXP3	S-PRGE
expression	O
.	O

The	O
in	O
vitro	O
generated	O
iTreg	O
cells	O
were	O
unable	O
to	O
further	O
up	O
-	O
regulate	O
FOXP3	S-PRGE
,	O
which	O
was	O
already	O
at	O
high	O
levels	O
under	O
the	O
resting	O
conditions	O
(	O
Figure	O
1B	O
,	O
right	O
panel	O
)	O
.	O

Th2	O
cells	O
are	O
known	O
to	O
produce	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
upon	O
activation	O
,	O
which	O
may	O
interact	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signaling	O
and	O
thus	O
prevent	O
FOXP3	S-PRGE
induction	O
.	O

However	O
,	O
the	O
neutralization	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
with	O
a	O
blocking	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
antibody	O
did	O
not	O
rescue	O
FOXP3	S-PRGE
expression	O
in	O
the	O
differentiated	O
Th2	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
a	O
limited	O
capacity	O
to	O
express	O
FOXP3	S-PRGE
(	O
Figure	O
1B	O
)	O
.	O

The	O
inability	O
of	O
Th2	O
cells	O
to	O
express	O
FOXP3	S-PRGE
was	O
also	O
documented	O
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
confirming	O
that	O
Th2	O
cells	O
lack	O
FOXP3	S-PRGE
expression	O
(	O
Figure	O
2A	O
)	O
.	O

Only	O
iTreg	O
cells	O
expressed	O
FOXP3	S-PRGE
in	O
resting	O
conditions	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
resting	O
iTreg	O
cells	O
express	O
FOXP3	S-PRGE
but	O
show	O
low	O
CD25	S-PRGE
surface	O
expression	O
.	O

Repeated	O
exposure	O
to	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
did	O
not	O
further	O
increase	O
the	O
FOXP3	S-PRGE
expression	O
in	O
the	O
iTreg	O
lineage	O
but	O
transiently	O
induced	O
FOXP3	S-PRGE
expression	O
in	O
Th1	O
cells	O
.	O

Naturally	O
occurring	O
Th2	O
cells	O
such	O
as	O
CRTH2	S-PRGE
+	O
T	O
cells	O
,	O
T	O
cells	O
isolated	O
according	O
to	O
their	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
secretion	O
,	O
or	O
an	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
producing	O
T	O
cell	O
clone	O
(	O
BR8	O
)	O
were	O
also	O
lacking	O
FOXP3	S-PRGE
expression	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
FOXP3	S-PRGE
induction	O
failed	O
in	O
these	O
cells	O
in	O
contrast	O
to	O
the	O
naive	O
T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O

Because	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
is	O
the	O
key	O
Th2	O
cytokine	O
,	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
FOXP3	S-PRGE
in	O
freshly	O
isolated	O
CD4	S-PRGE
+	O
T	O
cells	O
was	O
analyzed	O
by	O
fluorescence	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
expressing	O
cells	O
were	O
most	O
abundant	O
among	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
,	O
which	O
did	O
not	O
co	O
-	O
express	O
FOXP3	S-PRGE
(	O
Figure	O
3A	O
,	O
left	O
panel	O
)	O
.	O

In	O
contrast	O
,	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
+	O
cells	O
abundantly	O
expressed	O
FOXP3	S-PRGE
,	O
while	O
lacking	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
Figure	O
3A	O
,	O
right	O
panel	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
frequency	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
+	O
cells	O
was	O
always	O
below	O
1	O
%	O
in	O
the	O
FOXP3	S-PRGE
+	O
cells	O
close	O
to	O
the	O
background	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
+	O
cells	O
were	O
confined	O
to	O
the	O
FOXP3	S-PRGE
-	O
cells	O
,	O
as	O
shown	O
for	O
the	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
-	O
,	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
+	O
,	O
and	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
+	O
high	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

In	O
addition	O
,	O
neither	O
the	O
Th2	O
clone	O
(	O
BR8	O
)	O
nor	O
CRTH2	S-PRGE
cells	O
significantly	O
expressed	O
FOXP3	S-PRGE
(	O
Figure	O
3C	O
)	O
.	O

Cells	O
enriched	O
for	O
their	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
secretion	O
using	O
the	O
magnetic	O
cell	O
isolation	O
technology	O
contained	O
some	O
FOXP3	S-PRGE
-	O
expressing	O
cells	O
,	O
but	O
importantly	O
,	O
the	O
expression	O
did	O
not	O
overlap	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
FOXP3	S-PRGE
was	O
not	O
expressed	O
by	O
Th2	O
cells	O
and	O
was	O
not	O
inducible	O
in	O
those	O
cells	O
.	O

FOXP3	S-PRGE
and	O
GATA3	S-PRGE
Kinetics	O
in	O
Differentiating	O
Cells	O

The	O
limited	O
capacity	O
of	O
differentiated	O
effector	O
cells	O
to	O
induce	O
FOXP3	S-PRGE
expression	O
suggests	O
that	O
iTreg	O
induction	O
has	O
to	O
occur	O
before	O
effector	O
T	O
cell	O
differentiation	O
occurs	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
FOXP3	S-PRGE
and	O
GATA3	S-PRGE
during	O
the	O
differentiation	O
of	O
naive	O
CD4	S-PRGE
T	O
cells	O
into	O
Th0	O
(	O
neutral	O
,	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
anti	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
,	O
and	O
anti	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
)	O
,	O
Th2	O
,	O
and	O
iTreg	O
phenotypes	O
.	O

After	O
initiation	O
of	O
the	O
differentiation	O
process	O
,	O
FOXP3	S-PRGE
and	O
GATA3	S-PRGE
showed	O
a	O
similar	O
expression	O
kinetic	O
within	O
the	O
first	O
3	O
d	O
,	O
which	O
are	O
considered	O
to	O
be	O
critical	O
in	O
T	O
cell	O
commitment	O
[	O
18	O
]	O
.	O

Under	O
Th2	O
differentiation	O
conditions	O
,	O
FOXP3	S-PRGE
mRNA	O
expression	O
increased	O
only	O
marginally	O
(	O
Figure	O
4A	O
,	O
left	O
panel	O
)	O
.	O

Thus	O
,	O
although	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
showed	O
similar	O
kinetics	O
,	O
their	O
expression	O
polarizes	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
when	O
cells	O
were	O
cultured	O
towards	O
Th2	O
or	O
iTreg	O
cells	O
,	O
respectively	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Interestingly	O
,	O
the	O
Th0	O
cells	O
were	O
expressing	O
more	O
FOXP3	S-PRGE
than	O
the	O
Th2	O
cells	O
,	O
but	O
expressed	O
low	O
levels	O
of	O
GATA3	S-PRGE
;	O
however	O
,	O
the	O
protein	O
expression	O
slightly	O
differed	O
from	O
mRNA	O
expression	O
,	O
suggesting	O
also	O
posttranslational	O
regulation	O
and	O
degradation	O
as	O
potential	O
additional	O
mechanisms	O
in	O
the	O
differentiation	O
process	O
.	O

The	O
phenotype	O
of	O
iTreg	O
cells	O
included	O
an	O
anergic	O
phenotype	O
upon	O
anti	O
-	O
CD3	S-PRGE
re	O
-	O
stimulation	O
(	O
Figure	O
S1A	O
)	O
,	O
CD103	S-PRGE
,	O
CTLA	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
GITR	S-PRGE
,	O
and	O
PD	B-PRGE
-	I-PRGE
1	E-PRGE
surface	O
expression	O
(	O
Figure	O
S1B	O
)	O
.	O

On	O
the	O
single	O
-	O
cell	O
level	O
,	O
it	O
can	O
be	O
seen	O
that	O
cells	O
progress	O
through	O
a	O
transition	O
phase	O
,	O
where	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
expression	O
coexist	O
to	O
some	O
degree	O
in	O
the	O
same	O
cells	O
,	O
which	O
is	O
resolved	O
in	O
iTreg	O
cells	O
after	O
7	O
d	O
(	O
Figure	O
4B	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
lost	O
their	O
capacity	O
to	O
express	O
FOXP3	S-PRGE
and	O
showed	O
that	O
Th2	O
and	O
iTreg	O
cells	O
arise	O
from	O
two	O
different	O
differentiation	O
pathways	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
Inhibits	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
Mediated	O
iTreg	O
Commitment	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
induces	O
differentiation	O
of	O
naive	O
T	O
cells	O
,	O
upon	O
antigen	O
encounter	O
,	O
into	O
the	O
Th2	O
cell	O
lineage	O
.	O

We	O
therefore	O
asked	O
whether	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
is	O
able	O
to	O
inhibit	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
induction	O
of	O
FOXP3	S-PRGE
during	O
the	O
priming	O
of	O
naive	O
T	O
cells	O
.	O

Human	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
in	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
/	O
or	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
harvested	O
after	O
5	O
d	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
efficiently	O
repressed	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
induction	O
of	O
FOXP3	S-PRGE
expression	O
(	O
Figure	O
5A	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
5B	O
)	O
.	O

Low	O
levels	O
of	O
GATA3	S-PRGE
were	O
induced	O
also	O
in	O
the	O
absence	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
as	O
it	O
was	O
previously	O
observed	O
[	O
3	O
]	O
.	O

However	O
,	O
at	O
low	O
concentration	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
was	O
able	O
to	O
marginally	O
induce	O
FOXP3	S-PRGE
expression	O
.	O

Of	O
note	O
,	O
GATA3	S-PRGE
was	O
also	O
induced	O
in	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
at	O
high	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
concentration	O
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
mediated	O
prevention	O
of	O
FOXP3	S-PRGE
expression	O
was	O
not	O
caused	O
by	O
interferences	O
of	O
the	O
receptor	O
signaling	O
,	O
because	O
the	O
phosphorylation	O
of	O
SMAD2	S-PRGE
or	O
STAT6	S-PRGE
was	O
not	O
affected	O
by	O
the	O
addition	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
/	O
or	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
which	O
demonstrates	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
as	O
well	O
as	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signaling	O
were	O
functional	O
under	O
these	O
conditions	O
(	O
Figure	O
5C	O
)	O
.	O

Increasing	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
increase	O
intracellular	O
GATA3	S-PRGE
,	O
whereas	O
FOXP3	S-PRGE
decreased	O
,	O
which	O
is	O
consistent	O
with	O
the	O
mRNA	O
analysis	O
(	O
Figure	O
5D	O
)	O
.	O

Furthermore	O
,	O
injection	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
into	O
wild	O
-	O
type	O
B6	O
mice	O
decreased	O
the	O
inducible	O
or	O
natural	O
Treg	O
number	O
in	O
vivo	O
.	O

A	O
distinction	O
of	O
the	O
Treg	O
subsets	O
is	O
not	O
possible	O
,	O
because	O
recently	O
activated	O
iTreg	O
cells	O
also	O
express	O
surface	O
CD25	S-PRGE
.	O

We	O
used	O
complexes	O
of	O
recombinant	O
mouse	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
rmIL	B-PRGE
-	I-PRGE
4	E-PRGE
)	O
plus	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
which	O
have	O
been	O
shown	O
to	O
dramatically	O
increase	O
the	O
potency	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O

In	O
these	O
mice	O
,	O
the	O
percentage	O
of	O
CD4	S-PRGE
+	O
CD25	S-PRGE
+	O
and	O
FOXP3	S-PRGE
+	O
T	O
cells	O
dramatically	O
decreased	O
when	O
the	O
antibody	O
-	O
cytokine	O
immune	O
complexes	O
were	O
injected	O
(	O
Figure	O
S2	O
)	O
.	O

Upon	O
administration	O
of	O
rmIL	B-PRGE
-	I-PRGE
4	E-PRGE
plus	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
complexes	O
,	O
the	O
total	O
number	O
of	O
CD4	S-PRGE
+	O
CD25	S-PRGE
+	O
T	O
cell	O
,	O
as	O
well	O
as	O
the	O
Foxp3	S-PRGE
+	O
T	O
cells	O
diminished	O
by	O
half	O
(	O
Figure	O
S2G	O
and	O
S2H	O
)	O
,	O
confirming	O
that	O
the	O
lower	O
percentage	O
was	O
not	O
due	O
to	O
an	O
increase	O
in	O
the	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
,	O
but	O
a	O
real	O
decrease	O
of	O
CD4	S-PRGE
+	O
CD25	S-PRGE
+	O
T	O
cells	O
.	O

In	O
conclusion	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
negatively	O
regulates	O
the	O
natural	O
or	O
inducible	O
Treg	O
cell	O
turnover	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O

To	O
study	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
on	O
already	O
-	O
existing	O
human	O
natural	O
or	O
inducible	O
Treg	O
cells	O
,	O
we	O
exposed	O
sorted	O
CD25	S-PRGE
+	O
T	O
cells	O
(	O
nTreg	O
cells	O
)	O
to	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
analyzed	O
FOXP3	S-PRGE
expression	O
and	O
suppressive	O
capacity	O
.	O

In	O
already	O
-	O
existing	O
Treg	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
failed	O
to	O
inhibit	O
FOXP3	S-PRGE
expression	O
(	O
Figure	O
S3A	O
)	O
,	O
and	O
the	O
suppressive	O
capacity	O
was	O
not	O
altered	O
(	O
Figure	O
S3C	O
)	O
.	O

Similarly	O
pre	O
-	O
existing	O
iTreg	O
cells	O
did	O
not	O
decrease	O
FOXP3	S-PRGE
expression	O
upon	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
exposure	O
(	O
Figure	O
S3B	O
)	O
.	O

The	O
Role	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
in	O
T	O
Cell	O
Differentiation	O

Although	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
reduced	O
CD25	S-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
expression	O
,	O
and	O
CD25	S-PRGE
expression	O
(	O
Figure	O
6B	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
significantly	O
inhibited	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
induction	O
of	O
FOXP3	S-PRGE
in	O
naive	O
T	O
cells	O
driven	O
toward	O
FOXP3	S-PRGE
+	O
T	O
cells	O
,	O
as	O
shown	O
by	O
FACS	O
analysis	O
(	O
Figure	O
6A	O
)	O
.	O

It	O
is	O
known	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
is	O
a	O
potent	O
growth	O
factor	O
and	O
may	O
therefore	O
favor	O
the	O
proliferation	O
of	O
FOXP3	S-PRGE
-	O
cells	O
and	O
thus	O
decrease	O
the	O
relative	O
percentage	O
of	O
FOXP3	S-PRGE
+	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
cell	O
division	O
kinetics	O
by	O
CFSE	O
-	O
labeling	O
demonstrated	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
did	O
not	O
differentially	O
promote	O
cell	O
growth	O
of	O
FOXP3	S-PRGE
+	O
over	O
that	O
of	O
FOXP3	S-PRGE
-	O
.	O

In	O
fact	O
both	O
populations	O
showed	O
similarly	O
enhanced	O
proliferation	O
(	O
Figure	O
6A	O
)	O
.	O

Furthermore	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
induction	O
of	O
FOXP3	S-PRGE
expression	O
was	O
not	O
caused	O
by	O
overgrowth	O
of	O
a	O
CD25	S-PRGE
-	O
FOXP3	S-PRGE
+	O
minority	O
,	O
since	O
the	O
number	O
of	O
FOXP3	S-PRGE
+	O
cells	O
was	O
low	O
/	O
absent	O
in	O
the	O
purified	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
(	O
between	O
0	O
%	O
and	O
1	O
%	O
)	O
,	O
and	O
the	O
FOXP3	S-PRGE
+	O
cells	O
were	O
not	O
confined	O
to	O
the	O
highly	O
divided	O
cells	O
.	O

CD25	S-PRGE
was	O
down	O
-	O
regulated	O
in	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
treated	O
cells	O
compare	O
to	O
activated	O
T	O
cells	O
,	O
which	O
was	O
even	O
more	O
pronounced	O
in	O
cells	O
cultured	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

The	O
addition	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
to	O
iTreg	O
-	O
driving	O
conditions	O
decreased	O
the	O
number	O
of	O
FOXP3	S-PRGE
+	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
line	O
with	O
the	O
previous	O
findings	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
producing	O
cells	O
and	O
the	O
FOXP3	S-PRGE
expressing	O
cells	O
are	O
nonoverlapping	O
populations	O
.	O

Since	O
FOXP3	S-PRGE
is	O
known	O
to	O
act	O
as	O
a	O
repressor	O
of	O
cytokine	O
expression	O
[	O
20	O
]	O
,	O
we	O
therefore	O
analyzed	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
expression	O
.	O

The	O
expression	O
kinetic	O
of	O
naive	O
T	O
cells	O
exposed	O
to	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
demonstrated	O
that	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
are	O
initially	O
found	O
in	O
separate	O
populations	O
(	O
day	O
2	O
)	O
,	O
but	O
transiently	O
co	O
-	O
express	O
both	O
factors	O
(	O
days	O
4	O
-	O
8	O
)	O
,	O
before	O
establishing	O
separate	O
populations	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
(	O
day	O
10	O
;	O
Figure	O
6C	O
)	O
,	O
suggesting	O
that	O
GATA3	S-PRGE
inhibits	O
the	O
development	O
of	O
iTreg	O
cells	O
by	O
repressing	O
FOXP3	S-PRGE
.	O

These	O
results	O
showed	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
acts	O
in	O
vitro	O
as	O
an	O
inhibitor	O
of	O
FOXP3	S-PRGE
expression	O
,	O
without	O
interfering	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signaling	O
,	O
probably	O
acting	O
at	O
the	O
level	O
of	O
transcription	O
factors	O
,	O
and	O
possibly	O
by	O
a	O
GATA3	S-PRGE
-	O
dependent	O
mechanism	O
.	O

GATA3	S-PRGE
Is	O
a	O
Negative	O
Regulator	O
of	O
FOXP3	S-PRGE
Expression	O

FOXP3	S-PRGE
expression	O
decreased	O
once	O
GATA3	S-PRGE
expression	O
is	O
high	O
;	O
therefore	O
,	O
we	O
hypothesized	O
a	O
potential	O
role	O
for	O
GATA3	S-PRGE
in	O
repressing	O
FOXP3	S-PRGE
.	O

Besides	O
GATA3	S-PRGE
'	O
s	O
well	O
-	O
known	O
positive	O
effect	O
on	O
gene	O
regulation	O
,	O
GATA3	S-PRGE
'	O
s	O
repressive	O
capabilities	O
were	O
previously	O
shown	O
to	O
restrict	O
Th1	O
commitment	O
by	O
inhibiting	O
STAT4	S-PRGE
expression	O
[	O
2	O
,	O
21	O
]	O
,	O
and	O
therefore	O
GATA3	S-PRGE
prevents	O
differentiation	O
into	O
Th1	O
cells	O
.	O

To	O
investigate	O
whether	O
GATA3	S-PRGE
can	O
directly	O
inhibit	O
FOXP3	S-PRGE
induction	O
,	O
we	O
transduced	O
GATA3	S-PRGE
or	O
a	O
truncated	O
GATA3	S-PRGE
lacking	O
the	O
DNA	O
-	O
binding	O
domain	O
in	O
human	O
primary	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
using	O
a	O
TAT	B-PRGE
-	I-PRGE
fused	I-PRGE
,	I-PRGE
recombinantly	I-PRGE
expressed	I-PRGE
GATA3	E-PRGE
.	O

After	O
transduction	O
,	O
the	O
cells	O
were	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

TAT	B-PRGE
-	I-PRGE
GATA3	E-PRGE
was	O
successfully	O
transduced	O
in	O
a	O
homogeneous	O
and	O
dose	O
-	O
dependent	O
manner	O
into	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
(	O
Figure	O
7A	O
,	O
upper	O
panel	O
)	O
.	O

TAT	B-PRGE
-	I-PRGE
GATA3	E-PRGE
reduced	O
FOXP3	S-PRGE
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
a	O
DNA	O
-	O
binding	O
domain	O
truncated	O
version	O
(	O
TAT	O
-	O
deltaDBD	O
-	O
GATA3	S-PRGE
)	O
did	O
not	O
affect	O
FOXP3	S-PRGE
expression	O
as	O
compared	O
with	O
expression	O
in	O
untransduced	O
cells	O
(	O
Figure	O
7A	O
)	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
inhibitory	O
effect	O
of	O
GATA3	S-PRGE
on	O
FOXP3	S-PRGE
in	O
transgenic	O
DO11	O
.	O
10	O
mice	O
,	O
constitutively	O
overexpressing	O
GATA3	S-PRGE
under	O
the	O
control	O
of	O
the	O
CD2	S-PRGE
locus	O
control	O
region	O
(	O
DO11	O
.	O
10xCD2	S-PRGE
-	O
GATA3	S-PRGE
)	O
.	O

The	O
thymic	O
selection	O
into	O
the	O
CD4	S-PRGE
lineage	O
is	O
largely	O
intact	O
in	O
DO11	O
.	O
10xCD2	S-PRGE
-	O
GATA3	S-PRGE
(	O
RW	O
Hendriks	O
,	O
unpublished	O
data	O
)	O
.	O

These	O
mice	O
develop	O
lymphomas	O
at	O
an	O
older	O
age	O
,	O
but	O
signs	O
of	O
autoimmune	O
disease	O
were	O
not	O
described	O
[	O
22	O
]	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
GATA3	S-PRGE
on	O
iTreg	O
,	O
CD4	S-PRGE
+	O
CD62L	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
were	O
isolated	O
,	O
activated	O
with	O
OVA	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
and	O
Foxp3	S-PRGE
expression	O
was	O
analyzed	O
after	O
4	O
d	O
.	O

The	O
naive	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
were	O
Foxp3	S-PRGE
-	O
(	O
unpublished	O
data	O
)	O
.	O

As	O
described	O
for	O
the	O
human	O
cells	O
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
dramatically	O
up	O
-	O
regulated	O
Foxp3	S-PRGE
in	O
the	O
DO11	O
.	O
10	O
littermate	O
control	O
mice	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
the	O
CD2	S-PRGE
-	O
GATA3xDO11	S-PRGE
.	O
10	O
mice	O
showed	O
dramatically	O
reduced	O
Foxp3	S-PRGE
expression	O
when	O
activated	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
OVA	O
(	O
Figure	O
7B	O
)	O
.	O

All	O
mice	O
produced	O
similar	O
amounts	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
;	O
in	O
addition	O
,	O
Smad7	S-PRGE
was	O
equally	O
expressed	O
[	O
23	O
]	O
in	O
T	O
cells	O
of	O
both	O
mice	O
strains	O
(	O
Figure	O
7C	O
)	O
,	O
indicating	O
intact	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signaling	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
a	O
repressive	O
role	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
induced	O
GATA3	S-PRGE
transcription	O
factor	O
in	O
the	O
generation	O
of	O
iTreg	O
cells	O
.	O

GATA3	S-PRGE
Represses	O
the	O
FOXP3	S-PRGE
Promoter	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
GATA3	S-PRGE
-	O
mediated	O
repression	O
of	O
human	O
FOXP3	S-PRGE
,	O
the	O
human	O
FOXP3	S-PRGE
promoter	O
was	O
studied	O
and	O
a	O
palindromic	O
binding	O
site	O
for	O
GATA3	S-PRGE
was	O
discovered	O
.	O

The	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
[	O
24	O
]	O
.	O

This	O
site	O
is	O
highly	O
conserved	O
between	O
humans	O
,	O
mice	O
,	O
and	O
rats	O
(	O
Figure	O
S4	O
)	O
and	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
FOXP3	S-PRGE
regulation	O
.	O

The	O
functional	O
relevance	O
of	O
this	O
site	O
was	O
studied	O
using	O
a	O
FOXP3	S-PRGE
-	O
promoter	O
construct	O
[	O
24	O
]	O
.	O

We	O
transfected	O
human	O
primary	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
in	O
vitro	O
differentiated	O
Th2	O
cells	O
,	O
and	O
Jurkat	O
cells	O
(	O
Jurkat	O
cells	O
are	O
known	O
to	O
constitutively	O
express	O
GATA3	S-PRGE
[	O
25	O
,	O
26	O
]	O
)	O
,	O
and	O
we	O
measured	O
FOXP3	S-PRGE
promoter	O
activity	O
.	O

The	O
promoter	O
was	O
not	O
active	O
in	O
the	O
GATA3	S-PRGE
-	O
expressing	O
cell	O
line	O
Jurkat	O
or	O
in	O
the	O
in	O
vitro	O
-	O
differentiated	O
Th2	O
cells	O
,	O
whereas	O
the	O
construct	O
was	O
active	O
in	O
the	O
CD4	S-PRGE
cells	O
,	O
which	O
express	O
a	O
lower	O
amount	O
of	O
GATA3	S-PRGE
(	O
Figure	O
8A	O
)	O
.	O

Overexpression	O
of	O
GATA3	S-PRGE
in	O
naive	O
T	O
cells	O
diminished	O
luciferase	O
activity	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
compared	O
with	O
the	O
control	O
vector	O
(	O
Figure	O
8B	O
)	O
.	O

To	O
further	O
address	O
the	O
function	O
of	O
the	O
GATA3	O
site	O
,	O
we	O
inserted	O
a	O
site	O
-	O
specific	O
mutation	O
deleting	O
the	O
GATA3	O
-	O
binding	O
site	O
.	O

This	O
mutation	O
increased	O
luciferase	O
activity	O
by	O
3	O
-	O
fold	O
in	O
memory	O
CD4	S-PRGE
+	O
CD45RO	S-PRGE
+	O
T	O
cells	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
naive	O
(	O
GATA3	S-PRGE
-	O
)	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
,	O
revealing	O
a	O
repressor	O
activity	O
of	O
GATA3	S-PRGE
on	O
the	O
FOXP3	S-PRGE
promoter	O
(	O
Figure	O
8C	O
)	O
.	O

Furthermore	O
GATA3	S-PRGE
binds	O
directly	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
as	O
investigated	O
by	O
pull	O
-	O
down	O
assay	O
.	O

HEK	O
cells	O
were	O
transiently	O
transfected	O
with	O
GATA3	S-PRGE
or	O
a	O
control	O
vector	O
,	O
and	O
increasing	O
amounts	O
of	O
lysates	O
were	O
incubated	O
with	O
oligonucleotides	O
containing	O
the	O
GATA3	O
site	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
or	O
a	O
control	O
oligonucleotide	O
with	O
a	O
mutated	O
GATA3	O
-	O
binding	O
site	O
.	O

After	O
the	O
pull	O
-	O
down	O
,	O
GATA3	S-PRGE
binding	O
was	O
detected	O
by	O
Western	O
blot	O
.	O

Similarly	O
,	O
GATA3	S-PRGE
-	O
expressing	O
Th2	O
cells	O
and	O
iTreg	O
cells	O
were	O
subjected	O
to	O
this	O
approach	O
.	O

Only	O
HEK	O
cells	O
overexpressing	O
GATA3	S-PRGE
and	O
Th2	O
cells	O
showed	O
GATA3	S-PRGE
-	O
binding	O
activity	O
(	O
Figure	O
8D	O
and	O
8E	O
)	O
.	O

These	O
experiments	O
demonstrated	O
that	O
GATA3	S-PRGE
binds	O
the	O
palindromic	O
FOXP3	S-PRGE
promoter	O
.	O

To	O
gain	O
insights	O
into	O
the	O
in	O
vivo	O
situation	O
,	O
we	O
performed	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
using	O
an	O
anti	O
-	O
GATA3	S-PRGE
antibody	O
and	O
showed	O
that	O
GATA3	S-PRGE
binds	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
in	O
Th2	O
cells	O
,	O
but	O
not	O
in	O
iTreg	O
cells	O
(	O
Figure	O
7F	O
)	O
.	O

Taken	O
together	O
these	O
data	O
demonstrate	O
that	O
the	O
GATA3	S-PRGE
-	O
binding	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
is	O
repressing	O
FOXP3	S-PRGE
expression	O
.	O

The	O
current	O
study	O
reveals	O
that	O
FOXP3	S-PRGE
induction	O
,	O
an	O
important	O
step	O
in	O
iTreg	O
commitment	O
,	O
is	O
inhibited	O
by	O
GATA3	S-PRGE
,	O
which	O
is	O
the	O
key	O
regulator	O
for	O
polarization	O
toward	O
Th2	O
cells	O
.	O

After	O
differentiation	O
,	O
the	O
effector	O
Th2	O
cells	O
become	O
refractory	O
to	O
conversion	O
into	O
a	O
FOXP3	S-PRGE
+	O
phenotype	O
.	O

In	O
accordance	O
with	O
other	O
studies	O
,	O
we	O
found	O
that	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
were	O
able	O
to	O
up	O
-	O
regulate	O
FOXP3	S-PRGE
[	O
12	O
,	O
27	O
]	O
.	O

Already	O
-	O
committed	O
cells	O
such	O
as	O
memory	O
T	O
cells	O
and	O
Th1	O
cells	O
showed	O
only	O
moderate	O
and	O
transient	O
FOXP3	S-PRGE
induction	O
,	O
which	O
is	O
not	O
sufficient	O
to	O
change	O
the	O
phenotype	O
toward	O
a	O
regulatory	O
T	O
cell	O
profile	O
.	O

In	O
contrast	O
,	O
naive	O
T	O
cells	O
could	O
efficiently	O
up	O
-	O
regulate	O
FOXP3	S-PRGE
when	O
treated	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
to	O
induce	O
iTreg	O
cells	O
[	O
10	O
,	O
28	O
-	O
34	O
]	O
,	O
suggesting	O
that	O
FOXP3	S-PRGE
plays	O
an	O
important	O
role	O
in	O
the	O
early	O
differentiation	O
process	O
and	O
may	O
act	O
in	O
a	O
way	O
similar	O
to	O
that	O
known	O
for	O
the	O
Th1	O
/	O
Th2	O
decision	O
factors	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
and	O
GATA3	S-PRGE
.	O

This	O
commitment	O
is	O
characterized	O
by	O
competitive	O
expression	O
of	O
these	O
factors	O
[	O
35	O
,	O
36	O
]	O
,	O
which	O
we	O
also	O
observed	O
in	O
differentiating	O
FOXP3	S-PRGE
+	O
iTreg	O
cells	O
including	O
a	O
phase	O
of	O
co	O
-	O
expression	O
,	O
which	O
turns	O
into	O
nonoverlapping	O
expression	O
upon	O
completed	O
differentiation	O
.	O

In	O
this	O
competitive	O
process	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
appeared	O
to	O
be	O
mandatory	O
for	O
the	O
induction	O
of	O
FOXP3	S-PRGE
,	O
possibly	O
by	O
keeping	O
the	O
expression	O
of	O
GATA3	S-PRGE
and	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
low	O
[	O
37	O
,	O
38	O
]	O
.	O

In	O
contrast	O
,	O
differentiating	O
naive	O
T	O
cells	O
in	O
the	O
absence	O
of	O
polarization	O
factors	O
(	O
Th0	O
)	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
,	O
or	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
showed	O
only	O
a	O
transient	O
FOXP3	S-PRGE
expression	O
and	O
failed	O
to	O
generate	O
a	O
population	O
of	O
FOXP3	S-PRGE
-	O
expressing	O
cells	O
,	O
but	O
GATA3	S-PRGE
and	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
were	O
up	O
-	O
regulated	O
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
as	O
we	O
and	O
others	O
previously	O
described	O
,	O
FOXP3	S-PRGE
-	O
promoting	O
factors	O
,	O
such	O
as	O
dexamethasone	O
[	O
39	O
]	O
,	O
CTLA	B-PRGE
-	I-PRGE
4	E-PRGE
[	O
40	O
]	O
,	O
and	O
estrogens	O
[	O
41	O
]	O
,	O
are	O
also	O
known	O
as	O
inhibitors	O
of	O
GATA3	S-PRGE
expression	O
[	O
42	O
-	O
45	O
]	O
.	O

Therefore	O
GATA3	S-PRGE
not	O
only	O
induces	O
differentiation	O
into	O
Th2	O
cells	O
but	O
also	O
inhibits	O
FOXP3	S-PRGE
expression	O
and	O
commitment	O
into	O
iTreg	O
cells	O
.	O

The	O
Th2	O
cytokine	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
but	O
not	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
(	O
unpublished	O
data	O
)	O
was	O
able	O
to	O
inhibit	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
FOXP3	S-PRGE
induction	O
and	O
therefore	O
prevented	O
conversion	O
into	O
the	O
regulatory	O
phenotype	O
.	O

To	O
prove	O
the	O
inhibitory	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
on	O
inducible	O
or	O
natural	O
Treg	O
commitment	O
in	O
vivo	O
,	O
we	O
treated	O
mice	O
with	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

This	O
has	O
been	O
shown	O
to	O
increase	O
the	O
effect	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O

Only	O
the	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
/	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
complex	O
resulted	O
in	O
a	O
decrease	O
of	O
the	O
amount	O
of	O
natural	O
or	O
inducible	O
Treg	O
(	O
CD25	S-PRGE
+	O
and	O
Foxp3	S-PRGE
+	O
)	O
cells	O
7	O
d	O
after	O
treatment	O
.	O

Our	O
results	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
is	O
only	O
interfering	O
with	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
into	O
iTreg	O
cells	O
.	O

But	O
since	O
a	O
distinction	O
of	O
nTreg	O
and	O
iTreg	O
cells	O
is	O
currently	O
not	O
possible	O
,	O
because	O
iTreg	O
cells	O
also	O
transiently	O
express	O
CD25	S-PRGE
after	O
activation	O
,	O
we	O
cannot	O
exclude	O
that	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
may	O
also	O
inhibit	O
Foxp3	S-PRGE
expression	O
in	O
nTreg	O
cells	O
in	O
vivo	O
or	O
that	O
additional	O
effects	O
may	O
contribute	O
to	O
the	O
observed	O
drop	O
in	O
Foxp3	S-PRGE
expression	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
has	O
already	O
been	O
shown	O
to	O
negatively	O
regulate	O
the	O
development	O
of	O
naive	O
T	O
cells	O
into	O
Th1	O
or	O
the	O
IL	B-PRGE
-	I-PRGE
17	E-PRGE
-	O
producing	O
T	O
cells	O
(	O
Th17	O
)	O
[	O
46	O
,	O
47	O
]	O
.	O

Similar	O
effects	O
have	O
been	O
recently	O
described	O
for	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
which	O
,	O
combined	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
inhibits	O
the	O
generation	O
of	O
iTreg	O
cells	O
and	O
induces	O
differentiation	O
into	O
the	O
Th17	O
cells	O
by	O
an	O
unknown	O
mechanism	O
[	O
48	O
,	O
49	O
]	O
.	O

Thus	O
the	O
polarization	O
into	O
iTreg	O
cells	O
is	O
negatively	O
regulated	O
by	O
the	O
effector	O
cytokines	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
has	O
been	O
previously	O
shown	O
to	O
induce	O
the	O
generation	O
of	O
FOXP3	S-PRGE
+	O
Treg	O
cells	O
out	O
of	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
[	O
50	O
]	O
.	O

In	O
those	O
experiments	O
,	O
the	O
concentrations	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
used	O
were	O
low	O
,	O
and	O
as	O
we	O
also	O
observed	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
at	O
low	O
concentration	O
slightly	O
enhanced	O
FOXP3	S-PRGE
expression	O
.	O

Importantly	O
,	O
these	O
concentrations	O
were	O
not	O
sufficient	O
to	O
induce	O
GATA3	S-PRGE
expression	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
may	O
favor	O
proliferation	O
of	O
nTreg	O
cells	O
[	O
47	O
]	O
or	O
directly	O
regulate	O
FOXP3	S-PRGE
expression	O
in	O
a	O
STAT	O
-	O
dependent	O
fashion	O
[	O
51	O
]	O
.	O

Since	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
does	O
not	O
effectively	O
reduce	O
FOXP3	S-PRGE
and	O
fails	O
to	O
induce	O
GATA3	S-PRGE
,	O
we	O
hypothesized	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
dependent	O
inhibition	O
of	O
FOXP3	S-PRGE
could	O
be	O
mediated	O
by	O
GATA3	S-PRGE
.	O

In	O
fact	O
,	O
GATA3	S-PRGE
-	O
inducing	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
concentrations	O
repressed	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
FOXP3	S-PRGE
expression	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
as	O
well	O
as	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
signaling	O
were	O
intact	O
.	O

This	O
result	O
suggested	O
a	O
competitive	O
mechanism	O
between	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
transcription	O
factors	O
in	O
determining	O
lineage	O
commitment	O
during	O
the	O
early	O
phase	O
of	O
differentiation	O
.	O

Accordingly	O
,	O
we	O
investigated	O
naturally	O
high	O
GATA3	S-PRGE
-	O
expressing	O
cells	O
and	O
confirmed	O
the	O
absence	O
of	O
FOXP3	S-PRGE
.	O

Protein	O
transduction	O
of	O
GATA3	S-PRGE
into	O
naive	O
T	O
cells	O
inhibited	O
FOXP3	S-PRGE
induction	O
in	O
human	O
,	O
differentiating	O
,	O
naive	O
T	O
cells	O
.	O

This	O
inhibitory	O
effect	O
of	O
GATA3	S-PRGE
was	O
further	O
confirmed	O
in	O
BALB	O
/	O
c	O
transgenic	O
mice	O
,	O
expressing	O
GATA3	S-PRGE
in	O
T	O
cells	O
(	O
DO11	O
.	O
10	O
:	O
CD2	S-PRGE
-	O
GATA3	S-PRGE
transgenic	O
mice	O
)	O
.	O

In	O
line	O
with	O
the	O
transient	O
overexpression	O
of	O
GATA3	S-PRGE
in	O
human	O
T	O
cells	O
,	O
cells	O
of	O
these	O
mice	O
failed	O
to	O
induce	O
FOXP3	S-PRGE
expression	O
upon	O
exposure	O
with	O
antigen	O
in	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

Strikingly	O
,	O
the	O
DO11	O
.	O
10	O
:	O
CD2	S-PRGE
-	O
GATA3	S-PRGE
mice	O
do	O
have	O
peripheral	O
FOXP3	S-PRGE
+	O
cells	O
,	O
which	O
however	O
displayed	O
a	O
10	O
%	O
-	O
25	O
%	O
lower	O
frequency	O
compared	O
to	O
wild	O
-	O
type	O
DO11	O
.	O
10	O
mice	O
.	O

Thus	O
GATA3	S-PRGE
restrains	O
the	O
development	O
of	O
certain	O
Treg	O
subsets	O
,	O
presumably	O
the	O
inducible	O
,	O
peripheral	O
population	O
and	O
not	O
those	O
of	O
thymic	O
origin	O
.	O

Thymic	O
T	O
cells	O
undergo	O
a	O
different	O
maturation	O
process	O
,	O
which	O
may	O
explain	O
the	O
insensitivity	O
of	O
nTreg	O
to	O
GATA3	S-PRGE
overexpression	O
[	O
52	O
]	O
.	O

In	O
contrast	O
to	O
the	O
Th2	O
-	O
differentiating	O
and	O
iTreg	O
-	O
inhibiting	O
function	O
of	O
GATA3	S-PRGE
in	O
peripheral	O
T	O
cells	O
,	O
GATA3	S-PRGE
acts	O
in	O
the	O
thymus	O
together	O
with	O
other	O
transcription	O
factors	O
such	O
as	O
the	O
Repressor	B-PRGE
of	I-PRGE
GATA3	E-PRGE
(	O
ROG	S-PRGE
)	O
in	O
the	O
differentiation	O
process	O
toward	O
CD8	S-PRGE
cells	O
[	O
53	O
,	O
54	O
]	O
or	O
participates	O
in	O
complex	O
transcriptional	O
feedback	O
network	O
to	O
regulate	O
sympathoadrenal	O
differentiation	O
[	O
55	O
]	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
GATA3	S-PRGE
appears	O
to	O
be	O
tissue	O
specific	O
and	O
cannot	O
be	O
generalized	O
.	O

Our	O
study	O
demonstrates	O
that	O
GATA3	S-PRGE
repressed	O
FOXP3	S-PRGE
expression	O
directly	O
by	O
binding	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
.	O

A	O
palindromic	O
GATA	O
-	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
of	O
the	O
TSS	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
which	O
we	O
have	O
previously	O
identified	O
as	O
the	O
FOXP3	S-PRGE
promoter	O
[	O
24	O
]	O
.	O

Site	O
-	O
specific	O
mutation	O
of	O
this	O
site	O
increased	O
the	O
activity	O
of	O
the	O
promoter	O
constructs	O
,	O
thus	O
revealing	O
the	O
repressive	O
nature	O
of	O
this	O
GATA	O
element	O
in	O
memory	O
T	O
cells	O
,	O
which	O
naturally	O
express	O
GATA3	S-PRGE
,	O
whereas	O
no	O
difference	O
was	O
seen	O
in	O
naive	O
T	O
cells	O
,	O
which	O
do	O
not	O
express	O
GATA3	S-PRGE
.	O

This	O
palindromic	O
GATA	O
element	O
is	O
bound	O
by	O
GATA3	S-PRGE
protein	O
as	O
proven	O
with	O
pull	O
-	O
down	O
experiments	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
by	O
ChIP	O
that	O
GATA3	S-PRGE
binds	O
this	O
element	O
also	O
in	O
intact	O
cells	O
.	O

It	O
is	O
known	O
that	O
GATA3	S-PRGE
can	O
induce	O
transcription	O
by	O
chromatin	O
remodeling	O
[	O
56	O
]	O
,	O
by	O
directly	O
transactivating	O
promoters	O
[	O
36	O
]	O
,	O
or	O
,	O
as	O
shown	O
in	O
the	O
current	O
study	O
,	O
acts	O
as	O
a	O
repressor	O
of	O
gene	O
expression	O
[	O
21	O
,	O
57	O
-	O
59	O
]	O
.	O

Therefore	O
keeping	O
GATA3	S-PRGE
expression	O
low	O
might	O
be	O
required	O
to	O
induce	O
efficient	O
FOXP3	S-PRGE
+	O
iTreg	O
cell	O
generation	O
.	O

The	O
molecular	O
interactions	O
enabling	O
GATA3	S-PRGE
to	O
inhibit	O
FOXP3	S-PRGE
are	O
not	O
identified	O
yet	O
,	O
but	O
the	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
adjacent	O
to	O
positive	O
,	O
inducing	O
sites	O
,	O
composed	O
of	O
AP	O
-	O
1	O
-	O
NFATc2	O
sites	O
[	O
24	O
]	O
,	O
and	O
GATA3	S-PRGE
may	O
compete	O
with	O
the	O
binding	O
of	O
AP	B-PRGE
-	I-PRGE
1	E-PRGE
/	O
NFAT	S-PRGE
to	O
the	O
promoter	O
(	O
unpublished	O
observations	O
)	O
.	O

In	O
summary	O
,	O
we	O
demonstrated	O
that	O
FOXP3	S-PRGE
is	O
negatively	O
regulated	O
by	O
cytokines	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

GATA3	S-PRGE
acts	O
as	O
an	O
inhibitor	O
of	O
FOXP3	S-PRGE
expression	O
in	O
early	O
T	O
cell	O
differentiation	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
Th2	O
cells	O
by	O
directly	O
binding	O
and	O
repressing	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

We	O
therefore	O
describe	O
a	O
new	O
mechanism	O
of	O
how	O
Il	B-PRGE
-	I-PRGE
4	E-PRGE
avoids	O
tolerance	O
induction	O
by	O
repressing	O
FOXP3	S-PRGE
expression	O
.	O

These	O
findings	O
will	O
give	O
new	O
perspectives	O
toward	O
understanding	O
molecular	O
mechanisms	O
of	O
iTreg	O
induction	O
and	O
thus	O
pathways	O
of	O
peripheral	O
tolerance	O
induction	O
,	O
particularly	O
in	O
allergy	O
and	O
asthma	O
.	O

Mice	O
.	O

Normal	O
B6	O
mice	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Transgenic	O
DO11	O
.	O
10	O
mice	O
,	O
expressing	O
a	O
T	O
cell	O
receptor	O
for	O
OVA323	O
-	O
339	O
peptide	O
in	O
the	O
context	O
of	O
H	O
-	O
2d	O
,	O
were	O
backcrossed	O
with	O
mice	O
expressing	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
driven	O
by	O
the	O
human	O
CD2	S-PRGE
locus	O
control	O
region	O
(	O
CD2	S-PRGE
-	O
GATA3	S-PRGE
)	O
[	O
22	O
]	O
,	O
resulting	O
in	O
DO11	O
.	O
10xCD2	S-PRGE
-	O
GATA3	S-PRGE
mice	O
.	O

Mice	O
used	O
for	O
experiments	O
were	O
backcrossed	O
on	O
a	O
BALB	O
/	O
c	O
background	O
for	O
a	O
minimum	O
of	O
eight	O
generations	O
and	O
used	O
at	O
an	O
age	O
of	O
8	O
-	O
12	O
wk	O
.	O

Mice	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
and	O
all	O
animal	O
studies	O
were	O
performed	O
according	O
to	O
institutional	O
and	O
state	O
guidelines	O
.	O

Isolation	O
of	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

CD4	S-PRGE
+	O
T	O
cells	O
were	O
isolated	O
from	O
blood	O
of	O
healthy	O
human	O
volunteers	O
using	O
the	O
anti	O
-	O
CD4	S-PRGE
magnetic	O
beads	O
(	O
Dynal	O
,	O
Hamburg	O
,	O
Germany	O
)	O
as	O
previously	O
described	O
[	O
60	O
]	O
.	O

The	O
purity	O
of	O
CD4	S-PRGE
+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
FACS	O
and	O
was	O
>	O
=	O
95	O
%	O
.	O

Monoclonality	O
of	O
T	O
cell	O
clones	O
was	O
confirmed	O
by	O
TCR	O
-	O
chain	O
mapping	O
and	O
was	O
identified	O
to	O
be	O
Vbeta8	O
positive	O
.	O

The	O
clones	O
were	O
characterized	O
by	O
high	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
secretion	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	S-PRGE
forward	O
primer	O
5	O
'	O
-	O
GAA	O
ACA	O
GCA	O
CAT	O
TCC	O
CAG	O
AGT	O
TC	O
-	O
3	O
'	O
;	O
FOXP3	S-PRGE
reverse	O
primer	O
5	O
'	O
-	O
ATG	O
GCC	O
CAG	O
CGG	O
ATG	O
AG	O
-	O
3	O
'	O
;	O
EF	B-PRGE
-	I-PRGE
1alpha	E-PRGE
forward	O
primer	O
and	O
reverse	O
primer	O
as	O
described	O
[	O
61	O
]	O
;	O
GATA3	S-PRGE
forward	O
primer	O
5	O
'	O
-	O
GCG	O
GGC	O
TCT	O
ATC	O
ACA	O
AAA	O
TGA	O
-	O
3	O
'	O
and	O
rwd	O
5	O
'	O
-	O
GCT	O
CTC	O
CTG	O
GCT	O
GCA	O
GAC	O
AGC	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
-	O
PCR	O
mastermix	O
(	O
Biorad	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Quantitative	O
PCR	O
of	O
murine	O
samples	O
was	O
performed	O
with	O
Brilliant	O
SYBR	O
Green	O
QPCR	O
master	O
mix	O
(	O
Stratagene	O
)	O
and	O
the	O
following	O
primers	O
:	O
Ubiquitin	B-PRGE
C	E-PRGE
,	O
5	O
'	O
-	O
AGG	O
TCA	O
AAC	O
AGG	O
AAG	O
ACA	O
GAC	O
GTA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TCACACCCAAGAACAAGCACA	O
-	O
3	O
'	O
;	O
Smad	B-PRGE
-	I-PRGE
7	E-PRGE
,	O
5	O
'	O
-	O
GAA	O
ACC	O
GGG	O
GGA	O
ACG	O
AAT	O
TAT	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CGC	O
GAG	O
TCT	O
TCT	O
CCT	O
CCC	O
A	O
-	O
3	O
'	O
;	O
TGF	B-PRGE
-	I-PRGE
ss1	E-PRGE
,	O
5	O
'	O
-	O
TGA	O
CGT	O
CAC	O
TGG	O
AGT	O
TGT	O
ACG	O
G	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GGT	O
TCA	O
TGT	O
CAT	O
GGA	O
TGG	O
TGC	O
-	O
3	O
'	O
.	O

Primer	O
pairs	O
were	O
evaluated	O
for	O
integrity	O
by	O
analysis	O
of	O
the	O
amplification	O
plot	O
,	O
dissociation	O
curves	O
,	O
and	O
efficiency	O
of	O
PCR	O
amplification	O
.	O

PCR	O
conditions	O
were	O
10	O
min	O
at	O
95	O
degreesC	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
15	O
s	O
at	O
95	O
degreesC	O
and	O
60	O
degreesC	O
for	O
1	O
min	O
using	O
an	O
7300	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
ubiquitin	B-PRGE
C	E-PRGE
was	O
performed	O
during	O
each	O
run	O
for	O
each	O
sample	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
deltadeltaCT	O
method	O
.	O

Inducible	O
murine	O
Treg	O
culture	O
.	O

Naive	O
CD4	S-PRGE
+	O
T	O
cells	O
(	O
CD4	S-PRGE
+	O
,	O
CD62L	S-PRGE
+	O
,	O
and	O
CD25	S-PRGE
-	O
)	O
were	O
isolated	O
from	O
pooled	O
lymph	O
nodes	O
and	O
spleens	O
by	O
FACS	O
(	O
FACS	O
Aria	O
,	O
BD	O
Biosciences	O
)	O
.	O

5	O
x	O
105	O
T	O
cells	O
were	O
co	O
-	O
cultured	O
with	O
2	O
.	O
5	O
x	O
104	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
[	O
62	O
]	O
and	O
0	O
.	O
01	O
mug	O
/	O
ml	O
OVA323	O
-	O
339	O
peptide	O
(	O
Ansynth	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
-	O
ng	O
/	O
mul	O
rhTGF	B-PRGE
-	I-PRGE
ss1	E-PRGE
(	O
Peprotech	O
)	O
in	O
48	O
-	O
well	O
plates	O
.	O

After	O
4	O
d	O
,	O
cells	O
were	O
harvested	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	S-PRGE
expression	O
by	O
FACS	O
or	O
gene	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O

CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
magnetically	O
-	O
sorted	O
(	O
CD45RO	S-PRGE
depletion	O
,	O
MACS	O
,	O
according	O
to	O
the	O
protocol	O
of	O
the	O
manufacturer	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
(	O
1	O
mug	O
/	O
ml	O
,	O
Okt3	O
,	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	S-PRGE
(	O
2	O
mug	O
/	O
ml	O
)	O
in	O
Th1	O
conditions	O
:	O
25	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
in	O
Th2	O
conditions	O
:	O
25	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
or	O
in	O
Treg	O
conditions	O
:	O
10	O
ng	O
/	O
ml	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
(	O
30	O
ng	O
/	O
ml	O
)	O
.	O

Cloning	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
and	O
construction	O
of	O
mutant	O
constructs	O
.	O

The	O
FOXP3	S-PRGE
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
the	O
pGL3	O
FOXP3	S-PRGE
-	O
511	O
/	O
+	O
176	O
[	O
24	O
]	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
were	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
following	O
primer	O
and	O
its	O
complementary	O
strand	O
were	O
used	O
:	O
GTT	O
TCT	O
CAT	O
GAG	O
CCC	O
TAT	O
TAA	O
GTC	O
ATT	O
CTT	O
ACC	O
TCT	O
CAC	O
CTC	O
TGT	O
GGT	O
GA	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
overnight	O
.	O

3	O
.	O
5	O
mug	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
luciferase	S-PRGE
reporter	O
vector	O
and	O
0	O
.	O
5	O
mug	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4	S-PRGE
+	O
T	O
cells	O
resuspended	O
in	O
100	O
muL	O
of	O
Nucleofector	O
solution	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
electroporated	O
using	O
the	O
U	O
-	O
15	O
program	O
of	O
the	O
Nucleofector	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	S-PRGE
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	S-PRGE
assay	O
system	O
(	O
Promega	O
Biotech	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Data	O
were	O
normalized	O
by	O
the	O
activity	O
of	O
renilla	O
luciferase	S-PRGE
.	O

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
TaqMan	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Applied	O
Biosystems	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Recombinant	O
TAT	S-PRGE
proteins	O
.	O

The	O
cDNAs	O
encoding	O
GATA3	S-PRGE
protein	O
or	O
the	O
truncated	O
GATA3	S-PRGE
(	O
lacking	O
the	O
two	O
zinc	O
fingers	O
)	O
were	O
cloned	O
in	O
frame	O
into	O
an	O
expression	O
vector	O
along	O
with	O
the	O
TAT	S-PRGE
sequence	O
as	O
previously	O
described	O
[	O
63	O
]	O
.	O

Proteins	O
were	O
expressed	O
in	O
BL21	O
Star	O
(	O
DE3	O
)	O
pLysS	O
(	O
Invitrogen	O
)	O
and	O
lysates	O
were	O
purified	O
by	O
Ni2	O
+	O
-	O
chelate	O
column	O
chromatography	O
.	O

Both	O
TAT	S-PRGE
-	O
linked	O
proteins	O
were	O
more	O
than	O
95	O
%	O
pure	O
,	O
based	O
on	O
Coomassie	O
blue	O
staining	O
of	O
sodium	O
disulfate	O
acrylamide	O
gels	O
.	O

TAT	S-PRGE
-	O
GATA3	S-PRGE
transduction	O
.	O

CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
cells	O
were	O
cultured	O
in	O
AIMV	O
medium	O
and	O
transduced	O
with	O
20	O
nM	O
,	O
10	O
nM	O
,	O
or	O
500	O
nM	O
of	O
full	O
-	O
length	O
or	O
truncated	O
GATA3	S-PRGE
over	O
the	O
course	O
of	O
4	O
h	O
.	O

After	O
4	O
h	O
,	O
the	O
cells	O
were	O
washed	O
and	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3	S-PRGE
and	O
anti	O
-	O
CD28	S-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

Each	O
day	O
,	O
the	O
TAT	S-PRGE
proteins	O
were	O
freshly	O
added	O
to	O
the	O
medium	O
.	O

FOXP3	S-PRGE
expression	O
was	O
measured	O
after	O
5	O
d	O
by	O
intracellular	O
staining	O
.	O

Intracellular	O
cytokine	O
staining	O
.	O

T	O
cells	O
were	O
stimulated	O
with	O
2	O
x	O
10	O
-	O
7	O
M	O
PMA	O
and	O
1	O
mug	O
/	O
ml	O
of	O
ionomycin	O
(	O
Sigma	O
Chemicals	O
)	O
for	O
4	O
h	O
.	O

The	O
following	O
mAb	O
was	O
used	O
:	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
PE	O
(	O
8D4	O
-	O
8	O
,	O
BD	O
)	O
.	O

Matched	O
isotype	O
controls	O
were	O
used	O
at	O
the	O
same	O
protein	O
concentration	O
as	O
the	O
respective	O
antibodies	O
.	O

Four	O
-	O
color	O
FACS	O
was	O
performed	O
using	O
an	O
EPICS	O
XL	O
-	O
MCL	O
(	O
Beckman	O
Coulter	O
)	O
using	O
the	O
software	O
Expo32	O
version	O
for	O
data	O
acquisition	O
and	O
evaluation	O
.	O

Flow	O
cytometry	O
.	O

For	O
analysis	O
of	O
FOXP3	S-PRGE
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
antibody	O
CD25	S-PRGE
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
cells	O
were	O
incubated	O
with	O
PE	O
-	O
conjugated	O
monoclonal	O
antibody	O
PCH101	O
(	O
anti	O
-	O
human	O
FOXP3	S-PRGE
;	O
eBioscience	O
)	O
based	O
on	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
)	O
.	O

For	O
cell	O
surface	O
marker	O
staining	O
,	O
cells	O
were	O
incubated	O
for	O
20	O
min	O
at	O
4degreesC	O
in	O
staining	O
buffer	O
with	O
the	O
following	O
antibodies	O
:	O
anti	O
-	O
CD152	S-PRGE
-	O
PE	O
(	O
CTLA	O
-	O
4	O
;	O
BD	O
)	O
,	O
anti	O
-	O
PD	B-PRGE
-	I-PRGE
1	E-PRGE
(	O
eBiosciences	O
)	O
,	O
anti	O
-	O
GITR	S-PRGE
(	O
R	O
&	O
D	O
Systems	O
)	O
,	O
anti	O
-	O
CD69	S-PRGE
(	O
Beckman	O
Coulter	O
)	O
,	O
anti	O
-	O
CD103	S-PRGE
(	O
DakoCytomation	O
)	O
,	O
anti	O
-	O
CD62L	S-PRGE
(	O
Beckman	O
Coulter	O
)	O
,	O
or	O
anti	O
-	O
HLA	O
-	O
DR	O
(	O
Beckman	O
Coulter	O
)	O
.	O

The	O
controls	O
were	O
FITC	O
,	O
PE	O
,	O
or	O
ECD	O
-	O
conjugated	O
mouse	O
IgG1	O
or	O
rat	O
IgG2a	O
.	O

For	O
staining	O
of	O
mouse	O
cells	O
,	O
the	O
following	O
mAbs	O
from	O
BD	O
Biosciences	O
were	O
used	O
following	O
standard	O
techniques	O
as	O
described	O
above	O
:	O
anti	O
-	O
CD3	S-PRGE
,	O
anti	O
-	O
CD4	S-PRGE
,	O
and	O
anti	O
-	O
CD25	S-PRGE
.	O

Anti	O
-	O
FcgammaRII	O
/	O
III	O
antibody	O
(	O
2	O
.	O
4G2	O
,	O
ATCC	O
)	O
was	O
included	O
in	O
all	O
stainings	O
to	O
reduce	O
nonspecific	O
antibody	O
binding	O
.	O

To	O
isolate	O
naive	O
murine	O
CD4	S-PRGE
T	O
cells	O
from	O
murine	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10xCD2	S-PRGE
-	O
GATA3	S-PRGE
T	O
cells	O
,	O
cells	O
were	O
stained	O
with	O
anti	O
-	O
CD25	S-PRGE
-	O
FITC	O
,	O
anti	O
-	O
CD62L	S-PRGE
-	O
PE	O
,	O
and	O
anti	O
-	O
CD4	S-PRGE
-	O
APC	O
prior	O
to	O
sorting	O
.	O

Dead	O
cells	O
were	O
excluded	O
with	O
4	O
'	O
'	O
,	O
6	O
-	O
Diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
.	O

To	O
analyze	O
murine	O
Foxp3	S-PRGE
expression	O
in	O
inducible	O
Treg	O
cultures	O
,	O
cells	O
were	O
stained	O
intracellularly	O
with	O
anti	O
-	O
Foxp3	S-PRGE
-	O
PE	O
according	O
to	O
manufacturer	O
'	O
s	O
instruction	O
,	O
in	O
conjunction	O
with	O
anti	O
-	O
CD4	S-PRGE
-	O
APC	O
and	O
LIVE	O
/	O
DEAD	O
fixable	O
dead	O
cell	O
stain	O
kit	O
(	O
Invitrogen	O
)	O
to	O
discriminate	O
live	O
cells	O
.	O

All	O
monoclonal	O
antibodies	O
for	O
murine	O
cell	O
stainings	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
Biosciences	O
.	O

Western	O
blotting	O
.	O

For	O
FOXP3	S-PRGE
analysis	O
on	O
the	O
protein	O
level	O
,	O
1	O
x	O
106	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Magicmark	O
,	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Life	O
Science	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
BSA	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
an	O
1	O
:	O
200	O
dilution	O
of	O
goat	O
anti	O
-	O
FOXP3	S-PRGE
in	O
blocking	O
buffer	O
(	O
Abcam	O
)	O
overnight	O
at	O
4	O
degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
goat	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
1000	O
camera	O
(	O
Fuji	O
)	O
.	O

Membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
re	O
-	O
blocked	O
for	O
1	O
h	O
.	O

The	O
membranes	O
were	O
re	O
-	O
probed	O
using	O
anti	O
-	O
GATA3	S-PRGE
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
(	O
4B10	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
GAPDH	S-PRGE
(	O
6C5	O
,	O
Ambion	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
SMAD2	S-PRGE
(	O
138D4	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
STAT6	S-PRGE
(	O
5A4	O
)	O
,	O
and	O
anti	O
-	O
STAT6	S-PRGE
(	O
Cell	O
Signaling	O
Technology	O
)	O
,	O

Administration	O
of	O
cytokines	O
and	O
antibodies	O
in	O
vivo	O
.	O

Age	O
-	O
and	O
gender	O
-	O
matched	O
normal	O
B6	O
mice	O
received	O
every	O
other	O
day	O
intraperitoneal	O
(	O
ip	O
)	O
injections	O
of	O
PBS	O
,	O
1	O
.	O
5	O
mug	O
rmIL	O
-	O
4	O
,	O
50	O
mug	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
,	O
or	O
a	O
mixture	O
of	O
1	O
.	O
5	O
mug	O
rmIL	B-PRGE
-	I-PRGE
4	E-PRGE
plus	O
50	O
mug	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
for	O
7	O
d	O
.	O

Thereafter	O
,	O
spleen	O
and	O
lymph	O
node	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
for	O
CD3	S-PRGE
,	O
CD4	S-PRGE
,	O
and	O
CD25	S-PRGE
expression	O
.	O

The	O
anti	O
-	O
mouse	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
MAB404	O
was	O
obtained	O
from	O
R	O
&	O
D	O
Systems	O
,	O
the	O
second	O
anti	O
-	O
mouse	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAb	O
11B11	O
was	O
purchased	O
from	O
eBioscience	O
.	O

ChIP	O
.	O

ChIP	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Upstate	O
Biotechnology	O
)	O
with	O
the	O
following	O
modifications	O
.	O

iTreg	O
and	O
Th2	O
cells	O
were	O
fixed	O
with	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

The	O
chromatin	O
was	O
sheared	O
to	O
200	O
-	O
1000	O
bp	O
of	O
length	O
by	O
sonication	O
with	O
five	O
pulses	O
of	O
10	O
s	O
at	O
30	O
%	O
power	O
(	O
Bandelin	O
)	O
.	O

The	O
chromatin	O
was	O
pre	O
-	O
cleared	O
for	O
2	O
h	O
with	O
normal	O
mouse	O
IgG	O
beads	O
and	O
then	O
incubated	O
with	O
anti	O
-	O
GATA3	S-PRGE
-	O
agarose	O
beads	O
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
2	O
h	O
.	O

Washing	O
and	O
elution	O
buffers	O
were	O
used	O
according	O
to	O
the	O
protocol	O
of	O
Upstate	O
Biotechnology	O
.	O

Crosslinks	O
were	O
reversed	O
by	O
incubation	O
at	O
65	O
degreesC	O
for	O
4	O
h	O
in	O
the	O
presence	O
of	O
0	O
.	O
2	O
M	O
NaCl	O
,	O
and	O
the	O
DNA	O
was	O
purified	O
by	O
phenol	O
/	O
chloroform	O
extraction	O
.	O

The	O
amount	O
of	O
DNA	O
was	O
determined	O
by	O
conventional	O
PCR	O
.	O

The	O
PCR	O
addressed	O
for	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
-	O
246	O
to	O
-	O
511	O
and	O
was	O
performed	O
using	O
the	O
following	O
primers	O
:	O
5	O
'	O
-	O
gtgccctttacgagt	O
catctg	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
gtgccctttacgagtcatctg	O
-	O
3	O
'	O
.	O

The	O
PCR	O
products	O
were	O
visualized	O
using	O
an	O
ethidium	O
bromide	O
gel	O
.	O

Pull	O
-	O
down	O
assay	O
.	O

CD4	S-PRGE
+	O
T	O
cells	O
were	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
2	O
h	O
at	O
37degreesC	O
.	O

The	O
cells	O
were	O
pelleted	O
,	O
resuspended	O
in	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
[	O
pH	O
7	O
.	O
9	O
]	O
,	O
420	O
mM	O
NaCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
2	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
protease	O
inhibitors	O
[	O
Sigma	O
]	O
.	O
and	O
0	O
.	O
1	O
%	O
NP	O
-	O
40	O
)	O
and	O
lysed	O
on	O
ice	O
for	O
15	O
min	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

The	O
supernatant	O
was	O
diluted	O
1	O
:	O
3	O
with	O
buffer	O
D	O
(	O
as	O
buffer	O
C	O
,	O
but	O
without	O
NaCl	O
)	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
mug	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Sigma	O
)	O
and	O
70	O
mul	O
of	O
streptavidin	O
-	O
agarose	O
(	O
Amersham	O
Biosciences	O
)	O
carrying	O
biotinylated	O
oligonucleotides	O
,	O
for	O
3	O
h	O
at	O
4	O
degreesC	O
.	O

The	O
beads	O
were	O
washed	O
twice	O
with	O
buffer	O
C	O
:	O
D	O
(	O
1	O
:	O
3	O
)	O
and	O
resuspended	O
in	O
DTT	O
-	O
containing	O
loading	O
buffer	O
(	O
NuPAGE	O
;	O
Invitrogen	O
)	O
,	O
heated	O
to	O
70	O
degreesC	O
for	O
10	O
min	O
,	O
and	O
the	O
eluants	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
detected	O
using	O
an	O
anti	O
-	O
GATA3	S-PRGE
mAb	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O

Accumulated	O
signals	O
were	O
analyzed	O
using	O
AIDA	O
software	O
(	O
Raytest	O
)	O
.	O

Th2	O
Cells	O
Cannot	O
Induce	O
FOXP3	S-PRGE
Expression	O

(	O
A	O
)	O
Human	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
with	O
or	O
without	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
as	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
of	O
(	O
B	O
)	O
.	O

Cells	O
were	O
harvested	O
after	O
5	O
days	O
and	O
FOXP3	S-PRGE
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
4	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
In	O
vitro	O
differentiated	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
were	O
activated	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
or	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
as	O
indicated	O
.	O

The	O
phenotype	O
of	O
these	O
cells	O
was	O
confirmed	O
by	O
FACS	O
and	O
proliferation	O
analysis	O
(	O
Figure	O
S1	O
)	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
four	O
independent	O
experiments	O
.	O

Th2	O
Cells	O
Do	O
Not	O
Express	O
FOXP3	S-PRGE

(	O
A	O
)	O
Intracellular	O
FACS	O
analysis	O
of	O
FOXP3	S-PRGE
expression	O
in	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
-	O
differentiated	O
cells	O
(	O
two	O
rounds	O
,	O
phenotype	O
see	O
Figure	O
S1	O
)	O
,	O
rested	O
or	O
activated	O
,	O
with	O
or	O
without	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

FOXP3	S-PRGE
expression	O
was	O
measured	O
after	O
5	O
d	O
in	O
culture	O
.	O

The	O
dot	O
blots	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Shows	O
the	O
same	O
experimental	O
setup	O
,	O
but	O
naturally	O
occurring	O
Th2	O
cells	O
were	O
analyzed	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Th2	O
-	O
or	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
Producing	O
Cells	O
Lack	O
FOXP3	S-PRGE

(	O
A	O
)	O
FACS	O
analysis	O
of	O
intracellular	O
FOXP3	S-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
expression	O
following	O
PMA	O
/	O
Ionomycin	O
stimulation	O
.	O

CD4	S-PRGE
+	O
T	O
cells	O
were	O
gated	O
on	O
the	O
basis	O
of	O
CD45RO	S-PRGE
and	O
CD25	S-PRGE
surface	O
expression	O
(	O
upper	O
panel	O
)	O
,	O
and	O
gated	O
cells	O
are	O
shown	O
below	O
for	O
the	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
-	O
(	O
A	O
,	O
left	O
panel	O
)	O
,	O
the	O
CD45RO	S-PRGE
+	O
CD25	S-PRGE
+	O
(	O
right	O
panel	O
)	O
,	O
and	O
the	O
CD45RO	S-PRGE
-	O
CD25	S-PRGE
-	O
subsets	O
(	O
central	O
panel	O
)	O
.	O

A	O
statistical	O
analysis	O
of	O
eight	O
independent	O
donors	O
after	O
subtraction	O
of	O
the	O
isotype	O
control	O
are	O
shown	O
in	O
(	O
B	O
)	O
.	O

The	O
dotted	O
gray	O
line	O
indicates	O
the	O
IC	O
background	O
level	O
.	O

The	O
error	O
bars	O
show	O
the	O
error	O
of	O
the	O
mean	O
.	O

(	O
C	O
)	O
Similarly	O
,	O
a	O
Th2	O
clone	O
(	O
BR8	O
)	O
,	O
CRTH2	S-PRGE
+	O
Th2	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
-	O
secreting	O
cells	O
,	O
and	O
memory	O
T	O
cells	O
(	O
CD45RO	S-PRGE
)	O
were	O
stained	O
for	O
FOXP3	S-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

FOXP3	S-PRGE
Induction	O
During	O
the	O
Differentiation	O
Process	O

(	O
A	O
)	O
Human	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
in	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
5	O
ng	O
/	O
ml	O
)	O
or	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
25	O
ng	O
/	O
ml	O
)	O
.	O

The	O
cells	O
were	O
harvested	O
at	O
different	O
time	O
points	O
,	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
FOXP3	S-PRGE
and	O
GATA3	S-PRGE
expression	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Intracellular	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
staining	O
is	O
shown	O
after	O
exposure	O
of	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
to	O
differentiating	O
conditions	O
as	O
in	O
part	O
A	O
of	O
the	O
figure	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Effect	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
on	O
FOXP3	S-PRGE
Induction	O

(	O
A	O
)	O
A	O
statistical	O
analysis	O
was	O
performed	O
with	O
six	O
donors	O
on	O
day	O
5	O
(	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
10	O
ng	O
/	O
ml	O
)	O
and	O
with	O
or	O
without	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
100	O
ng	O
/	O
ml	O
)	O
)	O
;	O
Shown	O
is	O
the	O
mean	O
,	O
and	O
error	O
bars	O
indicated	O
the	O
SD	O
of	O
six	O
donors	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Dunnett	O
test	O
.	O

Statistical	O
significance	O
is	O
indicated	O
by	O
asterisks	O
(	O
*	O
p	O
<	O
=	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
01	O
,	O
Dunnett	O
)	O
.	O

(	O
B	O
)	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
a	O
constant	O
concentration	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
5	O
ng	O
/	O
ml	O
)	O
with	O
an	O
increasing	O
concentration	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
as	O
indicated	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
quantification	O
after	O
5	O
d	O
.	O

(	O
C	O
)	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
cells	O
were	O
stimulated	O
in	O
vitro	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
10ng	O
/	O
ml	O
)	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
100	O
ng	O
/	O
ml	O
)	O
as	O
indicated	O
.	O

After	O
1	O
h	O
,	O
cell	O
lysates	O
were	O
prepared	O
and	O
analyzed	O
by	O
Western	O
blot	O
for	O
phosphorylated	O
SMAD2	S-PRGE
and	O
STAT6	S-PRGE
.	O

Total	O
STAT6	S-PRGE
and	O
GAPDH	S-PRGE
served	O
as	O
internal	O
control	O
.	O

(	O
D	O
)	O
Intracellular	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
staining	O
are	O
shown	O
after	O
exposure	O
of	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
to	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
as	O
described	O
for	O
panel	O
B	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
Inhibits	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
Mediated	O
iTreg	O
Commitment	O

CFSE	O
-	O
labeled	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
as	O
indicated	O
.	O

After	O
5	O
d	O
,	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
A	O
)	O
and	O
results	O
of	O
six	O
independent	O
experiments	O
are	O
shown	O
in	O
the	O
bar	O
graph	O
below	O
(	O
B	O
)	O
.	O

Statistical	O
significance	O
(	O
one	O
-	O
way	O
Anova	O
,	O
Newman	O
-	O
Keuls	O
)	O
is	O
indicated	O
by	O
asterisks	O
(	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
001	O
)	O
.	O

(	O
C	O
)	O
Kinetic	O
analysis	O
of	O
intracellular	O
GATA3	S-PRGE
and	O
FOXP3	S-PRGE
staining	O
is	O
shown	O
in	O
panel	O
C	O
following	O
exposure	O
of	O
CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
T	O
cells	O
to	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

GATA3	S-PRGE
Acts	O
as	O
a	O
Negative	O
Regulator	O
of	O
FOXP3	S-PRGE
Expression	O

(	O
A	O
)	O
Human	O
naive	O
CD4	S-PRGE
+	O
CDRA	S-PRGE
+	O
T	O
cells	O
were	O
transduced	O
with	O
0	O
,	O
20	O
,	O
100	O
,	O
and	O
500	O
nM	O
of	O
TAT	B-PRGE
-	I-PRGE
GATA3	E-PRGE
protein	O
,	O
and	O
intracellular	O
presence	O
of	O
GATA3	S-PRGE
was	O
analyzed	O
using	O
FACS	O
following	O
anti	O
-	O
CD3	S-PRGE
/	O
CD28	S-PRGE
activation	O
of	O
the	O
cells	O
.	O

GFP	S-PRGE
-	O
positive	O
cells	O
were	O
gated	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	S-PRGE
expression	O
following	O
a	O
2	O
-	O
d	O
incubation	O
period	O
(	O
lower	O
panel	O
)	O
.	O

Data	O
are	O
representative	O
of	O
four	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
T	O
cells	O
were	O
isolated	O
from	O
D011	O
.	O
10	O
and	O
D011	O
.	O
10xCD2	S-PRGE
-	O
GATA3	S-PRGE
mice	O
and	O
treated	O
with	O
OVA	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
for	O
96	O
h	O
.	O

Surface	O
CD4	S-PRGE
and	O
intracellular	O
FOXP3	S-PRGE
were	O
measured	O
by	O
FACS	O
.	O

These	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
The	O
cells	O
treated	O
as	O
in	O
(	O
B	O
)	O
were	O
harvested	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
SMAD7	S-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
expression	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

GATA3	S-PRGE
Represses	O
the	O
Human	O
FOXP3	S-PRGE
Promoter	O

(	O
A	O
)	O
Jurkat	O
,	O
Th2	O
cells	O
,	O
and	O
human	O
primary	O
CD4	S-PRGE
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
basic	O
)	O
or	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	S-PRGE
promoter	O
region	O
fused	O
to	O
the	O
luciferase	S-PRGE
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	S-PRGE
of	O
four	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
B	O
)	O
Naive	O
CD4	S-PRGE
T	O
cells	O
were	O
transfected	O
with	O
the	O
FOXP3	S-PRGE
promoter	O
reporter	O
construct	O
together	O
with	O
a	O
GATA3	S-PRGE
expression	O
vector	O
or	O
an	O
empty	O
vector	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Naive	O
(	O
left	O
panel	O
)	O
or	O
memory	O
(	O
right	O
panel	O
)	O
CD4	S-PRGE
T	O
cells	O
were	O
transfected	O
with	O
wild	O
-	O
type	O
or	O
a	O
GATA3	S-PRGE
mutated	O
511	O
-	O
FOXP3	S-PRGE
promoter	O
reporter	O
construct	O
and	O
activated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	S-PRGE
of	O
eight	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
D	O
)	O
Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
cells	O
transfected	O
with	O
GATA3	S-PRGE
or	O
an	O
empty	O
vector	O
,	O
(	O
E	O
)	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
and	O
binding	O
factors	O
precipitated	O
using	O
biotinylated	O
oligonucleotides	O
.	O

The	O
oligonucleotides	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
on	O
a	O
SDS	O
-	O
PAGE	O
gel	O
.	O

The	O
amounts	O
of	O
GATA3	S-PRGE
protein	O
in	O
the	O
precipitates	O
were	O
assessed	O
by	O
immunoblotting	O
with	O
anti	O
-	O
GATA3	S-PRGE
mAb	O
.	O

Total	O
nuclear	O
extracts	O
were	O
also	O
run	O
as	O
controls	O
.	O

Data	O
are	O
representative	O
of	O
three	O
different	O
experiments	O
.	O

(	O
F	O
)	O
iTreg	O
or	O
Th2	O
cells	O
were	O
analyzed	O
by	O
ChIP	O
for	O
GATA3	S-PRGE
binding	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

The	O
"	O
input	O
"	O
represents	O
PCR	O
amplification	O
of	O
the	O
total	O
sample	O
,	O
which	O
was	O
not	O
subjected	O
to	O
any	O
precipitation	O
.	O

Results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Suppression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
Nuclear	O
Import	O
and	O
Phosphorylation	O
:	O
A	O
Novel	O
Mechanism	O
of	O
Corticosteroid	O
Action	O
in	O
Allergic	O
Disease	O

Background	O

GATA	B-PRGE
-	I-PRGE
3	E-PRGE
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
the	O
cytokines	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
from	O
T	O
helper	O
-	O
2	O
(	O
Th2	O
)	O
cells	O
and	O
therefore	O
is	O
a	O
key	O
mediator	O
of	O
allergic	O
diseases	O
.	O

Corticosteroids	O
are	O
highly	O
effective	O
in	O
suppressing	O
allergic	O
inflammation	O
,	O
but	O
their	O
effects	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
are	O
unknown	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
corticosteroid	O
fluticasone	O
propionate	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
regulation	O
in	O
human	O
T	O
-	O
lymphocytes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Methods	O
and	O
Findings	O

In	O
a	O
T	O
lymphocyte	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
stimulated	O
by	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
in	O
vitro	O
we	O
demonstrated	O
that	O
fluticasone	O
inhibits	O
nuclear	O
translocation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
expression	O
of	O
Th2	O
cytokines	O
via	O
a	O
mechanism	O
independent	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
competition	O
between	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
the	O
ligand	O
-	O
activated	O
glucocorticoid	B-PRGE
receptor	E-PRGE
for	O
nuclear	O
transport	O
through	O
the	O
nuclear	O
importer	O
importin	O
-	O
alpha	O
.	O

In	O
addition	O
,	O
fluticasone	O
induces	O
the	O
expression	O
of	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	I-PRGE
MAPK	I-PRGE
)	I-PRGE
phosphatase	I-PRGE
-	I-PRGE
1	E-PRGE
(	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
)	O
,	O
the	O
endogenous	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
which	O
is	O
necessary	O
for	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
translocation	O
.	O

These	O
inhibitory	O
effects	O
of	O
fluticasone	O
are	O
rapid	O
,	O
potent	O
,	O
and	O
prolonged	O
.	O

We	O
also	O
demonstrated	O
that	O
inhaled	O
fluticasone	O
inhibits	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
translocation	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
in	O
vivo	O
.	O

Conclusions	O

Corticosteroids	O
have	O
a	O
potent	O
inhibitory	O
effect	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
via	O
two	O
interacting	O
mechanisms	O
that	O
potently	O
suppress	O
Th2	O
cytokine	O
expression	O
.	O

This	O
novel	O
mechanism	O
of	O
action	O
of	O
corticosteroids	O
may	O
account	O
for	O
the	O
striking	O
clinical	O
efficacy	O
of	O
corticosteroids	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
.	O

Please	O
see	O
later	O
in	O
the	O
article	O
for	O
Editors	O
'	O
Summary	O

Inflammation	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
,	O
rhinitis	O
,	O
and	O
atopic	O
dermatitis	O
is	O
mediated	O
via	O
expression	O
of	O
the	O
cytokines	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
from	O
T	O
helper	O
-	O
2	O
(	O
Th2	O
)	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
regulate	O
the	O
expression	O
of	O
IgE	O
from	O
B	O
lymphocytes	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
plays	O
a	O
key	O
role	O
in	O
eosinophilic	O
inflammation	O
[	O
1	O
]	O
.	O

Th2	O
cytokines	O
are	O
regulated	O
by	O
the	O
zinc	O
finger	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
Th2	O
cells	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

GATA	B-PRGE
-	I-PRGE
3	E-PRGE
determines	O
Th2	O
cell	O
differentiation	O
and	O
selectively	O
activates	O
the	O
promoters	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
through	O
chromatin	O
remodelling	O
[	O
4	O
]	O
-	O
[	O
7	O
]	O
.	O

The	O
key	O
role	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
allergic	O
airway	O
inflammation	O
has	O
been	O
demonstrated	O
in	O
mice	O
by	O
the	O
reduced	O
release	O
of	O
Th2	O
cytokines	O
in	O
animals	O
treated	O
with	O
dominant	O
-	O
negative	O
mutants	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
by	O
local	O
application	O
of	O
antisense	O
oligonucleotides	O
to	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

Furthermore	O
,	O
conditional	O
knock	O
-	O
out	O
of	O
the	O
Gata3	S-PRGE
gene	O
in	O
mice	O
reduces	O
expression	O
of	O
Th2	O
cytokines	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
10	O
]	O
,	O
and	O
similar	O
results	O
have	O
been	O
reported	O
in	O
isolated	O
murine	O
CD4	S-PRGE
+	O
lymphocytes	O
[	O
11	O
]	O
.	O

Finally	O
,	O
knockdown	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
expression	O
using	O
siRNA	O
in	O
human	O
T	O
cells	O
results	O
in	O
loss	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
mediated	O
Th2	O
cytokine	O
expression	O
[	O
12	O
]	O
.	O

In	O
order	O
for	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
to	O
regulate	O
gene	O
expression	O
,	O
it	O
must	O
translocate	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
access	O
its	O
target	O
genes	O
.	O

Enhanced	O
nuclear	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
following	O
T	O
cell	O
receptor	O
activation	O
was	O
first	O
demonstrated	O
in	O
murine	O
T	O
cells	O
[	O
13	O
]	O
and	O
was	O
recently	O
confirmed	O
in	O
human	O
T	O
cells	O
following	O
T	O
cell	O
receptor	O
and	O
co	O
-	O
receptor	O
stimulation	O
[	O
12	O
]	O
.	O

GATA	B-PRGE
-	I-PRGE
3	E-PRGE
contains	O
a	O
classical	O
nuclear	O
import	O
signal	O
[	O
14	O
]	O
and	O
is	O
transported	O
into	O
the	O
nucleus	O
by	O
the	O
nuclear	O
import	O
protein	O
importin	O
-	O
alpha	O
(	O
also	O
known	O
as	O
karyopherin	O
-	O
alpha	O
)	O
[	O
12	O
]	O
.	O

Deletion	O
of	O
a	O
region	O
encompassing	O
the	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localisation	O
sequence	O
(	O
NLS	O
)	O
region	O
in	O
murine	O
and	O
human	O
cells	O
prevents	O
its	O
nuclear	O
localisation	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
.	O

The	O
affinity	O
of	O
the	O
importin	O
-	O
alpha	O
-	O
NLS	O
interaction	O
is	O
regulated	O
by	O
phosphorylation	O
[	O
15	O
]	O
,	O
and	O
we	O
have	O
shown	O
that	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
plays	O
a	O
critical	O
role	O
in	O
phosphorylating	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
to	O
enhance	O
its	O
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
subsequent	O
transport	O
into	O
the	O
nucleus	O
[	O
12	O
]	O
.	O

Corticosteroids	O
are	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
allergic	O
inflammation	O
,	O
with	O
marked	O
suppression	O
of	O
Th2	O
cytokines	O
in	O
airways	O
of	O
patients	O
with	O
asthma	O
[	O
16	O
]	O
.	O

Corticosteroids	O
mediate	O
their	O
anti	O
-	O
inflammatory	O
effects	O
through	O
binding	O
to	O
glucocorticoid	B-PRGE
receptors	E-PRGE
(	O
GRs	S-PRGE
)	O
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
interact	O
with	O
glucocorticoid	O
response	O
elements	O
(	O
GREs	O
)	O
in	O
the	O
promoter	O
regions	O
of	O
steroid	O
-	O
sensitive	O
genes	O
.	O

Alternatively	O
,	O
activated	O
GR	S-PRGE
interacts	O
with	O
coactivator	O
molecules	O
to	O
suppress	O
the	O
expression	O
of	O
inflammatory	O
genes	O
by	O
inhibiting	O
the	O
action	O
of	O
proinflammatory	O
transcription	O
factors	O
such	O
as	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
through	O
the	O
recruitment	O
of	O
co	O
-	O
repressor	O
molecules	O
such	O
as	O
histone	B-PRGE
deacetylase	I-PRGE
-	I-PRGE
2	E-PRGE
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Nuclear	O
localisation	O
and	O
retention	O
of	O
GR	S-PRGE
is	O
mediated	O
through	O
the	O
nuclear	O
localisation	O
sequences	O
NL1	O
and	O
NL2	O
[	O
19	O
]	O
,	O
by	O
nuclear	O
retention	O
signals	O
[	O
20	O
]	O
,	O
and	O
by	O
control	O
of	O
nuclear	O
export	O
via	O
a	O
chromosomal	B-PRGE
region	I-PRGE
maintenance	I-PRGE
1	E-PRGE
(	O
CRM	B-PRGE
-	I-PRGE
1	E-PRGE
)	O
dependent	O
pathway	O
[	O
21	O
]	O
.	O

NL1	O
,	O
which	O
is	O
similar	O
to	O
the	O
SV40	O
NLS	O
,	O
binds	O
to	O
importin	O
-	O
alpha	O
[	O
22	O
]	O
.	O

NL1	O
is	O
activated	O
both	O
by	O
glucocorticoid	O
agonists	O
such	O
as	O
dexamethasone	O
and	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
and	O
by	O
glucocorticoid	O
antagonists	O
such	O
as	O
mifepristone	O
(	O
RU486	O
)	O
[	O
23	O
]	O
.	O

NL1	O
can	O
be	O
mutated	O
,	O
and	O
the	O
resulting	O
GR	S-PRGE
still	O
translocates	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
ligands	O
,	O
but	O
via	O
interaction	O
with	O
importin	B-PRGE
7	E-PRGE
,	O
an	O
event	O
that	O
requires	O
an	O
as	O
-	O
yet	O
unknown	O
component	O
[	O
23	O
]	O
.	O

NL2	O
is	O
poorly	O
defined	O
,	O
residing	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
,	O
and	O
much	O
less	O
is	O
known	O
about	O
its	O
mechanism	O
of	O
GR	S-PRGE
import	O
[	O
24	O
]	O
.	O

A	O
variety	O
of	O
other	O
factors	O
are	O
also	O
important	O
for	O
the	O
regulation	O
of	O
GR	S-PRGE
activation	O
and	O
nuclear	O
import	O
including	O
chaperones	O
such	O
as	O
Hsp90	O
and	O
other	O
immunophilins	O
[	O
24	O
]	O
-	O
[	O
26	O
]	O
and	O
FK506	O
-	O
binding	O
proteins	O
that	O
may	O
be	O
linked	O
to	O
dynein	O
and	O
/	O
or	O
peptidylprolyl	O
isomerase	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
inhibition	O
of	O
Th2	O
cytokines	O
by	O
corticosteroids	O
is	O
not	O
well	O
understood	O
,	O
because	O
the	O
genes	O
encoding	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
do	O
not	O
have	O
any	O
recognisable	O
GRE	O
sequence	O
[	O
29	O
]	O
and	O
are	O
only	O
partly	O
regulated	O
by	O
NF	O
-	O
kappaB	O
in	O
human	O
cells	O
[	O
30	O
]	O
-	O
[	O
32	O
]	O
.	O

Using	O
overexpression	O
and	O
CAT	S-PRGE
-	O
reporter	O
genes	O
,	O
Lavender	O
and	O
colleagues	O
[	O
33	O
]	O
have	O
shown	O
that	O
GR	S-PRGE
reduced	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
mediated	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
and	O
-	B-PRGE
13	E-PRGE
promoter	O
activity	O
in	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

The	O
authors	O
postulated	O
that	O
local	O
recruitment	O
of	O
GR	S-PRGE
may	O
alter	O
the	O
ability	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
either	O
to	O
bind	O
to	O
its	O
target	O
site	O
,	O
to	O
cause	O
transcriptional	O
up	O
-	O
regulation	O
,	O
or	O
to	O
maintain	O
an	O
environment	O
that	O
is	O
permissive	O
for	O
transcription	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
a	O
synthetic	O
corticosteroid	O
,	O
FP	O
,	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
a	O
T	O
lymphocyte	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
activated	O
by	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
antibodies	O
in	O
vitro	O
.	O

We	O
also	O
studied	O
the	O
effects	O
of	O
inhaled	O
fluticasone	O
therapy	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
subcellular	O
localization	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
patients	O
with	O
asthma	O
.	O

Participants	O
and	O
Study	O
Design	O

We	O
studied	O
patients	O
with	O
mild	O
asthma	O
who	O
were	O
not	O
treated	O
with	O
inhaled	O
corticosteroids	O
who	O
had	O
been	O
included	O
in	O
a	O
previously	O
reported	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
with	O
FP	O
[	O
34	O
]	O
.	O

Seven	O
patients	O
with	O
mild	O
asthma	O
entered	O
the	O
study	O
and	O
were	O
randomized	O
to	O
receive	O
a	O
single	O
inhalation	O
of	O
FP	O
(	O
100	O
and	O
500	O
microg	O
)	O
or	O
a	O
matched	O
placebo	O
control	O
via	O
a	O
spacer	O
chamber	O
,	O
and	O
the	O
other	O
treatment	O
was	O
given	O
after	O
a	O
wash	O
-	O
out	O
period	O
of	O
at	O
least	O
6	O
d	O
.	O

Blood	O
was	O
taken	O
for	O
preparation	O
of	O
PBMCs	O
at	O
1	O
and	O
2	O
h	O
after	O
drug	O
administration	O
.	O

All	O
patients	O
gave	O
informed	O
consent	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Royal	O
Brompton	O
and	O
Harefield	O
Hospitals	O
NHS	O
Trust	O
.	O

The	O
clinical	O
study	O
was	O
conducted	O
before	O
the	O
requirement	O
for	O
Clinical	O
Trial	O
Registration	O
.	O

Antibodies	O
and	O
Reagents	O

The	O
monoclonal	O
antibodies	O
against	O
human	O
CD3	S-PRGE
,	O
CD28	S-PRGE
,	O
GR	S-PRGE
,	O
and	O
importin	O
-	O
alpha	O
were	O
purchased	O
from	O
BD	O
Biosciences	O
(	O
Oxford	O
,	O
United	O
Kingdom	O
)	O
.	O

Rabbit	O
antibodies	O
against	O
human	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
(	O
H	O
-	O
48	O
)	O
and	O
GR	S-PRGE
(	O
E	O
-	O
20	O
,	O
sc	O
-	O
1003	O
)	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
polyclonal	O
rabbit	O
antibodies	O
against	O
phospho	O
-	O
p38	O
MAP	O
kinase	O
and	O
phospho	O
-	O
ATF	B-PRGE
-	I-PRGE
2	E-PRGE
from	O
Cell	O
Signaling	O
Technology	O
(	O
New	O
England	O
Biolabs	O
,	O
Hertford	O
,	O
UK	O
)	O
,	O
monoclonal	O
antibody	O
against	O
phosphoserine	O
(	O
clone	O
4H4	O
)	O
from	O
Affiniti	O
Research	O
Products	O
(	O
Exeter	O
,	O
UK	O
)	O
,	O
and	O
antibodies	O
against	O
rabbit	O
IgG	O
-	O
conjugated	O
TRITC	O
from	O
Dako	O
Cytomation	O
(	O
Cambridge	O
,	O
UK	O
)	O
.	O

The	O
anti	O
-	O
GR	O
antibody	O
(	O
Clone	O
41	O
)	O
from	O
BD	O
Transduction	O
Laboratories	O
(	O
Oxford	O
,	O
UK	O
)	O
was	O
used	O
for	O
Western	O
blot	O
analysis	O
.	O

All	O
other	O
reagents	O
were	O
purchased	O
from	O
Sigma	O
(	O
Poole	O
,	O
UK	O
)	O
.	O

Cell	O
Culture	O
and	O
PBMC	O
Isolation	O

A	O
human	O
T	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
was	O
purchased	O
from	O
ECACC	O
European	O
Collection	O
of	O
Cell	O
Culture	O
(	O
Wiltshire	O
,	O
UK	O
)	O
were	O
cultured	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

PBMCs	O
were	O
isolated	O
by	O
density	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
(	O
density	O
,	O
1	O
.	O
077	O
g	O
/	O
ml	O
;	O
Amersham	O
Biosciences	O
,	O
Amersham	O
,	O
UK	O
)	O
as	O
previously	O
described	O
[	O
34	O
]	O
.	O

Cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
(	O
1	O
microg	O
/	O
ml	O
each	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
to	O
stimulate	O
Th2	O
cytokine	O
release	O
in	O
the	O
presence	O
or	O
absence	O
of	O
FP	O
(	O
10	O
-	O
12	O
to	O
10	O
-	O
8M	O
)	O
.	O

Cytospins	O
were	O
prepared	O
and	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
localization	O
determined	O
by	O
confocal	O
microscopy	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Reverse	O
Transcription	O
PCR	O

Total	O
RNA	O
was	O
extracted	O
using	O
lysis	O
buffer	O
(	O
RNeasy	O
kit	O
;	O
Qiagen	O
,	O
Crawley	O
,	O
UK	O
)	O
.	O

During	O
RNA	O
purification	O
,	O
genomic	O
DNA	O
was	O
digested	O
with	O
RNase	O
-	O
free	O
DNase	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Next	O
,	O
0	O
.	O
5	O
microg	O
of	O
total	O
RNA	O
was	O
reversed	O
transcribed	O
using	O
the	O
avian	O
myeloblastosis	O
virus	O
RT	O
(	O
Promega	O
,	O
Southampton	O
,	O
UK	O
)	O
.	O

For	O
relative	O
quantification	O
,	O
RT	O
-	O
PCR	O
was	O
carried	O
out	O
using	O
cDNA	O
probes	O
.	O

Primers	O
for	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
were	O
from	O
Sigma	O
-	O
Genosys	O
(	O
Cambridge	O
,	O
UK	O
)	O
.	O

Sequences	O
of	O
GADPH	O
used	O
are	O
as	O
follows	O
:	O
forward	O
5	O
'	O
-	O
CCACCCATGGCAAATTCCATGGC	O
,	O
reverse	O
3	O
'	O
-	O
TCTAGACGGCAGGTCAGGTCCAC	O
.	O

Cell	O
Fractionation	O
,	O
Immunoprecipitation	O
,	O
and	O
Western	O
Blot	O
Analysis	O

Nuclear	O
and	O
cytoplasmic	O
fractions	O
were	O
prepared	O
as	O
previously	O
described	O
[	O
35	O
]	O
.	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
NP	O
-	O
40	O
lysis	O
buffer	O
(	O
0	O
.	O
5	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
20	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
)	O
in	O
the	O
presence	O
of	O
complete	O
protease	O
cocktail	O
inhibitor	O
.	O

Lysates	O
were	O
centrifuged	O
at	O
4degreesC	O
for	O
10	O
min	O
at	O
12	O
,	O
000	O
rpm	O
in	O
an	O
Eppendorf	O
microcentrifuge	O
to	O
remove	O
cellular	O
debris	O
.	O

Samples	O
were	O
then	O
immunoprecipitated	O
with	O
either	O
10	O
microl	O
of	O
antibody	O
against	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
or	O
importin	O
-	O
alpha	O
using	O
A	O
/	O
G	O
agarose	O
slurry	O
in	O
the	O
presence	O
of	O
protease	O
inhibitor	O
using	O
the	O
Catch	O
and	O
Release	O
methodology	O
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
USA	O
)	O
.	O

Western	O
blot	O
analysis	O
was	O
performed	O
using	O
anti	O
-	O
GATA	O
-	O
3	O
,	O
anti	O
-	O
importin	O
-	O
alpha	O
,	O
anti	O
-	O
GR	O
,	O
anti	O
-	O
p	O
-	O
p38	O
MAP	O
kinase	O
,	O
anti	O
-	O
p	O
-	O
ATF	O
-	O
2	O
,	O
and	O
anti	O
-	O
p	O
-	O
serine	O
.	O

Immunoreactive	O
proteins	O
were	O
detected	O
using	O
an	O
enhanced	O
chemiluminescence	O
ECL	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O

Chromatin	O
immunoprecipitation	O
(	O
IP	O
)	O
was	O
performed	O
as	O
previously	O
described	O
[	O
12	O
]	O
in	O
HuT	O
-	O
78	O
T	O
-	O
cells	O
with	O
2	O
microg	O
of	O
anti	O
-	O
GATA	O
-	O
3	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
or	O
isotypic	O
immunoglobulin	O
G	O
as	O
a	O
non	O
-	O
specific	O
control	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
overnight	O
at	O
4degreesC	O
.	O

Promoter	O
sequences	O
were	O
detected	O
with	O
PCR	O
primers	O
for	O
the	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
promoter	O
(	O
-	O
445	O
to	O
+	O
4	O
)	O
:	O
forward	O
5	O
'	O
-	O
TTAATCTAGCCACAGTCATAG	O
-	O
3	O
'	O
and	O
reverse	O
:	O
5	O
'	O
-	O
TCATGGCTCTGAAACGTTCTG	O
-	O
3	O
'	O
.	O

PCR	O
was	O
performed	O
using	O
a	O
Hybaid	O
Omnigene	O
thermal	O
cycler	O
(	O
Hybaid	O
,	O
Ashford	O
,	O
UK	O
)	O
with	O
cycling	O
parameters	O
of	O
72degreesC	O
for	O
10	O
min	O
,	O
35	O
cycles	O
at	O
94degreesC	O
for	O
45	O
s	O
,	O
52degreesC	O
for	O
45	O
s	O
,	O
72degreesC	O
for	O
45	O
s	O
.	O

GR	S-PRGE
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
In	O
Vitro	O
Competition	O
Assay	O
for	O
Importin	O
-	O
alpha	O
(	O
Far	O
-	O
Western	O
ELISA	O
)	O

Immunoprecipitated	O
importin	O
-	O
alpha	O
(	O
anti	O
-	O
importin	O
-	O
alpha	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
from	O
HuT	O
-	O
78	O
cells	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
purified	O
from	O
the	O
excised	O
gel	O
by	O
electroelution	O
[	O
36	O
]	O
.	O

Similarly	O
,	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
was	O
isolated	O
from	O
nonstimulated	O
HuT	O
-	O
78	O
cells	O
or	O
cells	O
stimulated	O
for	O
30	O
min	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
and	O
GR	S-PRGE
was	O
isolated	O
from	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
30	O
min	O
)	O
stimulated	O
HuT	O
-	O
78	O
cells	O
.	O

These	O
proteins	O
were	O
subsequently	O
refolded	O
in	O
glycine	O
solution	O
.	O

100	O
microl	O
of	O
importin	O
-	O
alpha	O
solution	O
(	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
was	O
added	O
to	O
96	O
-	O
well	O
plates	O
coated	O
with	O
goat	O
anti	O
-	O
importin	O
-	O
alpha	O
antibody	O
.	O

After	O
1	O
h	O
incubation	O
,	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
(	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
from	O
stimulated	O
or	O
unstimulated	O
cells	O
were	O
added	O
to	O
the	O
importin	O
-	O
alpha	O
-	O
coated	O
wells	O
.	O

GR	S-PRGE
(	O
10	O
or	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
from	O
stimulated	O
or	O
unstimulated	O
cells	O
were	O
added	O
to	O
some	O
wells	O
.	O

After	O
a	O
further	O
1	O
h	O
incubation	O
,	O
the	O
plate	O
was	O
washed	O
and	O
incubated	O
with	O
primary	O
antibodies	O
(	O
a	O
mixture	O
of	O
rabbit	O
anti	O
-	O
GATA	O
-	O
3	O
and	O
mouse	O
anti	O
-	O
GR	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
1	O
.	O
5	O
h	O
,	O
and	O
then	O
incubated	O
with	O
secondary	O
antibodies	O
.	O

FITC	O
swine	O
anti	O
-	O
rabbit	O
IgG	O
(	O
Dako	O
,	O
Cambridge	O
,	O
UK	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
and	O
rhodamine	O
donkey	O
anti	O
-	O
mouse	O
IgG	O
(	O
Novus	O
,	O
Littleton	O
,	O
Colorado	O
,	O
USA	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
GR	S-PRGE
.	O

FITC	O
and	O
rhodamine	O
levels	O
were	O
measured	O
with	O
a	O
fluorescent	O
micro	O
-	O
plate	O
reader	O
(	O
Bioline	O
,	O
London	O
,	O
UK	O
)	O
.	O

NF	O
-	O
kappaB	O
Activation	O

NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
was	O
determined	O
using	O
an	O
ELISA	O
-	O
based	O
kit	O
(	O
Trans	O
-	O
AM	O
p65	S-PRGE
,	O
Active	O
Motif	O
,	O
Rixensart	O
,	O
Belgium	O
)	O
.	O

In	O
brief	O
,	O
5	O
microg	O
of	O
nuclear	O
extracts	O
were	O
incubated	O
with	O
a	O
plate	O
coated	O
with	O
an	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotide	O
.	O

Plates	O
were	O
washed	O
before	O
addition	O
of	O
an	O
anti	O
-	O
p65	O
antibody	O
.	O

Antibody	O
binding	O
was	O
detected	O
with	O
a	O
secondary	O
HRP	O
-	O
conjugated	O
antibody	O
and	O
developed	O
with	O
TMB	O
substrate	O
.	O

The	O
intensity	O
of	O
the	O
reaction	O
was	O
measured	O
at	O
450	O
nm	O
.	O

Immunofluorescence	O
Staining	O

Immunofluorescence	O
staining	O
was	O
performed	O
as	O
previously	O
described	O
[	O
34	O
]	O
.	O

All	O
staining	O
was	O
performed	O
at	O
room	O
temperature	O
and	O
under	O
humidification	O
.	O

Cells	O
were	O
collected	O
and	O
cytospins	O
prepared	O
in	O
a	O
cytocentrifuge	O
(	O
Shandon	O
II	O
,	O
Shandon	O
,	O
Runcorn	O
,	O
UK	O
)	O
.	O

Cells	O
were	O
permeabilized	O
,	O
blocked	O
,	O
and	O
then	O
incubated	O
with	O
GR	S-PRGE
(	O
1	O
:	O
50	O
E	O
-	O
20	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
anti	O
-	O
GATA	O
-	O
3	O
(	O
H	O
-	O
48	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
antibody	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

After	O
three	O
washes	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
,	O
cells	O
were	O
incubated	O
with	O
tetrarhodamine	O
isothiocyanate	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
antibody	O
(	O
Dako	O
)	O
.	O

Cytospins	O
were	O
counterstained	O
with	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
dihydrochloride	O
(	O
DAPI	O
)	O
,	O
a	O
fluorescent	O
blue	O
nuclear	O
indole	O
chromatin	O
stain	O
,	O
and	O
mounted	O
in	O
PBS	O
:	O
glycerol	O
(	O
50	O
:	O
50	O
)	O
.	O

The	O
immunopositive	O
signal	O
was	O
characterised	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
on	O
a	O
Leica	O
TCS	O
NT	O
/	O
SP	O
interactive	O
laser	O
cytometer	O
equipped	O
with	O
confocal	O
optics	O
(	O
Leica	O
Microsystems	O
,	O
Wetzlar	O
,	O
Germany	O
)	O
.	O

To	O
determine	O
the	O
specificity	O
of	O
the	O
antibodies	O
,	O
rabbit	O
serum	O
immunoglobulin	O
(	O
Dako	O
)	O
and	O
secondary	O
antibodies	O
without	O
the	O
primary	O
were	O
used	O
as	O
controls	O
.	O

Positively	O
stained	O
nuclei	O
and	O
total	O
cells	O
were	O
counted	O
(	O
500	O
)	O
on	O
each	O
slide	O
with	O
the	O
observer	O
blinded	O
to	O
the	O
treatment	O
.	O

GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
GFP	S-PRGE
Construct	O

The	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
clone	O
(	O
BC003070	O
)	O
complete	O
cDNA	O
was	O
obtained	O
from	O
Invitrogen	O
Life	O
Technologies	O
as	O
a	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
XhoI	O
insert	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
the	O
pOTB7	O
vector	O
.	O

GATA	B-PRGE
-	I-PRGE
3	E-PRGE
was	O
excised	O
from	O
pOTB7	O
using	O
XhoI	S-PRGE
digestion	O
and	O
pEGFP	O
-	O
C2	O
(	O
Clontech	O
,	O
Saint	O
-	O
Germain	O
-	O
en	O
-	O
Laye	O
,	O
France	O
)	O
was	O
digested	O
with	O
BamHI	S-PRGE
.	O

DNA	O
was	O
recovered	O
by	O
phenol	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
and	O
both	O
the	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
fragment	O
and	O
the	O
pEGFP	O
-	O
C2	O
vector	O
blunt	O
-	O
ended	O
by	O
incubation	O
with	O
Klenow	O
(	O
Bioline	O
Bio	O
-	O
27029	O
)	O
for	O
30	O
min	O
at	O
37degreesC	O
.	O

Klenow	O
was	O
inactivated	O
by	O
incubation	O
for	O
10	O
min	O
at	O
75degreesC	O
.	O

DNA	O
was	O
recovered	O
by	O
phenol	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
and	O
both	O
the	O
blunt	O
-	O
ended	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
fragment	O
and	O
the	O
GFP	S-PRGE
vector	O
were	O
subsequently	O
digested	O
with	O
EcoRI	S-PRGE
before	O
the	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
blunt	O
end	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
fragment	O
was	O
inserted	O
into	O
the	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
blunt	O
ended	O
GFP	S-PRGE
vector	O
.	O

Positive	O
clones	O
were	O
confirmed	O
by	O
digestion	O
and	O
size	O
analysis	O
by	O
1	O
%	O
agarose	O
gel	O
electrophoresis	O
and	O
by	O
sequencing	O
.	O

Transfection	O

HuT	O
-	O
78	O
cells	O
were	O
transfected	O
with	O
either	O
EP8	O
or	O
GFP	O
vector	O
only	O
DNA	O
using	O
solution	O
R	O
,	O
programme	O
V	O
-	O
001	O
at	O
a	O
ratio	O
of	O
3x106	O
cells	O
/	O
4	O
microg	O
DNA	O
for	O
7	O
-	O
8	O
h	O
in	O
complete	O
medium	O
(	O
10	O
%	O
bovine	O
serum	O
in	O
RPMI1640	O
+	O
15	O
L	O
-	O
glutamine	O
)	O
according	O
to	O
the	O
general	O
Amaxa	O
protocol	O
for	O
nucleofection	O
.	O

The	O
medium	O
was	O
subsequently	O
changed	O
to	O
1	O
%	O
RPMI	O
for	O
24	O
h	O
before	O
transfected	O
cells	O
were	O
added	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
treated	O
wells	O
and	O
live	O
cell	O
videomicroscopy	O
performed	O
.	O

Time	O
-	O
Lapse	O
Microscopy	O

HuT	O
-	O
78	O
cells	O
expressing	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
GFP	E-PRGE
were	O
maintained	O
at	O
37degreesC	O
in	O
growth	O
medium	O
in	O
a	O
closed	O
FCS2	O
perfusion	O
chamber	O
(	O
Bioptechs	O
,	O
Butler	O
,	O
Pennsylvania	O
,	O
USA	O
)	O
combined	O
with	O
an	O
objective	O
heater	O
(	O
Bioptechs	O
)	O
on	O
the	O
stage	O
a	O
Zeiss	O
Axiovert	O
200	O
microscope	O
(	O
Thornwood	O
,	O
New	O
York	O
,	O
USA	O
)	O
.	O

Observations	O
were	O
made	O
by	O
40x1	O
.	O
0	O
NA	O
oil	O
-	O
immersion	O
objective	O
lens	O
,	O
and	O
fluorescence	O
and	O
phase	O
contrast	O
images	O
were	O
gathered	O
using	O
a	O
Hamamatsu	O
ORCA	O
-	O
ER	O
charged	O
coupled	O
device	O
camera	O
(	O
Bridgewater	O
,	O
New	O
Jersey	O
,	O
USA	O
)	O
driven	O
by	O
Openlab	O
software	O
(	O
Improvision	O
,	O
Coventry	O
,	O
UK	O
)	O
.	O

Photographs	O
were	O
taken	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
240	O
min	O
.	O

Densitometric	O
Analysis	O

Densitometry	O
of	O
ECL	O
immunoblots	O
was	O
performed	O
using	O
Gelworks	O
ID	O
intermediate	O
software	O
(	O
Ultraviolet	O
Products	O
,	O
Cambridgeshire	O
,	O
UK	O
)	O
.	O

Briefly	O
,	O
immunoblots	O
were	O
scanned	O
and	O
gates	O
were	O
drawn	O
tightly	O
around	O
each	O
band	O
.	O

Background	O
values	O
from	O
each	O
lane	O
were	O
subtracted	O
to	O
normalize	O
each	O
measurement	O
.	O

The	O
bands	O
were	O
quantified	O
using	O
the	O
Gelworks	O
software	O
.	O

All	O
Western	O
blots	O
were	O
exposed	O
to	O
film	O
for	O
varying	O
lengths	O
of	O
time	O
,	O
and	O
only	O
films	O
generating	O
subsaturating	O
levels	O
of	O
intensity	O
were	O
selected	O
for	O
densitometric	O
evaluation	O
.	O

Statistical	O
Analysis	O

Data	O
from	O
three	O
or	O
more	O
independent	O
experiments	O
are	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
,	O
except	O
where	O
stated	O
and	O
were	O
compared	O
using	O
GraphPad	O
Prism	O
4	O
(	O
GraphPad	O
Software	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
graphpad	O
.	O
com	O
)	O
.	O

Results	O
were	O
analysed	O
using	O
one	O
-	O
way	O
ANOVA	O
with	O
Newman	O
-	O
Keuls	O
post	O
test	O
except	O
for	O
the	O
data	O
from	O
the	O
in	O
vivo	O
inhaled	O
FP	O
study	O
,	O
which	O
was	O
analysed	O
by	O
Friedman	O
'	O
s	O
test	O
with	O
subsequent	O
Wilcoxson	O
matched	O
pair	O
signed	O
rank	O
sum	O
test	O
.	O

Data	O
from	O
this	O
analysis	O
are	O
presented	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
.	O

Friedman	O
'	O
s	O
test	O
was	O
used	O
as	O
three	O
matched	O
measures	O
were	O
obtained	O
using	O
placebo	O
,	O
100	O
microg	O
,	O
and	O
500	O
microg	O
of	O
inhaled	O
FP	O
,	O
which	O
had	O
variable	O
baseline	O
levels	O
.	O

We	O
did	O
not	O
assume	O
a	O
Gaussian	O
distribution	O
of	O
the	O
data	O
due	O
to	O
the	O
limited	O
numbers	O
of	O
participants	O
analysed	O
(	O
seven	O
)	O
.	O
The	O
null	O
hypothesis	O
was	O
rejected	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
Effect	O
of	O
Corticosteroids	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
Nuclear	O
Translocation	O
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mRNA	O

Corticosteroids	O
are	O
effective	O
in	O
inhibiting	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
regulated	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
32	O
]	O
.	O

We	O
therefore	O
investigated	O
whether	O
corticosteroids	O
affect	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
nuclear	O
import	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
.	O

Stimulation	O
of	O
cells	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
resulted	O
in	O
a	O
rapid	O
cytoplasmic	O
/	O
nuclear	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
translocation	O
(	O
Figure	O
1A	O
)	O
,	O
confirming	O
our	O
previous	O
results	O
[	O
12	O
]	O
.	O

We	O
also	O
confirmed	O
a	O
clear	O
separation	O
of	O
nuclear	O
and	O
cytosolic	O
fractions	O
as	O
indicated	O
by	O
histone	O
H1	O
and	O
MEK	B-PRGE
-	I-PRGE
1	E-PRGE
markers	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
potent	O
topical	O
corticosteroid	O
FP	O
caused	O
sustained	O
loss	O
of	O
nuclear	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
expression	O
and	O
cytoplasmic	O
retention	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
at	O
concentrations	O
ranging	O
from	O
10	O
-	O
12	O
to	O
10	O
-	O
8	O
M	O
,	O
which	O
cover	O
the	O
therapeutic	O
range	O
[	O
37	O
]	O
.	O

This	O
effect	O
was	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
,	O
with	O
a	O
peak	O
effect	O
of	O
11	O
.	O
6	O
-	O
fold	O
at	O
30	O
min	O
at	O
a	O
concentration	O
of	O
10	O
-	O
8	O
M	O
(	O
Figure	O
1C	O
)	O
and	O
was	O
associated	O
with	O
marked	O
reductions	O
in	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
mRNA	O
expression	O
(	O
Figure	O
1D	O
)	O
and	O
a	O
loss	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
binding	O
to	O
the	O
native	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
promoter	O
(	O
Figure	O
1E	O
)	O
.	O

Ligand	O
-	O
Activated	O
GR	S-PRGE
Competes	O
with	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
for	O
Importin	O
-	O
alpha	O

We	O
confirmed	O
and	O
extended	O
previous	O
data	O
[	O
20	O
]	O
to	O
show	O
that	O
ligand	O
-	O
activated	O
GR	S-PRGE
as	O
well	O
as	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
uses	O
importin	O
-	O
alpha	O
for	O
its	O
nuclear	O
import	O
(	O
Figure	O
2A	O
and	O
2B	O
)	O
.	O

This	O
interaction	O
between	O
GR	S-PRGE
and	O
importin	O
-	O
alpha	O
was	O
significant	O
at	O
concentrations	O
as	O
low	O
as	O
10	O
-	O
12	O
M	O
and	O
was	O
maximal	O
with	O
10	O
-	O
8	O
M	O
FP	O
.	O

Subsequent	O
GR	S-PRGE
nuclear	O
translocation	O
was	O
rapid	O
and	O
sustained	O
at	O
significant	O
levels	O
for	O
at	O
least	O
14	O
h	O
(	O
Figure	O
2B	O
)	O
.	O

Using	O
IP	O
-	O
Western	O
blotting	O
we	O
showed	O
that	O
FP	O
at	O
10	O
-	O
12	O
-	O
10	O
-	O
8	O
M	O
decreased	O
the	O
association	O
between	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
importin	O
-	O
alpha	O
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2C	O
)	O
.	O

In	O
addition	O
,	O
using	O
GFP	B-PRGE
-	I-PRGE
labelled	I-PRGE
GATA	I-PRGE
-	I-PRGE
3	E-PRGE
and	O
confocal	O
microscopy	O
we	O
demonstrated	O
that	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
following	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
for	O
30	O
min	O
was	O
attenuated	O
by	O
pretreatment	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
(	O
Figure	O
2D	O
)	O
.	O

Effect	O
on	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE

Dexamethasone	O
inhibits	O
p38	O
MAPK	O
function	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
through	O
the	O
rapid	O
induction	O
of	O
the	O
dual	O
kinase	O
phosphatase	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
(	O
MAPK	B-PRGE
phosphatase	I-PRGE
-	I-PRGE
1	E-PRGE
)	O
,	O
and	O
this	O
effect	O
lasts	O
for	O
up	O
to	O
24	O
h	O
[	O
28	O
]	O
.	O

FP	O
(	O
10	O
-	O
8	O
M	O
)	O
treatment	O
of	O
HuT	O
-	O
78	O
cells	O
activated	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
in	O
vitro	O
significantly	O
decreased	O
p38	O
MAPK	O
phosphorylation	O
(	O
Figure	O
3A	O
)	O
and	O
activity	O
measured	O
by	O
phosphorylation	O
of	O
the	O
downstream	O
target	O
ATF	B-PRGE
-	I-PRGE
2	E-PRGE
(	O
Figure	O
3B	O
)	O
.	O

This	O
effect	O
was	O
detected	O
at	O
30	O
min	O
and	O
lasted	O
for	O
at	O
least	O
14	O
h	O
(	O
Figure	O
3B	O
)	O
.	O

FP	O
(	O
10	O
-	O
8	O
M	O
)	O
also	O
significantly	O
reduced	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
serine	O
phosphorylation	O
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
in	O
both	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3C	O
)	O
.	O

This	O
reduction	O
in	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
phosphorylation	O
was	O
also	O
seen	O
with	O
lower	O
concentrations	O
of	O
FP	O
.	O

We	O
found	O
that	O
FP	O
significantly	O
induced	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
mRNA	O
in	O
both	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
reaching	O
a	O
plateau	O
at	O
10	O
-	O
8	O
M	O
after	O
10	O
min	O
(	O
Figure	O
3D	O
and	O
3E	O
)	O
.	O

However	O
,	O
the	O
effects	O
of	O
FP	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
,	O
importin	O
-	O
alpha	O
association	O
and	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mRNA	O
expression	O
are	O
seen	O
at	O
10	O
,	O
000	O
-	O
fold	O
lower	O
concentrations	O
(	O
10	O
-	O
12	O
M	O
,	O
see	O
Figure	O
2	O
)	O
.	O

Using	O
an	O
in	O
vitro	O
competition	O
assay	O
(	O
Figure	O
4A	O
)	O
utilizing	O
purified	O
activated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
importin	O
-	O
alpha	O
,	O
and	O
activated	O
GR	S-PRGE
,	O
we	O
demonstrated	O
that	O
activated	O
GR	S-PRGE
significantly	O
increased	O
GR	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
in	O
the	O
presence	O
and	O
absence	O
of	O
activated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
(	O
Figure	O
4B	O
)	O
.	O

This	O
effect	O
is	O
not	O
mutual	O
,	O
since	O
activated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
did	O
not	O
block	O
GR	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
(	O
Figure	O
4C	O
)	O
.	O

These	O
data	O
also	O
suggest	O
that	O
both	O
activated	O
GR	S-PRGE
and	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
can	O
directly	O
associate	O
with	O
importin	O
-	O
alpha	O
(	O
Figure	O
4D	O
)	O
and	O
that	O
activated	O
GR	S-PRGE
attenuates	O
the	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
/	O
importin	O
-	O
alpha	O
interaction	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
4E	O
)	O
.	O

Together	O
,	O
this	O
suggests	O
that	O
ligand	O
-	O
activated	O
GR	S-PRGE
may	O
compete	O
with	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
for	O
importin	O
-	O
alpha	O
and	O
thereby	O
limit	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
.	O

Other	O
possible	O
interpretations	O
of	O
our	O
results	O
could	O
include	O
an	O
effect	O
of	O
FP	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
export	O
and	O
/	O
or	O
degradation	O
.	O

Leptomycin	O
B	O
,	O
which	O
inhibits	O
nuclear	O
export	O
,	O
did	O
not	O
affect	O
the	O
ability	O
of	O
FP	O
to	O
block	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localization	O
(	O
Figure	O
5A	O
)	O
.	O

Additionally	O
,	O
FP	O
had	O
no	O
effect	O
on	O
whole	O
cell	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
expression	O
during	O
the	O
time	O
course	O
of	O
these	O
experiments	O
(	O
Figure	O
5B	O
)	O
.	O

Nor	O
did	O
addition	O
of	O
FP	O
subsequent	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
nuclear	O
translocation	O
affect	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
residency	O
(	O
Figure	O
5C	O
)	O
,	O
suggesting	O
that	O
activated	O
GR	S-PRGE
does	O
not	O
enhance	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
export	O
.	O

Finally	O
,	O
the	O
effect	O
of	O
FP	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
was	O
not	O
nonspecific	O
,	O
since	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
had	O
no	O
effect	O
on	O
p65	S-PRGE
nuclear	O
translocation	O
measured	O
at	O
60	O
min	O
(	O
Figure	O
5D	O
)	O
.	O

The	O
Inhibitory	O
Effect	O
of	O
Corticosteroids	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
Nuclear	O
Localization	O
in	O
Primary	O
T	O
Lymphocytes	O
Ex	O
Vivo	O
and	O
In	O
Vivo	O

Treatment	O
with	O
FP	O
ex	O
vivo	O
demonstrated	O
a	O
concentration	O
-	O
dependent	O
decrease	O
in	O
the	O
direct	O
interaction	O
between	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
importin	O
-	O
alpha	O
in	O
PBMCs	O
from	O
patients	O
with	O
asthma	O
(	O
Figure	O
6A	O
and	O
6B	O
)	O
,	O
which	O
was	O
significantly	O
inhibited	O
at	O
10	O
-	O
12	O
M	O
FP	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
ANOVA	O
and	O
Newman	O
-	O
Keuls	O
test	O
)	O
and	O
completely	O
attenuated	O
by	O
10	O
-	O
8	O
M	O
FP	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
ANOVA	O
and	O
Newman	O
-	O
Keuls	O
test	O
)	O
.	O

Our	O
previous	O
T	O
cell	O
line	O
studies	O
indicated	O
that	O
10	O
-	O
12	O
M	O
FP	O
suppresses	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
-	B-PRGE
5	E-PRGE
gene	O
expression	O
and	O
attenuated	O
the	O
interaction	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
with	O
importin	O
-	O
alpha	O
(	O
see	O
Figures	O
1D	O
and	O
2	O
)	O
.	O

This	O
concentration	O
is	O
close	O
to	O
peak	O
plasma	O
levels	O
obtained	O
from	O
asthmatic	O
patients	O
treated	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
[	O
27	O
]	O
.	O

Inhaled	O
FP	O
(	O
500	O
microg	O
)	O
treatment	O
of	O
seven	O
steroid	O
-	O
naive	O
asthma	O
patients	O
significantly	O
reduced	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
interaction	O
in	O
vivo	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

This	O
produced	O
a	O
>	O
90	O
%	O
decrease	O
in	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
association	O
at	O
2	O
h	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
13	O
,	O
494	O
[	O
6	O
,	O
828	O
-	O
17	O
,	O
829	O
]	O
versus	O
879	O
[	O
597	O
-	O
1	O
,	O
165	O
]	O
;	O
p	O
<	O
0	O
.	O
05	O
Friedman	O
'	O
s	O
analysis	O
)	O
.	O

However	O
,	O
this	O
did	O
not	O
reach	O
significance	O
using	O
Wilcoxon	O
'	O
s	O
post	O
-	O
test	O
analysis	O
(	O
W	O
=	O
6	O
.	O
00	O
)	O
probably	O
due	O
to	O
low	O
numbers	O
of	O
participants	O
.	O

Similar	O
results	O
were	O
observed	O
when	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
association	O
was	O
measured	O
(	O
Figure	O
6C	O
and	O
6D	O
)	O
.	O

The	O
lower	O
dose	O
of	O
FP	O
(	O
100	O
microg	O
)	O
was	O
not	O
effective	O
.	O

The	O
attenuated	O
interaction	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
did	O
not	O
result	O
from	O
the	O
defective	O
recycling	O
of	O
importin	O
-	O
alpha	O
,	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
abundance	O
of	O
importin	O
-	O
alpha	O
in	O
the	O
cytoplasmic	O
pool	O
was	O
not	O
detected	O
(	O
Figure	O
6E	O
)	O
.	O

We	O
further	O
examined	O
whether	O
inhaled	O
FP	O
could	O
affect	O
cellular	O
localization	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

Treatment	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
for	O
2	O
h	O
significantly	O
increased	O
GR	S-PRGE
nuclear	O
translocation	O
(	O
Figure	O
7A	O
)	O
and	O
concomitantly	O
decreased	O
the	O
number	O
of	O
nuclear	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
immunoreactive	O
peripheral	O
blood	O
T	O
cells	O
(	O
37	O
%	O
+	O
/	O
-	O
4	O
.	O
2	O
%	O
versus	O
58	O
.	O
2	O
%	O
+	O
/	O
-	O
4	O
.	O
95	O
%	O
,	O
p	O
=	O
0	O
.	O
016	O
,	O
W	O
=	O
28	O
.	O
0	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
compared	O
with	O
placebo	O
as	O
measured	O
by	O
immunocytochemistry	O
(	O
Figure	O
7A	O
and	O
7B	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
Western	O
blotting	O
,	O
which	O
also	O
indicated	O
that	O
this	O
effect	O
was	O
both	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
(	O
Figure	O
7C	O
and	O
7D	O
)	O
.	O

Thus	O
,	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
induced	O
significant	O
loss	O
in	O
nuclear	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
at	O
2	O
h	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
.	O
40	O
[	O
0	O
.	O
27	O
-	O
0	O
.	O
53	O
]	O
versus	O
0	O
.	O
14	O
[	O
0	O
.	O
11	O
-	O
0	O
.	O
19	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
W	O
=	O
21	O
.	O
00	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
(	O
Figure	O
7C	O
)	O
and	O
cytoplasmic	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
levels	O
were	O
enhanced	O
by	O
inhaled	O
FP	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
.	O
0032	O
[	O
0	O
.	O
0026	O
-	O
0	O
.	O
0039	O
]	O
versus	O
0	O
.	O
658	O
[	O
0	O
.	O
592	O
-	O
0	O
.	O
720	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
W	O
=	O
-	O
21	O
.	O
00	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
(	O
Figure	O
7D	O
)	O
.	O

In	O
addition	O
,	O
FP	O
(	O
500	O
microg	O
)	O
inhibited	O
p38	O
MAPK	O
phosphorylation	O
in	O
primary	O
T	O
cells	O
in	O
vivo	O
at	O
2	O
h	O
in	O
samples	O
from	O
two	O
patients	O
(	O
Figure	O
7E	O
)	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
inhaled	O
FP	O
reduces	O
nuclear	O
localization	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
vivo	O
by	O
acutely	O
inhibiting	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
association	O
.	O

This	O
effect	O
may	O
be	O
direct	O
,	O
through	O
competition	O
for	O
importin	O
-	O
alpha	O
or	O
associated	O
molecules	O
,	O
or	O
secondary	O
to	O
an	O
effect	O
on	O
p38	O
MAPK	O
-	O
mediated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
phosphorylation	O
via	O
rapid	O
induction	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
.	O

The	O
combination	O
of	O
these	O
two	O
interacting	O
effects	O
can	O
result	O
in	O
complete	O
suppression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
and	O
thus	O
Th2	O
cytokine	O
gene	O
expression	O
.	O

Here	O
we	O
have	O
demonstrated	O
,	O
to	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
that	O
corticosteroids	O
may	O
inhibit	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
function	O
and	O
therefore	O
the	O
transcription	O
of	O
Th2	O
genes	O
via	O
two	O
distinct	O
but	O
interacting	O
molecular	O
mechanisms	O
.	O

Firstly	O
,	O
corticosteroid	O
-	O
activated	O
GR	S-PRGE
appears	O
to	O
compete	O
with	O
activated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
for	O
nuclear	O
import	O
via	O
importin	O
-	O
alpha	O
,	O
which	O
is	O
required	O
for	O
the	O
nuclear	O
transport	O
of	O
both	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
GR	S-PRGE
.	O

Secondly	O
,	O
corticosteroids	O
at	O
higher	O
concentrations	O
increase	O
the	O
expression	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
,	O
a	O
potent	O
inhibitor	O
of	O
p38	O
MAPK	O
activity	O
and	O
thereby	O
prevent	O
T	O
cell	O
receptor	O
/	O
co	O
-	O
receptor	O
activation	O
of	O
p38	O
MAPK	O
to	O
prevent	O
the	O
phosphorylation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
that	O
is	O
necessary	O
for	O
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
subsequent	O
nuclear	O
import	O
.	O

We	O
have	O
previously	O
shown	O
that	O
translocation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
involves	O
the	O
nuclear	O
transporter	O
protein	O
importin	O
-	O
alpha	O
,	O
which	O
interacts	O
with	O
phosphorylated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
[	O
12	O
]	O
.	O

We	O
have	O
also	O
previously	O
reported	O
that	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
knockdown	O
using	O
siRNA	O
results	O
in	O
suppression	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
/	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
mRNA	O
induction	O
,	O
thus	O
implicating	O
an	O
essential	O
role	O
for	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
the	O
transcription	O
of	O
these	O
genes	O
[	O
12	O
]	O
.	O

We	O
now	O
confirm	O
,	O
in	O
human	O
T	O
cells	O
,	O
that	O
GR	S-PRGE
also	O
uses	O
the	O
same	O
nuclear	O
import	O
mechanism	O
as	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
[	O
22	O
]	O
.	O

We	O
therefore	O
propose	O
that	O
there	O
is	O
competition	O
between	O
ligand	O
-	O
activated	O
GR	S-PRGE
and	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
for	O
nuclear	O
import	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
there	O
is	O
preferential	O
binding	O
of	O
importin	O
-	O
alpha	O
to	O
activated	O
GR	S-PRGE
over	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
so	O
that	O
corticosteroids	O
would	O
preferentially	O
reduce	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
entry	O
and	O
thus	O
rapidly	O
switch	O
off	O
Th2	O
gene	O
transcription	O
without	O
any	O
need	O
for	O
any	O
intermediate	O
steps	O
.	O

Furthermore	O
,	O
there	O
was	O
some	O
degree	O
of	O
specificity	O
for	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
as	O
nuclear	O
translocation	O
of	O
the	O
p65	S-PRGE
subunit	O
of	O
NF	O
-	O
kappaB	O
was	O
not	O
affected	O
by	O
corticosteroid	O
exposure	O
.	O

We	O
tested	O
some	O
alternative	O
explanations	O
for	O
this	O
effect	O
of	O
FP	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
exclusion	O
and	O
failed	O
to	O
show	O
that	O
FP	O
either	O
enhances	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
export	O
directly	O
or	O
induces	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
degradation	O
.	O

The	O
evidence	O
from	O
the	O
in	O
vitro	O
competition	O
assays	O
does	O
,	O
however	O
,	O
suggest	O
that	O
purified	O
activated	O
GR	S-PRGE
can	O
clearly	O
attenuate	O
purified	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
association	O
and	O
that	O
the	O
converse	O
does	O
not	O
occur	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
only	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
can	O
associate	O
with	O
importin	O
-	O
alpha	O
.	O

This	O
mechanism	O
is	O
sensitive	O
to	O
very	O
low	O
concentrations	O
of	O
corticosteroid	O
and	O
would	O
be	O
rapid	O
in	O
onset	O
as	O
no	O
changes	O
in	O
protein	O
synthesis	O
are	O
required	O
.	O

This	O
acute	O
mechanism	O
may	O
also	O
contribute	O
to	O
the	O
reduction	O
in	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
and	O
may	O
play	O
a	O
major	O
role	O
at	O
low	O
corticosteroid	O
concentrations	O
and	O
/	O
or	O
at	O
early	O
time	O
points	O
prior	O
to	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
induction	O
.	O

Corticosteroids	O
can	O
modulate	O
p38	O
MAPK	O
activity	O
through	O
the	O
induction	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
,	O
a	O
potent	O
endogenous	O
inhibitor	O
of	O
MAPK	O
function	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

We	O
report	O
here	O
a	O
rapid	O
induction	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
mRNA	O
following	O
stimulation	O
of	O
cells	O
with	O
relatively	O
high	O
concentrations	O
of	O
FP	O
.	O

We	O
hypothesize	O
that	O
this	O
rapid	O
induction	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
can	O
reduce	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
by	O
attenuating	O
p38	O
MAPK	O
activity	O
and	O
subsequent	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
phosphorylation	O
,	O
thus	O
preventing	O
nuclear	O
translocation	O
.	O

The	O
location	O
of	O
the	O
serine	O
residue	O
(	O
s	O
)	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
that	O
are	O
phosphorylated	O
by	O
p38	O
MAPK	O
are	O
currently	O
unknown	O
,	O
but	O
a	O
bioinformatics	O
search	O
(	O
Motif	O
Scanner	O
,	O
http	O
:	O
/	O
/	O
scansite	O
.	O
mit	O
.	O
edu	O
/	O
motifscan	O
_	O
seq	O
.	O
phtml	O
)	O
indicates	O
at	O
least	O
three	O
potential	O
p38	O
MAPK	O
-	O
sensitive	O
serine	O
residues	O
.	O

As	O
predicted	O
from	O
these	O
in	O
vitro	O
data	O
,	O
impairment	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
by	O
FP	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
underlie	O
the	O
efficacy	O
of	O
corticosteroids	O
in	O
suppressing	O
allergic	O
inflammation	O
.	O

Although	O
we	O
did	O
not	O
assess	O
the	O
acute	O
inhibitory	O
effect	O
of	O
FP	O
on	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mRNA	O
in	O
vivo	O
,	O
a	O
single	O
inhalation	O
of	O
FP	O
(	O
500	O
microg	O
)	O
may	O
have	O
comparable	O
effects	O
,	O
as	O
it	O
provides	O
plasma	O
levels	O
within	O
a	O
relevant	O
range	O
of	O
concentrations	O
used	O
to	O
suppress	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
transcription	O
in	O
our	O
in	O
vitro	O
system	O
[	O
37	O
]	O
.	O

A	O
lower	O
dose	O
of	O
inhaled	O
FP	O
(	O
100	O
microg	O
)	O
was	O
not	O
effective	O
,	O
but	O
plasma	O
concentrations	O
may	O
be	O
below	O
those	O
required	O
for	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
inhibition	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
the	O
higher	O
concentrations	O
of	O
FP	O
in	O
the	O
airways	O
after	O
inhaled	O
administration	O
would	O
be	O
effective	O
in	O
inhibiting	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
in	O
airway	O
T	O
cells	O
of	O
asthma	O
patients	O
.	O

The	O
study	O
of	O
PBMCs	O
from	O
asthma	O
patients	O
treated	O
with	O
inhaled	O
corticosteroid	O
therapy	O
clearly	O
demonstrates	O
that	O
these	O
molecular	O
mechanisms	O
are	O
likely	O
to	O
also	O
occur	O
in	O
patients	O
at	O
therapeutic	O
doses	O
of	O
inhaled	O
corticosteroids	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
have	O
shown	O
that	O
corticosteroids	O
can	O
suppress	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
release	O
from	O
peripheral	O
blood	O
cells	O
of	O
asthma	O
patients	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
40	O
]	O
-	O
[	O
42	O
]	O
.	O

In	O
summary	O
,	O
our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
action	O
of	O
corticosteroids	O
:	O
suppression	O
of	O
allergic	O
inflammation	O
through	O
a	O
rapid	O
inhibitory	O
effect	O
on	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
translocation	O
by	O
preferential	O
binding	O
to	O
the	O
shared	O
nuclear	O
import	O
protein	O
importin	O
-	O
alpha	O
and	O
by	O
a	O
second	O
mechanism	O
involving	O
increased	O
synthesis	O
of	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
,	O
which	O
inhibits	O
p38	O
MAPK	O
,	O
thus	O
preventing	O
the	O
phosphorylation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
that	O
is	O
necessary	O
for	O
nuclear	O
translocation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
.	O

These	O
two	O
mechanisms	O
are	O
likely	O
to	O
be	O
synergistic	O
,	O
accounting	O
for	O
the	O
rapid	O
and	O
potent	O
effect	O
of	O
corticosteroids	O
on	O
allergic	O
inflammation	O
.	O

This	O
is	O
exemplified	O
by	O
the	O
rapid	O
inhibitory	O
effect	O
of	O
topical	O
corticosteroids	O
on	O
nasal	O
Th2	O
cytokine	O
release	O
after	O
allergen	O
provocation	O
in	O
individuals	O
with	O
seasonal	O
allergic	O
rhinitis	O
(	O
hay	O
fever	O
)	O
[	O
43	O
]	O
.	O

Prevention	O
of	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
interaction	O
with	O
importin	O
-	O
alpha	O
may	O
provide	O
a	O
new	O
approach	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
.	O

Fluticasone	O
propionate	O
down	O
-	O
regulates	O
Th2	O
cytokine	O
gene	O
expression	O
and	O
inhibits	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
.	O

(	O
A	O
)	O
Anti	O
-	O
CD3	O
/	O
CD28	O
treatment	O
of	O
HuT	O
-	O
78	O
cells	O
results	O
in	O
translocation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
within	O
30	O
min	O
.	O

(	O
B	O
)	O
Histone	O
H1	O
and	O
MEK	B-PRGE
-	I-PRGE
1	E-PRGE
were	O
used	O
to	O
confirm	O
distinct	O
separation	O
of	O
cytoplasmic	O
and	O
nuclear	O
extracts	O
in	O
three	O
separate	O
experiments	O
.	O

(	O
C	O
)	O
Western	O
blot	O
analysis	O
of	O
FP	O
-	O
treated	O
HuT	O
-	O
78	O
cells	O
demonstrated	O
impaired	O
nuclear	O
localization	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
in	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
manner	O
.	O

Cells	O
were	O
pretreated	O
with	O
FP	O
for	O
30	O
min	O
prior	O
to	O
stimulation	O
.	O

MEK1	S-PRGE
and	O
histone	O
H1	O
were	O
used	O
to	O
demonstrate	O
equal	O
cytoplasmic	O
and	O
nuclear	O
loading	O
respectively	O
.	O

Results	O
are	O
presented	O
graphically	O
below	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
t	O
=	O
0	O
.	O

(	O
D	O
)	O
RT	O
-	O
PCR	O
showing	O
that	O
FP	O
inhibits	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
mRNA	O
expression	O
in	O
CD3	S-PRGE
/	O
CD28	S-PRGE
-	O
costimulated	O
cells	O
.	O

GAPDH	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Lower	O
panels	O
show	O
graphical	O
analysis	O
of	O
results	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
.	O

(	O
E	O
)	O
FP	O
(	O
10	O
nM	O
)	O
reduces	O
the	O
ability	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
to	O
associate	O
with	O
the	O
native	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
promoter	O
60	O
min	O
after	O
stimulation	O
.	O

Data	O
are	O
also	O
shown	O
graphically	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O

All	O
data	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
reduces	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
association	O
with	O
importin	O
-	O
alpha	O
and	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
import	O
.	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
demonstrates	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
induction	O
of	O
FP	O
-	O
activated	O
GR	S-PRGE
interaction	O
with	O
importin	O
-	O
alpha	O
(	O
Imp	O
-	O
alpha	O
)	O
.	O

A	O
positive	O
control	O
for	O
GR	S-PRGE
association	O
with	O
importin	O
is	O
shown	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
B	O
)	O
Western	O
blot	O
analysis	O
demonstrated	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
induction	O
of	O
FP	O
-	O
activated	O
GR	S-PRGE
nuclear	O
translocation	O
measured	O
by	O
IP	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
.	O

(	O
C	O
)	O
Western	O
blot	O
analysis	O
of	O
HuT	O
-	O
78	O
cells	O
treated	O
with	O
FP	O
and	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
demonstrated	O
a	O
concentration	O
-	O
dependent	O
decrease	O
in	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
association	O
at	O
20	O
min	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
alphaCD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
D	O
)	O
GFP	O
-	O
tagged	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
was	O
overexpressed	O
and	O
cells	O
stimulated	O
(	O
b	O
,	O
c	O
)	O
or	O
not	O
(	O
a	O
)	O
for	O
30	O
min	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
.	O

The	O
effect	O
of	O
30	O
min	O
pretreatment	O
of	O
cells	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
c	O
)	O
is	O
also	O
shown	O
.	O

All	O
data	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
-	O
mediated	O
inhibition	O
of	O
p38	O
MAP	O
kinase	O
phosphorylation	O
and	O
activation	O
is	O
associated	O
with	O
a	O
marked	O
down	O
-	O
regulation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
serine	O
phosphorylation	O
.	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
shows	O
that	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
30	O
min	O
)	O
treatment	O
reduced	O
dual	O
phosphorylation	O
(	O
threonine	O
-	O
180	O
and	O
tyrosine	O
-	O
182	O
)	O
of	O
p38	O
MAPK	O
in	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
co	O
-	O
stimulated	O
HuT	O
-	O
78	O
cells	O
.	O

(	O
B	O
)	O
Time	O
course	O
of	O
the	O
effect	O
of	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
on	O
phosphorylation	O
of	O
activated	B-PRGE
transcription	I-PRGE
factor	I-PRGE
2	E-PRGE
(	O
ATF	B-PRGE
-	I-PRGE
2	E-PRGE
)	O
,	O
a	O
measure	O
of	O
p38	O
MAPK	O
activity	O
.	O

(	O
C	O
)	O
FP	O
-	O
induced	O
inhibition	O
of	O
p38	O
MAPK	O
activity	O
is	O
associated	O
with	O
the	O
decrease	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
-	O
induced	O
serine	O
phosphorylation	O
(	O
P	O
-	O
Ser	O
)	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
.	O

For	O
(	O
A	O
-	O
C	O
)	O
,	O
quantification	O
of	O
the	O
densitometry	O
data	O
is	O
also	O
shown	O
.	O

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
alphaCD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
D	O
)	O
FP	O
induced	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
mRNA	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

All	O
results	O
are	O
representative	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
where	O
appropriate	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
E	O
)	O
FP	O
induces	O
MKP	B-PRGE
-	I-PRGE
1	E-PRGE
mRNA	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Results	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

All	O
data	O
except	O
(	O
E	O
)	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
competes	O
with	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
for	O
importin	O
-	O
alpha	O
.	O

(	O
A	O
)	O
schematic	O
representation	O
of	O
the	O
in	O
vitro	O
binding	O
competition	O
assay	O
.	O

(	O
B	O
)	O
GR	S-PRGE
isolated	O
from	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
stimulated	O
cells	O
enhances	O
GR	S-PRGE
-	O
importin	O
-	O
alpha	O
binding	O
in	O
the	O
presence	O
(	O
*	O
)	O
and	O
absence	O
(	O
=	O
=	O
blacksquare	O
,	O
square	O
,	O
filled	O
=	O
=	O
)	O
of	O
activated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
no	O
activated	O
GR	S-PRGE
.	O

(	O
C	O
)	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
isolated	O
from	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
does	O
not	O
attenuate	O
GR	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
control	O
.	O

(	O
D	O
)	O
Activated	O
GR	S-PRGE
blocks	O
the	O
ability	O
of	O
purified	O
phospho	O
-	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
isolated	O
from	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
interacting	O
with	O
immobilised	O
importin	O
-	O
alpha	O
in	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
isolated	O
from	O
unstimulated	O
cells	O
.	O

#	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
stimulated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
binding	O
.	O

(	O
E	O
)	O
The	O
effect	O
of	O
activated	O
(	O
*	O
)	O
versus	O
unstimulated	O
(	O
o	O
)	O
GR	S-PRGE
on	O
attenuation	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
-	O
importin	O
-	O
alpha	O
association	O
was	O
concentration	O
-	O
dependent	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
between	O
groups	O
.	O

All	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
three	O
independent	O
experiments	O
and	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
does	O
not	O
affect	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
export	O
.	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
showing	O
that	O
the	O
nuclear	O
export	O
inhibitor	O
leptomycin	O
B	O
(	O
2	O
nM	O
)	O
does	O
not	O
affect	O
the	O
ability	O
of	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
to	O
prevent	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localization	O
measured	O
at	O
60	O
min	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
unstimulated	O
cells	O
,	O
#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
B	O
)	O
Western	O
blot	O
analysis	O
showing	O
that	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
does	O
not	O
affect	O
whole	O
-	O
cell	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
degradation	O
over	O
17	O
h	O
.	O

(	O
C	O
)	O
GFP	O
-	O
tagged	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
is	O
overexpressed	O
and	O
cells	O
stimulated	O
(	O
b	O
-	O
j	O
)	O
or	O
not	O
(	O
a	O
)	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
.	O

The	O
effect	O
of	O
treating	O
cells	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
f	O
-	O
j	O
)	O
after	O
30	O
min	O
stimulation	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
is	O
also	O
shown	O
.	O

(	O
D	O
)	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
does	O
not	O
prevent	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
p65	S-PRGE
nuclear	O
translocation	O
at	O
60	O
min	O
after	O
stimulation	O
.	O

*	O
*	O
p	O
<	O
0	O
.	O
01	O
compared	O
to	O
unstimulated	O
cells	O
.	O

All	O
results	O
are	O
representative	O
of	O
at	O
least	O
four	O
independent	O
experiments	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Results	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
test	O
.	O

Fluticasone	O
propionate	O
impairs	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localization	O
in	O
vivo	O
and	O
ex	O
vivo	O
.	O

(	O
A	O
and	O
B	O
)	O
Co	O
-	O
immunoprecipitation	O
analysis	O
of	O
PBMCs	O
from	O
steroid	O
-	O
naive	O
asthma	O
patients	O
treated	O
with	O
FP	O
in	O
vitro	O
demonstrated	O
impaired	O
interaction	O
between	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
importin	O
-	O
alpha	O
measured	O
at	O
60	O
min	O
.	O

Each	O
bar	O
represents	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
control	O
as	O
determined	O
by	O
ANOVA	O
/	O
Newman	O
-	O
Keuls	O
analysis	O
.	O

(	O
C	O
and	O
D	O
)	O
Co	O
-	O
immunoprecipitation	O
analyses	O
of	O
PBMCs	O
from	O
steroid	O
-	O
naive	O
asthma	O
patients	O
treated	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
via	O
a	O
spacer	O
)	O
in	O
vivo	O
demonstrated	O
decreased	O
association	O
between	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
and	O
importin	O
-	O
alpha	O
.	O

The	O
individual	O
values	O
for	O
each	O
treatment	O
are	O
presented	O
graphically	O
.	O

(	O
E	O
)	O
Representative	O
Western	O
blot	O
showing	O
that	O
importin	O
-	O
alpha	O
expression	O
was	O
unaffected	O
by	O
inhalation	O
of	O
FP	O
.	O

Blot	O
is	O
representative	O
of	O
gels	O
from	O
three	O
participants	O
.	O

Inhaled	O
fluticasone	O
propionate	O
impairs	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localization	O
in	O
PBMCs	O
.	O

(	O
A	O
)	O
Representative	O
immunocytochemistry	O
of	O
showing	O
the	O
effect	O
of	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
on	O
GR	S-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
nuclear	O
localisation	O
.	O

(	O
B	O
)	O
Nuclear	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
immunoreactivity	O
in	O
PBMCs	O
from	O
seven	O
steroid	O
-	O
naive	O
asthma	O
patients	O
2	O
h	O
following	O
inhaled	O
FP	O
treatment	O
(	O
100	O
or	O
500	O
microg	O
via	O
spacer	O
)	O
.	O

The	O
median	O
and	O
interquartile	O
ranges	O
for	O
each	O
treatment	O
are	O
presented	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
(	O
n	O
=	O
7	O
)	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
compared	O
with	O
placebo	O
.	O

(	O
C	O
)	O
Immunoblotting	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
nuclear	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
and	O
increased	O
cytoplasmic	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
expression	O
after	O
inhalation	O
of	O
FP	O
.	O

(	O
D	O
)	O
Immunoblotting	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
nuclear	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
,	O
and	O
increased	O
cytoplasmic	O
GATA	B-PRGE
-	I-PRGE
3	E-PRGE
expression	O
2	O
h	O
after	O
inhalation	O
of	O
FP	O
.	O

Histone	O
H1	O
and	O
MEK	B-PRGE
-	I-PRGE
1	E-PRGE
immunoblotting	O
confirmed	O
equivalent	O
total	O
protein	O
loading	O
for	O
the	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
respectively	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
in	O
(	O
C	O
)	O
and	O
(	O
D	O
)	O
is	O
shown	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
of	O
results	O
from	O
n	O
=	O
6	O
participants	O
for	O
which	O
data	O
were	O
available	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
control	O
.	O

(	O
E	O
)	O
Western	O
blot	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
dual	O
phosphorylation	O
(	O
threonine	O
-	O
180	O
and	O
tyrosine	O
-	O
182	O
)	O
of	O
p38	O
MAPK	O
after	O
inhalation	O
of	O
FP	O
(	O
500	O
microg	O
)	O
.	O

The	O
results	O
shown	O
in	O
(	O
E	O
)	O
are	O
representative	O
of	O
samples	O
from	O
two	O
participants	O
.	O

Degraded	O
Carrageenan	O
Causing	O
Colitis	O
in	O
Rats	O
Induces	O
TNF	S-PRGE
Secretion	O
and	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
Upregulation	O
in	O
Monocytes	O
through	O
NF	O
-	O
kappaB	O
Activation	O

Carrageenan	O
(	O
CGN	O
)	O
is	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
derived	O
from	O
red	O
seaweeds	O
.	O

In	O
rodents	O
,	O
its	O
degraded	O
forms	O
(	O
dCGN	O
)	O
can	O
induce	O
intestinal	O
inflammation	O
associated	O
with	O
macrophage	O
recruitment	O
and	O
activation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
:	O
1	O
)	O
to	O
analyze	O
the	O
size	O
-	O
dependent	O
effects	O
of	O
dCGN	O
on	O
colon	O
inflammation	O
in	O
vivo	O
,	O
and	O
2	O
)	O
to	O
correlate	O
these	O
effects	O
with	O
monocyte	O
/	O
macrophage	O
proliferation	O
,	O
cytokine	O
production	O
and	O
expression	O
of	O
various	O
cell	O
surface	O
antigens	O
including	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
adhesion	B-PRGE
molecule	E-PRGE
.	O

Peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
either	O
10	O
or	O
40	O
kDa	O
,	O
dCGN	O
.	O

The	O
40	O
kDa	O
,	O
but	O
not	O
the	O
10	O
kDa	O
dCGN	O
,	O
induced	O
colitis	O
in	O
in	O
vivo	O
.	O

Degraded	O
CGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
arresting	O
the	O
cells	O
in	O
G1	O
phase	O
.	O

In	O
addition	O
,	O
dCGN	O
increased	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
in	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
with	O
a	O
major	O
effect	O
seen	O
after	O
40	O
kDa	O
dCGN	O
exposure	O
.	O

Also	O
,	O
dCGN	O
stimulated	O
monocyte	O
aggregation	O
in	O
vitro	O
that	O
was	O
prevented	O
by	O
incubation	O
with	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
.	O

Finally	O
,	O
dCGN	O
stimulated	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
expression	O
and	O
secretion	O
by	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O

All	O
these	O
effects	O
were	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
the	O
degraded	O
forms	O
of	O
CGN	O
have	O
a	O
pronounced	O
effect	O
on	O
monocytes	O
,	O
characteristic	O
of	O
an	O
inflammatory	O
phenotype	O
.	O

Carrageenan	O
(	O
CGN	O
)	O
is	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
(	O
>	O
200	O
kDa	O
)	O
derived	O
from	O
red	O
algae	O
(	O
Rhodophyceae	O
)	O
.	O

Three	O
main	O
forms	O
of	O
CGN	O
have	O
been	O
identified	O
:	O
kappa	O
,	O
iota	O
,	O
and	O
lambda	O
.	O

They	O
differ	O
from	O
each	O
other	O
in	O
sulphation	O
degree	O
and	O
solubility	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Native	O
CGN	O
is	O
thought	O
to	O
be	O
harmless	O
and	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
to	O
improve	O
texture	O
.	O

It	O
is	O
also	O
used	O
in	O
cosmetics	O
and	O
pharmaceuticals	O
.	O

However	O
,	O
acid	O
treatment	O
at	O
high	O
temperature	O
(	O
80degreesC	O
)	O
triggers	O
CGN	O
hydrolysis	O
to	O
lower	O
molecular	O
weight	O
(	O
<	O
50	O
kDa	O
)	O
compounds	O
known	O
as	O
poligeenan	O
or	O
degraded	O
CGN	O
(	O
dCGN	O
)	O
.	O

These	O
dCGNs	O
induce	O
inflammation	O
and	O
have	O
been	O
widely	O
used	O
as	O
models	O
of	O
colitis	O
in	O
several	O
species	O
,	O
including	O
rats	O
[	O
3	O
]	O
,	O
rabbits	O
[	O
4	O
]	O
and	O
guinea	O
pigs	O
[	O
5	O
]	O
.	O

The	O
role	O
of	O
dCGN	O
as	O
a	O
tumor	O
-	O
promoting	O
factor	O
remains	O
controversial	O
[	O
4	O
]	O
,	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
.	O

Although	O
the	O
native	O
form	O
is	O
thought	O
to	O
be	O
harmless	O
for	O
human	O
consumption	O
,	O
small	O
amounts	O
of	O
dCGN	O
are	O
probably	O
produced	O
by	O
acid	O
hydrolysis	O
during	O
gastric	O
digestion	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
or	O
interaction	O
with	O
intestinal	O
bacteria	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

Whereas	O
the	O
effects	O
of	O
native	O
and	O
dCGN	O
on	O
intestinal	O
inflammation	O
have	O
been	O
extensively	O
analyzed	O
in	O
animal	O
models	O
,	O
only	O
few	O
studies	O
have	O
been	O
conducted	O
using	O
human	O
cell	O
lines	O
.	O

Recent	O
studies	O
have	O
shown	O
a	O
link	O
between	O
exposure	O
to	O
native	O
form	O
CGN	O
and	O
IL	B-PRGE
-	I-PRGE
8	E-PRGE
production	O
by	O
the	O
human	O
intestinal	O
epithelial	O
cell	O
line	O
,	O
NCM460	O
,	O
via	O
Nuclear	O
Factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
.	O

NF	O
-	O
kappaB	O
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
the	O
expression	O
of	O
genes	O
associated	O
with	O
inflammation	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

Macrophage	O
infiltration	O
and	O
accumulation	O
is	O
a	O
common	O
characteristic	O
of	O
intestinal	O
diseases	O
[	O
17	O
]	O
.	O

Macrophages	O
represent	O
10	O
%	O
of	O
total	O
lamina	O
propria	O
cells	O
,	O
secrete	O
a	O
wide	O
range	O
of	O
biologically	O
active	O
compounds	O
and	O
express	O
cell	O
-	O
adhesion	O
molecules	O
.	O

The	O
immune	O
cell	O
response	O
to	O
an	O
inflammatory	O
stimulus	O
seems	O
to	O
be	O
amplified	O
or	O
directly	O
generated	O
by	O
cells	O
exposed	O
to	O
sulphated	O
polysaccharides	O
such	O
as	O
carrageenans	O
.	O

Indeed	O
,	O
inflammation	O
induced	O
by	O
dCGN	O
was	O
associated	O
with	O
recruitment	O
of	O
macrophages	O
to	O
inflammation	O
sites	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

Also	O
,	O
inflammation	O
induced	O
by	O
Dextran	O
Sulphate	O
Sodium	O
(	O
DSS	O
)	O
,	O
another	O
sulphated	O
compound	O
,	O
was	O
directly	O
associated	O
with	O
macrophages	O
recruitment	O
[	O
20	O
]	O
,	O
since	O
DSS	O
still	O
provoked	O
inflammation	O
after	O
T	O
-	O
lymphocyte	O
and	O
NK	O
cell	O
depletion	O
[	O
20	O
]	O
.	O

Although	O
inflammation	O
can	O
be	O
induced	O
by	O
dCGN	O
,	O
there	O
are	O
no	O
data	O
on	O
human	O
monocyte	O
responses	O
to	O
dCGN	O
exposure	O
.	O

Therefore	O
,	O
to	O
investigate	O
the	O
effects	O
of	O
dCGN	O
on	O
human	O
monocytes	O
,	O
normal	O
Peripheral	O
Blood	O
Monocytes	O
(	O
PBM	O
)	O
and	O
tumoral	O
monocyte	O
/	O
macrophage	O
THP	O
-	O
1	O
cells	O
were	O
exposed	O
to	O
10	O
kDa	O
and	O
40	O
kDa	O
dCGN	O
.	O

We	O
found	O
that	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
increased	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
,	O
stimulated	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
-	O
dependent	O
monocyte	O
aggregation	O
,	O
and	O
stimulated	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
expression	O
and	O
secretion	O
.	O

These	O
responses	O
were	O
more	O
pronounced	O
after	O
40	O
kDa	O
dCGN	O
exposure	O
and	O
were	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
addition	O
,	O
the	O
40	O
kDa	O
dCGN	O
,	O
but	O
not	O
the	O
10	O
kDa	O
dCGN	O
induced	O
in	O
vivo	O
colitis	O
as	O
shown	O
by	O
the	O
inflammatory	O
response	O
in	O
the	O
rat	O
colon	O
.	O

These	O
results	O
suggest	O
that	O
the	O
degraded	O
forms	O
of	O
CGN	O
have	O
an	O
important	O
effect	O
on	O
monocytes	O
resulting	O
in	O
an	O
inflammatory	O
phenotype	O
.	O

Preparation	O
of	O
Degraded	O
Carrageenan	O

Two	O
preparations	O
of	O
degraded	O
carrageenan	O
with	O
low	O
,	O
(	O
~	O
10	O
kDa	O
;	O
C10	O
)	O
,	O
and	O
medium	O
,	O
(	O
~	O
40	O
kDa	O
;	O
C40	O
)	O
molecular	O
weight	O
were	O
prepared	O
from	O
native	O
iota	O
-	O
carrageenan	O
extracted	O
from	O
Euchema	O
spinosum	O
(	O
generously	O
provided	O
by	O
Sanofi	O
Biosystems	O
Industry	O
,	O
Boulogne	O
-	O
Billancourt	O
,	O
France	O
)	O
.	O

Native	O
carrageenan	O
was	O
dissolved	O
in	O
distilled	O
water	O
(	O
5	O
%	O
w	O
/	O
v	O
)	O
under	O
vigorous	O
stirring	O
and	O
heated	O
to	O
60degreesC	O
.	O

Then	O
,	O
the	O
carrageenan	O
solution	O
was	O
submitted	O
to	O
two	O
different	O
treatments	O
to	O
obtain	O
both	O
low	O
and	O
medium	O
molecular	O
weight	O
fractions	O
.	O

Briefly	O
,	O
for	O
the	O
low	O
molecular	O
weight	O
fraction	O
,	O
carrageenan	O
solution	O
was	O
hydrolyzed	O
with	O
0	O
.	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
sulphuric	O
acid	O
for	O
15	O
min	O
at	O
80degreesC	O
.	O

After	O
neutralization	O
with	O
NaOH	O
4N	O
,	O
the	O
solution	O
was	O
ultra	O
filtered	O
through	O
a	O
hollow	O
fibre	O
cartridge	O
with	O
MW	O
cut	O
-	O
off	O
5	O
kDa	O
,	O
(	O
Amicon	O
Inc	O
,	O
Beverly	O
,	O
USA	O
)	O
.	O

For	O
the	O
medium	O
molecular	O
weight	O
fraction	O
,	O
the	O
carrageenan	O
solution	O
was	O
hydrolyzed	O
with	O
0	O
.	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
sulphuric	O
acid	O
for	O
30	O
min	O
at	O
60degreesC	O
.	O

After	O
neutralization	O
,	O
the	O
supernatant	O
was	O
ultra	O
filtered	O
(	O
MW	O
cut	O
-	O
off	O
100	O
kDa	O
)	O
.	O

The	O
filtrate	O
was	O
submitted	O
to	O
a	O
second	O
ultra	O
filtration	O
(	O
MW	O
cut	O
-	O
off	O
5	O
kDa	O
)	O
.	O

Both	O
preparations	O
of	O
dCGN	O
were	O
precipitated	O
with	O
4	O
volumes	O
of	O
95	O
%	O
ethanol	O
,	O
dried	O
at	O
room	O
temperature	O
and	O
ground	O
to	O
small	O
particles	O
(	O
1	O
mm	O
in	O
diameter	O
)	O
.	O

Using	O
gel	O
-	O
permeation	O
chromatography	O
in	O
combination	O
with	O
light	O
scattering	O
measurements	O
(	O
see	O
Viebke	O
et	O
al	O
.	O
[	O
21	O
]	O
)	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
low	O
fraction	O
had	O
an	O
average	O
molecular	O
weight	O
of	O
10	O
kDa	O
,	O
and	O
the	O
medium	O
fraction	O
of	O
40	O
kDa	O
.	O

The	O
sulphate	O
content	O
of	O
polysaccharides	O
in	O
both	O
fractions	O
was	O
measured	O
following	O
the	O
method	O
of	O
Quemener	O
et	O
al	O
.	O

[	O
22	O
]	O
.	O

Finally	O
,	O
the	O
absence	O
of	O
polysaccharide	O
structure	O
modifications	O
in	O
the	O
two	O
fractions	O
was	O
confirmed	O
using	O
2H	O
-	O
NMR	O
spectroscopy	O
.	O

The	O
absence	O
of	O
LPS	O
contamination	O
in	O
the	O
two	O
fractions	O
was	O
confirmed	O
using	O
the	O
e	O
-	O
Toxate	O
(	O
R	O
)	O
kit	O
(	O
Sigma	O
,	O
St	O
Quentin	O
Fallavier	O
,	O
France	O
)	O
.	O

Before	O
use	O
in	O
cell	O
culture	O
,	O
the	O
two	O
fractions	O
were	O
dissolved	O
in	O
complete	O
medium	O
during	O
30	O
min	O
at	O
56degreesC	O
.	O

Animals	O
,	O
Chemicals	O
and	O
Diet	O

Male	O
Wistar	O
rats	O
(	O
150	O
g	O
average	O
weight	O
)	O
were	O
housed	O
under	O
standard	O
conditions	O
and	O
fed	O
ad	O
libitum	O
with	O
standard	O
rodent	O
laboratory	O
chow	O
.	O

Degraded	O
iota	O
-	O
carrageenans	O
were	O
administered	O
in	O
the	O
drinking	O
water	O
(	O
5	O
%	O
w	O
/	O
v	O
)	O
for	O
55	O
days	O
to	O
2	O
groups	O
of	O
six	O
animals	O
each	O
.	O

The	O
first	O
group	O
received	O
the	O
low	O
molecular	O
weight	O
carrageenan	O
(	O
10	O
kDa	O
dCGN	O
)	O
and	O
the	O
second	O
received	O
the	O
medium	O
molecular	O
weight	O
carrageenan	O
(	O
40	O
kDa	O
dCGN	O
)	O
.	O

An	O
additional	O
group	O
of	O
four	O
rats	O
were	O
maintained	O
on	O
regular	O
tap	O
water	O
(	O
control	O
group	O
)	O
.	O

To	O
increase	O
palatability	O
0	O
.	O
2	O
%	O
sucrose	O
was	O
added	O
to	O
the	O
drinking	O
water	O
of	O
all	O
groups	O
(	O
Van	O
der	O
Waaji	O
et	O
al	O
.	O
,	O
[	O
23	O
]	O
)	O
.	O

Fresh	O
carrageenan	O
solutions	O
were	O
prepared	O
daily	O
.	O

Evaluation	O
of	O
Colitis	O

Body	O
weight	O
,	O
liquid	O
and	O
food	O
consumption	O
,	O
diarrhea	O
and	O
rectal	O
bleeding	O
(	O
detected	O
by	O
eye	O
inspection	O
)	O
were	O
recorded	O
throughout	O
the	O
feeding	O
period	O
.	O

After	O
55	O
days	O
,	O
animals	O
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
.	O

The	O
length	O
of	O
the	O
colon	O
was	O
measured	O
as	O
described	O
by	O
Okayashu	O
et	O
al	O
.	O

[	O
24	O
]	O
.	O

Then	O
,	O
each	O
colon	O
was	O
ligated	O
in	O
sections	O
of	O
2	O
cm	O
and	O
1	O
to	O
2	O
ml	O
of	O
10	O
%	O
formalin	O
was	O
infused	O
into	O
the	O
intestinal	O
lumen	O
.	O

The	O
moderately	O
distended	O
segment	O
was	O
sectioned	O
and	O
fixed	O
in	O
10	O
%	O
formalin	O
.	O

The	O
following	O
day	O
,	O
the	O
intestinal	O
content	O
was	O
removed	O
by	O
vortexing	O
.	O

The	O
fixed	O
segment	O
was	O
kept	O
in	O
10	O
%	O
formalin	O
at	O
4degreesC	O
until	O
the	O
paraffin	O
embedding	O
procedure	O
.	O

To	O
evaluate	O
the	O
degree	O
of	O
inflammation	O
,	O
this	O
segment	O
of	O
colon	O
was	O
opened	O
longitudinally	O
and	O
macroscopic	O
and	O
histological	O
scores	O
of	O
inflammation	O
were	O
recorded	O
as	O
previously	O
described	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
.	O

The	O
toluidine	O
blue	O
staining	O
was	O
used	O
for	O
identification	O
of	O
sulphated	O
polysaccharides	O
in	O
the	O
intestinal	O
mucosa	O
.	O

On	O
the	O
day	O
of	O
sacrifice	O
,	O
a	O
fresh	O
sample	O
of	O
each	O
colon	O
(	O
50	O
mg	O
)	O
was	O
collected	O
for	O
myeloperoxidase	S-PRGE
(	O
MPO	S-PRGE
)	O
assay	O
according	O
to	O
Krawisz	O
et	O
al	O
.	O
,	O
[	O
27	O
]	O
.	O

The	O
level	O
of	O
MPO	S-PRGE
,	O
mainly	O
expressed	O
by	O
neutrophils	O
,	O
indicates	O
the	O
rate	O
of	O
recruitment	O
of	O
neutrophils	O
to	O
the	O
intestinal	O
mucosa	O
.	O

One	O
unit	O
of	O
MPO	O
activity	O
corresponds	O
to	O
the	O
degradation	O
of	O
1	O
micromol	O
of	O
peroxide	O
per	O
minute	O
at	O
25degreesC	O
.	O

Cell	O
Culture	O

All	O
tissue	O
culture	O
reagents	O
were	O
from	O
Invitrogen	O
(	O
Cergy	O
Pontoise	O
,	O
France	O
)	O
.	O

THP	O
-	O
1	O
human	O
monocytic	O
cells	O
were	O
maintained	O
in	O
RPMI	O
-	O
1640	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
U	O
/	O
ml	O
penicillin	O
and	O
50	O
mg	O
/	O
ml	O
streptomycin	O
at	O
37degreesC	O
in	O
a	O
5	O
%	O
CO2	O
incubator	O
.	O

Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
obtained	O
from	O
heparinized	O
blood	O
by	O
Ficoll	O
-	O
Hypaque	O
density	O
gradient	O
.	O

Monocytes	O
were	O
then	O
isolated	O
by	O
adherence	O
to	O
culture	O
flasks	O
as	O
described	O
[	O
28	O
]	O
.	O

For	O
cell	O
aggregation	O
,	O
monocytes	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
C10	O
or	O
C40	O
for	O
72	O
h	O
.	O

Cell	O
colonies	O
were	O
monitored	O
under	O
an	O
inverted	O
phase	O
contrast	O
microscope	O
coupled	O
through	O
a	O
video	O
camera	O
to	O
a	O
computer	O
.	O

In	O
some	O
wells	O
,	O
neutralizing	O
monoclonal	O
antibody	O
to	O
ICAM	O
-	O
1	O
(	O
2	O
.	O
5	O
microg	O
/	O
ml	O
)	O
(	O
Tebu	O
,	O
Le	O
Perray	O
en	O
Yvelines	O
,	O
France	O
)	O
was	O
added	O
.	O

Cell	O
Cycle	O
Analysis	O

THP	O
-	O
1	O
cells	O
in	O
exponential	O
growth	O
phase	O
were	O
exposed	O
to	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenans	O
for	O
24	O
h	O
before	O
being	O
stained	O
with	O
propidium	O
iodide	O
using	O
the	O
DNA	O
-	O
Prep	O
Coulter	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
(	O
Beckman	O
-	O
Coulter	O
,	O
Villepinte	O
,	O
France	O
)	O
.	O

Cell	O
DNA	O
content	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
using	O
an	O
EPICS	O
XL2	O
(	O
Beckman	O
-	O
Coulter	O
)	O
.	O

Raw	O
data	O
for	O
the	O
distribution	O
of	O
DNA	O
content	O
of	O
30	O
,	O
000	O
cells	O
retrieved	O
from	O
the	O
cytometer	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
G0	O
/	O
G1	O
through	O
G2	O
/	O
M	O
populations	O
.	O

Multicycle	O
AV	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
used	O
to	O
generate	O
DNA	O
content	O
frequency	O
histograms	O
and	O
facilitate	O
data	O
analysis	O
.	O

Cell	O
Surface	O
Antigen	O
Expression	O
Analysis	O

Peripheral	O
Blood	O
Monocytes	O
or	O
THP	O
-	O
1	O
cells	O
were	O
exposed	O
to	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
36	O
h	O
.	O

After	O
two	O
washes	O
in	O
PBS	O
without	O
Ca2	O
+	O
and	O
Mg2	O
+	O
,	O
cells	O
were	O
incubated	O
in	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
gelatin	O
and	O
8	O
%	O
AB	O
human	O
serum	O
to	O
prevent	O
binding	O
to	O
Fc	O
receptors	O
.	O

Then	O
,	O
5x105	O
cells	O
were	O
incubated	O
with	O
primary	O
antibodies	O
at	O
4degreesC	O
for	O
30	O
min	O
.	O

Two	O
other	O
washes	O
in	O
PBS	O
preceded	O
incubation	O
with	O
FITC	O
-	O
conjugated	O
goat	O
antibody	O
anti	O
-	O
mouse	O
IgG	O
diluted	O
1	O
/	O
1000	O
at	O
4degreesC	O
for	O
30	O
min	O
(	O
Tebu	O
)	O
.	O

After	O
two	O
additional	O
washes	O
,	O
analysis	O
of	O
stained	O
cells	O
was	O
performed	O
on	O
an	O
EPICS	O
XL2	O
(	O
Beckman	O
-	O
Coulter	O
)	O
.	O

The	O
cell	O
population	O
was	O
gated	O
according	O
to	O
its	O
forward	O
and	O
wide	O
-	O
angle	O
light	O
scattering	O
.	O

Data	O
were	O
expressed	O
as	O
mean	O
relative	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
3000	O
cells	O
.	O

TNF	S-PRGE
Activity	O
Bioassay	O

Monocytes	O
or	O
THP	O
-	O
1	O
cells	O
were	O
cultured	O
with	O
or	O
without	O
different	O
concentrations	O
of	O
CGNs	O
or	O
LPS	O
(	O
Salmonella	O
typhosa	O
,	O
Sigma	O
)	O
for	O
24	O
h	O
or	O
the	O
indicated	O
time	O
.	O

Biologically	O
active	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
/	O
beta	S-PRGE
in	O
tissue	O
culture	O
supernatant	O
was	O
measured	O
using	O
the	O
WEHI	O
164	O
clone	O
13	O
-	O
cell	O
killing	O
assay	O
[	O
29	O
]	O
.	O

TNF	S-PRGE
concentrations	O
are	O
expressed	O
as	O
pg	O
/	O
ml	O
.	O

RT	O
-	O
PCR	O
Analysis	O

Total	O
RNA	O
from	O
monocytes	O
was	O
isolated	O
using	O
TRIzol	O
Reagent	O
(	O
TM	O
)	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
generated	O
on	O
1	O
microg	O
of	O
total	O
RNA	O
in	O
a	O
reaction	O
volume	O
of	O
20	O
microl	O
,	O
using	O
M	O
-	O
MLV	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
was	O
done	O
in	O
the	O
linear	O
range	O
of	O
amplification	O
(	O
determined	O
for	O
each	O
primer	O
pair	O
-	O
cDNA	O
combination	O
)	O
.	O

Standard	O
PCR	O
reactions	O
were	O
performed	O
with	O
1	O
microl	O
of	O
the	O
cDNA	O
solution	O
,	O
50	O
microM	O
of	O
each	O
primer	O
solution	O
,	O
10	O
mM	O
of	O
each	O
dNTP	O
,	O
25	O
mM	O
MgCl2	O
,	O
10X	O
Goldstar	O
DNA	O
polymerase	O
reaction	O
buffer	O
,	O
and	O
0	O
.	O
5	O
units	O
of	O
Goldstar	O
DNA	O
polymerase	O
(	O
Eurogentec	O
,	O
Seraing	O
,	O
Belgium	O
)	O
.	O

First	O
PCR	O
cycle	O
consisted	O
of	O
1	O
min	O
at	O
92degreesC	O
,	O
1	O
min	O
at	O
58degreesC	O
and	O
1	O
min	O
at	O
72degreesC	O
;	O
then	O
each	O
PCR	O
cycle	O
consisted	O
of	O
40	O
sec	O
at	O
92degreesC	O
,	O
40	O
sec	O
at	O
58degreesC	O
and	O
50	O
sec	O
at	O
72degreesC	O
.	O

cDNA	O
for	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
was	O
amplified	O
for	O
28	O
cycles	O
using	O
the	O
oligos	O
:	O
sense	O
5	O
'	O
-	O
GGCATCGTGATGGACTCCG	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
GCTGGAAGGTGGACAGCGA	O
-	O
3	O
'	O
.	O

cDNA	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
amplified	O
for	O
35	O
cycles	O
using	O
the	O
oligos	O
:	O
sense	O
5	O
'	O
-	O
AAGCCTGTAGCCCATGTTGT	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
-	O
CAGATAGATGGGCTCATACC	O
-	O
3	O
'	O
.	O

cDNA	O
for	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
was	O
amplified	O
for	O
35	O
cycles	O
using	O
the	O
oligos	O
sense	O
5	O
'	O
-	O
GTAGCAGCCGCAGTCATAATGG	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
-	O
A	O
TGCTGTTGTATCTGACTGAGG	O
-	O
3	O
'	O
.	O

NF	O
-	O
kB	O
Transcription	O
Reporter	O
Gene	O
Assay	O

The	O
plasmid	O
3XMHC	O
-	O
luc	O
(	O
a	O
generous	O
gift	O
from	O
Drs	O
.	O
J	O
.	O
Westwick	O
and	O
D	O
.	O
A	O
.	O
Brenner	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
)	O
contains	O
three	O
copies	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
element	O
from	O
the	O
MHC	O
class	O
I	O
locus	O
,	O
placed	O
upstream	O
of	O
the	O
luciferase	S-PRGE
gene	O
.	O

Human	O
monocytic	O
THP	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
as	O
previously	O
described	O
[	O
30	O
]	O
,	O
and	O
then	O
cultured	O
for	O
4	O
h	O
alone	O
or	O
with	O
increasing	O
concentration	O
of	O
either	O
C10	O
or	O
C40	O
.	O

Luciferase	S-PRGE
activity	O
was	O
determined	O
using	O
a	O
luminometer	O
(	O
Monolight	O
2010	O
Luminometer	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

Western	O
Blot	O
Analysis	O

THP	O
-	O
1	O
cells	O
were	O
stimulated	O
for	O
various	O
lengths	O
of	O
time	O
with	O
0	O
.	O
1	O
mg	O
/	O
ml	O
C10	O
or	O
C40	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
.	O

Cells	O
were	O
then	O
pelleted	O
,	O
washed	O
and	O
homogenised	O
in	O
lysis	O
buffer	O
(	O
10	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
9	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
6	O
%	O
NP	O
-	O
40	O
,	O
and	O
0	O
.	O
5	O
mM	O
PMSF	O
)	O
on	O
ice	O
.	O

Homogenates	O
were	O
sonicated	O
,	O
centrifuged	O
at	O
10	O
,	O
000	O
rpm	O
to	O
remove	O
cellular	O
debris	O
,	O
and	O
supernatant	O
collected	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
the	O
DC	O
Protein	O
Assay	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Proteins	O
in	O
samples	O
(	O
15	O
microg	O
total	O
proteins	O
)	O
were	O
resolved	O
in	O
a	O
denaturing	O
12	O
%	O
polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

I	B-PRGE
-	I-PRGE
kappaBalpha	E-PRGE
protein	O
was	O
detected	O
using	O
a	O
rabbit	O
polyclonal	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
)	O
followed	O
by	O
a	O
horseradish	O
peroxidase	O
-	O
coupled	O
goat	O
polyclonal	O
antibody	O
against	O
rabbit	O
Ig	O
(	O
Caltag	O
Laboratories	O
)	O
.	O

Finally	O
,	O
IkappaB	O
bands	O
were	O
revealed	O
using	O
the	O
ECL	O
(	O
TM	O
)	O
detection	O
system	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Les	O
Ullis	O
,	O
France	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
instruction	O
.	O

Antibody	O
to	O
alpha	O
-	O
Tubulin	O
(	O
Santa	O
Cruz	O
)	O
was	O
use	O
as	O
loading	O
control	O
.	O

For	O
nuclear	O
NF	O
-	O
kappaB	O
,	O
THP	O
-	O
1	O
cells	O
were	O
stimulated	O
with	O
1	O
mg	O
/	O
ml	O
C10	O
or	O
C40	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Cells	O
were	O
then	O
pelleted	O
and	O
nuclei	O
separated	O
as	O
described	O
[	O
31	O
]	O
.	O

Nuclei	O
were	O
washed	O
and	O
homogenized	O
directly	O
in	O
loading	O
(	O
Laemli	O
)	O
buffer	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
100degreesC	O
.	O

Proteins	O
in	O
samples	O
were	O
resolved	O
in	O
a	O
denaturing	O
8	O
%	O
polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
polyvinylidine	O
fluoride	O
(	O
PVDF	O
)	O
membrane	O
(	O
Immobilon	O
-	O
P	O
;	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
)	O
.	O

Membranes	O
were	O
incubated	O
in	O
blocking	O
buffer	O
(	O
1	O
%	O
BSA	O
,	O
in	O
PBS	O
)	O
for	O
two	O
hours	O
at	O
room	O
temperature	O
.	O

Membranes	O
were	O
subsequently	O
probed	O
with	O
the	O
corresponding	O
antibody	O
in	O
blocking	O
buffer	O
,	O
overnight	O
.	O

Rabbit	O
polyclonal	O
antibody	O
anti	O
-	O
NF	O
-	O
kappaB	O
p50	O
subunit	O
(	O
#	O
sc	O
-	O
114	O
)	O
or	O
anti	O
-	O
NF	O
-	O
kappaB	O
p65	O
subunit	O
(	O
#	O
sc	O
-	O
109	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
were	O
used	O
.	O

Membranes	O
were	O
washed	O
six	O
times	O
in	O
PBS	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
,	O
5	O
minutes	O
each	O
time	O
,	O
and	O
incubated	O
with	O
a	O
1	O
/	O
3000	O
dilution	O
of	O
HRP	O
-	O
conjugated	O
F	O
(	O
ab	O
'	O
)	O
2	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
in	O
5	O
%	O
nonfat	O
dry	O
milk	O
and	O
0	O
.	O
05	O
%	O
Tween	O
20	O
in	O
PBS	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
six	O
more	O
times	O
in	O
PBS	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
,	O
antibody	O
-	O
reactive	O
proteins	O
were	O
detected	O
using	O
a	O
chemiluminescence	O
substrate	O
(	O
SuperSignal	O
;	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

To	O
confirm	O
that	O
equivalent	O
amounts	O
of	O
protein	O
were	O
loaded	O
in	O
each	O
line	O
,	O
membranes	O
were	O
also	O
Western	O
blotted	O
for	O
ERK	O
as	O
described	O
[	O
32	O
]	O
.	O

Analysis	O
of	O
NF	O
-	O
kappaB	O
Activation	O
by	O
Flow	O
Cytometry	O

Nuclear	O
activation	O
of	O
NF	O
-	O
kappabeta	O
by	O
flow	O
cytometry	O
was	O
performed	O
as	O
described	O
[	O
31	O
]	O
.	O

Statistical	O
Analysis	O

The	O
results	O
were	O
expressed	O
as	O
the	O
mean	O
value	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
of	O
individual	O
experiments	O
.	O

The	O
statistical	O
significance	O
of	O
the	O
differences	O
between	O
mean	O
values	O
was	O
assessed	O
by	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Degraded	O
CGN	O
Induce	O
Colonic	O
Inflammation	O

All	O
rats	O
developed	O
diarrhea	O
during	O
degraded	O
carrageenan	O
administration	O
and	O
gross	O
evidence	O
of	O
blood	O
was	O
frequently	O
detected	O
in	O
the	O
stools	O
.	O

Colon	O
length	O
dramatically	O
decreased	O
in	O
all	O
treated	O
rats	O
with	O
a	O
more	O
pronounced	O
effect	O
being	O
observed	O
in	O
the	O
40	O
kDa	O
dCGN	O
treated	O
group	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Furthermore	O
,	O
prolonged	O
exposure	O
to	O
40	O
kDa	O
dCGN	O
resulted	O
in	O
high	O
macroscopic	O
and	O
histological	O
scores	O
of	O
inflammation	O
(	O
Fig	O
.	O
1B	O
,	O
C	O
)	O
.	O

Only	O
weak	O
myeloperoxidase	S-PRGE
activity	O
was	O
detected	O
in	O
both	O
control	O
and	O
dCGN	O
-	O
treated	O
groups	O
(	O
Fig	O
.	O
1D	O
)	O
,	O
indicating	O
that	O
granulocytes	O
did	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
inflammation	O
at	O
that	O
stage	O
.	O

Histological	O
examination	O
revealed	O
various	O
degrees	O
of	O
mucosal	O
inflammation	O
.	O

Rats	O
treated	O
with	O
10	O
kDa	O
dCGN	O
showed	O
edema	O
,	O
epithelium	O
atrophy	O
and	O
slight	O
lymphocyte	O
infiltration	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
symptoms	O
were	O
totally	O
absent	O
in	O
the	O
colon	O
of	O
control	O
rats	O
(	O
Fig	O
.	O
1E	O
)	O
.	O

More	O
severe	O
mucosal	O
injuries	O
including	O
ulceration	O
,	O
hyperplastic	O
epithelium	O
,	O
crypt	O
distortion	O
and	O
a	O
strong	O
macrophage	O
infiltration	O
,	O
were	O
observed	O
in	O
the	O
40	O
kDa	O
dCGN	O
-	O
treated	O
rats	O
(	O
Fig	O
.	O
1F	O
)	O
.	O

No	O
sulphated	O
polysaccharides	O
were	O
detected	O
by	O
toluidine	O
blue	O
staining	O
of	O
colon	O
mucosa	O
from	O
rats	O
treated	O
with	O
either	O
the	O
10	O
or	O
40	O
kDa	O
dCGN	O
(	O
not	O
shown	O
)	O
.	O

Although	O
we	O
cannot	O
exclude	O
that	O
dCGN	O
mat	O
not	O
have	O
retained	O
in	O
the	O
section	O
during	O
the	O
histology	O
procedure	O
,	O
this	O
indicates	O
that	O
these	O
polymers	O
may	O
not	O
have	O
been	O
phagocytosed	O
.	O

Degraded	O
CGN	O
Induced	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
Production	O
by	O
Monocytes	O
In	O
Vitro	O

In	O
order	O
to	O
study	O
the	O
capacity	O
of	O
dCGN	O
to	O
stimulate	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
,	O
peripheral	O
blood	O
monocytes	O
were	O
cultivated	O
in	O
the	O
presence	O
of	O
dCGN	O
(	O
0	O
.	O
1	O
to	O
1	O
mg	O
/	O
ml	O
)	O
.	O

Very	O
low	O
levels	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
were	O
induced	O
in	O
PBM	O
after	O
stimulation	O
with	O
native	O
CGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Addition	O
of	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
resulted	O
in	O
approximately	O
a	O
60	O
-	O
fold	O
increase	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
by	O
PBM	O
.	O

This	O
was	O
a	O
dose	O
-	O
dependent	O
effect	O
that	O
reached	O
a	O
180	O
-	O
fold	O
increase	O
when	O
cells	O
were	O
exposed	O
to	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

A	O
250	O
-	O
fold	O
increase	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
was	O
detected	O
at	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
increased	O
in	O
time	O
reaching	O
a	O
maximum	O
level	O
at	O
8	O
hours	O
of	O
culture	O
(	O
Figure	O
2B	O
)	O
.	O

After	O
24	O
h	O
,	O
the	O
amount	O
of	O
secreted	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
still	O
one	O
third	O
of	O
the	O
total	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
a	O
known	O
activator	O
of	O
immune	O
cells	O
also	O
induced	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
with	O
similar	O
kinetics	O
as	O
dCGN	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

However	O
,	O
the	O
amount	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
produced	O
by	O
LPS	O
was	O
4	O
-	O
fold	O
less	O
than	O
the	O
one	O
produced	O
by	O
dCGN	O
and	O
it	O
was	O
not	O
detected	O
after	O
8	O
hours	O
of	O
culture	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Similarly	O
,	O
monocytic	O
THP	O
-	O
1	O
cells	O
cultivated	O
in	O
the	O
presence	O
of	O
variable	O
concentration	O
of	O
dCGN	O
showed	O
an	O
increase	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

This	O
increase	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
was	O
significantly	O
smaller	O
(	O
about	O
10	O
-	O
fold	O
)	O
than	O
the	O
one	O
presented	O
by	O
PBM	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

No	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
released	O
from	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
native	O
CGN	O
(	O
not	O
shown	O
)	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
by	O
THP	O
-	O
1	O
cells	O
was	O
not	O
dose	O
dependent	O
to	O
the	O
amount	O
of	O
dCGN	O
used	O
.	O

Also	O
there	O
was	O
no	O
difference	O
between	O
the	O
two	O
forms	O
(	O
10	O
and	O
40	O
kDa	O
)	O
of	O
dCGN	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

Interestingly	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
release	O
from	O
THP	O
-	O
1	O
cells	O
stimulated	O
with	O
dCGN	O
reached	O
a	O
maximum	O
level	O
at	O
32	O
h	O
,	O
while	O
stimulation	O
with	O
LPS	O
reached	O
a	O
maximum	O
level	O
at	O
56	O
h	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

Effect	O
of	O
Native	O
and	O
Degraded	O
CGN	O
on	O
THP	O
-	O
1	O
Proliferation	O
and	O
Cell	O
Cycle	O

Preliminary	O
observations	O
by	O
enumeration	O
of	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
different	O
concentrations	O
of	O
native	O
and	O
dCGN	O
(	O
10	O
and	O
40	O
kDa	O
)	O
during	O
2	O
,	O
5	O
and	O
7	O
days	O
,	O
showed	O
a	O
decline	O
in	O
cell	O
number	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
suggested	O
that	O
dCGN	O
might	O
cause	O
an	O
alteration	O
in	O
the	O
cell	O
cycle	O
.	O

Cell	O
cycle	O
analysis	O
using	O
flow	O
cytometry	O
showed	O
an	O
accumulation	O
of	O
THP	O
-	O
1	O
cells	O
in	O
G0	O
/	O
G1	O
phase	O
,	O
which	O
was	O
associated	O
with	O
a	O
decrease	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

The	O
percentage	O
of	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
was	O
45	O
.	O
2	O
%	O
for	O
control	O
cells	O
,	O
62	O
.	O
6	O
%	O
for	O
C10	O
dCGN	O
(	O
at	O
2	O
mg	O
/	O
ml	O
)	O
,	O
and	O
64	O
.	O
2	O
%	O
for	O
C40	O
dCGN	O
-	O
treated	O
cells	O
(	O
at	O
2	O
mg	O
/	O
ml	O
)	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

The	O
effect	O
of	O
dCGN	O
on	O
cell	O
cycle	O
was	O
dose	O
-	O
dependent	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Neither	O
native	O
nor	O
dCGN	O
had	O
an	O
effect	O
on	O
the	O
number	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
phase	O
(	O
Fig	O
.	O
3	O
)	O
.	O

This	O
effect	O
is	O
not	O
due	O
to	O
cytotoxicity	O
of	O
dCGN	O
even	O
at	O
the	O
highest	O
concentration	O
(	O
i	O
.	O
e	O
.	O
2	O
mg	O
/	O
ml	O
)	O
since	O
cell	O
viability	O
was	O
not	O
affected	O
(	O
data	O
not	O
shown	O
)	O
.	O

ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
Expression	O
Is	O
Induced	O
by	O
Degraded	O
CGN	O
and	O
Is	O
Responsible	O
for	O
Monocytes	O
Aggregation	O
In	O
Vitro	O

In	O
order	O
to	O
study	O
the	O
effect	O
of	O
dCGN	O
on	O
the	O
expression	O
of	O
cell	O
surface	O
antigens	O
,	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
for	O
36	O
h	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dCGN	O
.	O

The	O
expression	O
of	O
various	O
cell	O
surface	O
molecules	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
as	O
described	O
in	O
materials	O
and	O
methods	O
.	O

Both	O
forms	O
of	O
dCGN	O
clearly	O
stimulated	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
(	O
CD54	S-PRGE
)	O
on	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

The	O
increase	O
in	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
was	O
higher	O
on	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Another	O
surface	O
antigen	O
,	O
the	O
lymphocyte	B-PRGE
function	I-PRGE
-	I-PRGE
associated	I-PRGE
antigen	I-PRGE
3	E-PRGE
(	O
CD58	S-PRGE
)	O
was	O
slightly	O
reduced	O
on	O
PBM	O
after	O
treatment	O
with	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Interestingly	O
,	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
molecules	O
of	O
class	O
I	O
(	O
HLA	O
-	O
ABC	O
)	O
and	O
of	O
class	O
II	O
(	O
HLA	O
-	O
DR	O
)	O
,	O
as	O
well	O
as	O
the	O
monocyte	B-PRGE
marker	E-PRGE
CD14	S-PRGE
,	O
seemed	O
to	O
be	O
reduced	O
by	O
treatment	O
with	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

However	O
,	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

Treatment	O
with	O
dCGN	O
also	O
induced	O
a	O
strong	O
aggregation	O
of	O
monocytes	O
,	O
detected	O
by	O
phase	O
contrast	O
inverse	O
microscopy	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Although	O
this	O
effect	O
was	O
easily	O
observed	O
in	O
monocytes	O
incubated	O
with	O
the	O
10	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
5B	O
)	O
,	O
a	O
more	O
robust	O
cell	O
aggregation	O
was	O
observed	O
in	O
monocytes	O
incubated	O
with	O
the	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
has	O
been	O
proposed	O
to	O
be	O
the	O
main	O
adhesion	O
molecule	O
responsible	O
for	O
monocyte	O
aggregation	O
.	O

To	O
confirm	O
this	O
,	O
monocytes	O
were	O
incubated	O
with	O
both	O
types	O
of	O
dCGN	O
in	O
the	O
presence	O
of	O
an	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
,	O
an	O
anti	O
-	O
CD58	O
antibody	O
and	O
an	O
isotype	O
control	O
IgG1	O
antibody	O
.	O

The	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
effectively	O
blocked	O
the	O
cell	O
aggregates	O
induced	O
by	O
dCGN	O
(	O
Fig	O
.	O
5D	O
,	O
5E	O
)	O
,	O
strongly	O
suggesting	O
that	O
indeed	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
is	O
responsible	O
for	O
monocyte	O
aggregation	O
.	O

Both	O
the	O
control	O
IgG1	O
and	O
the	O
anti	O
-	O
CD58	O
antibody	O
did	O
not	O
modify	O
monocyte	O
aggregation	O
(	O
data	O
not	O
shown	O
)	O
.	O

Degraded	O
CGN	O
Induce	O
an	O
Increase	O
in	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
mRNA	O
Expression	O

The	O
increase	O
in	O
surface	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
by	O
monocytes	O
correlated	O
with	O
an	O
upregulation	O
of	O
mRNA	O
for	O
these	O
molecules	O
.	O

Both	O
10	O
kDa	O
and	O
40	O
kDa	O
dCGN	O
induced	O
a	O
robust	O
increase	O
in	O
mRNA	O
for	O
both	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
Fig	O
.	O
6	O
)	O
.	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
dCGN	O
treatment	O
.	O

Degraded	O
CGN	O
Induce	O
IkappaB	O
Degradation	O
and	O
NF	O
-	O
kappaB	O
Activation	O

The	O
expression	O
of	O
genes	O
encoding	O
for	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
is	O
controlled	O
by	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
.	O

Site	O
-	O
specific	O
phosphorylation	O
of	O
the	O
inhibitor	O
IkappaB	O
leads	O
to	O
its	O
degradation	O
by	O
proteasome	O
and	O
to	O
a	O
consequential	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

Using	O
a	O
reporter	O
plasmid	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
it	O
was	O
confirmed	O
that	O
dCGN	O
induced	O
a	O
strong	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
as	O
reflected	O
by	O
an	O
increase	O
in	O
luciferase	S-PRGE
activity	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

Both	O
forms	O
of	O
dCGN	O
used	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

However	O
,	O
the	O
effect	O
was	O
more	O
strongly	O
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

These	O
results	O
were	O
further	O
confirmed	O
by	O
directly	O
detecting	O
NF	O
-	O
kappaB	O
in	O
the	O
cell	O
nucleus	O
by	O
Western	O
blotting	O
(	O
Fig	O
.	O
7C	O
)	O
and	O
by	O
FACS	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

These	O
assays	O
also	O
allowed	O
us	O
to	O
determine	O
what	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
subunits	E-PRGE
were	O
activated	O
by	O
dCGN	O
.	O

Both	O
forms	O
(	O
10	O
or	O
40	O
kDa	O
)	O
of	O
dCGN	O
induced	O
activation	O
of	O
the	O
p50	S-PRGE
and	O
p65	S-PRGE
subunits	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
nuclear	O
factor	O
was	O
present	O
in	O
low	O
levels	O
in	O
the	O
cell	O
nucleus	O
and	O
increased	O
considerably	O
after	O
treatment	O
with	O
dCGN	O
.	O

Western	O
blots	O
suggested	O
the	O
the	O
40	O
kDa	O
form	O
of	O
dCGN	O
induced	O
a	O
stronger	O
activation	O
of	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

A	O
more	O
sentive	O
assay	O
for	O
nuclear	O
factor	O
activation	O
is	O
flow	O
cytometry	O
of	O
nuclei	O
stained	O
with	O
specific	O
antibodies	O
for	O
the	O
nuclear	O
factor	O
of	O
interest	O
.	O

In	O
agreement	O
with	O
the	O
previous	O
data	O
,	O
FACS	O
analysis	O
of	O
nuclei	O
from	O
THP	O
-	O
1	O
cells	O
showed	O
that	O
there	O
was	O
a	O
basal	O
level	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

Again	O
,	O
both	O
forms	O
(	O
10	O
or	O
40	O
kDa	O
)	O
of	O
dCGN	O
induced	O
an	O
increase	O
of	O
the	O
p50	S-PRGE
and	O
p65	S-PRGE
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

The	O
40	O
kDa	O
degraded	O
CGN	O
gave	O
a	O
stronger	O
increase	O
of	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
the	O
heterodimer	O
p50	O
/	O
p65	O
is	O
the	O
NF	O
-	O
kappaB	O
isoform	O
activated	O
by	O
degraded	O
CGN	O
in	O
monocytes	O
.	O

In	O
addition	O
,	O
degradation	O
of	O
the	O
inhibitor	S-PRGE
IkappaBalpha	S-PRGE
was	O
also	O
observed	O
in	O
cells	O
treated	O
with	O
dCGN	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

No	O
significant	O
IkappaBalpha	S-PRGE
degradation	O
was	O
detected	O
within	O
two	O
hours	O
of	O
dCGN	O
treatment	O
,	O
but	O
IkappaBalpha	S-PRGE
was	O
markedly	O
degraded	O
by	O
four	O
hours	O
of	O
dCGN	O
treatment	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

We	O
focused	O
on	O
IkappaBalpha	S-PRGE
subunit	O
,	O
since	O
it	O
masks	O
the	O
nuclear	O
localisation	O
sequence	O
of	O
p65	S-PRGE
,	O
it	O
is	O
the	O
most	O
rapidly	O
degraded	O
subunit	O
and	O
the	O
most	O
studied	O
one	O
.	O

Inflammation	O
of	O
the	O
intestinal	O
tract	O
is	O
usually	O
associated	O
with	O
infiltration	O
and	O
activation	O
of	O
intestinal	O
macrophages	O
[	O
17	O
]	O
.	O

These	O
macrophages	O
are	O
able	O
to	O
initiate	O
immune	O
responses	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
cells	O
that	O
either	O
exacerbate	O
or	O
inhibit	O
the	O
inflammation	O
.	O

Accumulation	O
of	O
different	O
types	O
of	O
leukocytes	O
,	O
including	O
monocytes	O
/	O
macrophages	O
,	O
neutrophils	O
,	O
and	O
lymphocytes	O
in	O
the	O
intestinal	O
mucosa	O
during	O
inflammation	O
,	O
is	O
normally	O
followed	O
by	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
[	O
33	O
]	O
.	O

Several	O
stimuli	O
can	O
induce	O
these	O
leukocytes	O
to	O
produce	O
and	O
secrete	O
cytokines	O
during	O
inflammation	O
.	O

One	O
of	O
the	O
most	O
potent	O
and	O
known	O
stimuli	O
for	O
leukocyte	O
activation	O
is	O
LPS	O
from	O
Gram	O
-	O
negative	O
bacteria	O
[	O
34	O
]	O
.	O

In	O
addition	O
,	O
other	O
factors	O
are	O
also	O
able	O
to	O
stimulate	O
cytokine	O
secretion	O
from	O
various	O
leukocytes	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
.	O

One	O
such	O
factor	O
is	O
CGN	O
,	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
(	O
>	O
200	O
kDa	O
)	O
derived	O
from	O
red	O
algae	O
(	O
Rhodophyceae	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Native	O
CGN	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
(	O
E	O
407	O
)	O
to	O
improve	O
texture	O
.	O

It	O
is	O
also	O
used	O
in	O
cosmetics	O
and	O
pharmaceuticals	O
.	O

Although	O
native	O
form	O
CGN	O
(	O
200	O
-	O
800	O
kDa	O
)	O
has	O
been	O
declared	O
harmless	O
to	O
humans	O
[	O
8	O
]	O
,	O
its	O
degraded	O
forms	O
(	O
<	O
50	O
kDa	O
)	O
,	O
also	O
known	O
as	O
poligeenan	O
,	O
are	O
widely	O
used	O
to	O
induce	O
colitis	O
in	O
rodents	O
[	O
3	O
]	O
-	O
[	O
5	O
]	O
.	O

These	O
degraded	O
CGN	O
may	O
also	O
have	O
a	O
possible	O
carcinogenic	O
effect	O
[	O
4	O
]	O
,	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
;	O
however	O
this	O
is	O
still	O
controversial	O
.	O

Although	O
acid	O
treatment	O
at	O
high	O
temperature	O
(	O
80degreesC	O
)	O
is	O
required	O
for	O
CGN	O
hydrolysis	O
in	O
vitro	O
to	O
lower	O
molecular	O
weight	O
dCGN	O
,	O
it	O
is	O
probable	O
that	O
some	O
dCGN	O
are	O
produced	O
by	O
acid	O
hydrolysis	O
during	O
gastric	O
digestion	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
or	O
interaction	O
with	O
intestinal	O
bacteria	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

Thus	O
,	O
understanding	O
the	O
mechanisms	O
of	O
dCGN	O
-	O
induced	O
bowel	O
inflammation	O
is	O
of	O
great	O
importance	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
human	O
monocytes	O
(	O
PBM	O
and	O
THP	O
-	O
1	O
)	O
in	O
dCGN	O
-	O
induced	O
inflammation	O
.	O

Preliminary	O
in	O
vivo	O
studies	O
in	O
rats	O
treated	O
with	O
dCGN	O
revealed	O
significant	O
shortening	O
of	O
the	O
large	O
intestine	O
associated	O
with	O
an	O
inflammatory	O
state	O
,	O
i	O
.	O
e	O
.	O
strong	O
infiltration	O
of	O
macrophages	O
to	O
the	O
intestinal	O
mucosa	O
similar	O
to	O
DSS	O
-	O
induced	O
inflammation	O
[	O
20	O
]	O
.	O

Using	O
two	O
fractions	O
of	O
dCGN	O
(	O
10	O
and	O
40	O
kDa	O
)	O
,	O
we	O
observed	O
a	O
strong	O
correlation	O
between	O
the	O
severity	O
of	O
the	O
inflammation	O
and	O
the	O
dCGN	O
molecular	O
size	O
,	O
thus	O
confirming	O
the	O
size	O
related	O
inflammation	O
in	O
vivo	O
.	O

This	O
macrophage	O
accumulation	O
was	O
not	O
due	O
to	O
cell	O
proliferation	O
because	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
monocytes	O
proliferation	O
in	O
vitro	O
.	O

These	O
results	O
are	O
similar	O
to	O
those	O
obtained	O
with	O
human	O
colonic	O
epithelial	O
cells	O
(	O
NCM460	O
cell	O
line	O
)	O
exposed	O
to	O
native	O
CGN	O
for	O
1	O
-	O
8	O
days	O
[	O
37	O
]	O
.	O

Thus	O
,	O
it	O
seems	O
that	O
dCGN	O
promote	O
macrophage	O
infiltration	O
by	O
recruiting	O
new	O
cells	O
to	O
the	O
inflamed	O
intestinal	O
mucosa	O
and	O
not	O
by	O
inducing	O
cell	O
proliferation	O
.	O

In	O
addition	O
,	O
very	O
few	O
polymorphonuclear	O
cells	O
were	O
detected	O
in	O
the	O
mucosa	O
at	O
the	O
time	O
point	O
analyzed	O
as	O
demonstrated	O
by	O
a	O
very	O
low	O
level	O
of	O
MPO	O
in	O
the	O
intestinal	O
tissue	O
.	O

These	O
results	O
suggest	O
that	O
monocytes	O
might	O
produce	O
cytokines	O
associated	O
with	O
activation	O
into	O
macrophages	O
in	O
response	O
to	O
dCGN	O
.	O

Thus	O
,	O
we	O
analyzed	O
the	O
production	O
of	O
TNF	S-PRGE
by	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
in	O
response	O
to	O
dCGN	O
.	O

Degraded	O
CGN	O
induced	O
a	O
robust	O
production	O
of	O
TNF	S-PRGE
by	O
monocytes	O
.	O

The	O
40	O
kDa	O
form	O
of	O
dCGN	O
was	O
more	O
potent	O
for	O
monocyte	O
stimulation	O
than	O
the	O
10	O
kDa	O
or	O
the	O
native	O
ones	O
.	O

Surprisingly	O
,	O
monocyte	O
activation	O
by	O
dCGN	O
to	O
produce	O
TNF	S-PRGE
was	O
much	O
stronger	O
than	O
the	O
activation	O
induced	O
by	O
LPS	O
,	O
an	O
inflammatory	O
factor	O
considered	O
to	O
be	O
among	O
the	O
most	O
potent	O
stimuli	O
for	O
leukocyte	O
activation	O
.	O

These	O
results	O
underline	O
the	O
fact	O
that	O
partially	O
degraded	O
forms	O
of	O
CGN	O
have	O
important	O
cellular	O
effects	O
.	O

The	O
amount	O
of	O
TNF	S-PRGE
secreted	O
by	O
PBM	O
induced	O
with	O
LPS	O
was	O
much	O
larger	O
than	O
the	O
one	O
secreted	O
by	O
THP	O
-	O
1	O
monocytes	O
.	O

Since	O
monocyte	O
activation	O
by	O
LPS	O
is	O
associated	O
with	O
the	O
presence	O
of	O
the	O
CD14	S-PRGE
and	O
TLR4	B-PRGE
receptors	E-PRGE
[	O
38	O
]	O
-	O
[	O
40	O
]	O
,	O
the	O
different	O
response	O
observed	O
could	O
be	O
due	O
to	O
the	O
different	O
expression	O
of	O
these	O
receptors	O
in	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O

CD14	S-PRGE
is	O
not	O
expressed	O
by	O
THP	O
-	O
1	O
monocytes	O
,	O
but	O
it	O
is	O
expressed	O
by	O
PBM	O
.	O

This	O
fact	O
could	O
explain	O
why	O
THP	O
-	O
1	O
cells	O
produced	O
a	O
much	O
smaller	O
response	O
to	O
LPS	O
than	O
PBM	O
and	O
also	O
the	O
difference	O
of	O
kinetics	O
in	O
the	O
LPS	O
induced	O
TNF	S-PRGE
secretion	O
.	O

The	O
peak	O
of	O
TNF	S-PRGE
response	O
was	O
observed	O
after	O
8	O
h	O
stimulation	O
followed	O
by	O
a	O
rapid	O
decrease	O
to	O
baseline	O
at	O
10	O
h	O
,	O
whereas	O
on	O
THP	O
-	O
1	O
cells	O
the	O
peak	O
was	O
not	O
reached	O
until	O
after	O
56	O
h	O
.	O

Moreover	O
,	O
the	O
amount	O
of	O
TNF	S-PRGE
secreted	O
by	O
monocytes	O
induced	O
with	O
dCGN	O
was	O
much	O
larger	O
than	O
the	O
one	O
induced	O
by	O
LPS	O
.	O

On	O
the	O
other	O
hand	O
,	O
LPS	O
and	O
dCGN	O
displayed	O
a	O
very	O
different	O
TNF	S-PRGE
secretion	O
curve	O
in	O
THP	O
-	O
1	O
cells	O
.	O

These	O
differences	O
suggest	O
that	O
dCGN	O
and	O
LPS	O
could	O
use	O
different	O
activation	O
mechanisms	O
.	O

It	O
is	O
noteworthy	O
that	O
neutralizing	O
antibody	O
to	O
CD14	O
only	O
partially	O
(	O
<	O
40	O
%	O
)	O
inhibited	O
dCGN	O
-	O
induced	O
TNF	S-PRGE
secretion	O
(	O
not	O
shown	O
)	O
.	O

TLR4	S-PRGE
has	O
been	O
recently	O
identified	O
as	O
a	O
surface	O
membrane	O
receptor	S-PRGE
for	O
CGN	O
in	O
human	O
colonic	O
epithelial	O
cells	O
[	O
41	O
]	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
TLR4	S-PRGE
is	O
activated	O
by	O
dCGN	O
to	O
induce	O
cytokine	O
secretion	O
by	O
monocytes	O
.	O

We	O
can	O
only	O
speculate	O
that	O
TLR4	S-PRGE
may	O
have	O
a	O
higher	O
affinity	O
-	O
binding	O
site	O
for	O
dCGN	O
than	O
for	O
LPS	O
,	O
however	O
,	O
this	O
hypothesis	O
remains	O
to	O
be	O
tested	O
.	O

Another	O
indicator	O
that	O
dCGN	O
stimulate	O
monocytes	O
leading	O
to	O
a	O
more	O
active	O
phenotype	O
is	O
the	O
fact	O
that	O
surface	O
expression	O
of	O
the	O
adhesion	B-PRGE
molecule	E-PRGE
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
was	O
enhanced	O
in	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O

The	O
over	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
caused	O
the	O
activated	O
monocytes	O
to	O
form	O
cell	O
aggregates	O
that	O
were	O
more	O
abundant	O
among	O
cells	O
treated	O
with	O
the	O
40	O
kDa	O
dCGN	O
.	O

This	O
correlates	O
with	O
the	O
higher	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
,	O
suggesting	O
that	O
the	O
partially	O
degraded	O
CGN	O
is	O
more	O
biologically	O
active	O
.	O

In	O
addition	O
,	O
the	O
cell	O
aggregates	O
are	O
reminiscent	O
of	O
monocyte	O
aggregates	O
,	O
which	O
form	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
42	O
]	O
.	O

These	O
giant	O
cells	O
were	O
not	O
observed	O
in	O
healthy	O
individuals	O
or	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
[	O
42	O
]	O
.	O

Moreover	O
,	O
increased	O
expression	O
levels	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	E-PRGE
(	O
CD58	S-PRGE
)	O
were	O
also	O
detected	O
in	O
monocytes	O
from	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
.	O

Thus	O
,	O
degraded	O
CGN	O
clearly	O
can	O
activate	O
monocytes	O
to	O
express	O
an	O
increased	O
number	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
adhesion	B-PRGE
molecules	E-PRGE
,	O
therefore	O
being	O
capable	O
of	O
creating	O
the	O
conditions	O
characteristic	O
of	O
Crohn	O
'	O
s	O
disease	O
symptomatology	O
,	O
i	O
.	O
e	O
.	O
PBM	O
accumulation	O
and	O
MGC	O
formation	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

The	O
NF	O
-	O
kappaB	O
pathway	O
regulates	O
genes	O
responsible	O
for	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
expression	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
associated	O
with	O
the	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
IkappaB	O
[	O
47	O
]	O
.	O

Indeed	O
,	O
dCGN	O
induced	O
NF	O
-	O
kappaB	O
activation	O
as	O
shown	O
by	O
degradation	O
of	O
IkappaBalpha	S-PRGE
,	O
translocation	O
of	O
p65	S-PRGE
and	O
p50	S-PRGE
sub	O
-	O
units	O
to	O
the	O
nucleus	O
and	O
by	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
responsive	O
luciferase	S-PRGE
reporter	O
plasmid	O
.	O

Again	O
,	O
a	O
stronger	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
compared	O
to	O
10	O
kDa	O
dCGN	O
,	O
suggesting	O
that	O
the	O
partially	O
degraded	O
CGN	O
is	O
more	O
biologically	O
active	O
.	O

Our	O
data	O
are	O
in	O
agreement	O
with	O
a	O
previous	O
study	O
showing	O
that	O
native	O
CGN	O
also	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
human	O
colonic	O
epithelial	O
cells	O
[	O
48	O
]	O
.	O

NF	O
-	O
kappaB	O
pathway	O
is	O
often	O
associated	O
to	O
promote	O
cell	O
survival	O
and	O
cancer	O
cell	O
growth	O
,	O
however	O
it	O
has	O
been	O
sometimes	O
reported	O
to	O
behave	O
as	O
a	O
tumor	O
suppressor	O
,	O
arresting	O
cell	O
proliferation	O
[	O
49	O
]	O
.	O

Such	O
relationship	O
between	O
NF	O
-	O
kB	O
activation	O
and	O
cell	O
cycle	O
regulation	O
has	O
been	O
reported	O
in	O
normal	O
human	O
epidermal	O
cells	O
[	O
50	O
]	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
shown	O
that	O
NF	O
-	O
kappaB	O
activation	O
suppressed	O
cdk4	S-PRGE
expression	O
,	O
which	O
is	O
necessary	O
for	O
the	O
transition	O
to	O
S	O
phase	O
.	O

Finally	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
reported	O
to	O
induce	O
growth	O
arrest	O
in	O
normal	O
human	O
keratinocytes	O
by	O
a	O
mechanims	O
involving	O
the	O
cdk	O
inhibitor	O
p21	S-PRGE
[	O
51	O
]	O
.	O

The	O
effects	O
of	O
dCGN	O
on	O
p21	S-PRGE
and	O
cdk4	S-PRGE
expression	O
remain	O
to	O
be	O
studied	O
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
demonstrated	O
a	O
direct	O
action	O
of	O
dCGN	O
on	O
monocytes	O
.	O

Monocytes	O
exposed	O
to	O
dCGN	O
acquired	O
an	O
inflammatory	O
phenotype	O
that	O
included	O
higher	O
expression	O
of	O
the	O
adhesion	O
molecule	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
production	O
,	O
via	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

This	O
higher	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
resulted	O
in	O
formation	O
of	O
cell	O
aggregates	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
.	O

We	O
presume	O
that	O
the	O
differential	O
effects	O
of	O
10	O
and	O
40	O
kDa	O
dCGN	O
to	O
induce	O
these	O
effects	O
on	O
monocytes	O
are	O
tightly	O
linked	O
to	O
their	O
capacity	O
to	O
induce	O
inflammation	O
in	O
vivo	O
.	O

However	O
,	O
in	O
vivo	O
,	O
macrophages	O
do	O
not	O
come	O
in	O
direct	O
contact	O
with	O
the	O
intestinal	O
lumen	O
and	O
are	O
separated	O
by	O
the	O
epithelial	O
barrier	O
.	O

The	O
way	O
by	O
which	O
dCGN	O
may	O
leave	O
the	O
intestinal	O
lumen	O
and	O
cross	O
the	O
epithelial	O
barrier	O
to	O
reach	O
the	O
macrophages	O
is	O
an	O
intriguing	O
open	O
question	O
.	O

One	O
possible	O
explanation	O
resides	O
in	O
the	O
potential	O
of	O
dCGN	O
to	O
"	O
induce	O
"	O
cellular	O
and	O
paracellular	O
injurious	O
effects	O
at	O
the	O
intestinal	O
epithelial	O
cell	O
monolayer	O
[	O
48	O
]	O
.	O

In	O
conclusion	O
,	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
accumulating	O
the	O
cells	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
increased	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
,	O
stimulated	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
-	O
dependent	O
monocyte	O
aggregation	O
in	O
vitro	O
,	O
and	O
stimulated	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
expression	O
and	O
secretion	O
.	O

These	O
responses	O
were	O
more	O
pronounced	O
following	O
40	O
kDa	O
dCGN	O
,	O
and	O
were	O
all	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
,	O
although	O
CGN	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
,	O
its	O
degraded	O
forms	O
have	O
an	O
important	O
effect	O
on	O
monocytes	O
characteristic	O
of	O
an	O
inflammatory	O
phenotype	O
.	O

Degraded	O
CGN	O
induced	O
colon	O
inflammation	O
in	O
rats	O
.	O

Histograms	O
showing	O
the	O
effect	O
of	O
degraded	O
CGN	O
on	O
:	O
colon	O
length	O
(	O
A	O
)	O
;	O
macroscopic	O
(	O
B	O
)	O
and	O
histological	O
(	O
C	O
)	O
inflammation	O
score	O
of	O
colon	O
;	O
Myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
(	O
D	O
)	O
.	O

Control	O
rats	O
(	O
white	O
bars	O
)	O
;	O
10	O
kDa	O
degraded	O
CGN	O
-	O
treated	O
rats	O
(	O
grey	O
bars	O
)	O
;	O
40	O
kDa	O
degraded	O
CGN	O
-	O
treated	O
rats	O
(	O
black	O
bars	O
)	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
from	O
control	O
.	O

*	O
*	O
p	O
<	O
0	O
.	O
01	O
from	O
control	O
.	O

Histological	O
analysis	O
of	O
colon	O
from	O
control	O
rats	O
(	O
E	O
)	O
,	O
and	O
from	O
40	O
kDa	O
dCGN	O
-	O
treated	O
rats	O
(	O
F	O
)	O
.	O

Degraded	O
CGN	O
stimulated	O
TNF	S-PRGE
secretion	O
from	O
monocytes	O
.	O

Levels	O
of	O
TNF	S-PRGE
released	O
from	O
peripheral	O
blood	O
monocytes	O
(	O
A	O
-	O
B	O
)	O
and	O
THP	O
-	O
1	O
cells	O
(	O
C	O
-	O
D	O
)	O
after	O
stimulation	O
with	O
dCGN	O
.	O

A	O
:	O
TNF	S-PRGE
release	O
induced	O
by	O
native	O
CGN	O
(	O
open	O
bars	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
grey	O
bars	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
black	O
bars	O
)	O
.	O

B	O
:	O
Kinetics	O
of	O
TNF	S-PRGE
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
black	O
diamonds	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
black	O
triangles	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
black	O
squares	O
)	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
open	O
squares	O
)	O
.	O

C	O
:	O
TNF	S-PRGE
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
open	O
bars	O
)	O
,	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
hatched	O
bars	O
)	O
,	O
or	O
increasing	O
concentrations	O
of	O
10	O
kDa	O
dCGN	O
(	O
grey	O
bars	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
black	O
bars	O
)	O
.	O

D	O
:	O
Kinetics	O
of	O
TNF	S-PRGE
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
black	O
diamonds	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
black	O
triangles	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
black	O
squares	O
)	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
open	O
squares	O
)	O
.	O

Degraded	O
CGN	O
induced	O
THP1	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
.	O

THP	O
-	O
1	O
cells	O
in	O
exponential	O
growth	O
phase	O
were	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
24	O
h	O
before	O
being	O
stained	O
with	O
propidium	O
iodide	O
.	O

Cell	O
DNA	O
content	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

A	O
:	O
Histograms	O
of	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

B	O
:	O
Percentage	O
of	O
cells	O
in	O
each	O
phase	O
of	O
the	O
cell	O
cycle	O
when	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
different	O
concentrations	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
,	O
or	O
of	O
native	O
CGN	O
(	O
Native	O
)	O
.	O

Degraded	O
CGN	O
stimulated	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
in	O
monocytes	O
.	O

Peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
or	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
24	O
h	O
before	O
being	O
stained	O
for	O
various	O
cell	O
surface	O
antigens	O
.	O

Antigen	O
expression	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

A	O
:	O
Histograms	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
expression	O
in	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

B	O
:	O
Fluorescence	O
intensity	O
for	O
expression	O
of	O
the	O
antigens	O
HLA	O
-	O
ABC	O
,	O
HLA	O
-	O
DR	O
,	O
CD14	S-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
,	O
and	O
CD58	S-PRGE
in	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

Data	O
are	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Degraded	O
CGN	O
induced	O
monocytes	O
aggregation	O
in	O
vitro	O
.	O

Monocytes	O
were	O
incubated	O
in	O
the	O
absence	O
(	O
A	O
)	O
or	O
the	O
presence	O
of	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
B	O
)	O
,	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
C	O
)	O
,	O
or	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
plus	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
(	O
D	O
)	O
.	O

Cells	O
were	O
observed	O
by	O
phase	O
contrast	O
inverse	O
microscopy	O
at	O
150X	O
magnification	O
.	O

Inserts	O
in	O
A	O
and	O
B	O
show	O
a	O
close	O
up	O
of	O
cells	O
at	O
300X	O
magnification	O
.	O

E	O
:	O
Number	O
of	O
monocyte	O
aggregates	O
in	O
24	O
wells	O
plate	O
of	O
PBM	O
cell	O
cultured	O
with	O
nothing	O
(	O
control	O
)	O
,	O
with	O
10	O
kDa	O
degraded	O
CGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
40	O
kDa	O
degraded	O
CGN	O
(	O
C40	O
)	O
.	O

Some	O
cultures	O
had	O
also	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
.	O

Data	O
are	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Degraded	O
CGN	O
stimulated	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
gene	O
expression	O
in	O
monocytes	O
.	O

Representative	O
samples	O
of	O
RT	O
-	O
PCR	O
analysis	O
showing	O
over	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
after	O
stimulation	O
of	O
monocytes	O
with	O
1	O
g	O
/	O
l	O
of	O
degraded	O
CGN	O
.	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
expression	O
was	O
used	O
as	O
normalization	O
gene	O
.	O

Degraded	O
CGN	O
activated	O
the	O
NF	O
-	O
kB	O
pathway	O
in	O
monocytes	O
.	O

A	O
:	O
THP	O
-	O
1	O
cells	O
were	O
transfected	O
with	O
a	O
NF	O
-	O
kappaB	O
reporter	O
plasmid	O
driving	O
expression	O
of	O
luciferase	S-PRGE
.	O

Cells	O
were	O
then	O
treated	O
with	O
various	O
concentrations	O
of	O
10	O
kDa	O
(	O
triangles	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
squares	O
)	O
.	O

B	O
:	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
were	O
lysed	O
after	O
various	O
periods	O
of	O
time	O
.	O

Proteins	O
in	O
cell	O
extracts	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
then	O
Western	O
blotted	O
for	O
IkappaBalpha	S-PRGE
or	O
alpha	O
-	O
tubulin	O
as	O
loading	O
control	O
.	O

C	O
:	O
Degraded	O
carrageenans	O
(	O
dCGN	O
)	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
nothing	O
(	O
control	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Nuclei	O
were	O
isolated	O
and	O
lysed	O
.	O

Proteins	O
in	O
nuclear	O
extracts	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
then	O
Western	O
blotted	O
for	O
NF	O
-	O
kappaB	O
p50	S-PRGE
subunit	O
(	O
p50	S-PRGE
)	O
or	O
NF	O
-	O
kappaB	O
p65	S-PRGE
subunit	O
(	O
p65	S-PRGE
)	O
.	O

Lower	O
panels	O
show	O
Western	O
blots	O
of	O
nuclear	O
ERK	O
revealing	O
equivalent	O
amount	O
of	O
protein	O
in	O
each	O
sample	O
.	O

Data	O
are	O
representative	O
of	O
three	O
separate	O
experiments	O
.	O

D	O
:	O
Degraded	O
carrageenan	O
(	O
dCGN	O
)	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Nuclei	O
isolated	O
from	O
THP	O
-	O
1	O
cells	O
were	O
fluorescence	O
-	O
stained	O
for	O
NF	O
-	O
kappaB	O
p50	S-PRGE
subunit	O
or	O
NF	O
-	O
kappaB	O
p65	S-PRGE
subunit	O
before	O
(	O
filled	O
area	O
)	O
or	O
after	O
cells	O
were	O
treated	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Dashed	O
line	O
corresponds	O
to	O
nuclei	O
stained	O
only	O
with	O
secondary	O
fluorescence	O
antibody	O
.	O

Fluorescence	O
intensity	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
as	O
described	O
.	O

Transcription	O
factors	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
in	O
the	O
induction	O
and	O
suppressive	O
function	O
of	O
Foxp3	S-PRGE
+	O
inducible	O
regulatory	O
T	O
cells	O

Forkhead	B-PRGE
box	I-PRGE
P3	E-PRGE
(	O
FOXP3	S-PRGE
)	O
+	O
CD4	S-PRGE
+	O
CD25	S-PRGE
+	O
inducible	O
regulatory	O
T	O
(	O
iT	O
reg	O
)	O
cells	O
play	O
an	O
important	O
role	O
in	O
immune	O
tolerance	O
and	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	E-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
)	O
induces	O
the	O
expression	O
of	O
the	O
Runt	O
-	O
related	O
transcription	O
factors	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
in	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

This	O
induction	O
seems	O
to	O
be	O
a	O
prerequisite	O
for	O
the	O
binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
to	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

Inactivation	O
of	O
the	O
gene	O
encoding	O
RUNX	S-PRGE
cofactor	O
core	B-PRGE
-	I-PRGE
binding	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	E-PRGE
(	O
CBFbeta	S-PRGE
)	O
in	O
mice	O
and	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
suppression	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
in	O
human	O
T	O
cells	O
resulted	O
in	O
reduced	O
expression	O
of	O
Foxp3	S-PRGE
.	O

The	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
into	O
Foxp3	S-PRGE
+	O
iT	O
reg	O
cells	O
was	O
significantly	O
decreased	O
in	O
adoptively	O
transferred	O
CbfbF	S-PRGE
/	O
F	O
CD4	S-PRGE
-	O
cre	S-PRGE
naive	O
T	O
cells	O
into	O
Rag2	S-PRGE
-	O
/	O
-	O
mice	O
.	O

Both	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
silenced	O
human	O
T	O
reg	O
cells	O
and	O
CbfbF	S-PRGE
/	O
F	O
CD4	S-PRGE
-	O
cre	S-PRGE
mouse	O
T	O
reg	O
cells	O
showed	O
diminished	O
suppressive	O
function	O
in	O
vitro	O
.	O

Circulating	O
human	O
CD4	S-PRGE
+	O
CD25high	S-PRGE
CD127	S-PRGE
-	O
T	O
reg	O
cells	O
significantly	O
expressed	O
higher	O
levels	O
of	O
RUNX3	S-PRGE
,	O
FOXP3	S-PRGE
,	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
mRNA	O
compared	O
with	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
.	O

Furthermore	O
,	O
FOXP3	S-PRGE
and	O
RUNX3	S-PRGE
were	O
colocalized	O
in	O
human	O
tonsil	O
T	O
reg	O
cells	O
.	O

These	O
data	O
demonstrate	O
Runx	S-PRGE
transcription	O
factors	O
as	O
a	O
molecular	O
link	O
in	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
induced	O
Foxp3	S-PRGE
expression	O
in	O
iT	O
reg	O
cell	O
differentiation	O
and	O
function	O
.	O

Regulatory	O
T	O
(	O
T	O
reg	O
)	O
cells	O
expressing	O
the	O
transcription	O
factor	O
forkhead	B-PRGE
box	I-PRGE
P3	E-PRGE
(	O
FOXP3	S-PRGE
,	O
human	O
;	O
Foxp3	S-PRGE
,	O
mouse	O
)	O
play	O
an	O
essential	O
role	O
in	O
controlling	O
immune	O
responses	O
to	O
autoantigens	O
,	O
allergens	O
,	O
tumor	O
antigens	O
,	O
transplantation	O
antigens	O
,	O
and	O
infectious	O
agents	O
(	O
Hori	O
et	O
al	O
.	O
,	O
2003	O
;	O
Akdis	O
,	O
2006	O
)	O
.	O

Foxp3	S-PRGE
is	O
a	O
member	O
of	O
the	O
forkhead	O
/	O
winged	O
-	O
helix	O
family	O
of	O
transcriptional	O
regulators	O
,	O
and	O
its	O
expression	O
in	O
T	O
reg	O
cells	O
is	O
essential	O
for	O
their	O
development	O
and	O
function	O
(	O
Fontenot	O
et	O
al	O
.	O
,	O
2003	O
;	O
Williams	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

A	O
spontaneous	O
mutation	O
of	O
the	O
X	O
-	O
linkedFoxp3gene	S-PRGE
inscurfymice	O
causes	O
an	O
autoimmune	O
-	O
like	O
disease	O
,	O
whereas	O
the	O
mutation	O
in	O
humans	O
leads	O
to	O
immunodysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
and	O
X	O
-	O
linked	O
syndrome	O
that	O
is	O
also	O
a	O
severe	O
multiorgan	O
autoimmune	O
disease	O
with	O
hyper	O
-	O
IgE	O
(	O
Ziegler	O
,	O
2006	O
)	O
.	O
Although	O
the	O
essential	O
role	O
of	O
Foxp3	S-PRGE
in	O
central	O
and	O
peripheral	O
tolerance	O
has	O
been	O
extensively	O
studied	O
,	O
its	O
regulation	O
,	O
cooperation	O
with	O
other	O
transcription	O
factors	O
,	O
and	O
how	O
it	O
functions	O
in	O
inducible	O
T	O
reg	O
(	O
iT	O
reg	O
)	O
cells	O
to	O
suppress	O
various	O
target	O
genes	O
is	O
mostly	O
not	O
yet	O
understood	O
.	O

It	O
is	O
known	O
that	O
Foxp3	S-PRGE
cooperates	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
to	O
regulate	O
the	O
transcription	O
of	O
different	O
target	O
genes	O
(	O
Schubert	O
et	O
al	O
.	O
,	O
2001	O
;	O
Bettelli	O
et	O
al	O
.	O
,	O
2005	O
;	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

The	O
Th2	O
cytokine	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
inhibits	O
FOXP3	S-PRGE
expression	O
during	O
T	O
cell	O
priming	O
.	O

GATA3	S-PRGE
binds	O
to	O
theFOXP3promoter	S-PRGE
and	O
can	O
repress	O
the	O
FOXP3	S-PRGE
trans	O
-	O
activation	O
process	O
directly	O
in	O
Th2	O
cells	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
was	O
further	O
demonstrated	O
that	O
both	O
Th1	O
and	O
Th2	O
transcription	O
factors	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
and	O
GATA3	S-PRGE
oppose	O
peripheral	O
induction	O
of	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cells	O
in	O
mice	O
through	O
STAT1	S-PRGE
-	O
,	O
STAT4	S-PRGE
-	O
,	O
and	O
STAT6	S-PRGE
-	O
dependent	O
pathways	O
(	O
Wei	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Although	O
natural	O
T	O
reg	O
(	O
nT	O
reg	O
)	O
cells	O
that	O
differentiate	O
in	O
the	O
thymus	O
are	O
characterized	O
by	O
their	O
stable	O
Foxp3	S-PRGE
expression	O
,	O
the	O
generation	O
of	O
iT	O
reg	O
cells	O
specific	O
for	O
allergens	O
,	O
alloantigens	O
,	O
and	O
autoantigens	O
in	O
the	O
periphery	O
has	O
been	O
associated	O
with	O
a	O
transient	O
Foxp3	S-PRGE
+	O
phenotype	O
(	O
Fontenot	O
et	O
al	O
.	O
,	O
2003	O
;	O
Hori	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

The	O
crucial	O
role	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
in	O
their	O
generation	O
has	O
been	O
demonstrated	O
.	O
The	O
RUNX	S-PRGE
gene	O
family	O
(	O
Runt	O
-	O
related	O
transcription	O
factor	O
,	O
acute	O
myeloid	O
leukemia	O
[	O
AML	O
]	O
,	O
core	O
-	O
binding	O
factor	O
-	O
alpha	O
[	O
CBFalpha	O
]	O
,	O
and	O
polyoma	O
enhancer	O
-	O
binding	O
protein	O
-	O
2alpha	O
[	O
PEBP2alpha	O
]	O
)	O
contains	O
three	O
members	O
,	O
RUNX1	S-PRGE
(	O
AML1	S-PRGE
/	O
CBFA2	S-PRGE
/	O
PEBP2alphaB	S-PRGE
)	O
,	O
RUNX2	S-PRGE
(	O
AML3	S-PRGE
/	O
CBFA1	S-PRGE
/	O
PEBP2alphaA	S-PRGE
)	O
,	O
and	O
RUNX3	S-PRGE
(	O
AML2	O
/	O
CBFA3	O
/	O
PEBP2alphaC	O
)	O
.	O

They	O
are	O
essential	O
transcriptional	O
regulators	O
of	O
different	O
developmental	O
pathways	O
.	O

RUNX2	S-PRGE
is	O
mostly	O
important	O
for	O
bone	O
development	O
and	O
osteoblast	O
differentiation	O
(	O
Komori	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

RUNX1	S-PRGE
plays	O
an	O
important	O
role	O
in	O
hematopoiesis	O
during	O
development	O
,	O
and	O
RUNX3	S-PRGE
has	O
important	O
functions	O
in	O
thymogenesis	O
and	O
neurogenesis	O
(	O
Wang	O
et	O
al	O
.	O
,	O
1996	O
;	O
Inoue	O
et	O
al	O
.	O
,	O
2002	O
;	O
Levanon	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
also	O
work	O
together	O
in	O
the	O
establishment	O
of	O
lineage	O
specification	O
of	O
T	O
lymphocytes	O
(	O
Taniuchi	O
et	O
al	O
.	O
,	O
2002	O
;	O
Egawa	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
RUNX1is	S-PRGE
a	O
frequent	O
target	O
for	O
chromosomal	O
translocations	O
associated	O
with	O
leukemias	O
(	O
Look	O
,	O
1997	O
)	O
,	O
andRUNX3methylation	S-PRGE
and	O
silencing	O
is	O
observed	O
in	O
various	O
human	O
epithelial	O
cancers	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
RUNX	S-PRGE
family	O
members	O
share	O
the	O
Runt	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
DNA	O
binding	O
(	O
Ito	O
,	O
1999	O
)	O
.	O

The	O
Runt	O
domain	O
-	O
containing	O
protein	O
constitutes	O
the	O
alpha	O
-	O
chain	O
partner	O
of	O
the	O
heterodimeric	O
CBF	S-PRGE
complex	O
.	O

RUNX	O
proteins	O
heterodimerize	O
with	O
the	O
non	O
-	O
DNA	O
-	O
binding	O
partner	O
,	O
CBFbeta	S-PRGE
,	O
which	O
increases	O
the	O
affinity	O
for	O
DNA	O
binding	O
and	O
stabilizes	O
the	O
complex	O
by	O
preventing	O
ubiquitin	S-PRGE
-	O
dependent	O
degradation	O
(	O
Wang	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
CBF	S-PRGE
complexes	O
regulate	O
the	O
expression	O
of	O
cellular	O
genes	O
through	O
binding	O
to	O
promoters	O
or	O
enhancer	O
elements	O
.	O

The	O
effects	O
of	O
the	O
RUNX	S-PRGE
-	O
CBFbeta	S-PRGE
complex	O
regulation	O
are	O
clearly	O
cell	O
lineage	O
and	O
stage	O
specific	O
.	O

They	O
include	O
the	O
crucial	O
choices	O
between	O
cell	O
-	O
cycle	O
exit	O
and	O
continued	O
proliferation	O
,	O
as	O
well	O
as	O
between	O
cell	O
differentiation	O
and	O
self	O
-	O
renewal	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Because	O
of	O
the	O
involvement	O
of	O
RUNX	S-PRGE
mutations	O
in	O
different	O
autoimmune	O
diseases	O
and	O
the	O
known	O
interaction	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
we	O
investigated	O
the	O
impact	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
on	O
the	O
expression	O
of	O
FOXP3	S-PRGE
and	O
subsequently	O
on	O
the	O
development	O
and	O
function	O
of	O
iT	O
reg	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
induced	O
by	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
are	O
involved	O
in	O
the	O
development	O
and	O
suppressive	O
function	O
of	O
Foxp3	S-PRGE
+	O
iT	O
reg	O
cells	O
.	O

The	O
role	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
transcription	O
factors	O
in	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
iT	O
reg	O
cell	O
generation	O

To	O
investigate	O
the	O
role	O
of	O
RUNX	S-PRGE
transcription	O
factors	O
in	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
,	O
we	O
cultured	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
isolated	O
from	O
human	O
PBMCs	O
,	O
in	O
conditions	O
that	O
enable	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
.	O

Stimulation	O
with	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAbs	O
or	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
alone	O
resulted	O
in	O
a	O
minimal	O
up	O
-	O
regulation	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
mRNA	O
(	O
Fig	O
.	O
1	O
A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
combination	O
of	O
both	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAbs	O
induced	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
mRNAs	O
,	O
as	O
well	O
as	O
FOXP3	S-PRGE
mRNA	O
,	O
within	O
48	O
h	O
in	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

This	O
result	O
suggested	O
further	O
experiments	O
to	O
investigate	O
whether	O
the	O
up	O
-	O
regulation	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
might	O
be	O
a	O
feature	O
of	O
iT	O
reg	O
cells	O
during	O
their	O
development	O
or	O
even	O
a	O
prerequisite	O
for	O
their	O
induction	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
expression	O
was	O
knocked	O
down	O
in	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
by	O
transfection	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
;	O
Fig	O
.	O
1	O
B	O
)	O
.	O

Deficiency	O
of	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
resulted	O
in	O
markedly	O
reduced	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
induction	O
of	O
FOXP3	S-PRGE
mRNA	O
in	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
compared	O
with	O
control	O
cells	O
transfected	O
with	O
scrambled	O
siRNA	O
.	O

The	O
level	O
of	O
FOXP3	S-PRGE
mRNA	O
was	O
further	O
reduced	O
when	O
both	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
were	O
knocked	O
down	O
in	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
during	O
their	O
differentiation	O
to	O
iT	O
reg	O
cells	O
(	O
Fig	O
.	O
1	O
B	O
)	O
.	O

The	O
influence	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
on	O
the	O
development	O
of	O
other	O
T	O
cell	O
subsets	O
and	O
their	O
specific	O
transcription	O
factor	O
expression	O
was	O
further	O
investigated	O
.	O

Naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
cultured	O
under	O
Th1	O
,	O
Th2	O
,	O
T	O
reg	O
cell	O
,	O
and	O
Th17	O
differentiation	O
conditions	O
and	O
the	O
mRNA	O
expression	O
of	O
the	O
predominant	O
transcription	O
factor	O
for	O
each	O
cell	O
type	O
was	O
subsequently	O
analyzed	O
.	O

We	O
observed	O
no	O
change	O
in	O
GATA3	S-PRGE
expression	O
in	O
Th2	O
cells	O
,	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
expression	O
in	O
Th1	O
cells	O
,	O
or	O
RORC2	S-PRGE
mRNA	O
expression	O
in	O
Th17	O
cells	O
in	O
which	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
were	O
knocked	O
down	O
compared	O
with	O
control	O
cells	O
.	O

On	O
the	O
contrary	O
,	O
FOXP3	S-PRGE
mRNA	O
was	O
significantly	O
decreased	O
in	O
RUNX1	S-PRGE
-	O
and	O
RUNX3	S-PRGE
-	O
deficient	O
T	O
reg	O
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O
1	O
C	O
)	O
.	O

The	O
effect	O
of	O
RUNX	S-PRGE
silencing	O
on	O
the	O
expression	O
level	O
of	O
intracellular	O
FOXP3	S-PRGE
during	O
naive	O
CD4	S-PRGE
+	O
T	O
cell	O
differentiation	O
to	O
iT	O
reg	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
.	O

FOXP3	S-PRGE
was	O
only	O
slightly	O
reduced	O
after	O
RUNX1	S-PRGE
silencing	O
.	O

Transfection	O
of	O
siRNA	O
for	O
RUNX3	S-PRGE
had	O
a	O
stronger	O
effect	O
.	O

The	O
most	O
striking	O
FOXP3	S-PRGE
reduction	O
was	O
observed	O
when	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
were	O
silenced	O
together	O
(	O
Fig	O
.	O
1	O
D	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
total	O
CD4	S-PRGE
+	O
T	O
cells	O
(	O
Fig	O
.	O
S1	O
and	O
Fig	O
.	O
S2	O
)	O
.	O

The	O
increased	O
impact	O
of	O
combined	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
knockdown	O
implies	O
that	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
might	O
have	O
redundant	O
functions	O
in	O
the	O
induction	O
of	O
FOXP3	S-PRGE
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
in	O
control	O
siRNA	O
-	O
transfected	O
or	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
-	O
transfected	O
CD4	S-PRGE
+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
or	O
without	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAb	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
did	O
not	O
show	O
any	O
significant	O
difference	O
(	O
Fig	O
.	O
S3	O
)	O
.	O

To	O
determine	O
whether	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
are	O
also	O
expressed	O
in	O
human	O
T	O
reg	O
cells	O
in	O
vivo	O
,	O
we	O
isolated	O
peripheral	O
blood	O
CD4	S-PRGE
+	O
CD127	S-PRGE
-	O
CD25high	S-PRGE
T	O
reg	O
cells	O
and	O
compared	O
them	O
with	O
CD4	S-PRGE
+	O
CD127	S-PRGE
+	O
CD25	S-PRGE
-	O
T	O
cells	O
.	O

Circulating	O
T	O
reg	O
cells	O
expressed	O
significantly	O
higher	O
levels	O
of	O
RUNX3	S-PRGE
mRNA	O
compared	O
with	O
CD4	S-PRGE
+	O
CD25	S-PRGE
-	O
cells	O
.	O

As	O
expected	O
,	O
IL	B-PRGE
-	I-PRGE
10	E-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
and	O
FOXP3	S-PRGE
mRNAs	O
are	O
also	O
expressed	O
in	O
circulating	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
RUNX1	S-PRGE
mRNA	O
expression	O
between	O
these	O
two	O
cell	O
subsets	O
.	O

We	O
also	O
performed	O
an	O
analysis	O
of	O
human	O
tonsils	O
,	O
which	O
contain	O
high	O
numbers	O
of	O
FOXP3	S-PRGE
+	O
T	O
reg	O
cells	O
(	O
Verhagen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Staining	O
of	O
tonsil	O
sections	O
for	O
FOXP3	S-PRGE
and	O
RUNX3	S-PRGE
demonstrated	O
in	O
vivo	O
coexpression	O
of	O
these	O
two	O
molecules	O
in	O
a	O
subset	O
of	O
T	O
reg	O
cells	O
,	O
whereas	O
there	O
was	O
low	O
RUNX1	S-PRGE
expression	O
in	O
all	O
tonsil	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O

RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
bind	O
to	O
the	O
FOXP3	S-PRGE
promoter	O

Transcription	O
element	O
search	O
system	O
analysis	O
of	O
the	O
human	O
FOXP3	S-PRGE
promoter	O
predicted	O
3	O
putative	O
RUNX	O
binding	O
sites	O
at	O
333	O
,	O
287	O
,	O
and	O
53	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
.	O

All	O
three	O
binding	O
sites	O
are	O
conserved	O
between	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
(	O
Fig	O
.	O
S4	O
)	O
.	O

To	O
verify	O
the	O
putative	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
,	O
we	O
transiently	O
transfected	O
HEK293T	O
cells	O
with	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
.	O

After	O
the	O
pull	O
-	O
down	O
with	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
binding	O
sequences	O
,	O
but	O
not	O
mutant	O
sequences	O
,	O
RUNX	S-PRGE
binding	O
to	O
the	O
FOXP3	S-PRGE
promoter	O
oligonucleotides	O
was	O
detected	O
by	O
Western	O
blot	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

To	O
confirm	O
these	O
results	O
and	O
test	O
the	O
ability	O
of	O
single	O
binding	O
site	O
sequences	O
to	O
bind	O
either	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
,	O
we	O
used	O
the	O
promoter	O
enzyme	O
immunoassay	O
.	O

Cell	O
lysates	O
were	O
obtained	O
from	O
HEK293T	O
cells	O
that	O
had	O
been	O
transiently	O
transfected	O
with	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
expression	O
vectors	O
.	O

The	O
biotinylated	O
FOXP3	S-PRGE
promoter	O
oligonucleotides	O
were	O
linked	O
to	O
a	O
streptavidin	O
-	O
coated	O
microtiter	O
plate	O
,	O
and	O
bound	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
was	O
detected	O
by	O
using	O
anti	O
-	O
RUNX	S-PRGE
antibodies	O
and	O
a	O
peroxidase	O
-	O
labeled	O
secondary	O
antibody	O
.	O

We	O
showed	O
binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
binding	O
sites	O
,	O
whereas	O
there	O
was	O
no	O
binding	O
detectable	O
when	O
a	O
combination	O
of	O
the	O
mutated	O
oligonucleotides	O
was	O
used	O
in	O
the	O
assay	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

Although	O
there	O
was	O
a	O
similar	O
and	O
high	O
degree	O
of	O
binding	O
to	O
the	O
-	O
333	O
and	O
-	O
287	O
sites	O
,	O
a	O
lower	O
degree	O
of	O
binding	O
was	O
detected	O
when	O
the	O
oligonucleotide	O
containing	O
the	O
-	O
53	O
site	O
in	O
the	O
Foxp3	S-PRGE
promoter	O
was	O
used	O
.	O

This	O
effect	O
was	O
observed	O
both	O
for	O
binding	O
to	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

The	O
binding	O
to	O
the	O
two	O
single	O
binding	O
sites	O
at	O
-	O
333	O
and	O
-	O
287	O
was	O
comparable	O
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
results	O
confirmed	O
the	O
binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
complexes	O
containing	O
CBFbeta	S-PRGE
to	O
FOXP3	S-PRGE
promoter	O
during	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
toward	O
T	O
reg	O
cells	O
.	O

Here	O
,	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
cultured	O
with	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAb	O
,	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
as	O
a	O
Foxp3	S-PRGE
-	O
inducing	O
stimulation	O
.	O

Amplification	O
of	O
PCR	O
products	O
from	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
with	O
the	O
predicted	O
RUNX	O
binding	O
sites	O
showed	O
that	O
RUNX1	S-PRGE
,	O
RUNX3	S-PRGE
,	O
and	O
CBFbeta	S-PRGE
were	O
immunoprecipitated	O
together	O
with	O
the	O
FOXP3	S-PRGE
promoter	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

Negative	O
control	O
primer	O
targeting	O
open	O
reading	O
frame	O
-	O
free	O
intergenic	O
DNA	O
,	O
IGX1A	O
did	O
not	O
show	O
any	O
significant	O
change	O
in	O
site	O
occupancy	O
.	O

Regulation	O
of	O
FOXP3	S-PRGE
promoter	O
activity	O
and	O
FOXP3	S-PRGE
protein	O
expression	O
by	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE

To	O
investigate	O
the	O
effect	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
binding	O
to	O
the	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
,	O
we	O
transfected	O
human	O
peripheral	O
blood	O
CD4	S-PRGE
+	O
T	O
cells	O
with	O
a	O
FOXP3	B-PRGE
promoter	I-PRGE
luciferase	E-PRGE
reporter	O
vector	O
and	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
expression	O
vectors	O
.	O

An	O
increase	O
in	O
luciferase	S-PRGE
activity	O
was	O
observed	O
only	O
when	O
the	O
FOXP3	B-PRGE
promoter	I-PRGE
(	I-PRGE
-	I-PRGE
511	I-PRGE
to	I-PRGE
+	I-PRGE
176	I-PRGE
)	I-PRGE
luciferase	E-PRGE
construct	O
was	O
cotransfected	O
with	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
expression	O
vectors	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

The	O
increase	O
in	O
promoter	O
activity	O
was	O
greater	O
upon	O
cotransfection	O
of	O
RUNX3	S-PRGE
compared	O
with	O
RUNX1	S-PRGE
.	O

Luciferase	S-PRGE
expression	O
was	O
abrogated	O
when	O
the	O
Runx	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
(	O
-	O
511	O
to	O
+	O
176	O
)	O
luciferase	S-PRGE
construct	O
were	O
mutated	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

In	O
these	O
experiments	O
,	O
the	O
overexpression	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
eliminated	O
the	O
need	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
for	O
FOXP3	S-PRGE
promoter	O
activation	O
and	O
PMA	O
/	O
ionomycin	O
stimulation	O
was	O
sufficient	O
.	O

To	O
examine	O
the	O
role	O
of	O
each	O
of	O
the	O
three	O
RUNX	O
binding	O
sites	O
for	O
the	O
FOXP3	S-PRGE
promoter	O
activity	O
,	O
we	O
mutated	O
each	O
individually	O
or	O
in	O
combination	O
.	O

No	O
reduction	O
in	O
luciferase	S-PRGE
activity	O
was	O
observed	O
when	O
the	O
-	O
53	O
site	O
was	O
mutated	O
and	O
only	O
a	O
slight	O
reduction	O
when	O
either	O
the	O
-	O
287	O
or	O
-	O
333	O
site	O
was	O
mutated	O
(	O
Fig	O
.	O
4	O
B	O
)	O
.	O

However	O
,	O
mutating	O
the	O
-	O
53	O
site	O
in	O
combination	O
with	O
one	O
of	O
the	O
other	O
two	O
sites	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
luciferase	S-PRGE
activity	O
,	O
with	O
the	O
greatest	O
reduction	O
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
(	O
Fig	O
.	O
4	O
B	O
)	O
,	O
suggesting	O
that	O
the	O
identified	O
binding	O
sites	O
have	O
redundant	O
functions	O
and	O
RUNX	S-PRGE
binding	O
to	O
more	O
than	O
one	O
site	O
is	O
necessary	O
for	O
the	O
full	O
activation	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

Supporting	O
these	O
findings	O
,	O
the	O
overexpression	O
of	O
RUNX1	S-PRGE
in	O
human	O
primary	O
CD4	S-PRGE
+	O
T	O
cells	O
resulted	O
in	O
significantly	O
elevated	O
levels	O
of	O
FOXP3	S-PRGE
protein	O
measured	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
.	O

This	O
was	O
achieved	O
without	O
any	O
requirement	O
for	O
anti	O
-	O
CD3	S-PRGE
,	O
anti	O
-	O
CD28	S-PRGE
stimulation	O
,	O
or	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

Although	O
there	O
was	O
a	O
trend	O
,	O
the	O
transfection	O
of	O
CD4	S-PRGE
+	O
T	O
cells	O
with	O
RUNX3	S-PRGE
did	O
not	O
lead	O
to	O
statistically	O
significant	O
increase	O
in	O
FOXP3	S-PRGE
(	O
Fig	O
.	O
S5	O
)	O
.	O

Role	O
of	O
CBFbeta	S-PRGE
in	O
the	O
induction	O
of	O
Foxp3	S-PRGE

CBFbeta	S-PRGE
,	O
a	O
common	O
cofactor	O
of	O
all	O
RUNX	S-PRGE
proteins	O
,	O
stabilizes	O
and	O
increases	O
the	O
binding	O
of	O
the	O
runt	O
domain	O
to	O
target	O
DNA	O
sequences	O
.	O

To	O
target	O
all	O
Runx	S-PRGE
proteins	O
that	O
might	O
be	O
involved	O
in	O
the	O
induction	O
of	O
Foxp3	S-PRGE
,	O
we	O
used	O
mice	O
in	O
which	O
loxP	O
-	O
flanked	O
Cbfb	S-PRGE
alleles	O
were	O
inactivated	O
in	O
T	O
cells	O
through	O
expression	O
of	O
a	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
transgene	O
.	O

Retinoic	O
acid	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
synergize	O
in	O
the	O
induction	O
of	O
Foxp3	S-PRGE
in	O
naive	O
T	O
cells	O
(	O
Kang	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

To	O
investigate	O
whether	O
Runx	S-PRGE
-	O
mediated	O
induction	O
of	O
Foxp3	S-PRGE
is	O
dependent	O
on	O
the	O
expression	O
of	O
CBFbeta	S-PRGE
,	O
naive	O
CD4	S-PRGE
+	O
CD8	S-PRGE
-	O
T	O
cells	O
from	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
control	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
mAbs	O
,	O
retinoic	O
acid	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
and	O
analyzed	O
for	O
intracellular	O
Foxp3	S-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
expression	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
induced	O
Foxp3	S-PRGE
in	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
cells	O
in	O
a	O
dose	O
dependent	O
manner	O
,	O
and	O
this	O
was	O
significantly	O
reduced	O
in	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
cells	O
.	O

Retinoic	O
acid	O
enhanced	O
Foxp3	S-PRGE
expression	O
even	O
in	O
20	O
pg	O
/	O
ml	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
more	O
than	O
95	O
%	O
of	O
the	O
CD4	S-PRGE
+	O
T	O
cells	O
from	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
became	O
Foxp3	S-PRGE
+	O
in	O
100	O
and	O
500	O
pg	O
/	O
ml	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
doses	O
.	O

The	O
induction	O
of	O
Foxp3	S-PRGE
was	O
again	O
significantly	O
lower	O
in	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
CD4	S-PRGE
+	O
T	O
cells	O
even	O
in	O
the	O
presence	O
of	O
retinoic	O
acid	O
,	O
demonstrating	O
that	O
deficiency	O
in	O
Runx	S-PRGE
binding	O
to	O
DNA	O
affects	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
induction	O
of	O
Foxp3	S-PRGE
in	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
5	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
induction	O
of	O
Foxp3	S-PRGE
when	O
endogenous	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
were	O
neutralized	O
(	O
Fig	O
.	O
S6	O
)	O
.	O

The	O
importance	O
of	O
RUNX	S-PRGE
transcription	O
factors	O
for	O
the	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
into	O
iT	O
reg	O
cells	O
was	O
examined	O
.	O

Control	O
CbfbF	S-PRGE
/	O
F	O
or	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
naive	O
T	O
cells	O
,	O
harboring	O
a	O
Foxp3	S-PRGE
-	O
IRES	O
-	O
GFP	S-PRGE
allele	O
were	O
adoptively	O
transferred	O
into	O
Rag2	S-PRGE
-	O
/	O
-	O
mice	O
.	O

6	O
wk	O
later	O
,	O
CD4	S-PRGE
+	O
T	O
cells	O
in	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
expression	O
(	O
Fig	O
.	O
5	O
B	O
)	O
.	O

There	O
was	O
a	O
consistently	O
lower	O
percentage	O
of	O
CD4	S-PRGE
+	O
T	O
cells	O
that	O
had	O
developed	O
Foxp3	S-PRGE
expression	O
in	O
the	O
mesenteric	O
lymph	O
node	O
and	O
lamina	O
propria	O
of	O
mice	O
transferred	O
with	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O
5	O
,	O
B	O
and	O
C	O
)	O
.	O

These	O
data	O
affirm	O
the	O
significance	O
of	O
RUNX	S-PRGE
proteins	O
for	O
the	O
in	O
vivo	O
generation	O
of	O
CD4	S-PRGE
+	O
Foxp3	S-PRGE
+	O
T	O
cells	O
.	O

CBFbeta	S-PRGE
,	O
RUNX1	S-PRGE
,	O
and	O
RUNX3	S-PRGE
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
CD25	S-PRGE
+	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cells	O

Even	O
though	O
Cbfb	S-PRGE
-	O
deficient	O
CD4	S-PRGE
+	O
T	O
cells	O
had	O
impaired	O
induction	O
of	O
Foxp3	S-PRGE
after	O
stimulation	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
mAbs	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
sufficient	O
numbers	O
of	O
Foxp3	S-PRGE
+	O
cells	O
could	O
be	O
generated	O
to	O
permit	O
analysis	O
of	O
their	O
suppressive	O
activity	O
.	O

Purified	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
from	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
control	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
(	O
Cd45	B-PRGE
.	I-PRGE
2	E-PRGE
)	O
harboring	O
a	O
Foxp3	S-PRGE
-	O
ires	O
-	O
GFP	S-PRGE
allele	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
)	O
were	O
stimulated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
mAbs	O
,	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

After	O
3	O
d	O
,	O
Foxp3	S-PRGE
+	O
-	O
GFP	S-PRGE
+	O
cells	O
were	O
sorted	O
by	O
flow	O
cytometry	O
and	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
at	O
ratios	O
of	O
1	O
:	O
4	O
,	O
1	O
:	O
2	O
,	O
and	O
1	O
:	O
1	O
.	O

The	O
cells	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
mAb	O
for	O
four	O
more	O
days	O
.	O

CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
(	O
Fig	O
.	O
6	O
A	O
)	O
.	O

CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
CD4	S-PRGE
+	O
T	O
cells	O
activated	O
in	O
the	O
presence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
showed	O
a	O
clear	O
suppression	O
of	O
T	O
cell	O
proliferation	O
that	O
became	O
even	O
more	O
apparent	O
when	O
an	O
increased	O
ratio	O
of	O
FOXP3	S-PRGE
+	O
/	O
CD25	S-PRGE
-	O
cells	O
was	O
used	O
(	O
Fig	O
.	O
6	O
B	O
)	O
.	O

The	O
suppression	O
was	O
significantly	O
reduced	O
when	O
cells	O
from	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
were	O
used	O
,	O
demonstrating	O
that	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
induced	O
Runx	O
complexes	O
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
6	O
B	O
)	O
.	O

As	O
a	O
control	O
,	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
CD4	S-PRGE
+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
were	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
.	O

No	O
suppression	O
could	O
be	O
observed	O
in	O
all	O
control	O
groups	O
without	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
at	O
all	O
tested	O
ratios	O
(	O
Fig	O
.	O
6	O
C	O
)	O
.	O

The	O
decreased	O
suppression	O
capacity	O
of	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
iT	O
reg	O
cells	O
was	O
unlikely	O
to	O
be	O
caused	O
by	O
decreased	O
survival	O
or	O
proliferation	O
.	O

Foxp3	S-PRGE
+	O
and	O
Foxp3	S-PRGE
-	O
cells	O
generated	O
from	O
both	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
control	O
cells	O
all	O
displayed	O
similar	O
proliferation	O
rates	O
and	O
cell	O
death	O
as	O
measured	O
by	O
CFSE	O
dilution	O
and	O
annexin	B-PRGE
V	E-PRGE
staining	O
,	O
respectively	O
(	O
Fig	O
.	O
S7	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
we	O
tested	O
the	O
requirement	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
for	O
the	O
development	O
of	O
the	O
suppressive	O
capacity	O
in	O
human	O
iT	O
reg	O
cells	O
.	O

We	O
isolated	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
and	O
transfected	O
them	O
with	O
a	O
combination	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
,	O
or	O
with	O
a	O
scrambled	O
control	O
siRNA	O
.	O

Cells	O
were	O
cultured	O
under	O
T	O
reg	O
conditions	O
,	O
and	O
then	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
autologous	O
CD4	S-PRGE
+	O
T	O
cells	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
mAb	O
.	O

Cells	O
in	O
which	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
were	O
knocked	O
down	O
showed	O
markedly	O
lower	O
suppressive	O
activity	O
compared	O
with	O
control	O
iT	O
reg	O
cells	O
at	O
a	O
T	O
reg	O
/	O
CD4	S-PRGE
+	O
T	O
responder	O
cell	O
ratio	O
of	O
1	O
:	O
20	O
,	O
but	O
not	O
when	O
the	O
T	O
reg	O
/	O
CD4	S-PRGE
+	O
T	O
responder	O
cell	O
ratio	O
was	O
increased	O
to	O
1	O
:	O
5	O
(	O
Fig	O
.	O
6	O
D	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
important	O
role	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
not	O
only	O
for	O
the	O
induction	O
of	O
FOXP3	S-PRGE
,	O
but	O
also	O
for	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
both	O
in	O
humans	O
and	O
in	O
mice	O
.	O

The	O
data	O
suggest	O
both	O
quantity	O
and	O
quality	O
of	O
T	O
reg	O
cells	O
are	O
hampered	O
.	O

Reduced	O
intrinsic	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
was	O
demonstrated	O
in	O
mice	O
,	O
because	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
+	O
cells	O
were	O
FACS	O
sorted	O
and	O
same	O
numbers	O
of	O
iT	O
reg	O
cells	O
are	O
included	O
in	O
control	O
experiments	O
.	O

In	O
the	O
suppression	O
experiment	O
with	O
human	O
cells	O
,	O
reduced	O
suppressive	O
activity	O
was	O
caused	O
by	O
reduced	O
FOXP3	S-PRGE
expression	O
in	O
T	O
cells	O
by	O
siRNA	O
inhibition	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
.	O

This	O
study	O
demonstrates	O
that	O
RUNX	B-PRGE
transcription	I-PRGE
factors	I-PRGE
1	E-PRGE
and	O
3	S-PRGE
play	O
an	O
important	O
role	O
in	O
the	O
generation	O
of	O
FOXP3	S-PRGE
+	O
iT	O
reg	O
cells	O
by	O
TGF	O
-	O
beta	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
mediates	O
RUNX	S-PRGE
induction	O
and	O
FOXP3	S-PRGE
is	O
efficiently	O
up	O
-	O
regulated	O
by	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
in	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

There	O
are	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
proximal	O
FOXP3	S-PRGE
promoter	O
.	O

One	O
binding	O
site	O
was	O
predicted	O
as	O
a	O
binding	O
site	O
for	O
RUNX2	S-PRGE
.	O

Promoter	O
enzyme	O
immunoassay	O
results	O
showed	O
that	O
binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
also	O
occurred	O
at	O
this	O
site	O
(	O
as	O
well	O
as	O
at	O
the	O
other	O
two	O
)	O
,	O
which	O
were	O
initially	O
identified	O
as	O
RUNX1	O
binding	O
sites	O
.	O

This	O
finding	O
is	O
not	O
surprising	O
because	O
RUNX	S-PRGE
proteins	O
bind	O
to	O
promoter	O
or	O
enhancer	O
elements	O
of	O
their	O
target	O
genes	O
via	O
the	O
runt	O
domain	O
,	O
which	O
is	O
conserved	O
between	O
members	O
of	O
the	O
RUNX	S-PRGE
family	O
.	O

The	O
RUNX	S-PRGE
protein	O
that	O
actually	O
induces	O
the	O
expression	O
of	O
FOXP3	S-PRGE
might	O
therefore	O
be	O
dependent	O
on	O
the	O
availability	O
of	O
the	O
specific	O
RUNX	S-PRGE
family	O
member	O
at	O
certain	O
stages	O
of	O
T	O
cell	O
development	O
.	O

RUNX	S-PRGE
proteins	O
are	O
able	O
to	O
increase	O
or	O
inhibit	O
transcriptional	O
activity	O
of	O
their	O
target	O
genes	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
target	O
gene	O
(	O
Otto	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

Mutation	O
of	O
only	O
one	O
of	O
the	O
three	O
binding	O
sites	O
had	O
only	O
a	O
little	O
effect	O
on	O
the	O
promoter	O
activity	O
;	O
however	O
,	O
when	O
two	O
binding	O
sites	O
were	O
mutated	O
,	O
the	O
FOXP3	S-PRGE
promoter	O
activity	O
dropped	O
to	O
a	O
greater	O
extent	O
.	O

The	O
most	O
striking	O
effect	O
was	O
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
.	O

We	O
therefore	O
assume	O
that	O
these	O
binding	O
sites	O
have	O
partially	O
redundant	O
functions	O
,	O
but	O
binding	O
to	O
at	O
least	O
two	O
sites	O
seems	O
to	O
be	O
necessary	O
for	O
full	O
promoter	O
activation	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
promotes	O
or	O
inhibits	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
a	O
wide	O
array	O
of	O
different	O
cells	O
.	O

It	O
is	O
also	O
produced	O
in	O
activated	O
T	O
cells	O
and	O
it	O
inhibits	O
T	O
cell	O
proliferation	O
(	O
Kehrl	O
et	O
al	O
.	O
,	O
1986	O
;	O
Siegel	O
and	O
Massague	O
,	O
2003	O
)	O
.	O

It	O
was	O
shown	O
that	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
is	O
mandatory	O
for	O
the	O
maintenance	O
of	O
peripheral	O
T	O
reg	O
cells	O
and	O
their	O
expression	O
of	O
Foxp3	S-PRGE
(	O
Marie	O
et	O
al	O
.	O
,	O
2005	O
;	O
Rubtsov	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

RUNX	S-PRGE
transcription	O
factors	O
are	O
targets	O
of	O
the	O
TGF	O
-	O
beta	O
superfamily	O
and	O
they	O
are	O
involved	O
in	O
the	O
TGF	O
-	O
beta	O
pathway	O
.	O

They	O
interact	O
directly	O
with	O
regulatory	O
SMADs	O
(	O
Miyazawa	O
et	O
al	O
.	O
,	O
2002	O
;	O
Ito	O
and	O
Miyazono	O
,	O
2003	O
)	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
can	O
activate	O
RUNX	S-PRGE
genes	O
at	O
the	O
transcriptional	O
level	O
,	O
and	O
at	O
the	O
posttranscriptional	O
level	O
through	O
activation	O
or	O
stabilization	O
of	O
RUNX	S-PRGE
proteins	O
(	O
Jin	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

It	O
was	O
shown	O
that	O
RUNX2	S-PRGE
regulates	O
the	O
expression	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
type	I-PRGE
I	I-PRGE
receptor	E-PRGE
(	O
Ji	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
suggesting	O
that	O
other	O
mechanisms	O
for	O
their	O
function	O
could	O
be	O
involved	O
.	O

The	O
fusion	O
proteins	O
RUNX1	B-PRGE
-	I-PRGE
EVI1	E-PRGE
and	O
RUNX1	B-PRGE
-	I-PRGE
ETO	E-PRGE
block	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
inhibition	O
of	O
leukemic	O
cell	O
growth	O
.	O

RUNX3	S-PRGE
plays	O
an	O
important	O
role	O
in	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
mediated	O
growth	O
control	O
in	O
epithelial	O
cells	O
,	O
as	O
loss	O
of	O
RUNX3	S-PRGE
leads	O
to	O
decreased	O
sensitivity	O
to	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
hyperproliferation	O
of	O
the	O
gastric	O
mucosa	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
RUNX3	S-PRGE
expression	O
is	O
more	O
dominant	O
in	O
circulating	O
human	O
T	O
reg	O
cells	O
and	O
tonsil	O
T	O
reg	O
cells	O
compared	O
with	O
RUNX1	S-PRGE
.	O

This	O
could	O
be	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
cells	O
and	O
organ	O
from	O
which	O
they	O
were	O
isolated	O
.	O

We	O
observed	O
that	O
single	O
siRNA	O
interference	O
of	O
either	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
alone	O
shows	O
a	O
slight	O
decrease	O
in	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cell	O
induction	O
,	O
which	O
could	O
be	O
caused	O
by	O
redundancy	O
of	O
these	O
proteins	O
.	O

For	O
this	O
reason	O
,	O
we	O
decided	O
to	O
use	O
CbfbetaF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
.	O

Foxp3	S-PRGE
induction	O
by	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
is	O
reduced	O
in	O
CD4	S-PRGE
+	O
T	O
cells	O
of	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
compared	O
with	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
.	O

Retinoic	O
acid	O
is	O
secreted	O
by	O
a	O
subset	O
of	O
dendritic	O
cells	O
in	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
.	O

It	O
inhibits	O
the	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
-	O
driven	O
induction	O
of	O
Th17	O
cells	O
and	O
facilitates	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
to	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cells	O
(	O
Mucida	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

We	O
observed	O
an	O
increased	O
number	O
of	O
Foxp3	S-PRGE
+	O
cells	O
by	O
retinoic	O
acid	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
compared	O
with	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
treatment	O
alone	O
in	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
and	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
.	O

In	O
addition	O
,	O
we	O
showed	O
a	O
defective	O
in	O
vivo	O
generation	O
of	O
T	O
reg	O
cells	O
from	O
Cbfb	S-PRGE
-	O
deficient	O
CD4	S-PRGE
+	O
T	O
cells	O
in	O
Rag2	S-PRGE
-	O
/	O
-	O
mice	O
.	O

These	O
data	O
in	O
mice	O
confirm	O
the	O
human	O
data	O
that	O
RUNX	S-PRGE
proteins	O
play	O
an	O
important	O
role	O
for	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
-	O
dependent	O
FOXP3	S-PRGE
induction	O
,	O
as	O
well	O
as	O
in	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
.	O

As	O
an	O
additional	O
support	O
for	O
this	O
concept	O
,	O
the	O
overexpression	O
of	O
RUNX1	S-PRGE
induced	O
increased	O
FOXP3	S-PRGE
protein	O
expression	O
without	O
any	O
requirement	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
anti	O
-	O
CD3	S-PRGE
and	O
anti	O
-	O
CD28	S-PRGE
stimulation	O
in	O
human	O
primary	O
CD4	S-PRGE
+	O
cells	O
.	O

In	O
both	O
human	O
and	O
mouse	O
systems	O
,	O
reduced	O
Foxp3	S-PRGE
expression	O
was	O
associated	O
with	O
reduced	O
T	O
reg	O
cell	O
suppressive	O
activity	O
.	O

In	O
a	O
recent	O
study	O
,	O
the	O
role	O
of	O
Runx	S-PRGE
-	O
CBFbeta	S-PRGE
was	O
investigated	O
in	O
nT	O
reg	O
cell	O
development	O
in	O
the	O
thymus	O
(	O
Rudra	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

It	O
was	O
reported	O
that	O
Foxp3	S-PRGE
expression	O
in	O
nT	O
reg	O
cells	O
is	O
unstable	O
in	O
the	O
absence	O
of	O
Runx	O
-	O
CBFbeta	S-PRGE
complexes	O
.	O

Cbfb	S-PRGE
-	O
deficient	O
nT	O
reg	O
cells	O
progressively	O
lose	O
Foxp3	S-PRGE
upon	O
division	O
,	O
and	O
there	O
is	O
no	O
evidence	O
of	O
increased	O
death	O
of	O
Cbfb	S-PRGE
-	O
deficient	O
nT	O
reg	O
cells	O
in	O
that	O
study	O
.	O

The	O
experiments	O
in	O
Cbfb	S-PRGE
-	O
deficient	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
T	O
cells	O
in	O
mice	O
and	O
the	O
knockdown	O
experiments	O
in	O
humans	O
in	O
this	O
study	O
suggest	O
that	O
the	O
induction	O
of	O
Foxp3	S-PRGE
expression	O
is	O
a	O
major	O
contributing	O
factor	O
in	O
the	O
in	O
vivo	O
conversion	O
experiment	O
.	O

Here	O
,	O
we	O
observed	O
that	O
there	O
is	O
a	O
twofold	O
increased	O
Foxp3	S-PRGE
+	O
iT	O
reg	O
cell	O
generation	O
in	O
vivo	O
.	O

This	O
is	O
in	O
the	O
same	O
range	O
with	O
previously	O
published	O
studies	O
targeting	O
different	O
mechanisms	O
in	O
Foxp3	S-PRGE
induction	O
(	O
Maynard	O
et	O
al	O
.	O
,	O
2007	O
;	O
Sun	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Whether	O
the	O
diminished	O
capacity	O
of	O
Cbfb	S-PRGE
-	O
deficient	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
T	O
cells	O
in	O
the	O
generation	O
of	O
Foxp3	S-PRGE
may	O
be	O
caused	O
by	O
peripheral	O
expansion	O
of	O
Cbfb	S-PRGE
-	O
deficient	O
non	O
-	O
T	O
reg	O
cells	O
or	O
survival	O
problems	O
faced	O
by	O
Cbfb	S-PRGE
-	O
deficient	O
iT	O
reg	O
cells	O
after	O
Foxp3	S-PRGE
induction	O
remains	O
to	O
be	O
elucidated	O
.	O

The	O
involvement	O
of	O
RUNX	S-PRGE
proteins	O
in	O
autoimmune	O
diseases	O
has	O
been	O
previously	O
suggested	O
(	O
Alarcon	O
-	O
Riquelme	O
,	O
2003	O
)	O
.	O

A	O
mutation	O
in	O
the	O
RUNX1	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
programmed	B-PRGE
cell	I-PRGE
death	I-PRGE
1	E-PRGE
gene	O
(	O
PDCD	B-PRGE
-	I-PRGE
1	E-PRGE
)	O
has	O
been	O
implicated	O
in	O
systemic	O
lupus	O
erythematosus	O
pathogenesis	O
(	O
Prokunina	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Polymorphisms	O
that	O
alter	O
RUNX1	S-PRGE
binding	O
to	O
other	O
genes	O
have	O
also	O
been	O
described	O
in	O
rheumatoid	O
arthritis	O
linkage	O
at	O
5q31	O
in	O
Japanese	O
patients	O
(	O
Tokuhiro	O
et	O
al	O
.	O
,	O
2003	O
)	O
and	O
in	O
a	O
psoriasis	O
linkage	O
at	O
17q25	O
(	O
Prokunina	O
et	O
al	O
.	O
,	O
2002	O
;	O
Helms	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

RUNX3	S-PRGE
-	O
deficient	O
mice	O
spontaneously	O
develop	O
inflammatory	O
bowel	O
disease	O
and	O
hyperplastic	O
gastritis	O
-	O
like	O
lesions	O
(	O
Brenner	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

These	O
disease	O
symptoms	O
resemble	O
those	O
occurring	O
after	O
depletion	O
of	O
Foxp3	S-PRGE
-	O
expressing	O
T	O
reg	O
cells	O
(	O
Sakaguchi	O
,	O
2004	O
)	O
.	O

Derepression	O
of	O
Th2	O
cytokines	O
might	O
also	O
account	O
for	O
some	O
of	O
the	O
observed	O
disease	O
symptoms	O
,	O
as	O
it	O
was	O
shown	O
that	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
first	O
induces	O
Runx3	S-PRGE
in	O
Th1	O
cells	O
and	O
then	O
partners	O
with	O
Runx3	S-PRGE
to	O
direct	O
lineage	O
-	O
specific	O
gene	O
activation	O
.	O

Runx3	S-PRGE
/	O
Cbfbeta	S-PRGE
are	O
both	O
required	O
for	O
the	O
activation	O
of	O
the	O
Ifng	S-PRGE
gene	O
and	O
silencing	O
of	O
the	O
Il4	S-PRGE
gene	O
in	O
Th1	O
cells	O
(	O
Djuretic	O
et	O
al	O
.	O
,	O
2007	O
;	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Runx	S-PRGE
proteins	O
also	O
play	O
an	O
essential	O
role	O
during	O
T	O
lymphocyte	O
differentiation	O
in	O
the	O
thymus	O
(	O
Taniuchi	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Runx1	S-PRGE
regulates	O
the	O
transitions	O
of	O
developing	O
thymocytes	O
from	O
the	O
CD4	S-PRGE
-	O
CD8	S-PRGE
-	O
double	O
-	O
negative	O
stage	O
to	O
the	O
CD4	S-PRGE
+	O
CD8	S-PRGE
+	O
double	O
-	O
positive	O
stage	O
and	O
from	O
the	O
DP	O
stage	O
to	O
the	O
mature	O
single	O
-	O
positive	O
stage	O
(	O
Egawa	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Runx1	S-PRGE
and	O
Runx3	S-PRGE
deficiencies	O
caused	O
marked	O
reductions	O
in	O
mature	O
thymocytes	O
and	O
T	O
cells	O
of	O
the	O
CD4	S-PRGE
+	O
helper	O
and	O
CD8	S-PRGE
+	O
cytotoxic	O
T	O
cell	O
lineages	O
.	O

In	O
addition	O
,	O
inactivation	O
of	O
both	O
Runx1	S-PRGE
and	O
Runx3	S-PRGE
at	O
the	O
double	O
-	O
positive	O
stages	O
resulted	O
in	O
a	O
severe	O
blockage	O
in	O
the	O
development	O
of	O
CD8	S-PRGE
+	O
mature	O
thymocytes	O
.	O

These	O
results	O
indicate	O
that	O
Runx	S-PRGE
proteins	O
have	O
important	O
roles	O
at	O
multiple	O
stages	O
of	O
T	O
cell	O
development	O
and	O
in	O
the	O
homeostasis	O
of	O
mature	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
nT	O
reg	O
cell	O
development	O
,	O
which	O
remains	O
to	O
be	O
elucidated	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
Runx1	S-PRGE
activates	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
gene	O
expression	O
in	O
conventional	O
CD4	S-PRGE
+	O
T	O
cells	O
by	O
binding	O
to	O
their	O
respective	O
promoter	O
.	O

RUNX1	S-PRGE
interacts	O
physically	O
with	O
Foxp3	S-PRGE
protein	O
,	O
and	O
it	O
was	O
demonstrated	O
that	O
this	O
interaction	O
might	O
be	O
responsible	O
for	O
the	O
suppression	O
of	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
production	O
and	O
up	O
-	O
regulation	O
of	O
T	O
reg	O
cell	O
-	O
associated	O
molecules	O
(	O
Ono	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
Foxp3	S-PRGE
also	O
influences	O
Th17	O
differentiation	O
.	O

Specifically	O
,	O
Foxp3	S-PRGE
physically	O
interacts	O
with	O
RORgammat	S-PRGE
,	O
and	O
this	O
interaction	O
inhibits	O
RORgammat	S-PRGE
function	O
(	O
Zhou	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

This	O
relationship	O
of	O
RORgammat	S-PRGE
and	O
Foxp3	S-PRGE
and	O
probably	O
yet	O
unknown	O
mechanisms	O
might	O
be	O
the	O
basis	O
of	O
the	O
observation	O
that	O
the	O
differentiation	O
of	O
Th17	O
cells	O
and	O
T	O
reg	O
cells	O
is	O
often	O
reciprocal	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Recently	O
,	O
data	O
suggests	O
that	O
Runx1	S-PRGE
may	O
also	O
be	O
involved	O
in	O
regulating	O
Il17	S-PRGE
transcription	O
,	O
functioning	O
in	O
complex	O
with	O
RORgammat	S-PRGE
to	O
activate	O
transcription	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

The	O
Runx3	S-PRGE
-	O
deficient	O
mice	O
develop	O
spontaneous	O
Th2	O
-	O
dominated	O
autoimmune	O
colitis	O
and	O
asthma	O
(	O
Brenner	O
et	O
al	O
.	O
,	O
2004	O
;	O
Fainaru	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Cbfbf	S-PRGE
/	O
f	O
Cd4	S-PRGE
mice	O
also	O
show	O
a	O
spontaneous	O
Th2	O
dominated	O
disease	O
,	O
with	O
increased	O
serum	O
IgA	O
,	O
IgG1	O
,	O
and	O
IgE	O
titers	O
and	O
lymphocyte	O
and	O
eosinophil	O
infiltration	O
of	O
the	O
lung	O
(	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

All	O
these	O
phenotypes	O
were	O
previously	O
attributed	O
to	O
a	O
loss	O
of	O
Th2	O
silencing	O
whereas	O
our	O
findings	O
additionally	O
suggest	O
that	O
loss	O
of	O
T	O
reg	O
function	O
plays	O
a	O
role	O
.	O

We	O
have	O
shown	O
a	O
link	O
between	O
Foxp3	S-PRGE
induction	O
in	O
iT	O
reg	O
cells	O
and	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
.	O

RUNX	S-PRGE
proteins	O
play	O
a	O
central	O
role	O
in	O
pathways	O
regulating	O
cell	O
growth	O
and	O
differentiation	O
,	O
and	O
their	O
interaction	O
with	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
pathway	O
is	O
of	O
particular	O
interest	O
.	O

Foxp3	S-PRGE
protein	O
interacts	O
not	O
only	O
with	O
RUNX	S-PRGE
proteins	O
but	O
also	O
with	O
several	O
other	O
transcriptional	O
partners	O
,	O
such	O
as	O
NFAT	O
and	O
possibly	O
NF	O
-	O
kappaB	O
;	O
with	O
histone	O
acetyl	O
transferases	O
,	O
such	O
as	O
TIP60	S-PRGE
;	O
and	O
histone	O
deacetyl	O
transferase	O
(	O
HDAC	O
)	O
complexes	O
,	O
such	O
as	O
HDAC7	O
and	O
HDAC9	O
(	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
;	O
Sakaguchi	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

NFAT	O
forms	O
a	O
complex	O
with	O
AP	B-PRGE
-	I-PRGE
1	E-PRGE
and	O
NF	O
-	O
kappaB	O
and	O
regulates	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
,	O
and	O
CTLA4	S-PRGE
in	O
conventional	O
T	O
cells	O
,	O
which	O
leads	O
to	O
the	O
activation	O
and	O
differentiation	O
to	O
effector	O
T	O
cells	O
(	O
Dolganov	O
et	O
al	O
.	O
,	O
1996	O
;	O
Hu	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
NFAT	O
-	O
AP	B-PRGE
-	I-PRGE
1	E-PRGE
complex	O
also	O
binds	O
to	O
the	O
Foxp3	S-PRGE
promoter	O
after	O
TCR	O
triggering	O
and	O
regulates	O
its	O
gene	O
expression	O
positively	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

It	O
was	O
shown	O
that	O
NFAT	O
and	O
Smad3	S-PRGE
cooperate	O
to	O
induce	O
Foxp3	S-PRGE
expression	O
through	O
its	O
enhancer	O
(	O
Tone	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
but	O
no	O
TGF	O
-	O
beta	O
response	O
element	O
was	O
identified	O
in	O
the	O
Foxp3	S-PRGE
gene	O
or	O
in	O
the	O
surrounding	O
regions	O
.	O

The	O
initial	O
induction	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
and	O
the	O
subsequent	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
Foxp3	S-PRGE
promoter	O
that	O
we	O
showed	O
here	O
might	O
explain	O
the	O
relatively	O
late	O
induction	O
of	O
Foxp3	S-PRGE
mRNA	O
that	O
peaks	O
24	O
-	O
48	O
h	O
after	O
stimulation	O
.	O

The	O
interaction	O
of	O
Foxp3	S-PRGE
and	O
NFAT	O
is	O
dependent	O
on	O
their	O
cooperative	O
binding	O
to	O
DNA	O
(	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

RUNX1	S-PRGE
alone	O
,	O
or	O
together	O
with	O
its	O
interacting	O
partners	O
p300	S-PRGE
and	O
CREB	S-PRGE
-	O
binding	O
protein	O
,	O
may	O
cooperate	O
with	O
the	O
NFAT	O
transcription	O
complex	O
to	O
activate	O
the	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
promoter	O
(	O
Sakaguchi	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

Similar	O
to	O
this	O
interaction	O
,	O
NFAT	O
may	O
also	O
cooperate	O
with	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
to	O
activate	O
Foxp3	S-PRGE
,	O
but	O
further	O
studies	O
are	O
necessary	O
to	O
elaborate	O
on	O
this	O
concept	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
elucidate	O
the	O
role	O
of	O
RUNX	S-PRGE
proteins	O
in	O
iT	O
reg	O
cell	O
development	O
and	O
function	O
.	O

The	O
induction	O
of	O
the	O
transcription	O
factors	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
by	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
the	O
subsequent	O
up	O
-	O
regulation	O
of	O
Foxp3	S-PRGE
play	O
a	O
role	O
in	O
iT	O
reg	O
cell	O
generation	O
and	O
its	O
suppressive	O
capacity	O
.	O

Mice	O
.	O

CbfbF	S-PRGE
/	O
F	O
CD4	S-PRGE
-	O
cre	S-PRGE
and	O
Foxp3GFP	S-PRGE
mice	O
have	O
previously	O
been	O
described	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
;	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Cd45	B-PRGE
.	I-PRGE
1	E-PRGE
and	O
Rag2	S-PRGE
-	O
/	O
-	O
mice	O
were	O
purchased	O
from	O
Jackson	O
ImmunoResearch	O
Laboratories	O
and	O
Taconic	O
,	O
respectively	O
.	O

For	O
the	O
in	O
vivo	O
Foxp3	S-PRGE
conversion	O
assay	O
,	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
from	O
Cbfb	S-PRGE
CD4	S-PRGE
-	O
cre	S-PRGE
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3	S-PRGE
-	O
IRES	O
-	O
GFP	S-PRGE
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	S-PRGE
-	O
deficient	O
mice	O
.	O

5	O
x	O
106	O
cells	O
were	O
used	O
per	O
transfer	O
.	O

6	O
wk	O
later	O
,	O
TCRbeta	S-PRGE
+	O
CD4	S-PRGE
+	O
gated	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
expression	O
.	O

All	O
analyses	O
and	O
experiments	O
were	O
performed	O
on	O
animals	O
at	O
6	O
-	O
8	O
wk	O
of	O
age	O
.	O

Animals	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
at	O
the	O
animal	O
facility	O
of	O
the	O
Skirball	O
Institute	O
,	O
and	O
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
approved	O
protocols	O
for	O
the	O
New	O
York	O
University	O
Institutional	O
Animal	O
Care	O
and	O
Usage	O
Committee	O
.	O

Isolation	O
of	O
PBMCs	O
,	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
and	O
culture	O
conditions	O
.	O

Human	O
PBMCs	O
were	O
isolated	O
by	O
Ficoll	O
(	O
Biochrom	O
)	O
density	O
gradient	O
centrifugation	O
and	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
then	O
isolated	O
using	O
the	O
Dynal	O
CD4	S-PRGE
+	O
Isolation	O
kit	S-PRGE
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
purity	O
of	O
CD4	S-PRGE
+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
flow	O
cytometry	O
and	O
was	O
>	O
=	O
95	O
%	O
.	O

Cells	O
were	O
stimulated	O
with	O
the	O
following	O
combination	O
of	O
mAbs	O
to	O
T	O
cell	O
surface	O
molecules	O
(	O
Meiler	O
et	O
al	O
.	O
,	O
2008	O
)	O
:	O
anti	O
-	O
CD2	S-PRGE
(	O
clone	O
4B2	O
and	O
6G4	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
)	O
,	O
anti	O
-	O
CD3	S-PRGE
(	O
clone	O
OKT3	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
)	O
,	O
and	O
anti	O
-	O
CD28	S-PRGE
mAb	O
(	O
clone	O
B7G5	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
;	O
all	O
from	O
Sanquin	O
)	O
and	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
with	O
the	O
addition	O
of	O
1	O
nmol	O
/	O
liter	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
(	O
Roche	O
)	O
.	O

TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
(	O
R	O
&	O
D	O
Systems	O
)	O
was	O
used	O
at	O
5	O
ng	O
/	O
ml	O
,	O
if	O
not	O
stated	O
otherwise	O
.	O

A	O
combination	O
of	O
PMA	O
(	O
25	O
ng	O
/	O
ml	O
)	O
and	O
ionomycin	O
(	O
1	O
mg	O
/	O
ml	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
used	O
.	O

Human	O
CD4	S-PRGE
+	O
CD127	S-PRGE
-	O
CD25high	S-PRGE
and	O
CD4	S-PRGE
+	O
CD127	S-PRGE
+	O
CD25neg	S-PRGE
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
using	O
anti	O
-	O
CD127	S-PRGE
,	O
anti	O
-	O
CD25	S-PRGE
-	O
PC5	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
anti	O
-	O
CD4	S-PRGE
-	O
FITC	O
antibodies	O
(	O
Dako	O
)	O
.	O

Mouse	O
naive	O
(	O
CD62Lhi44lo25	S-PRGE
-	O
)	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
and	O
activated	O
in	O
vitro	O
with	O
5	O
microg	O
/	O
ml	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
and	O
1	O
microg	O
/	O
ml	O
soluble	O
anti	O
-	O
CD28	S-PRGE
antibodies	O
(	O
eBioscience	O
)	O
in	O
RPMI	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
5	O
mM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
antibiotics	O
.	O

Neutralizing	O
anti	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
and	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
mAbs	O
(	O
BD	O
)	O
were	O
used	O
at	O
1	O
microg	O
/	O
ml	O
concentrations	O
when	O
indicated	O
.	O

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O

CD4	S-PRGE
+	O
CD45RA	S-PRGE
+	O
magnetically	O
sorted	O
(	O
CD45RO	S-PRGE
depletion	O
with	O
AutoMACS	O
;	O
Miltenyi	O
Biotec	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	S-PRGE
(	O
1	O
microg	O
/	O
ml	O
;	O
OKT3	O
;	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	S-PRGE
(	O
2	O
microg	O
/	O
ml	O
)	O
.	O

For	O
Th1	O
differentiation	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
and	O
25	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
Th2	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
25	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
and	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
T	O
reg	O
cell	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
5	O
ng	O
/	O
ml	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
.	O

For	O
Th17	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
20	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
5	O
ng	O
/	O
ml	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
20	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
23	E-PRGE
(	O
Alexis	O
Biochemicals	O
Corp	O
.	O
)	O
,	O
10	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
and	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
12	E-PRGE
were	O
used	O
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
.	O

The	O
cytokine	O
profile	O
of	O
these	O
cells	O
demonstrated	O
that	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
is	O
the	O
predominant	O
cytokine	O
in	O
Th1	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
in	O
Th2	O
cells	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
17	E-PRGE
in	O
Th17	O
cells	O
(	O
Akdis	O
et	O
al	O
.	O
,	O
2000	O
;	O
Burgler	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Immunohistochemistry	O
.	O

Human	O
tonsils	O
were	O
obtained	O
from	O
tonsillectomy	O
samples	O
of	O
hypertrophic	O
and	O
obstructive	O
tonsils	O
without	O
a	O
current	O
infection	O
.	O

Ethical	O
permission	O
was	O
obtained	O
from	O
Cantonal	O
Ethics	O
Commission	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
patients	O
.	O

Paraformaldehyde	O
-	O
fixed	O
tonsil	O
cryosections	O
were	O
stained	O
with	O
unconjugated	O
rabbit	O
IgG	O
polyclonal	O
antibody	O
to	O
human	O
RUNX1	S-PRGE
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
or	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
RUNX3	S-PRGE
(	O
Abcam	O
)	O
.	O

After	O
a	O
washing	O
step	O
,	O
the	O
sections	O
were	O
stained	O
with	O
the	O
corresponding	O
secondary	O
antibodies	O
.	O

RUNX1	S-PRGE
-	O
binding	O
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
633	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
and	O
RUNX3	S-PRGE
-	O
binding	O
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
532	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG1	O
.	O

Afterward	O
,	O
the	O
sections	O
were	O
washed	O
and	O
in	O
the	O
case	O
of	O
RUNX3	S-PRGE
staining	O
a	O
blocking	O
step	O
with	O
an	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
was	O
used	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
stained	O
with	O
Alexa	O
Fluor	O
488	O
-	O
conjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
FOXP3	S-PRGE
(	O
eBioscience	O
)	O
or	O
the	O
corresponding	O
isotype	O
control	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
DAPI	O
for	O
the	O
demonstration	O
of	O
nuclei	O
and	O
mounted	O
with	O
Prolong	O
antifade	O
(	O
Invitrogen	O
)	O
.	O

Images	O
were	O
acquired	O
and	O
analyzed	O
using	O
the	O
confocal	O
microscope	O
DMI	O
4000B	O
and	O
the	O
TCS	O
SPE	O
system	O
(	O
both	O
from	O
Leica	O
)	O
.	O

In	O
vitro	O
suppression	O
assays	O
.	O

Mouse	O
Foxp3	S-PRGE
+	O
CD4	S-PRGE
+	O
CD8	S-PRGE
-	O
T	O
cells	O
were	O
FACS	O
purified	O
based	O
on	O
GFP	S-PRGE
expressed	O
from	O
a	O
Foxp3	S-PRGE
-	O
IRES	O
-	O
GFP	S-PRGE
knock	O
-	O
in	O
allele	O
(	O
Foxp3GFP	S-PRGE
)	O
.	O

Naive	O
(	O
CD62Lhi44lo25	S-PRGE
-	O
)	O
CD4	S-PRGE
+	O
T	O
cells	O
(	O
effectors	O
)	O
were	O
FACS	O
-	O
purified	O
from	O
Cd45	B-PRGE
.	I-PRGE
1	E-PRGE
mice	O
,	O
then	O
loaded	O
with	O
5	O
microM	O
CFSE	O
(	O
Invitrogen	O
)	O
.	O

Total	O
splenocytes	O
from	O
C57BL	O
/	O
6	O
mice	O
inactivated	O
with	O
50	O
microg	O
/	O
ml	O
mitomycin	O
C	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
45	O
min	O
were	O
used	O
as	O
APCs	O
.	O

A	O
total	O
of	O
4	O
x	O
105	O
CD4	S-PRGE
+	O
cells	O
(	O
CFSE	O
-	O
loaded	O
CD25	S-PRGE
-	O
plus	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
+	O
)	O
was	O
mixed	O
with	O
105	O
APCs	O
+	O
1	O
microg	O
/	O
ml	O
anti	O
-	O
CD3	S-PRGE
mAb	O
per	O
well	O
of	O
a	O
96	O
well	O
round	O
bottom	O
plate	O
.	O

Proliferation	O
of	O
the	O
effector	O
cells	O
was	O
analyzed	O
by	O
CFSE	O
dilution	O
.	O

Apoptosis	O
of	O
the	O
cells	O
was	O
investigated	O
by	O
annexin	B-PRGE
V	E-PRGE
staining	O
and	O
flow	O
cytometry	O
.	O

Positive	O
and	O
negative	O
control	O
gates	O
were	O
made	O
according	O
to	O
T	O
cells	O
cultured	O
only	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
without	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
stimulation	O
.	O

Human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
isolated	O
by	O
negative	O
selection	O
by	O
MACS	O
from	O
PBMCs	O
and	O
either	O
transfected	O
with	O
a	O
scrambled	O
siRNA	O
or	O
with	O
a	O
combination	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
.	O

Cells	O
were	O
then	O
cultured	O
under	O
iT	O
reg	O
cell	O
differentiating	O
conditions	O
and	O
mixed	O
with	O
2	O
x	O
105	O
autologous	O
irradiated	O
PBMCs	O
that	O
were	O
used	O
as	O
APCs	O
and	O
autologous	O
CFSE	O
-	O
labeled	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

T	O
reg	O
cell	O
to	O
responder	O
cell	O
ratio	O
was	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O

To	O
check	O
the	O
proliferation	O
of	O
the	O
CD4	S-PRGE
+	O
T	O
cells	O
without	O
suppression	O
,	O
no	O
T	O
reg	O
cells	O
were	O
added	O
in	O
a	O
control	O
group	O
.	O

Cells	O
were	O
stimulated	O
with	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
CD3	S-PRGE
mAb	O
,	O
cultured	O
in	O
a	O
96	O
-	O
well	O
plate	O
and	O
the	O
proliferation	O
of	O
the	O
effector	O
cells	O
was	O
determined	O
by	O
analyzing	O
the	O
CFSE	O
dilution	O
by	O
flow	O
cytometry	O
after	O
5	O
d	O
of	O
culture	O
.	O

Gating	O
on	O
the	O
CD4	S-PRGE
+	O
CFSE	O
+	O
T	O
cells	O
enabled	O
the	O
exclusion	O
of	O
APCs	O
and	O
T	O
reg	O
cells	O
.	O

Cloning	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
,	O
construction	O
of	O
mutant	O
FOXP3	S-PRGE
promoter	O
,	O
and	O
RUNX	S-PRGE
expression	O
plasmids	O
.	O

The	O
FOXP3	S-PRGE
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
pGL3	O
FOXP3	S-PRGE
-	O
511	O
/	O
+	O
176	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
for	O
the	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
region	O
was	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
confirmed	O
by	O
sequencing	O
the	O
DNA	O
.	O

The	O
following	O
primers	O
and	O
their	O
complementary	O
strands	O
were	O
used	O
:	O
foxp	O
runx	O
-	O
333	O
,	O
forward	O
5	O
'	O
-	O
CACTTTTGTTTTAAAAACTGTCCTTTCTCATGAGCCCTATTATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
333	O
reverse	O
5	O
'	O
-	O
GATAATAGGGCTCATGAGAAAGGACAGTTTTTAAAACAAAAGTG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
forward	O
5	O
'	O
-	O
CCTCTCACCTCTGTCCTGAGGGGAAGAAATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
reverse	O
5	O
'	O
-	O
GATTTCTTCCCCTCAGGACAGAGGTGAGAGG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
forward	O
5	O
'	O
-	O
GCTTCCACACCGTACAGCGTCCTTTTTCTTCTCGGTATAAAAG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
reverse	O
5	O
'	O
-	O
CTTTTATACCGAGAAGAAAAAGGACGCTGTACGGTGTGGAAGC	O
-	O
3	O
'	O
.	O

The	O
human	O
RUNX1	S-PRGE
fragment	O
from	O
the	O
Addgene	O
plasmid	O
12504	O
(	O
Biggs	O
et	O
al	O
.	O
,	O
2006	O
)	O
pFlagCMV2	O
-	O
AML1B	O
was	O
sub	O
-	O
cloned	O
in	O
the	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
)	O
.	O

The	O
RUNX3	S-PRGE
vector	O
pCMV	O
human	O
RUNX3	S-PRGE
,	O
which	O
was	O
a	O
gift	O
from	O
K	O
.	O

Ito	O
(	O
Institute	O
of	O
Molecular	O
and	O
Cell	O
Biology	O
,	O
Proteos	O
,	O
Singapore	O
)	O
was	O
subcloned	O
into	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
;	O
Yamamura	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
overnight	O
.	O

3	O
.	O
5	O
microg	O
of	O
the	O
FOXP3	S-PRGE
promoter	O
luciferase	S-PRGE
reporter	O
vector	O
or	O
a	O
combination	O
together	O
with	O
the	O
RUNX1	S-PRGE
,	O
RUNX3	S-PRGE
pEGFPN1	O
vector	O
,	O
and	O
0	O
.	O
5	O
microg	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4	S-PRGE
+	O
T	O
cells	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
using	O
the	O
program	O
U	O
-	O
15	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	S-PRGE
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	S-PRGE
assay	O
system	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

PMA	O
/	O
ionomycin	O
was	O
used	O
to	O
stimulate	O
the	O
cells	O
,	O
because	O
the	O
transfection	O
was	O
only	O
transient	O
and	O
the	O
luciferase	S-PRGE
assay	O
required	O
a	O
strong	O
and	O
fast	O
stimulation	O
of	O
the	O
cells	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
overexpression	O
of	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
on	O
FOXP3	S-PRGE
protein	O
levels	O
,	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
preactivated	O
with	O
2	O
microg	O
/	O
ml	O
phytohemagglutinin	S-PRGE
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
in	O
the	O
presence	O
of	O
1	O
nmol	O
/	O
liter	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
(	O
Roche	O
)	O
for	O
12	O
h	O
,	O
and	O
then	O
transfected	O
with	O
the	O
vector	O
pEGFPN1	O
containing	O
the	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
fragment	O
using	O
the	O
Nucleofector	O
system	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
the	O
program	O
T	O
-	O
23	O
.	O

FOXP3	S-PRGE
expression	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
of	O
culture	O
in	O
AIM	O
-	O
V	O
medium	O
containing	O
1	O
nmol	O
/	O
liter	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
.	O

RNA	O
interference	O
.	O

CD4	S-PRGE
+	O
or	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
with	O
2	O
microM	O
siRNA	O
using	O
the	O
Nucleofector	O
technology	O
program	O
U	O
-	O
14	O
(	O
Lonza	O
)	O
.	O

Five	O
different	O
Silencer	O
or	O
Silencer	O
Select	O
Pre	O
-	O
designed	O
siRNAs	O
for	O
RUNX1	S-PRGE
(	O
Applied	O
Biosystems	O
)	O
and	O
three	O
Silencer	O
Pre	O
-	O
designed	O
siRNAs	O
for	O
RUNX3	S-PRGE
(	O
Applied	O
Biosystems	O
)	O
were	O
tested	O
,	O
and	O
the	O
best	O
was	O
selected	O
for	O
all	O
further	O
experiments	O
.	O

The	O
Silencer	O
Negative	O
Control	O
#	O
1	O
siRNA	O
(	O
Applied	O
Biosystems	O
)	O
was	O
used	O
for	O
normalization	O
.	O

Cells	O
were	O
then	O
left	O
unstimulated	O
or	O
were	O
stimulated	O
after	O
12	O
h	O
with	O
anti	O
-	O
CD2	S-PRGE
,	O
anti	O
-	O
CD3	S-PRGE
,	O
and	O
anti	O
-	O
CD28	S-PRGE
.	O

Cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	B-PRGE
-	I-PRGE
V	E-PRGE
medium	O
with	O
the	O
addition	O
of	O
1	O
nmol	O
/	O
l	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
detection	O
of	O
the	O
target	O
genes	O
after	O
24	O
h	O
and	O
for	O
protein	O
detection	O
after	O
48	O
h	O
.	O

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
kit	O
(	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Fermentas	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Real	O
-	O
time	O
PCR	O
.	O

PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	S-PRGE
forward	O
primer	O
,	O
5	O
'	O
-	O
GAAACAGCACATTCCCAGAGTTC	O
-	O
3	O
'	O
;	O
FOXP3	S-PRGE
reverse	O
primer	O
,	O
5	O
'	O
-	O
ATGGCCCAGCGGATGAG	O
-	O
3	O
'	O
;	O
EF	B-PRGE
-	I-PRGE
1a	E-PRGE
forward	O
primer	O
,	O
5	O
'	O
-	O
CTGAACCATCCAGGCCAAAT	O
-	O
3	O
'	O
;	O
and	O
EF	B-PRGE
-	I-PRGE
1a	E-PRGE
reverse	O
primer	O
,	O
5	O
'	O
-	O
GCCGTGTGGCAATCCAAT	O
-	O
3	O
'	O
,	O
as	O
previously	O
described	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

GATA3	S-PRGE
forward	O
primer	O
,	O
5	O
'	O
-	O
GCGGGCTCTATCACAAAATGA	O
-	O
3	O
'	O
;	O
and	O
GATA3	S-PRGE
reverse	O
primer	O
5	O
'	O
-	O
GCTCTCCTGGCTGCAGACAGC	O
-	O
3	O
'	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

T	B-PRGE
-	I-PRGE
bet	E-PRGE
forward	O
primer	O
,	O
5	O
'	O
-	O
GATGCGCCAGGAAGTTTCAT	O
-	O
3	O
'	O
;	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
reverse	O
primer	O
,	O
5	O
'	O
-	O
GCACAATCATCTGGGTCACATT	O
-	O
3	O
'	O
;	O
RORC2	S-PRGE
forward	O
primer	O
,	O
5	O
'	O
-	O
CAGTCATGAGAACACAAATTGAAGTG	O
-	O
3	O
'	O
;	O
and	O
RORC2	S-PRGE
reverse	O
primer	O
5	O
'	O
-	O
CAGGTGATAACCCCGTAGTGGAT	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
green	O
PCR	O
master	O
mix	O
(	O
Fermentas	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
mRNA	O
was	O
detected	O
by	O
using	O
TaqMan	O
Gene	O
Expression	O
Assays	O
from	O
Applied	O
Biosystems	O
and	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
using	O
TaqMan	O
master	O
mix	O
using	O
a	O
7000	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
elongation	B-PRGE
factor	I-PRGE
(	I-PRGE
EF	I-PRGE
)	I-PRGE
-	I-PRGE
1alpha	E-PRGE
or	O
by	O
using	O
the	O
18S	B-PRGE
rRNA	E-PRGE
Gene	O
Expression	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
was	O
performed	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
deltadeltaCT	O
method	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
percentage	O
of	O
FOXP3	S-PRGE
mRNA	O
in	O
siRNA	O
-	O
mediated	O
RUNX	S-PRGE
knockdown	O
cells	O
was	O
calculated	O
in	O
relation	O
to	O
cells	O
,	O
which	O
were	O
transfected	O
with	O
scrambled	O
control	O
siRNA	O
.	O

Arbitrary	O
units	O
show	O
the	O
2	O
-	O
(	O
deltact	O
)	O
values	O
multiplied	O
by	O
10	O
,	O
000	O
incorporating	O
the	O
ct	O
values	O
of	O
the	O
gene	O
of	O
interest	O
and	O
the	O
housekeeping	O
gene	O
.	O

Flow	O
cytometry	O
.	O

For	O
analysis	O
of	O
human	O
FOXP3	S-PRGE
expression	O
on	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
CD4	S-PRGE
mAb	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
they	O
were	O
incubated	O
with	O
anti	O
-	O
human	O
Foxp3	S-PRGE
-	O
Alexa	O
Fluor	O
488	O
antibody	O
(	O
BioLegend	O
)	O
based	O
on	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
;	O
Beckman	O
Coulter	O
)	O
.	O

A	O
mouse	O
IgG1	O
antibody	O
(	O
BioLegend	O
)	O
was	O
used	O
as	O
an	O
isotype	O
control	O
.	O

Data	O
were	O
analyzed	O
with	O
the	O
CXP	O
software	O
(	O
Beckman	O
Coulter	O
)	O
.	O

Cells	O
were	O
cultured	O
with	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
and	O
then	O
left	O
unstimulated	O
or	O
stimulated	O
with	O
anti	O
-	O
CD2	S-PRGE
/	O
-	O
CD3	S-PRGE
/	O
-	O
CD28	S-PRGE
mAb	O
.	O

Flow	O
cytometry	O
analyses	O
of	O
the	O
mouse	O
cells	O
were	O
performed	O
on	O
an	O
LSRII	O
(	O
BD	O
)	O
and	O
cell	O
sorting	O
was	O
performed	O
on	O
a	O
FACSAria	O
(	O
BD	O
)	O
.	O

All	O
antibodies	O
for	O
these	O
experiments	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
.	O

Western	O
blotting	O
.	O

For	O
human	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
analysis	O
on	O
the	O
protein	O
level	O
,	O
106	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
a	O
1	O
:	O
1	O
,	O
000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	S-PRGE
(	O
ab11903	O
;	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	S-PRGE
(	O
H	O
-	O
50	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
in	O
blocking	O
buffer	O
containing	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
overnight	O
at	O
4degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
rabbit	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
-	O
1000	O
gel	O
documentation	O
system	O
(	O
Fujifilm	O
)	O
.	O

To	O
confirm	O
sample	O
loading	O
and	O
transfer	O
membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
reblocked	O
for	O
1	O
h	O
and	O
reprobed	O
using	O
anti	O
-	O
GAPDH	S-PRGE
(	O
6C5	O
;	O
Ambion	O
)	O
and	O
developed	O
using	O
an	O
anti	O
-	O
mouse	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Pull	O
-	O
down	O
assay	O
.	O

HEK293T	O
cells	O
were	O
transfected	O
with	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
using	O
the	O
Lipofectamine	O
2000	O
reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Cells	O
were	O
lysed	O
by	O
sonication	O
in	O
HKMG	O
buffer	O
(	O
10	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
9	O
,	O
100	O
mM	O
KCl	O
,	O
5	O
mM	O
MgCl2	O
,	O
10	O
%	O
glycerol	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
%	O
Nonidet	O
P	O
-	O
40	O
)	O
containing	O
a	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
Diagnostics	O
)	O
.	O

The	O
cell	O
lysate	O
was	O
precleared	O
using	O
streptavidin	O
-	O
agarose	O
beads	O
(	O
GE	O
Healthcare	O
)	O
,	O
incubated	O
with	O
biotinylated	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
RUNX	O
binding	O
sites	O
,	O
and	O
polydeoxyinosinicdeoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

A	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
in	O
the	O
assay	O
.	O

DNA	O
-	O
bound	O
proteins	O
were	O
collected	O
with	O
streptavidin	O
-	O
agarose	O
beads	O
,	O
washed	O
with	O
HKMG	O
buffer	O
,	O
and	O
finally	O
resuspended	O
in	O
NuPAGE	O
loading	O
buffer	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
,	O
heated	O
to	O
70degreesC	O
for	O
10	O
min	O
,	O
and	O
separated	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
and	O
detected	O
using	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
antibodies	O
described	O
in	O
the	O
previous	O
section	O
.	O

Promoter	O
enzyme	O
immuno	O
assay	O
.	O

As	O
performed	O
in	O
the	O
pull	O
-	O
down	O
assay	O
,	O
HEK293T	B-PRGE
cells	E-PRGE
were	O
transfected	O
with	O
RUNX1	S-PRGE
or	O
RUNX3	S-PRGE
and	O
subsequently	O
lysed	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

384	O
-	O
well	O
plates	O
,	O
precoated	O
with	O
streptavidin	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
were	O
washed	O
3	O
times	O
with	O
washing	O
buffer	O
(	O
PBS	O
and	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
.	O

Biotinylated	O
FOXP3	S-PRGE
promoter	O
/	O
oligonucleotides	O
probes	O
containing	O
the	O
RUNX	O
binding	O
sites	O
were	O
added	O
(	O
1	O
pmol	O
per	O
well	O
;	O
50	O
fmol	O
/	O
microl	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Either	O
a	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
or	O
single	O
oligonucleotides	O
were	O
used	O
in	O
the	O
assay	O
.	O

After	O
3	O
washing	O
steps	O
with	O
washing	O
buffer	O
,	O
the	O
nuclear	O
extract	O
was	O
added	O
(	O
concentration	O
>	O
0	O
.	O
2	O
microg	O
/	O
microl	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
microg	O
of	O
poly	O
-	O
deoxyinosinic	O
-	O
deoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

The	O
plate	O
was	O
washed	O
with	O
HKMG	O
buffer	O
and	O
incubated	O
with	O
a	O
1	O
:	O
1000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	S-PRGE
(	O
ab11903	O
,	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	S-PRGE
(	O
H	O
-	O
50	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
at	O
4degreesC	O
for	O
2	O
h	O
.	O

After	O
three	O
washing	O
steps	O
with	O
HKMG	O
buffer	O
,	O
a	O
secondary	O
antibody	O
(	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
,	O
1	O
:	O
3	O
,	O
000	O
in	O
HKMG	O
buffer	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
was	O
added	O
,	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
1	O
h	O
at	O
4degreesC	O
.	O

The	O
wells	O
were	O
washed	O
4	O
times	O
with	O
HKMG	O
buffer	O
before	O
adding	O
the	O
substrate	O
reagent	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

The	O
colorimetric	O
reaction	O
was	O
stopped	O
by	O
adding	O
2	O
M	O
H2SO4	O
.	O

Absorbance	O
at	O
450	O
nm	O
was	O
measured	O
using	O
a	O
microplate	O
reader	O
(	O
Berthold	O
Technologies	O
)	O
.	O

ChIP	O
.	O

Human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
cultured	O
either	O
with	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
only	O
or	O
with	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
,	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
for	O
72	O
h	O
,	O
and	O
protein	O
-	O
DNA	O
complexes	O
were	O
fixed	O
by	O
cross	O
-	O
linking	O
with	O
formaldehyde	O
in	O
a	O
final	O
concentration	O
of	O
1	O
.	O
42	O
%	O
for	O
15	O
min	O
.	O

Formaldehyde	O
was	O
quenched	O
with	O
125	O
mM	O
glycine	O
for	O
5	O
min	O
,	O
and	O
cells	O
were	O
subsequently	O
harvested	O
.	O

The	O
ChIP	O
assay	O
was	O
performed	O
as	O
described	O
in	O
the	O
fast	O
chromatin	O
immunoprecipitation	O
method	O
(	O
Nelson	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Cells	O
were	O
lysed	O
with	O
immunoprecipitation	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
,	O
5	O
mM	O
EDTA	O
,	O
NP	O
-	O
40	O
[	O
0	O
.	O
5	O
%	O
vol	O
/	O
vol	O
]	O
)	O
containing	O
phosphatase	O
(	O
Roche	O
)	O
and	O
protease	O
inhibitors	O
cocktails	O
(	O
Roche	O
)	O
,	O
the	O
nuclear	O
pellet	O
was	O
washed	O
,	O
the	O
chromatin	O
was	O
sheared	O
by	O
sonication	O
and	O
incubated	O
with	O
antibodies	O
for	O
RUNX1	S-PRGE
(	O
H	O
-	O
65	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
RUNX3	S-PRGE
(	O
H	O
-	O
50	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
CBFbeta	S-PRGE
(	O
PEBP2beta	O
;	O
FL	O
-	O
182	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
and	O
as	O
controls	O
normal	O
rabbit	O
IgG	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
anti	O
-	O
human	O
RNA	B-PRGE
polymerase	I-PRGE
II	E-PRGE
antibody	O
,	O
and	O
mouse	O
control	O
IgG	O
(	O
both	O
from	O
SA	O
Biosciences	O
)	O
.	O

The	O
cleared	O
chromatin	O
was	O
incubated	O
with	O
protein	B-PRGE
A	E-PRGE
agarose	O
beads	O
and	O
,	O
after	O
several	O
washing	O
steps	O
,	O
DNA	O
was	O
isolated	O
with	O
10	O
%	O
(	O
wt	O
/	O
vol	O
)	O
Chelex	O
100	O
resin	O
.	O

Samples	O
were	O
treated	O
with	O
proteinase	B-PRGE
K	E-PRGE
at	O
55degreesC	O
for	O
30	O
min	O
.	O

The	O
proteinase	B-PRGE
K	E-PRGE
was	O
then	O
inactivated	O
by	O
boiling	O
the	O
samples	O
for	O
10	O
min	O
.	O

The	O
purified	O
DNA	O
was	O
used	O
in	O
a	O
real	O
-	O
time	O
PCR	O
reaction	O
.	O

Specific	O
primers	O
for	O
the	O
FOXP3	S-PRGE
promoter	O
,	O
spanning	O
the	O
region	O
from	O
-	O
87	O
to	O
-	O
3	O
,	O
FOXP3	S-PRGE
promoter	O
forward	O
primer	O
5	O
'	O
-	O
AGAGGTCTGCGGCTTCCA	O
-	O
3	O
'	O
,	O
FOXP3	S-PRGE
promoter	O
reverse	O
primer	O
5	O
'	O
-	O
GGAAACTGTCACGTATCAAAAACAA	O
-	O
3	O
'	O
,	O
or	O
control	O
GAPDH	S-PRGE
primer	O
(	O
SA	O
Biosciences	O
)	O
for	O
the	O
RNA	B-PRGE
polymerase	I-PRGE
II	E-PRGE
were	O
used	O
.	O

A	O
negative	O
control	O
PCR	O
for	O
each	O
immunoprecipitation	O
using	O
IGX1A	O
negative	O
control	O
primer	O
targeting	O
ORF	O
-	O
free	O
intergenic	O
DNA	O
(	O
SA	O
Biosciences	O
)	O
was	O
used	O
.	O

The	O
fold	O
enrichment	O
in	O
site	O
occupancy	O
was	O
calculated	O
incorporating	O
IgG	O
control	O
values	O
and	O
input	O
DNA	O
values	O
using	O
the	O
ChampionChIP	O
qPCR	O
data	O
analysis	O
file	O
(	O
SA	O
Biosciences	O
)	O
.	O

Quantification	O
of	O
cytokine	O
levels	O
.	O

IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
17	E-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
secretion	O
was	O
assessed	O
using	O
fluorescent	O
bead	O
-	O
based	O
technology	O
.	O

The	O
Bio	O
-	O
Plex	O
-	O
hu	O
Cytokine	O
Panel	O
,	O
17	O
-	O
Plex	O
Group	O
1	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Fluorescent	O
signals	O
were	O
read	O
and	O
analyzed	O
using	O
the	O
Bio	O
-	O
Plex	O
200	O
System	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Online	O
supplemental	O
material	O
.	O

Fig	O
.	O

S1	O
shows	O
the	O
induction	O
of	O
RUNX1	S-PRGE
,	O
RUNX3	S-PRGE
,	O
and	O
FOXP3	S-PRGE
mRNA	O
in	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
after	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAb	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
stimulation	O
.	O

Fig	O
.	O

S2	O
shows	O
decreased	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
mRNA	O
and	O
protein	O
expression	O
after	O
siRNA	O
-	O
mediated	O
knockdown	O
and	O
decreased	O
FOXP3	S-PRGE
expression	O
in	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
after	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
knockdown	O
.	O

Fig	O
.	O

S3	O
shows	O
the	O
quantification	O
of	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	E-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
levels	O
in	O
control	O
siRNA	O
transfected	O
or	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
transfected	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

Fig	O
.	O

S4	O
shows	O
the	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
core	O
promoter	O
sequence	O
of	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
.	O

Fig	O
.	O

S5	O
shows	O
the	O
induction	O
of	O
FOXP3	S-PRGE
protein	O
after	O
overexpression	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
in	O
human	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

Fig	O
.	O

S6	O
shows	O
that	O
endogenous	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
do	O
not	O
effect	O
Foxp3	S-PRGE
expression	O
in	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
of	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
CbfbF	S-PRGE
/	O
F	O
control	O
mice	O
,	O
which	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
and	O
anti	O
-	O
CD28	S-PRGE
mAbs	O
,	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
in	O
the	O
absence	O
or	O
presence	O
of	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
4	E-PRGE
and	O
anti	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
neutralizing	O
mAbs	O
.	O

Fig	O
.	O

S7	O
shows	O
similar	O
cell	O
death	O
(	O
A	O
)	O
and	O
proliferation	O
(	O
B	O
)	O
of	O
Foxp3	S-PRGE
+	O
and	O
Foxp3	S-PRGE
-	O
cells	O
in	O
CbfbF	S-PRGE
/	O
F	O
CD4	S-PRGE
-	O
cre	S-PRGE
and	O
CbfbF	S-PRGE
/	O
F	O
control	O
mice	O
cultures	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20090596	O
/	O
DC1	O
.	O

RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
are	O
involved	O
in	O
the	O
induction	O
of	O
Foxp3	S-PRGE
in	O
iT	O
reg	O
cells	O
.	O

(	O
A	O
)	O
RUNX1	S-PRGE
,	O
RUNX3	S-PRGE
,	O
and	O
FOXP3	S-PRGE
mRNA	O
induction	O
in	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
after	O
alone	O
or	O
combined	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAb	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
stimulation	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
.	O

Real	O
-	O
time	O
PCR	O
of	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
after	O
48	O
h	O
of	O
culture	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
FOXP3	S-PRGE
mRNA	O
induction	O
by	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
mAb	O
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
in	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
is	O
reduced	O
after	O
siRNA	O
-	O
mediated	O
RUNX1	S-PRGE
/	O
3	S-PRGE
knockdown	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
RNA	O
from	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	S-PRGE
and	O
/	O
or	O
RUNX3	S-PRGE
siRNA	O
or	O
with	O
a	O
control	O
siRNA	O
and	O
cultured	O
with	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
FOXP3	S-PRGE
mRNA	O
is	O
down	O
-	O
regulated	O
in	O
iT	O
reg	O
cells	O
after	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
.	O

Real	O
-	O
time	O
PCR	O
for	O
FOXP3	S-PRGE
,	O
T	B-PRGE
-	I-PRGE
bet	E-PRGE
,	O
GATA3	S-PRGE
,	O
and	O
RORC2	S-PRGE
from	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
or	O
with	O
scrambled	O
siRNA	O
(	O
control	O
)	O
and	O
cultured	O
under	O
iT	B-PRGE
reg	E-PRGE
,	O
Th1	O
,	O
Th2	O
,	O
or	O
Th17	S-PRGE
-	O
driving	O
conditions	O
for	O
12	O
d	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
FOXP3	S-PRGE
protein	O
induction	O
in	O
iT	O
reg	O
cells	O
is	O
reduced	O
after	O
siRNA	O
-	O
mediated	O
RUNX1	S-PRGE
/	O
3	S-PRGE
knockdown	O
.	O

Human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
were	O
transfected	O
with	O
RUNX1	S-PRGE
and	O
/	O
or	O
RUNX3	S-PRGE
siRNA	O
or	O
with	O
a	O
control	O
siRNA	O
and	O
stimulated	O
with	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
.	O

CD4	S-PRGE
and	O
intracellular	O
FOXP3	S-PRGE
analysis	O
by	O
flow	O
cytometry	O
after	O
72	O
h	O
.	O

One	O
of	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
P	O
<	O
0	O
.	O
01	O
.	O

RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
expression	O
in	O
Foxp3	S-PRGE
+	O
T	O
reg	O
cells	O
and	O
in	O
human	O
CD4	S-PRGE
+	O
,	O
CD127	S-PRGE
-	O
,	O
CD25high	S-PRGE
cells	O
.	O

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
analysis	O
of	O
CD4	S-PRGE
+	O
,	O
CD127	S-PRGE
-	O
,	O
and	O
CD25high	S-PRGE
T	O
reg	O
cells	O
and	O
CD4	S-PRGE
+	O
,	O
CD127	S-PRGE
+	O
,	O
and	O
CD25neg	S-PRGE
T	O
cells	O
isolated	O
from	O
human	O
peripheral	O
blood	O
showed	O
an	O
increased	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
10	E-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
,	O
FOXP3	S-PRGE
,	O
and	O
RUNX3	S-PRGE
mRNA	O
in	O
CD25	S-PRGE
+	O
compared	O
with	O
CD25	S-PRGE
-	O
cells	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
tonsil	O
sections	O
were	O
analyzed	O
by	O
confocal	O
microscopy	O
.	O

Tissue	O
sections	O
were	O
stained	O
for	O
FOXP3	S-PRGE
,	O
RUNX1	S-PRGE
,	O
RUNX3	S-PRGE
,	O
and	O
DAPI	O
or	O
isotype	O
controls	O
.	O

HEK	B-PRGE
cells	E-PRGE
RUNX1	S-PRGE
-	O
transfected	O
or	O
not	O
transfected	O
served	O
as	O
additional	O
control	O
for	O
RUNX1	S-PRGE
staining	O
.	O

Data	O
shown	O
are	O
representative	O
from	O
one	O
of	O
the	O
three	O
tissue	O
samples	O
with	O
similar	O
results	O
.	O

Bars	O
,	O
5	O
microm	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
P	O
<	O
0	O
.	O
01	O
.	O

Binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
proteins	O
to	O
the	O
predicted	O
binding	O
sites	O
in	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

(	O
A	O
)	O
Mutated	O
and	O
wild	O
-	O
type	O
oligonucleotides	O
are	O
shown	O
.	O

The	O
predicted	O
RUNX	O
binding	O
sites	O
are	O
accentuated	O
(	O
boxed	O
and	O
in	O
green	O
letters	O
)	O
and	O
stars	O
mark	O
mutations	O
introduced	O
into	O
the	O
binding	O
site	O
of	O
the	O
control	O
oligonucleotides	O
.	O

Nuclear	O
extracts	O
from	O
HEK293T	O
cells	O
were	O
incubated	O
with	O
biotinylated	O
oligonucleotides	O
.	O

The	O
precipitated	O
oligonucleotide	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
identified	O
by	O
Western	O
blotting	O
with	O
anti	O
-	O
RUNX1	S-PRGE
and	O
anti	O
-	O
RUNX3	S-PRGE
antibodies	O
.	O

A	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
with	O
the	O
predicted	O
binding	O
sites	O
or	O
with	O
the	O
inserted	O
mutation	O
into	O
the	O
predicted	O
sites	O
was	O
used	O
.	O

Data	O
shown	O
are	O
one	O
representative	O
of	O
three	O
independent	O
experiments	O
with	O
similar	O
results	O
.	O

(	O
B	O
)	O
Promoter	O
enzyme	O
immunoassay	O
using	O
wild	O
-	O
type	O
and	O
mutated	O
oligonucleotides	O
within	O
the	O
FOXP3	S-PRGE
promoter	O
.	O

Bars	O
show	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Chromatin	O
immunoprecipitation	O
assay	O
results	O
show	O
binding	O
of	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
complexes	O
containing	O
CBFbeta	S-PRGE
to	O
the	O
human	O
FOXP3	S-PRGE
promoter	O
in	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
together	O
with	O
anti	O
-	O
CD2	S-PRGE
/	O
3	S-PRGE
/	O
28	S-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

There	O
was	O
no	O
change	O
in	O
site	O
occupancy	O
in	O
all	O
immunoprecipitations	O
when	O
IGX1A	O
negative	O
control	O
primers	O
were	O
used	O
.	O

The	O
results	O
are	O
normalized	O
to	O
input	O
and	O
isotype	O
control	O
antibody	O
.	O

Bars	O
show	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O

Regulation	O
of	O
FOXP3	S-PRGE
promoter	O
activity	O
by	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
.	O

(	O
A	O
)	O
Human	O
primary	O
CD4	S-PRGE
+	O
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
FOXP3	S-PRGE
promoter	O
region	O
(	O
FOXP3	S-PRGE
-	O
511	O
/	O
+	O
176	O
)	O
fused	O
to	O
the	O
luciferase	S-PRGE
reporter	O
gene	O
together	O
with	O
a	O
GFP	S-PRGE
,	O
RUNX1	S-PRGE
,	O
or	O
RUNX3	S-PRGE
expression	O
vector	O
.	O

Bars	O
show	O
the	O
mean	O
luciferase	S-PRGE
activity	O
+	O
/	O
-	O
SE	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
primary	O
CD4	S-PRGE
+	O
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	S-PRGE
promoter	O
region	O
(	O
FOXP3	S-PRGE
-	O
511	O
/	O
+	O
176	O
)	O
fused	O
to	O
the	O
luciferase	S-PRGE
reporter	O
gene	O
,	O
or	O
with	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	S-PRGE
promoter	O
region	O
(	O
FOXP3	O
-	O
511	O
/	O
+	O
176	O
)	O
with	O
single	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
or	O
with	O
the	O
combination	O
of	O
two	O
or	O
three	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
fused	O
to	O
the	O
luciferase	S-PRGE
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
luciferase	S-PRGE
activity	O
+	O
/	O
-	O
SD	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

Diminished	O
capacity	O
of	O
Cbfb	S-PRGE
-	O
deficient	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
T	O
cells	O
in	O
the	O
generation	O
of	O
Foxp3	S-PRGE
+	O
CD4	S-PRGE
+	O
T	O
cells	O
.	O

(	O
A	O
)	O
FACS	O
-	O
purified	O
naive	O
CD4	S-PRGE
+	O
CD8	S-PRGE
-	O
T	O
cells	O
from	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
control	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
mAb	O
,	O
50	O
U	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
+	O
/	O
-	O
10	O
nM	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
+	O
ionomycin	O
,	O
and	O
then	O
analyzed	O
for	O
intracellular	O
Foxp3	S-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	E-PRGE
expression	O
.	O

One	O
of	O
five	O
experiments	O
is	O
shown	O
.	O

(	O
B	O
)	O
Naive	O
CD4	S-PRGE
+	O
T	O
cells	O
from	O
Cbfb	S-PRGE
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3	S-PRGE
-	O
IRES	O
-	O
GFP	S-PRGE
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	S-PRGE
-	O
deficient	O
mice	O
(	O
5	O
x	O
106	O
cells	O
per	O
transfer	O
)	O
.	O

6	O
wk	O
later	O
,	O
TCRbeta	S-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
(	O
LP	O
)	O
were	O
analyzed	O
for	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
expression	O
.	O

Results	O
from	O
one	O
of	O
four	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
and	O
control	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
with	O
same	O
findings	O
are	O
shown	O
.	O

The	O
data	O
from	O
four	O
sets	O
of	O
mice	O
is	O
shown	O
in	O
C	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
between	O
groups	O
.	O

CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mouse	O
cells	O
and	O
iT	O
reg	O
cells	O
generated	O
from	O
human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
undergoing	O
siRNA	O
-	O
mediated	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
knock	O
down	O
show	O
a	O
diminished	O
suppressive	O
activity	O
.	O

Experimental	O
setup	O
(	O
A	O
)	O
and	O
results	O
of	O
the	O
mouse	O
suppression	O
assay	O
(	O
B	O
)	O
,	O
FACS	O
-	O
purified	O
naive	O
CD4	S-PRGE
+	O
8	S-PRGE
-	O
T	O
cells	O
from	O
CbfbF	S-PRGE
/	O
F	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
(	O
left	O
)	O
and	O
control	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
mice	O
(	O
Cd45	B-PRGE
.	I-PRGE
2	E-PRGE
;	O
right	O
)	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	S-PRGE
/	O
28	S-PRGE
mAb	O
,	O
50	O
U	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
2	E-PRGE
,	O
and	O
2	O
.	O
5	O
ng	O
/	O
ml	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
.	O

After	O
3	O
d	O
,	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
+	O
cells	O
were	O
FACS	O
-	O
sorted	O
and	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

These	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
anti	O
-	O
CD3	S-PRGE
mAb	O
.	O

After	O
a	O
further	O
4	O
d	O
,	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

(	O
C	O
)	O
As	O
a	O
control	O
,	O
CbfbF	S-PRGE
/	O
+	O
CD4	B-PRGE
-	I-PRGE
cre	E-PRGE
CD4	S-PRGE
+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	E-PRGE
were	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

Four	O
days	O
later	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

The	O
median	O
division	O
number	O
(	O
of	O
the	O
naive	O
CD45	B-PRGE
.	I-PRGE
1	E-PRGE
+	O
CD4	S-PRGE
+	O
cells	O
in	O
the	O
cultures	O
containing	O
Foxp3	B-PRGE
-	I-PRGE
GFP	E-PRGE
+	O
cells	O
)	O
is	O
indicated	O
in	O
each	O
of	O
the	O
histograms	O
.	O

One	O
of	O
three	O
experiments	O
is	O
shown	O
.	O

(	O
D	O
)	O
Human	O
naive	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	S-PRGE
and	O
RUNX3	S-PRGE
siRNA	O
and	O
cultured	O
under	O
iT	O
reg	O
differentiating	O
conditions	O
were	O
used	O
in	O
an	O
in	O
vitro	O
suppression	O
assay	O
,	O
cultured	O
together	O
with	O
autologous	O
CFSE	O
-	O
labeled	O
CD4	S-PRGE
+	O
T	O
cells	O
,	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	S-PRGE
mAb	O
.	O

The	O
CFSE	O
dilution	O
of	O
the	O
CD4	S-PRGE
+	O
T	O
cell	O
responder	O
cells	O
was	O
analyzed	O
after	O
5	O
d	O
by	O
flow	O
cytometry	O
.	O

The	O
T	O
reg	O
/	O
responder	O
CD4	S-PRGE
+	O
T	O
cell	O
ratios	O
used	O
were	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O

One	O
of	O
two	O
experiments	O
is	O
shown	O
.	O

IKKbeta	S-PRGE
phosphorylation	O
regulates	O
RPS3	S-PRGE
nuclear	O
translocation	O
and	O
NF	O
-	O
kappaB	O
function	O
duringEscherichia	O
coliO157	O
:	O
H7	O
infection	O

NF	O
-	O
kappaB	O
is	O
a	O
major	O
gene	O
regulator	O
in	O
immune	O
responses	O
and	O
ribosomal	B-PRGE
protein	I-PRGE
S3	E-PRGE
(	O
RPS3	S-PRGE
)	O
is	O
an	O
NF	O
-	O
kappaB	O
subunit	O
that	O
directs	O
specific	O
gene	O
transcription	O
.	O

However	O
,	O
it	O
is	O
unknown	O
how	O
RPS3	S-PRGE
nuclear	O
translocation	O
is	O
regulated	O
.	O

Here	O
we	O
report	O
that	O
IKKbeta	S-PRGE
phosphorylation	O
of	O
serine	O
209	O
(	O
S209	O
)	O
was	O
crucial	O
for	O
RPS3	S-PRGE
nuclear	O
localization	O
in	O
response	O
to	O
activating	O
stimuli	O
.	O

Moreover	O
,	O
the	O
foodborne	O
pathogen	O
Escherichia	O
coli	O
O157	O
:	O
H7	O
virulence	O
protein	O
NleH1	S-PRGE
specifically	O
inhibited	O
RPS3	S-PRGE
S209	O
phosphorylation	O
and	O
blocked	O
RPS3	S-PRGE
function	O
,	O
thereby	O
promoting	O
bacterial	O
colonization	O
and	O
diarrhea	O
but	O
decreasing	O
mortality	O
in	O
a	O
gnotobiotic	O
piglet	O
infection	O
model	O
.	O

Thus	O
,	O
the	O
IKKbeta	S-PRGE
-	O
dependent	O
modification	O
of	O
a	O
specific	O
amino	O
acid	O
in	O
RPS3	S-PRGE
promotes	O
specific	O
NF	O
-	O
kappaB	O
functions	O
that	O
underlie	O
the	O
molecular	O
pathogenetic	O
mechanisms	O
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

Nuclear	O
Factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
regulates	O
crucial	O
cellular	O
functions	O
and	O
diverse	O
stimuli	O
activate	O
this	O
pleiotropic	O
transcription	O
factor	O
,	O
which	O
in	O
turn	O
regulates	O
a	O
vast	O
array	O
of	O
genetic	O
targets1	O
-	O
3	O
.	O

The	O
best	O
-	O
known	O
mammalian	O
NF	O
-	O
kappaB	O
subunits	O
are	O
Rel	O
proteins	O
,	O
including	O
RelA	S-PRGE
(	O
p65	S-PRGE
)	O
,	O
RelB	S-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	E-PRGE
,	O
p50	S-PRGE
,	O
and	O
p52	S-PRGE
(	O
refs	O
.	O
4	O
,	O
5	O
)	O
.	O

However	O
,	O
we	O
recently	O
demonstrated	O
that	O
ribosomal	B-PRGE
protein	I-PRGE
S3	E-PRGE
(	O
RPS3	S-PRGE
)	O
is	O
a	O
key	O
non	O
-	O
Rel	S-PRGE
subunit	O
of	O
certain	O
native	O
NF	O
-	O
kappaB	O
complexes6	O
.	O

RPS3	S-PRGE
is	O
defined	O
as	O
a	O
"	O
specifier	O
"	O
subunit	O
of	O
NF	O
-	O
kappaB	O
,	O
because	O
it	O
facilitates	O
high	O
affinity	O
DNA	O
binding	O
thus	O
determining	O
the	O
regulatory	O
specificity	O
of	O
NF	O
-	O
kappaB	O
for	O
selected	O
target	O
genes7	O
.	O

RPS3	S-PRGE
regulation	O
of	O
NF	O
-	O
kappaB	O
governs	O
key	O
physiological	O
processes	O
,	O
including	O
immunoglobulin	B-PRGE
kappa	I-PRGE
light	I-PRGE
chain	E-PRGE
gene	O
expression	O
and	O
receptor	O
editing	O
in	O
B	O
cells6	O
,	O
8	O
,	O
cytokine	O
production	O
in	O
T	O
cells6	O
,	O
and	O
in	O
host	O
defense	O
against	O
enterohemorrhagicEscherichia	O
coli	O
(	O
EHEC	O
)	O
9	O
.	O

In	O
particular	O
,	O
theE	O
.	O

coliO157	O
:	O
H7	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
effector	O
protein	O
NleH1	S-PRGE
selectively	O
blocks	O
NF	O
-	O
kappaB	O
target	O
gene	O
transcription	O
by	O
attenuating	O
RPS3	S-PRGE
nuclear	O
translocation	O
,	O
without	O
affecting	O
p65	S-PRGE
localization9	O
.	O

Nonetheless	O
,	O
how	O
specific	O
NF	O
-	O
kappaB	O
activating	O
signals	O
induce	O
RPS3	S-PRGE
nuclear	O
translocation	O
is	O
unknown	O
.	O
Extra	O
-	O
ribosomal	O
functions	O
have	O
been	O
ascribed	O
to	O
ribosomal	O
proteins10	O
.	O

Besides	O
binding	O
RNA	O
within	O
the	O
40S	O
ribosomal	O
subunit	O
,	O
RPS3	S-PRGE
participates	O
in	O
transcription6	O
,	O
DNA	O
repair11	O
,	O
12	O
,	O
and	O
apoptosis13	O
.	O

Whether	O
or	O
not	O
RPS3	S-PRGE
is	O
phosphorylated	O
had	O
been	O
controversial14	O
-	O
18	O
.	O

Since	O
kinase	O
cascades	O
play	O
a	O
critical	O
role	O
in	O
NF	O
-	O
kappaB	O
regulation	O
,	O
we	O
tested	O
whether	O
RPS3	S-PRGE
is	O
phosphorylated	O
in	O
the	O
context	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
sought	O
to	O
identify	O
the	O
responsible	O
kinase19	O
.	O

Additionally	O
,	O
we	O
aimed	O
to	O
define	O
a	O
regulatory	O
role	O
for	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
RPS3	S-PRGE
whose	O
function	O
was	O
unknown	O
.	O
Here	O
we	O
show	O
that	O
the	O
Inhibitor	B-PRGE
of	I-PRGE
kappaB	I-PRGE
(	I-PRGE
IkappaB	I-PRGE
)	I-PRGE
kinase	I-PRGE
beta	E-PRGE
(	O
IKKbeta	S-PRGE
)	O
phosphorylated	O
RPS3	S-PRGE
at	O
serine	O
209	O
(	O
S209	O
)	O
.	O

RPS3	S-PRGE
S209	O
phosphorylation	O
enhanced	O
its	O
association	O
with	O
importin	O
-	O
alpha	O
,	O
mediating	O
RPS3	S-PRGE
entry	O
into	O
the	O
karyopherin	O
pathway	O
for	O
nuclear	O
translocation	O
.	O

Furthermore	O
,	O
theE	O
.	O

coliNleH1	S-PRGE
effector	O
specifically	O
inhibited	O
RPS3	S-PRGE
S209	O
revealing	O
howE	O
.	O

coliO157	O
:	O
H7	O
inhibits	O
this	O
important	O
innate	O
immune	O
response	O
mechanism	O
.	O

RPS3	S-PRGE
phosphorylation	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
activation	O

To	O
test	O
whether	O
RPS3	S-PRGE
is	O
phosphorylated	O
during	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
performed	O
32P	O
-	O
labeling	O
experiments	O
in	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
stimulated	O
HEK	O
293T	O
cells	O
.	O

While	O
RPS3	S-PRGE
was	O
scarcely	O
phosphorylated	O
in	O
unstimulated	O
cells	O
,	O
we	O
observed	O
a	O
marked	O
increase	O
in	O
32P	O
-	O
incorporation	O
after	O
TNF	O
stimulation	O
despite	O
no	O
increase	O
in	O
RPS3	S-PRGE
protein	O
(	O
Fig	O
.	O
1a	O
)	O
.	O

To	O
determine	O
which	O
RPS3	S-PRGE
residues	O
were	O
phosphorylated	O
,	O
we	O
immunoprecipitated	O
RPS3	S-PRGE
from	O
either	O
resting	O
or	O
stimulated	O
cells	O
and	O
performed	O
immunoblotting	O
with	O
phosphorylation	O
-	O
specific	O
antibodies	O
.	O

Both	O
TNF	O
and	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
(	O
PMA	O
+	O
I	O
)	O
stimulated	O
rapid	O
phosphorylation	O
and	O
degradaion	O
of	O
IkappaBalpha	S-PRGE
within	O
5	O
min	O
which	O
was	O
accompanied	O
by	O
RPS3	S-PRGE
phosphorylation	O
on	O
serine	O
residues	O
(	O
Fig	O
.	O
1b	O
and	O
data	O
not	O
shown	O
)	O
,	O
similar	O
to	O
the	O
in	O
vivo	O
labeling	O
.	O

We	O
did	O
not	O
detect	O
tyrosine	O
-	O
or	O
threonine	O
-	O
phosphorylation	O
of	O
RPS3	S-PRGE
(	O
Fig	O
.	O
1b	O
)	O
.	O

RPS3	S-PRGE
and	O
IKKbeta	S-PRGE
interaction	O

The	O
activation	O
of	O
the	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
,	O
consisting	O
of	O
a	O
regulatory	O
subunit	O
IKKgamma	S-PRGE
and	O
two	O
catalytic	O
subunits	O
,	O
IKKalpha	S-PRGE
and	O
IKKbeta	S-PRGE
,	O
is	O
critical	O
for	O
the	O
phosphorylation	O
and	O
dispatch	O
of	O
the	O
inhibitory	O
IkappaBs	O
and	O
the	O
liberation	O
of	O
NF	O
-	O
kappaB20	O
-	O
22	O
.	O

Given	O
that	O
RPS3	S-PRGE
can	O
be	O
found	O
in	O
the	O
cytoplasmic	O
p65	S-PRGE
-	O
p50	S-PRGE
-	O
IkappaBalpha	S-PRGE
inhibitory	O
complex	O
in	O
resting	O
cells6	O
,	O
we	O
hypothesized	O
that	O
activated	O
IKKbeta	S-PRGE
might	O
also	O
bind	O
to	O
and	O
phosphorylate	O
RPS3	S-PRGE
.	O

First	O
,	O
we	O
found	O
that	O
ectopically	O
expressed	O
IKKbeta	S-PRGE
and	O
RPS3	S-PRGE
interacted	O
(	O
Fig	O
.	O
1c	O
)	O
.	O

We	O
next	O
examined	O
resting	O
Jurkat	O
cells	O
and	O
detected	O
a	O
modest	O
endogenous	O
IKKbeta	S-PRGE
-	O
RPS3	S-PRGE
interaction	O
(	O
Fig	O
.	O
1d	O
)	O
,	O
potentially	O
accounting	O
for	O
the	O
basal	O
NF	O
-	O
kappaB	O
transcription	O
required	O
for	O
cell	O
proliferation	O
and	O
survival	O
.	O

RPS3	S-PRGE
-	O
IKKbeta	S-PRGE
association	O
was	O
clearly	O
augmented	O
upon	O
TNF	O
stimulation	O
,	O
peaking	O
at	O
10	O
min	O
.	O

(	O
Fig	O
.	O
1d	O
)	O
,	O
following	O
similar	O
kinetics	O
to	O
RPS3	S-PRGE
serine	O
phosphorylation	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

By	O
contrast	O
,	O
there	O
was	O
no	O
detectable	O
interaction	O
between	O
RPS3	S-PRGE
and	O
IKKalpha	S-PRGE
(	O
Fig	O
.	O
1d	O
)	O
.	O

IKKbeta	S-PRGE
is	O
required	O
for	O
RPS3	S-PRGE
nuclear	O
translocation	O

To	O
examine	O
whether	O
the	O
RPS3	S-PRGE
-	O
IKKbeta	S-PRGE
interaction	O
is	O
required	O
for	O
RPS3	S-PRGE
nuclear	O
translocation	O
,	O
we	O
knocked	O
down	O
IKKalpha	S-PRGE
or	O
IKKbeta	S-PRGE
expression	O
with	O
siRNAs	O
(	O
Supplementary	O
Fig	O
.	O
1	O
)	O
and	O
then	O
observed	O
stimulation	O
-	O
induced	O
RPS3	S-PRGE
nuclear	O
migration	O
by	O
confocal	O
microscopy	O
.	O

Both	O
TNF	O
and	O
PMA	O
+	O
I	O
triggered	O
RPS3	S-PRGE
nuclear	O
translocation	O
in	O
Jurkat	O
cells	O
transfected	O
with	O
a	O
scrambled	O
nonspecific	O
(	O
NS	O
)	O
siRNA	O
(	O
Fig	O
.	O
2a	O
)	O
6	O
.	O

RPS3	S-PRGE
nuclear	O
translocation	O
was	O
only	O
slightly	O
,	O
if	O
at	O
all	O
,	O
impaired	O
by	O
IKKalpha	S-PRGE
-	O
silencing	O
.	O

Conversely	O
,	O
knockdown	O
of	O
IKKbeta	S-PRGE
attenuated	O
60	O
-	O
70	O
%	O
of	O
RPS3	S-PRGE
nuclear	O
accumulation	O
following	O
stimulation	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

Immunoblotting	O
of	O
nuclear	O
fractions	O
confirmed	O
that	O
full	O
expression	O
of	O
IKKbeta	S-PRGE
,	O
but	O
not	O
IKKalpha	S-PRGE
,	O
was	O
necessary	O
for	O
activation	O
-	O
induced	O
RPS3	S-PRGE
nuclear	O
translocation	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

Control	O
immunoblots	O
revealed	O
that	O
p65	S-PRGE
nuclear	O
translocation	O
was	O
blocked	O
under	O
the	O
same	O
conditions	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

We	O
next	O
examined	O
the	O
nuclear	O
translocation	O
of	O
RPS3	S-PRGE
in	O
cells	O
ectopically	O
expressing	O
either	O
kinase	O
-	O
dead	O
(	O
SSAA	O
)	O
or	O
constitutively	O
-	O
active	O
(	O
SSEE	O
)	O
mutant	O
IKKbeta	S-PRGE
proteins	O
.	O

As	O
expected	O
,	O
the	O
SSEE	O
,	O
but	O
not	O
SSAA	O
,	O
mutant	O
of	O
IKKbeta	S-PRGE
induced	O
NF	O
-	O
kappaB	O
-	O
dependent	O
luciferase	S-PRGE
reporter	O
activity	O
(	O
Fig	O
.	O
2c	O
,	O
left	O
)	O
.	O

Whereas	O
RPS3	S-PRGE
remained	O
cytosolic	O
in	O
IKKbeta	S-PRGE
(	O
SSAA	O
)	O
-	O
expressing	O
cells	O
(	O
Fig	O
.	O
2c	O
,	O
right	O
)	O
,	O
a	O
substantial	O
proportion	O
of	O
RPS3	S-PRGE
translocated	O
to	O
the	O
nucleus	O
in	O
cells	O
expressing	O
IKKbeta	S-PRGE
(	O
SSEE	O
)	O
(	O
Fig	O
.	O
2c	O
,	O
right	O
)	O
.	O

The	O
percentage	O
of	O
cells	O
containing	O
detectable	O
nuclear	O
RPS3	S-PRGE
increased	O
5	O
-	O
fold	O
in	O
IKKbeta	S-PRGE
(	O
SSEE	O
)	O
-	O
expressing	O
cells	O
,	O
but	O
not	O
in	O
IKKbeta	S-PRGE
(	O
SSAA	O
)	O
-	O
expressing	O
ones	O
(	O
Fig	O
.	O
2d	O
and	O
Supplementary	O
Fig	O
.	O
2	O
)	O
.	O

Thus	O
,	O
IKKbeta	S-PRGE
activity	O
is	O
necessary	O
and	O
sufficient	O
for	O
RPS3	S-PRGE
nuclear	O
translocation	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
activating	O
stimuli	O
.	O

IkappaBalpha	S-PRGE
degradation	O
and	O
RPS3	S-PRGE
nuclear	O
translocation	O

Importin	O
-	O
alpha	O
regulates	O
the	O
nuclear	O
import	O
of	O
NF	O
-	O
kappaB	O
Rel	S-PRGE
subunits23	O
,	O
24	O
.	O

RPS3	S-PRGE
harbors	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
sequence	O
and	O
its	O
nuclear	O
translocation	O
occurs	O
in	O
parallel	O
to	O
,	O
but	O
independently	O
of	O
,	O
p65	S-PRGE
translocation6	O
.	O

We	O
envisioned	O
that	O
RPS3	S-PRGE
could	O
also	O
utilize	O
the	O
importin	O
-	O
alpha	O
/	O
beta	O
pathway	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
RPS3	S-PRGE
association	O
with	O
importin	O
-	O
alpha	O
,	O
but	O
not	O
importin	O
-	O
beta	O
,	O
was	O
enhanced	O
in	O
TNF	O
-	O
stimulated	O
cells	O
(	O
Fig	O
.	O
3a	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
RPS3	S-PRGE
binding	O
to	O
importin	O
-	O
alpha	O
is	O
essential	O
for	O
nuclear	O
translocation	O
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

Since	O
IkappaBalpha	S-PRGE
degradation	O
is	O
a	O
prerequisite	O
to	O
unmask	O
the	O
NLS	O
of	O
p65	S-PRGE
,	O
and	O
both	O
RPS3	S-PRGE
and	O
IkappaBalpha	S-PRGE
bind	O
to	O
p65	S-PRGE
in	O
the	O
cytoplasmic	O
inhibitory	O
complex	O
,	O
we	O
tested	O
whether	O
IkappaBalpha	S-PRGE
degradation	O
is	O
required	O
for	O
the	O
liberation	O
of	O
RPS3	S-PRGE
.	O

We	O
measured	O
the	O
association	O
of	O
RPS3	S-PRGE
with	O
importin	O
-	O
alpha	O
in	O
293T	O
cells	O
overexpressing	O
wild	O
-	O
type	O
IkappaBalpha	S-PRGE
or	O
an	O
IkappaBalpha	S-PRGE
mutant	O
(	O
SSAA	O
)	O
resistant	O
to	O
IKKbeta	S-PRGE
-	O
induced	O
phosphorylation	O
and	O
degradation	O
.	O

In	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
IkappaBalpha	S-PRGE
,	O
TNF	O
stimulation	O
augmented	O
the	O
interaction	O
of	O
RPS3	S-PRGE
and	O
importin	O
-	O
alpha	O
to	O
a	O
similar	O
degree	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
.	O

By	O
contrast	O
,	O
we	O
observed	O
that	O
the	O
RPS3	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
was	O
abolished	O
by	O
the	O
presence	O
of	O
non	O
-	O
degradable	O
IkappaBalpha	S-PRGE
(	O
Fig	O
.	O
3b	O
)	O
.	O

To	O
examine	O
whether	O
IkappaBalpha	S-PRGE
is	O
the	O
only	O
cytoplasmic	O
barrier	O
precluding	O
RPS3	S-PRGE
nuclear	O
translocation	O
,	O
we	O
measured	O
both	O
RPS3	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
and	O
nuclear	O
RPS3	S-PRGE
after	O
reducing	O
IkappaBalpha	S-PRGE
expression	O
.	O

Compared	O
with	O
nonspecific	O
siRNA	O
,	O
siRNA	S-PRGE
targeting	O
of	O
IkappaBalpha	S-PRGE
completely	O
depleted	O
IkappaBalpha	S-PRGE
in	O
Jurkat	O
cells	O
(	O
Fig	O
.	O
3c	O
,	O
input	O
)	O
.	O

Nevertheless	O
,	O
the	O
RPS3	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
was	O
not	O
augmented	O
(	O
Fig	O
.	O
3c	O
)	O
,	O
nor	O
was	O
significant	O
nuclear	O
RPS3	S-PRGE
detected	O
(	O
Fig	O
.	O
3d	O
)	O
.	O

Moreover	O
,	O
cells	O
treated	O
with	O
sodium	O
pervanadate	O
(	O
Pv	O
)	O
to	O
induce	O
IkappaBalpha	S-PRGE
degradation	O
through	O
an	O
IKK	O
-	O
independent	O
mechanism25	O
-	O
27	O
did	O
not	O
show	O
increased	O
association	O
between	O
RPS3	S-PRGE
and	O
importin	O
-	O
alpha	O
(	O
Fig	O
.	O
3e	O
and	O
Supplementary	O
Fig	O
.	O
3b	O
)	O
or	O
nuclear	O
accumulation	O
of	O
RPS3	S-PRGE
,	O
despite	O
complete	O
IkappaBalpha	S-PRGE
degradation	O
(	O
Supplementary	O
Fig	O
.	O
3c	O
)	O
.	O

We	O
further	O
examined	O
whether	O
a	O
subsequent	O
NF	O
-	O
kappaB	O
activation	O
signal	O
independently	O
promotes	O
the	O
importin	O
-	O
alpha	O
association	O
and	O
nuclear	O
transport	O
of	O
RPS3	S-PRGE
after	O
IkappaBalpha	S-PRGE
degradation	O
.	O

We	O
found	O
that	O
TNF	O
stimulation	O
following	O
Pv	O
treatment	O
was	O
required	O
for	O
the	O
RPS3	S-PRGE
-	O
importin	O
-	O
alpha	O
association	O
,	O
comparable	O
to	O
TNF	O
stimulation	O
alone	O
(	O
Fig	O
.	O
3e	O
)	O
.	O

Thus	O
,	O
IkappaBalpha	S-PRGE
phosphorylation	O
and	O
degradation	O
itself	O
is	O
required	O
but	O
not	O
sufficient	O
to	O
cause	O
RPS3	S-PRGE
association	O
with	O
importin	O
-	O
alpha	O
followed	O
by	O
nuclear	O
translocation	O
.	O

Rather	O
,	O
an	O
additional	O
signal	O
,	O
potentially	O
IKKbeta	S-PRGE
phosphorylation	O
of	O
RPS3	S-PRGE
,	O
is	O
required	O
.	O

IKKbeta	S-PRGE
phosphorylates	O
RPS3	S-PRGE
at	O
serine	O
209	O

Although	O
originally	O
defined	O
as	O
the	O
kinase	O
that	O
phosphorylates	O
IkappaB19	O
,	O
IKKbeta	S-PRGE
also	O
phosphorylates	O
unrelated	O
substrates	O
including	O
14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3beta	E-PRGE
and	O
Bcl10	S-PRGE
,	O
which	O
lack	O
the	O
IKK	O
consensus	O
motif	O
(	O
DpSGYXpS	O
/	O
T	O
)	O
28	O
.	O

We	O
therefore	O
hypothesized	O
that	O
IKKbeta	S-PRGE
could	O
directly	O
phosphorylate	O
RPS3	S-PRGE
.	O

By	O
in	O
vitro	O
kinase	O
assays	O
using	O
recombinant	O
IKK	O
and	O
RPS3	S-PRGE
proteins	O
,	O
we	O
observed	O
strong	O
incorporation	O
of	O
32P	O
in	O
autophosphorylatd	O
IKKalpha	S-PRGE
and	O
IKKbeta	S-PRGE
(	O
Fig	O
.	O
4a	O
,	O
lanes	O
2	O
-	O
7	O
)	O
as	O
well	O
as	O
phosporylated	O
GST	B-PRGE
-	I-PRGE
IkappaBalpha	E-PRGE
(	O
1	O
-	O
54	O
)	O
(	O
Supplementary	O
Fig	O
.	O
4	O
)	O
,	O
but	O
not	O
the	O
GST	S-PRGE
protein	O
alone	O
(	O
Fig	O
.	O
4a	O
,	O
lanes	O
3	O
and	O
6	O
)	O
,	O
when	O
either	O
IKKalpha	S-PRGE
or	O
IKKbeta	S-PRGE
was	O
used	O
.	O

We	O
discovered	O
that	O
GST	B-PRGE
-	I-PRGE
RPS3	E-PRGE
could	O
be	O
phosphorylated	O
by	O
IKKbeta	S-PRGE
,	O
but	O
not	O
IKKalpha	S-PRGE
,	O
in	O
vitro	O
(	O
Fig	O
.	O
4a	O
,	O
compare	O
lanes	O
4	O
and	O
7	O
)	O
.	O

To	O
identify	O
the	O
RPS3	S-PRGE
amino	O
acid	O
residue	O
(	O
s	O
)	O
phosphorylated	O
by	O
IKKbeta	S-PRGE
,	O
we	O
performed	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
analyses	O
using	O
in	O
vitro	O
phosphorylated	O
RPS3	S-PRGE
.	O

The	O
results	O
indicated	O
that	O
IKKbeta	S-PRGE
phosphorylated	O
S209	O
,	O
located	O
in	O
the	O
RPS3	S-PRGE
C	O
-	O
terminus	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

RPS3	S-PRGE
amino	O
acid	O
sequence	O
alignment	O
revealed	O
that	O
S209	O
is	O
conserved	O
in	O
many	O
species	O
throughout	O
phylogeny	O
with	O
the	O
exception	O
of	O
Caenorhabditis	O
elegans	O
and	O
Schizosaccharomyces	O
pombe	O
,	O
two	O
organisms	O
that	O
do	O
not	O
possess	O
the	O
NF	O
-	O
kappaB	O
signal	O
pathway	O
(	O
Supplementary	O
Fig	O
.	O
5	O
)	O
.	O

To	O
verify	O
biochemically	O
that	O
S209	O
is	O
an	O
IKKbeta	S-PRGE
substrate	O
,	O
we	O
performed	O
32P	O
-	O
labeling	O
in	O
vitro	O
kinase	S-PRGE
assays	O
with	O
recombinant	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	S-PRGE
proteins	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
protein	O
,	O
the	O
S209A	O
mutation	O
reduced	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
phosphorylation	O
(	O
Fig	O
.	O
4c	O
)	O
.	O

There	O
might	O
be	O
alternative	O
phosphorylation	O
site	O
(	O
s	O
)	O
under	O
these	O
conditions	O
given	O
modest	O
residual	O
phosphorylated	O
RPS3	S-PRGE
(	O
Fig	O
.	O
4c	O
)	O
.	O

RPS3	S-PRGE
S209	O
does	O
not	O
fall	O
within	O
a	O
conventional	O
IKK	O
recognition	O
motif	O
,	O
but	O
rather	O
resides	O
in	O
a	O
sequence	O
motif	O
(	O
XXXpS	O
/	O
TXXE	O
)	O
,	O
potentially	O
recognized	O
by	O
casein	O
kinase	O
II	O
(	O
CK2	O
)	O
.	O

Although	O
IKKbeta	S-PRGE
kinase	O
can	O
display	O
a	O
CK2	O
-	O
like	O
phosphorylation	O
specificity29	O
,	O
no	O
CK2	O
protein	O
was	O
detectable	O
in	O
our	O
recombinant	O
IKK	O
proteins	O
(	O
Supplementary	O
Fig	O
.	O
6	O
)	O
.	O

Thus	O
,	O
RPS3	S-PRGE
S209	O
phosphorylation	O
was	O
due	O
to	O
the	O
alternate	O
specificity	O
of	O
the	O
IKKbeta	S-PRGE
kinase	O
rather	O
than	O
any	O
trace	O
amount	O
of	O
CK2	O
bound	O
to	O
IKKs	O
.	O

To	O
determine	O
whether	O
S209	O
is	O
the	O
critical	O
site	O
at	O
which	O
IKKbeta	S-PRGE
phosphorylates	O
RPS3	S-PRGE
in	O
living	O
cells	O
,	O
we	O
transfected	O
the	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
Flag	B-PRGE
-	I-PRGE
RPS3	E-PRGE
alone	O
,	O
or	O
together	O
with	O
IKKbeta	S-PRGE
into	O
cells	O
.	O

Indeed	O
,	O
we	O
observed	O
that	O
overexpressing	O
IKKbeta	S-PRGE
enhanced	O
Flag	B-PRGE
-	I-PRGE
RPS3	E-PRGE
phosphorylation	O
,	O
but	O
phosphorylation	O
was	O
effectively	O
eliminated	O
by	O
alanine	O
substitution	O
indicating	O
that	O
S209	O
is	O
the	O
predominant	O
target	O
site	O
for	O
IKKbeta	S-PRGE
phosphorylation	O
(	O
Fig	O
.	O
4d	O
)	O
.	O

We	O
next	O
generated	O
a	O
phospho	B-PRGE
-	I-PRGE
S209	I-PRGE
RPS3	I-PRGE
antibody	E-PRGE
and	O
confirmed	O
that	O
endogenous	O
RPS3	S-PRGE
was	O
phosphorylated	O
at	O
S209	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
upon	O
TNF	O
stimulation	O
(	O
Fig	O
.	O
4e	O
)	O
.	O

Thus	O
,	O
the	O
RPS3	S-PRGE
C	O
-	O
terminal	O
tail	O
potentially	O
contains	O
an	O
important	O
regulatory	O
site	O
.	O

Phosphorylation	O
of	O
RPS3	S-PRGE
and	O
its	O
NF	O
-	O
kappaB	O
function	O

We	O
next	O
examined	O
whether	O
S209	O
phosphorylation	O
plays	O
a	O
role	O
in	O
the	O
nuclear	O
translocation	O
of	O
RPS3	S-PRGE
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

Subcellular	O
fractions	O
from	O
either	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	S-PRGE
-	O
transfected	O
cells	O
were	O
prepared	O
and	O
blotted	O
for	O
heat	O
-	O
shock	O
protein	O
90	O
(	O
hsp90	O
)	O
,	O
a	O
cytoplasmic	O
protein	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
a	O
nuclear	O
protein	O
,	O
confirming	O
a	O
clean	O
separation	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

As	O
expected	O
,	O
PMA	O
+	O
I	O
stimulation	O
triggered	O
wild	O
-	O
type	O
Flag	B-PRGE
-	I-PRGE
RPS3	E-PRGE
nuclear	O
translocation	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

However	O
,	O
RPS3	S-PRGE
(	O
S209A	O
)	O
nuclear	O
translocation	O
was	O
attenuated	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

We	O
also	O
tested	O
the	O
impact	O
of	O
activating	O
NF	O
-	O
kappaB	O
by	O
overexpressing	O
IKKbeta	S-PRGE
on	O
RPS3	S-PRGE
nuclear	O
translocation	O
.	O

IKKbeta	S-PRGE
overexpression	O
activated	O
NF	O
-	O
kappaB	O
measured	O
by	O
luciferase	S-PRGE
assays	O
(	O
Supplementary	O
Fig	O
.	O
7	O
)	O
,	O
and	O
also	O
induced	O
the	O
nuclear	O
translocation	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
S209A	O
,	O
RPS3	S-PRGE
(	O
Fig	O
.	O
5b	O
)	O
.	O

These	O
data	O
suggest	O
that	O
S209	O
phosphorylation	O
is	O
critical	O
for	O
the	O
NF	O
-	O
kappaB	O
activation	O
-	O
induced	O
RPS3	S-PRGE
nuclear	O
translocation	O
.	O

To	O
examine	O
the	O
role	O
of	O
S209	O
phosphorylation	O
of	O
RPS3	S-PRGE
to	O
its	O
NF	O
-	O
kappaB	O
function6	O
,	O
7	O
,	O
30	O
,	O
we	O
silenced	O
endogenous	O
RPS3	S-PRGE
expression	O
using	O
an	O
siRNA	O
that	O
targets	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
RPS3	S-PRGE
mRNA	O
,	O
followed	O
by	O
complementation	O
with	O
either	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	S-PRGE
via	O
transfection	O
.	O

As	O
expected	O
,	O
RPS3	B-PRGE
siRNA	E-PRGE
severely	O
reduced	O
endogenous	O
RPS3	S-PRGE
abundance	O
compared	O
to	O
NS	O
siRNA	O
,	O
but	O
did	O
not	O
affect	O
the	O
robust	O
expression	O
of	O
Flag	B-PRGE
-	I-PRGE
tagged	I-PRGE
RPS3	E-PRGE
from	O
a	O
transfected	O
construct	O
lacking	O
the	O
3	O
'	O
UTR	O
(	O
Fig	O
.	O
5c	O
)	O
.	O

We	O
also	O
found	O
that	O
RPS3	S-PRGE
knockdown	O
reduced	O
TNF	O
-	O
induced	O
expression	O
of	O
an	O
Ig	O
kappaB	O
-	O
driven	O
luciferase	S-PRGE
construct6	O
(	O
Fig	O
.	O
5d	O
)	O
.	O

The	O
impaired	O
luciferase	S-PRGE
signal	O
caused	O
by	O
RPS3	S-PRGE
deficiency	O
was	O
completely	O
restored	O
by	O
transfecting	O
wild	O
-	O
type	O
,	O
but	O
not	O
by	O
S209A	O
RPS3	S-PRGE
(	O
Fig	O
.	O
5d	O
)	O
,	O
despite	O
equivalent	O
expression	O
(	O
Fig	O
.	O
5c	O
)	O
.	O

Moreover	O
,	O
the	O
failure	O
of	O
S209A	O
RPS3	O
to	O
restore	O
luciferase	O
activity	O
did	O
not	O
result	O
from	O
defective	O
translation	O
because	O
the	O
transient	O
overexpression	O
of	O
green	B-PRGE
fluorescent	I-PRGE
protein	E-PRGE
(	O
GFP	S-PRGE
)	O
was	O
comparable	O
in	O
cells	O
complemented	O
with	O
wild	O
-	O
type	O
or	O
S029A	O
RPS3	S-PRGE
(	O
Supplementary	O
Fig	O
.	O
8	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
RPS3	S-PRGE
S209	O
phosphorylation	O
is	O
critical	O
for	O
NF	O
-	O
kappaB	O
activity	O
involving	O
the	O
canonical	O
Ig	O
kappaB	O
site	O
.	O

We	O
next	O
used	O
chromatin	O
immunoprecipitation	O
to	O
determine	O
whether	O
S209	O
phosphorylation	O
affects	O
RPS3	S-PRGE
and	O
p65	S-PRGE
recruitment	O
to	O
specific	O
kappaB	O
sites	O
in	O
intact	O
chromatin	O
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
RPS3	S-PRGE
knockdown	O
cells	O
,	O
PMA	O
+	O
I	O
stimulated	O
the	O
recruitment	O
of	O
ectopically	O
expressed	O
,	O
Flag	O
-	O
tagged	O
wild	O
-	O
type	O
,	O
but	O
not	O
S209A	O
RPS3	S-PRGE
to	O
the	O
kappaB	O
sites	O
of	O
the	O
NFKBIA	S-PRGE
and	O
IL8	S-PRGE
promoters	O
(	O
Fig	O
.	O
5e	O
)	O
.	O

While	O
expressing	O
RPS3	S-PRGE
S209A	O
had	O
no	O
impact	O
on	O
p65	S-PRGE
nuclear	O
translocation	O
,	O
it	O
substantially	O
attenuated	O
p65	S-PRGE
recruitment	O
(	O
Fig	O
.	O
5e	O
)	O
.	O

Additional	O
experiments	O
revealed	O
that	O
p65	S-PRGE
attraction	O
to	O
RPS3	S-PRGE
-	O
independent	O
NF	O
-	O
kappaB	O
target	O
gene	O
promoters	O
such	O
as	O
CD25	S-PRGE
was	O
increased	O
(	O
Supplementary	O
Fig	O
.	O
9	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
observations6	O
.	O

There	O
was	O
no	O
significant	O
Flag	B-PRGE
-	I-PRGE
RPS3	E-PRGE
or	O
p65	S-PRGE
recruitment	O
to	O
ACTB	S-PRGE
promoter	O
lacking	O
kappaB	O
sites	O
(	O
Fig	O
.	O
5e	O
)	O
,	O
suggesting	O
the	O
recruitment	O
was	O
kappaB	O
site	O
-	O
specific	O
.	O

Thus	O
,	O
the	O
recruitment	O
of	O
RPS3	S-PRGE
as	O
well	O
as	O
the	O
contingent	O
recruitment	O
of	O
p65	S-PRGE
to	O
key	O
promoters	O
depended	O
on	O
S209	O
.	O

Interleukin	B-PRGE
8	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	E-PRGE
)	O
secretion	O
induced	O
by	O
either	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
agonist	O
stimulation	O
or	O
PMA	O
+	O
I	O
was	O
decreased	O
as	O
a	O
consequence	O
of	O
reduced	O
RPS3	S-PRGE
/	O
p65	S-PRGE
recruitment	O
to	O
the	O
IL8	S-PRGE
kappaB	O
sites	O
in	O
the	O
presence	O
of	O
S209A	O
mutant	O
compared	O
to	O
wild	O
-	O
type	O
RPS3	S-PRGE
(	O
Supplementary	O
Fig	O
.	O
10	O
)	O
.	O

However	O
,	O
cell	O
surface	O
CD25	S-PRGE
expression	O
was	O
comparable	O
between	O
the	O
wild	O
-	O
type	O
and	O
S209A	O
RPS3	S-PRGE
transfected	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
11	O
)	O
.	O

Therefore	O
,	O
RPS3	S-PRGE
S209	O
phosphorylation	O
by	O
IKKbeta	S-PRGE
is	O
apparently	O
required	O
for	O
RPS3	S-PRGE
in	O
directing	O
NF	O
-	O
kappaB	O
to	O
a	O
specific	O
subset	O
of	O
target	O
genes	O
.	O

NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
phosphorylation	O
in	O
vitro	O

EHEC	O
pathogens	O
are	O
important	O
causative	O
agents	O
of	O
both	O
foodborne	O
disease	O
and	O
pediatric	O
renal	O
failure31	O
.	O

EHEC	O
utilize	O
T3SS	O
to	O
inject	O
effector	O
proteins	O
directly	O
into	O
intestinal	O
epithelial	O
cells32	O
,	O
a	O
subset	O
of	O
which	O
inhibit	O
NF	O
-	O
kappaB	O
-	O
dependent	O
innate	O
responses9	O
,	O
33	O
-	O
38	O
.	O

The	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
EDL933	O
effector	O
protein	O
NleH1	S-PRGE
binds	O
to	O
and	O
attenuates	O
RPS3	S-PRGE
nuclear	O
translocation	O
,	O
thus	O
impairing	O
RPS3	S-PRGE
-	O
dependent	O
NF	O
-	O
kappaB	O
signaling9	O
.	O

We	O
therefore	O
hypothesized	O
that	O
NleH1	S-PRGE
may	O
function	O
by	O
inhibiting	O
RPS3	S-PRGE
S209	O
phosphorylation	O
.	O

As	O
expected	O
,	O
transfecting	O
increasing	O
amounts	O
of	O
NleH1	B-PRGE
-	I-PRGE
HA	E-PRGE
plasmid	O
blocked	O
TNFalpha	S-PRGE
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
6a	O
-	O
b	O
)	O
9	O
.	O

Remarkably	O
,	O
NleH1	S-PRGE
reduced	O
both	O
TNF	S-PRGE
-	O
induced	O
,	O
as	O
well	O
as	O
basal	O
RPS3	S-PRGE
phosphorylation	O
to	O
roughly	O
20	O
%	O
of	O
vehicle	O
control	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Expressing	O
NleH1	S-PRGE
does	O
not	O
interfere	O
with	O
either	O
TNF	S-PRGE
-	O
induced	O
IKK	O
activation	O
or	O
IkappaBalpha	S-PRGE
degradation	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
NleH1	S-PRGE
impact	O
on	O
p65	S-PRGE
nuclear	O
translocation9	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

To	O
determine	O
if	O
NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
phosphorylation	O
,	O
we	O
infected	O
HeLa	O
cells	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
strains	O
possessing	O
or	O
lacking	O
either	O
nleH1	S-PRGE
(	O
deltanleH1	S-PRGE
)	O
or	O
with	O
a	O
strain	O
lacking	O
a	O
functional	O
T3SS	O
unable	O
to	O
inject	O
NleH1	S-PRGE
into	O
mammalian	O
cells	O
(	O
deltaescN	S-PRGE
)	O
.	O

In	O
uninfected	O
cells	O
,	O
TNF	S-PRGE
-	O
treatment	O
stimulated	O
a	O
~	O
7	O
-	O
fold	O
increase	O
in	O
RPS3	S-PRGE
S209	O
phosphorylation	O
,	O
peaking	O
at	O
30	O
minutes	O
(	O
Fig	O
.	O
6d	O
)	O
.	O

By	O
contrast	O
,	O
RPS3	S-PRGE
S209	O
phosphorylation	O
was	O
substantially	O
impaired	O
in	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
(	O
Fig	O
.	O
6d	O
)	O
.	O

However	O
,	O
TNF	S-PRGE
-	O
induced	O
RPS3	S-PRGE
S209	O
phosphorylation	O
was	O
unimpaired	O
in	O
cells	O
infected	O
with	O
either	O
deltanleH1	S-PRGE
or	O
deltaescN	S-PRGE
(	O
Fig	O
.	O
6d	O
)	O
.	O

We	O
showed	O
previously	O
that	O
wild	O
-	O
type	O
,	O
but	O
not	O
deltanleH1	S-PRGE
or	O
deltaescN	S-PRGE
E	O
.	O
coli	O
O157	O
:	O
H7	O
significantly	O
attenuated	O
TNF	S-PRGE
-	O
induced	O
RPS3	S-PRGE
nuclear	O
translocation9	O
.	O

The	O
parallel	O
between	O
RPS3	S-PRGE
phosphorylation	O
and	O
its	O
nuclear	O
translocation	O
during	O
E	O
.	O
coli	O
infection	O
provides	O
evidence	O
in	O
the	O
context	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
disease	O
process	O
that	O
RPS3	S-PRGE
S209	O
phosphorylation	O
is	O
important	O
for	O
nuclear	O
translocation	O
.	O

Our	O
discovery	O
that	O
NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
S209	O
phosphorylation	O
suggested	O
that	O
it	O
should	O
also	O
blocks	O
RPS3	S-PRGE
-	O
dependent	O
NF	O
-	O
kappaB	O
target	O
gene	O
transcription	O
(	O
e	O
.	O
g	O
.	O
IL8	S-PRGE
,	O
NFKBIA	S-PRGE
,	O
and	O
TNFAIP3	S-PRGE
)	O
.	O

Indeed	O
,	O
these	O
genes	O
were	O
only	O
modestly	O
upregulated	O
in	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
,	O
but	O
significantly	O
induced	O
in	O
cells	O
infected	O
with	O
either	O
deltanleH1	S-PRGE
or	O
deltaescN	S-PRGE
strains	O
(	O
Fig	O
.	O
6e	O
)	O
.	O

In	O
contrast	O
,	O
deleting	O
nleH1	S-PRGE
had	O
no	O
impact	O
on	O
the	O
expression	O
of	O
RPS3	O
-	O
independent	O
genes	O
,	O
including	O
CD25	S-PRGE
and	O
TNFSF13B	S-PRGE
(	O
Supplementary	O
Fig	O
.	O
12	O
)	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
NleH1	S-PRGE
specifically	O
inhibits	O
the	O
protective	O
immune	O
response	O
by	O
directly	O
blocking	O
RPS3	S-PRGE
S209	O
phosphorylation	O
and	O
thereby	O
impairing	O
critical	O
RPS3	S-PRGE
-	O
dependent	O
NF	O
-	O
kappaB	O
target	O
genes	O
.	O

NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
S209	O
phosphorylation	O
in	O
vivo	O

We	O
previously	O
utilized	O
a	O
gnotobiotic	O
piglet	O
infection	O
model	O
to	O
determine	O
that	O
piglets	O
infected	O
with	O
deltanleH1	S-PRGE
mutant	O
died	O
more	O
rapidly	O
than	O
those	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

Piglets	O
infected	O
with	O
deltanleH1	S-PRGE
displayed	O
clinical	O
disease	O
consistent	O
with	O
a	O
robust	O
inflammatory	O
response	O
,	O
but	O
with	O
reduced	O
bacterial	O
colonization	O
and	O
little	O
diarrhea9	O
.	O

While	O
seemingly	O
paradoxical	O
,	O
based	O
on	O
our	O
cell	O
culture	O
data	O
(	O
Fig	O
.	O
6d	O
)	O
,	O
we	O
hypothesized	O
that	O
NleH1	S-PRGE
blocked	O
RPS3	S-PRGE
S209	O
phosphorylation	O
in	O
vivo	O
,	O
thereby	O
preventing	O
RPS3	S-PRGE
nuclear	O
translocation	O
in	O
infected	O
piglets	O
.	O

We	O
isolated	O
piglet	O
colons	O
at	O
necropsy	O
,	O
and	O
subjected	O
them	O
to	O
immunohistochemistry	O
using	O
our	O
phospho	O
-	O
RPS3	O
antibody	O
.	O

Consistent	O
with	O
in	O
vitro	O
data	O
,	O
piglets	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
exhibited	O
diffuse	O
and	O
low	O
intensity	O
phospho	O
-	O
RPS3	S-PRGE
staining	O
,	O
whereas	O
in	O
piglets	O
infected	O
with	O
deltanleH1	S-PRGE
mutant	O
,	O
phospho	O
-	O
RPS3	S-PRGE
expression	O
was	O
florid	O
and	O
intense	O
(	O
Fig	O
.	O
6f	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
S209	O
phosphorylation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
might	O
benefit	O
the	O
bacterium	O
in	O
colonization	O
and	O
transmission	O
.	O

NleH1	S-PRGE
steers	O
the	O
IKKbeta	S-PRGE
substrate	O
specificities	O

NleH1	S-PRGE
is	O
an	O
autophosphorylated	O
serine	O
-	O
threonine	O
kinase	O
,	O
which	O
depends	O
on	O
the	O
lysine	O
159	O
(	O
K159	O
)	O
9	O
.	O

To	O
explore	O
the	O
mechanism	O
by	O
which	O
NleH1	S-PRGE
inhibits	O
RPS3	S-PRGE
S209	O
phosphorylation	O
,	O
we	O
first	O
performed	O
an	O
in	O
vitro	O
kinase	O
assay	O
with	O
purified	O
wild	O
-	O
type	O
His	B-PRGE
-	I-PRGE
NleH1	E-PRGE
protein	O
and	O
a	O
mutant	O
His	B-PRGE
-	I-PRGE
NleH1	E-PRGE
(	O
K159A	O
)	O
protein	O
,	O
confirming	O
that	O
NleH1	S-PRGE
is	O
autophosphorylated	O
and	O
the	O
K159A	O
is	O
an	O
NleH1	S-PRGE
kinase	O
-	O
dead	O
mutant	O
(	O
Fig	O
.	O
7a	O
)	O
.	O

To	O
examine	O
whether	O
the	O
kinase	O
activity	O
is	O
required	O
for	O
NleH1	S-PRGE
to	O
inhibit	O
IKKbeta	S-PRGE
phosphorlyation	O
of	O
RPS3	S-PRGE
on	O
S209	O
,	O
we	O
ectopically	O
expressing	O
either	O
wild	O
-	O
type	O
or	O
K159A	O
NleH1	S-PRGE
in	O
293T	O
cells	O
.	O

Wild	O
-	O
type	O
NleH1	S-PRGE
expression	O
significantly	O
reduced	O
TNF	O
-	O
induced	O
RPS3	S-PRGE
S209	O
phosphorylation	O
,	O
whereas	O
the	O
K159A	O
mutant	O
failed	O
to	O
do	O
so	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

Thus	O
NleH1	S-PRGE
kinase	O
activity	O
is	O
required	O
to	O
protect	O
RPS3	S-PRGE
from	O
IKKbeta	S-PRGE
-	O
mediated	O
phosphorylation	O
.	O

Citrobacter	O
rodentium	O
is	O
a	O
mouse	O
pathogen	O
that	O
shares	O
pathogenic	O
strategies	O
with	O
E	O
.	O
coli	O
39	O
,	O
most	O
notably	O
for	O
our	O
investigation	O
,	O
C	O
.	O
rodentium	O
NleH	S-PRGE
inhibited	O
RPS3	S-PRGE
nuclear	O
translocation	O
and	O
RPS3	S-PRGE
-	O
dependent	O
NF	O
-	O
kappaB	O
luciferase	S-PRGE
activity	O
to	O
an	O
extent	O
equivalent	O
to	O
E	O
.	O
coli	O
NleH1	S-PRGE
(	O
ref	O
.	O
9	O
)	O
.	O

We	O
assayed	O
RPS3	S-PRGE
S209	O
phosphorylation	O
in	O
HeLa	O
cells	O
infected	O
with	O
different	O
C	O
.	O
rodentium	O
strains	O
.	O

In	O
uninfected	O
cells	O
,	O
TNF	O
-	O
treatment	O
stimulated	O
a	O
~	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
RPS3	S-PRGE
S209	O
phosphorylation	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Such	O
augmentation	O
of	O
RPS3	S-PRGE
phosphorylation	O
was	O
reduced	O
by	O
about	O
60	O
%	O
by	O
wild	O
-	O
type	O
C	O
.	O
rodentium	O
infection	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

However	O
,	O
RPS3	S-PRGE
phosphorylation	O
was	O
enhanced	O
when	O
cells	O
were	O
infected	O
with	O
a	O
C	O
.	O
rodentium	O
strain	O
lacking	O
NleH	S-PRGE
(	O
Fig	O
.	O
7c	O
,	O
deltanleH	S-PRGE
)	O
.	O

We	O
further	O
examined	O
the	O
role	O
of	O
NleH1	S-PRGE
kinase	O
activity	O
using	O
the	O
C	O
.	O
rodentium	O
deltanleH	S-PRGE
strain	O
as	O
a	O
background	O
on	O
which	O
to	O
express	O
either	O
wild	O
-	O
type	O
or	O
K159A	O
E	O
.	O
coli	O
NleH1	S-PRGE
.	O

Complementing	O
deltanleH	S-PRGE
mutant	O
with	O
wild	O
-	O
type	O
NleH1	S-PRGE
almost	O
abolished	O
TNF	S-PRGE
-	O
induced	O
RPS3	S-PRGE
S209	O
phosphorylation	O
whereas	O
complementing	O
with	O
K159A	O
failed	O
to	O
inhibit	O
RPS3	S-PRGE
phosphorylation	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
NleH1	S-PRGE
kinase	O
activity	O
is	O
required	O
to	O
block	O
RPS3	S-PRGE
S209	O
phosphorylation	O
.	O

We	O
next	O
examined	O
whether	O
the	O
inhibitory	O
activity	O
of	O
NleH1	S-PRGE
is	O
sufficiently	O
robust	O
to	O
impair	O
the	O
strong	O
nuclear	O
translocation	O
of	O
RPS3	S-PRGE
trigged	O
by	O
the	O
constitutively	O
-	O
active	O
IKKbeta	S-PRGE
(	O
IKKbeta	S-PRGE
[	O
SSEE	O
]	O
)	O
(	O
Fig	O
.	O
2d	O
)	O
.	O

We	O
found	O
that	O
ectopically	O
expressing	O
either	O
wild	O
-	O
type	O
or	O
SSEE	B-PRGE
IKKbeta	E-PRGE
proteins	O
,	O
triggered	O
more	O
RPS3	S-PRGE
nuclear	O
translocation	O
than	O
the	O
kinase	O
-	O
dead	O
IKKbeta	S-PRGE
(	O
SSAA	O
)	O
protein	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

RPS3	S-PRGE
nuclear	O
accumulation	O
was	O
substantially	O
retarded	O
by	O
infecting	O
cells	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

In	O
contrast	O
,	O
infecting	O
with	O
either	O
deltanleH1	S-PRGE
or	O
deltaescN	S-PRGE
strains	O
only	O
slightly	O
impaired	O
RPS3	S-PRGE
nuclear	O
translocation	O
in	O
either	O
IKKbeta	S-PRGE
-	O
or	O
IKKbeta	S-PRGE
(	O
SSEE	O
)	O
-	O
expressing	O
cells	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

As	O
expected	O
,	O
E	O
.	O
coli	O
infections	O
did	O
not	O
affect	O
the	O
RPS3	S-PRGE
nuclear	O
translocation	O
in	O
IKKbeta	S-PRGE
(	O
SSAA	O
)	O
-	O
expressing	O
cells	O
,	O
where	O
NF	O
-	O
kappaB	O
signaling	O
was	O
low	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

Thus	O
,	O
during	O
infection	O
NleH1	S-PRGE
is	O
sufficiently	O
potent	O
to	O
inhibit	O
RPS3	S-PRGE
nuclear	O
translocation	O
even	O
in	O
cells	O
expressing	O
constitutively	O
-	O
activated	O
IKKbeta	S-PRGE
.	O

We	O
examined	O
whether	O
NleH1	S-PRGE
could	O
directly	O
phosphorylate	O
IKKbeta	S-PRGE
thus	O
inhibiting	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
S209	O
phosphorylation	O
.	O

We	O
performed	O
in	O
vitro	O
kinase	O
assays	O
using	O
immunoprecipitated	O
Flag	B-PRGE
-	I-PRGE
IKKbeta	I-PRGE
(	I-PRGE
K44A	I-PRGE
)	E-PRGE
as	O
substrate	O
and	O
recombinant	O
His	B-PRGE
-	I-PRGE
NleH1	E-PRGE
as	O
kinase	O
,	O
so	O
that	O
IKKbeta	S-PRGE
autophosphorylation	O
would	O
not	O
obscure	O
NleH1	S-PRGE
-	O
induced	O
phosphorylation	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
detectable	O
32P	O
incorporation	O
in	O
IKKbeta	S-PRGE
(	O
Supplementary	O
Fig	O
.	O
13	O
)	O
,	O
thus	O
ruling	O
out	O
this	O
possibility	O
.	O

We	O
then	O
tested	O
the	O
hypothesis	O
that	O
NleH1	S-PRGE
could	O
alter	O
the	O
IKKbeta	S-PRGE
substrate	O
specificities	O
.	O

To	O
this	O
end	O
,	O
we	O
performed	O
in	O
vitro	O
kinase	O
assays	O
using	O
both	O
CK2	O
and	O
IKK	O
substrates	O
for	O
IKKbeta	S-PRGE
.	O

As	O
expected	O
,	O
IKKbeta	S-PRGE
phosphorylated	O
RPS3	S-PRGE
(	O
Fig	O
.	O
7e	O
,	O
lane	O
7	O
)	O
and	O
GST	B-PRGE
-	I-PRGE
IkappaBalpha	E-PRGE
(	O
1	O
-	O
54	O
)	O
protein	O
(	O
Fig	O
.	O
7e	O
,	O
lane	O
9	O
)	O
,	O
demonstrating	O
it	O
harbors	O
either	O
CK2	O
or	O
IKK	O
substrate	O
specificity	O
.	O

Preincubation	O
of	O
IKKbeta	S-PRGE
with	O
NleH1	S-PRGE
reduced	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
phosphorylation	O
,	O
i	O
.	O
e	O
.	O
the	O
CK2	O
kinase	O
specificity	O
,	O
but	O
not	O
IKKbeta	S-PRGE
-	O
mediated	O
GST	B-PRGE
-	I-PRGE
IkappaBalpha	E-PRGE
phosphorylation	O
,	O
i	O
.	O
e	O
.	O
the	O
IKK	O
kinase	O
specificity	O
(	O
Fig	O
.	O
7e	O
)	O
.	O

Control	O
experiments	O
revealed	O
no	O
NleH1	S-PRGE
-	O
mediated	O
phosphorylation	O
or	O
autophosphorylation	O
of	O
RPS3	S-PRGE
or	O
GST	B-PRGE
-	I-PRGE
IkappaBalpha	E-PRGE
(	O
Fig	O
.	O
7e	O
)	O
.	O

Taken	O
together	O
,	O
NleH1	S-PRGE
blocks	O
the	O
CK2	O
substrate	O
specificity	O
of	O
IKKbeta	S-PRGE
thus	O
inhibiting	O
the	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
S209	O
phosphorylation	O
thus	O
representing	O
a	O
novel	O
strategy	O
by	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
to	O
alter	O
the	O
host	O
innate	O
immune	O
response	O
.	O

RPS3	S-PRGE
was	O
previously	O
demonstrated	O
to	O
function	O
as	O
an	O
integral	O
subunit	O
conferring	O
NF	O
-	O
kappaB	O
regulatory	O
specificity6	O
.	O

Here	O
we	O
sought	O
to	O
elucidate	O
how	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
triggers	O
RPS3	S-PRGE
to	O
translocate	O
and	O
participate	O
in	O
NF	O
-	O
kappaB	O
function	O
in	O
the	O
nucleus	O
.	O

We	O
demonstrate	O
that	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
S209	O
phosphorylation	O
represents	O
a	O
critical	O
determinant	O
in	O
governing	O
its	O
nuclear	O
import	O
thus	O
unveiling	O
a	O
novel	O
mechanism	O
behind	O
NF	O
-	O
kappaB	O
regulatory	O
specificity	O
.	O

IKKbeta	S-PRGE
is	O
the	O
major	O
kinase	O
that	O
phosphorylates	O
IkappaBs	O
in	O
the	O
classical	O
NF	O
-	O
kappaB	O
pathway	O
,	O
leading	O
to	O
their	O
subsequent	O
degradation40	O
.	O

Strikingly	O
,	O
RPS3	S-PRGE
possesses	O
not	O
any	O
consensus	O
IKK	O
motif	O
;	O
instead	O
,	O
S209	O
is	O
centered	O
in	O
a	O
consensus	O
CK2	O
motif	O
.	O

The	O
recent	O
observation	O
that	O
human	O
IKKbeta	S-PRGE
displayed	O
CK2	O
-	O
like	O
phosphorylation	O
specificity29	O
coincides	O
with	O
our	O
evidence	O
that	O
recombinant	O
IKKbeta	S-PRGE
,	O
but	O
not	O
IKKalpha	S-PRGE
,	O
phosphorylated	O
RPS3	S-PRGE
.	O

We	O
found	O
this	O
phosphorylation	O
is	O
a	O
critical	O
modulation	O
for	O
RPS3	S-PRGE
nuclear	O
translocation	O
(	O
via	O
importin	O
-	O
alpha	O
)	O
and	O
engagement	O
in	O
specific	O
NF	O
-	O
kappaB	O
transcription	O
.	O

CK2	O
was	O
previously	O
shown	O
to	O
phosphorylate	O
p65	S-PRGE
and	O
to	O
bind	O
to	O
and	O
phosphorylate	O
IKKbeta41	S-PRGE
-	O
43	O
,	O
however	O
,	O
we	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
IKKbeta	S-PRGE
-	O
bound	O
CK2	O
could	O
account	O
for	O
the	O
observed	O
RPS3	S-PRGE
phosphorylation	O
because	O
no	O
CK2	O
was	O
detected	O
in	O
the	O
IKKbeta	S-PRGE
preparations	O
used	O
for	O
the	O
in	O
vitro	O
kinase	O
assay	O
.	O

Because	O
RPS3	S-PRGE
only	O
harbors	O
the	O
CK2	O
motif	O
and	O
not	O
a	O
traditional	O
IKK	O
motif	O
,	O
this	O
RPS3	O
regulatory	O
function	O
could	O
explain	O
why	O
IKK	O
harbors	O
the	O
alternative	O
substrate	O
phosphorylation	O
capability	O
.	O

More	O
importantly	O
,	O
our	O
study	O
has	O
elucidated	O
how	O
RPS3	S-PRGE
is	O
biochemically	O
integrated	O
into	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
in	O
a	O
manner	O
that	O
is	O
pivotal	O
for	O
the	O
pathogenesis	O
of	O
foodborne	O
pathogen	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
S209	O
phosphorylation	O
is	O
a	O
critical	O
target	O
modulated	O
by	O
this	O
pathogen	O
to	O
subvert	O
host	O
NF	O
-	O
kappaB	O
signaling	O
.	O

The	O
bacterial	O
effector	O
NleH1	S-PRGE
specifically	O
binds	O
to	O
RPS3	S-PRGE
once	O
injected	O
into	O
host	O
cells	O
and	O
profoundly	O
suppresses	O
NF	O
-	O
kappaB	O
and	O
its	O
attendant	O
protective	O
immune	O
responses9	O
.	O

Our	O
data	O
now	O
show	O
that	O
NleH1	S-PRGE
selectively	O
inhibits	O
RPS3	S-PRGE
phosphorylation	O
,	O
thus	O
retarding	O
its	O
nuclear	O
translocation	O
and	O
subsequent	O
NF	O
-	O
kappaB	O
function	O
,	O
without	O
altering	O
other	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Although	O
NleH1	S-PRGE
did	O
not	O
directly	O
phosphorylate	O
IKKbeta	S-PRGE
,	O
its	O
kinase	O
activity	O
was	O
required	O
to	O
inhibit	O
IKKbeta	S-PRGE
-	O
mediated	O
RPS3	S-PRGE
S209	O
phosphorylation	O
.	O

Many	O
bacteria	O
pathogens	O
have	O
products	O
that	O
target	O
key	O
kinases	O
to	O
inactivate	O
them	O
in	O
host	O
cells	O
,	O
whereas	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
employed	O
NleH1	S-PRGE
to	O
steer	O
the	O
substrate	O
specificity	O
of	O
IKKbeta	S-PRGE
thus	O
specifically	O
fine	O
-	O
tuning	O
host	O
NF	O
-	O
kappaB	O
signaling	O
.	O

This	O
could	O
represent	O
a	O
novel	O
strategy	O
to	O
fine	O
-	O
tune	O
host	O
NF	O
-	O
kappaB	O
signaling	O
that	O
could	O
be	O
shared	O
by	O
other	O
pathogens	O
.	O

These	O
data	O
provide	O
new	O
insights	O
into	O
the	O
poorly	O
understood	O
action	O
mechanism	O
for	O
most	O
T3SS	O
effectors	O
.	O

NleH1	S-PRGE
attenuates	O
the	O
transcription	O
of	O
RPS3	S-PRGE
-	O
dependent	O
,	O
but	O
not	O
all	O
,	O
NF	O
-	O
kappaB	O
target	O
genes	O
,	O
in	O
particular	O
those	O
genes	O
associated	O
with	O
acute	O
proinflammatory	O
responses	O
,	O
including	O
IL8	S-PRGE
and	O
TNF	O
.	O

In	O
contrast	O
,	O
NleH1	S-PRGE
does	O
not	O
block	O
NF	O
-	O
kappaB	O
p65	S-PRGE
nuclear	O
translocation	O
,	O
which	O
suggests	O
that	O
certain	O
p65	S-PRGE
-	O
dependent	O
but	O
RPS3	S-PRGE
-	O
independent	O
NF	O
-	O
kappaB	O
target	O
genes	O
might	O
thus	O
be	O
beneficial	O
for	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
to	O
replicate	O
and	O
disseminate	O
in	O
the	O
host	O
.	O

By	O
selectively	O
inhibiting	O
RPS3	S-PRGE
and	O
its	O
attendant	O
NF	O
-	O
kappaB	O
function	O
with	O
NleH1	S-PRGE
,	O
the	O
pathogen	O
achieves	O
the	O
ability	O
to	O
increase	O
colonization	O
and	O
diarrhea	O
yet	O
limiting	O
the	O
mortality	O
of	O
the	O
host	O
.	O

This	O
seemingly	O
paradoxical	O
combination	O
of	O
effects	O
make	O
sense	O
when	O
one	O
considers	O
that	O
increased	O
bacterial	O
load	O
and	O
diarrhea	O
together	O
with	O
survival	O
of	O
the	O
infected	O
host	O
would	O
promote	O
the	O
spreading	O
of	O
the	O
bacteria	O
among	O
a	O
population	O
of	O
susceptible	O
individuals	O
.	O

Such	O
complex	O
and	O
paradoxical	O
pathological	O
effects	O
that	O
influence	O
the	O
spread	O
of	O
disease	O
are	O
often	O
poorly	O
understood	O
at	O
the	O
molecular	O
level	O
.	O

Our	O
data	O
elucidate	O
how	O
alterations	O
in	O
selective	O
NF	O
-	O
kappaB	O
function	O
,	O
achieved	O
by	O
impeding	O
RPS3	S-PRGE
,	O
but	O
not	O
altering	O
p65	S-PRGE
nuclear	O
translocation	O
,	O
can	O
influence	O
specific	O
cytokines	O
that	O
affect	O
bacterial	O
colonization	O
,	O
diarrhea	O
diseases	O
and	O
mortality	O
.	O

It	O
may	O
be	O
fruitful	O
in	O
attempting	O
to	O
understand	O
other	O
infectious	O
and	O
autoimmune	O
diseases	O
involving	O
NF	O
-	O
kappaB	O
to	O
consider	O
selective	O
effects	O
of	O
subunits	O
such	O
as	O
RPS3	S-PRGE
in	O
addition	O
to	O
global	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

Cells	O
and	O
Reagents	O

Jurkat	O
E6	O
.	O
1	O
,	O
HEK293T	O
and	O
HeLa	O
cells	O
were	O
cultured	O
in	O
RPMI	O
1640	O
and	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
2	O
mM	O
glutamine	O
,	O
and	O
100	O
U	O
/	O
ml	O
each	O
of	O
penicillin	O
and	O
streptomycin	O
,	O
respectively	O
.	O

IkappaBalpha	O
(	O
C	O
-	O
21	O
,	O
sc	O
-	O
371	O
)	O
,	O
p65	O
(	O
C	O
-	O
20	O
,	O
sc	O
-	O
372	O
)	O
,	O
and	O
phospho	O
-	O
threonine	O
(	O
H	O
-	O
2	O
,	O
sc	O
-	O
5267	O
)	O
antibodies	O
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
;	O
beta	O
-	O
actin	O
(	O
AC	O
-	O
15	O
,	O
A5441	O
)	O
,	O
Flag	O
(	O
M2	O
,	O
F3165	O
)	O
,	O
HA	O
(	O
HA	O
-	O
7	O
,	O
H3663	O
)	O
,	O
importin	O
-	O
alpha	O
(	O
IM	O
-	O
75	O
,	O
I1784	O
)	O
,	O
and	O
importin	O
-	O
beta	O
(	O
31H4	O
,	O
I2534	O
)	O
antibodies	O
were	O
from	O
Sigma	O
;	O
PARP	O
(	O
C2	O
-	O
10	O
,	O
556362	O
)	O
,	O
IKKalpha	O
(	O
B78	O
-	O
1	O
,	O
556532	O
)	O
,	O
and	O
IKKbeta	O
(	O
24	O
,	O
611254	O
)	O
antibodies	O
were	O
from	O
BD	O
Pharmingen	O
;	O
CK2alpha	O
(	O
31	O
,	O
611610	O
)	O
and	O
Hsp90	O
(	O
68	O
,	O
610418	O
)	O
antibodies	O
were	O
from	O
BD	O
Transduction	O
Laboratories	O
;	O
phospho	O
-	O
IkappaBalpha	O
(	O
5A5	O
,	O
9246S	O
)	O
and	O
phospho	O
-	O
IKKalpha	O
/	O
beta	O
(	O
16A6	O
,	O
2697S	O
)	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
;	O
phospho	O
-	O
serine	O
(	O
AB1603	O
)	O
and	O
phospho	O
-	O
tyrosine	O
(	O
4G10	O
,	O
05	O
-	O
777	O
)	O
antibodies	O
were	O
from	O
Millipore	O
.	O

The	O
rabbit	O
polyclonal	O
RPS3	O
antiserum	O
was	O
as	O
described	O
previously6	O
.	O

The	O
rabbit	O
polyclonal	O
antibody	O
specific	O
for	O
S209	O
phosphorylated	O
RPS3	O
was	O
generated	O
and	O
affinity	O
purified	O
by	O
Primm	O
Biotech	O
using	O
the	O
peptide	O
NH2	O
-	O
CKPLPDHV	O
(	O
Sp	O
)	O
IVE	O
-	O
COOH	O
.	O

Plasmid	O
Constructs	O

The	O
Flag	B-PRGE
-	I-PRGE
IKKbeta	I-PRGE
(	I-PRGE
SSEE	I-PRGE
)	E-PRGE
,	O
Flag	B-PRGE
-	I-PRGE
IKKbeta	I-PRGE
(	I-PRGE
SSAA	I-PRGE
)	E-PRGE
,	O
and	O
HA	B-PRGE
-	I-PRGE
IkappaBalpha	I-PRGE
(	I-PRGE
SSAA	I-PRGE
)	E-PRGE
constructs	O
were	O
provided	O
by	O
C	O
.	O

Wu	O
(	O
NCI	O
,	O
Bethesda	O
)	O
and	O
U	O
.	O

Siebenlist	O
(	O
NIAID	O
,	O
Bethesda	O
)	O
,	O
respectively	O
.	O

The	O
HA	B-PRGE
-	I-PRGE
IkappaBalpha	E-PRGE
and	O
IKKbeta	B-PRGE
(	I-PRGE
K44A	I-PRGE
)	I-PRGE
-	I-PRGE
Flag	E-PRGE
plasmids	O
were	O
purchased	O
from	O
Addgene44	O
,	O
45	O
.	O

The	O
Flag	B-PRGE
-	I-PRGE
RPS3	E-PRGE
,	O
GST	B-PRGE
-	I-PRGE
RPS3	E-PRGE
,	O
HA	B-PRGE
-	I-PRGE
RPS3	E-PRGE
,	O
VN	B-PRGE
-	I-PRGE
HA	E-PRGE
,	O
NleH1	B-PRGE
-	I-PRGE
HA	E-PRGE
plasmids	O
were	O
described	O
previously6	O
,	O
9	O
.	O

The	O
point	O
mutants	O
of	O
RPS3	S-PRGE
were	O
generated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
using	O
the	O
Quick	O
Change	O
Kit	O
(	O
Stratagene	O
)	O
with	O
primers	O
forward	O
5	O
'	O
-	O
CTGCCTGACCACGTGGCCATTGTGGAACCCAAA	O
-	O
3	O
'	O
and	O
reverse	O
5	O
'	O
-	O
TTTGGGTTCCACAATGGCCACGTGGTCAGGCAG	O
-	O
3	O
'	O
for	O
S209A	O
.	O

All	O
mutants	O
were	O
verified	O
by	O
DNA	O
sequencing	O
.	O

32P	O
in	O
vivo	O
Labeling	O

HEK	O
293T	O
cells	O
were	O
labeled	O
with	O
2	O
mCi	O
/	O
ml	O
32P	O
-	O
orthophosphate	O
(	O
Perkin	O
Elmer	O
)	O
in	O
phosphate	O
-	O
free	O
medium	O
(	O
Invitrogen	O
)	O
for	O
2	O
h	O
.	O

Cells	O
were	O
then	O
left	O
untreated	O
or	O
treated	O
with	O
TNF	O
(	O
50	O
ng	O
/	O
ml	O
,	O
R	O
&	O
D	O
Systems	O
)	O
for	O
indicated	O
periods	O
.	O

Cell	O
lysates	O
were	O
prepared	O
and	O
used	O
for	O
immunoprecipitations	O
with	O
RPS3	O
antibody	O
.	O

In	O
Vitro	O
Kinase	O
Assay	O

Kinase	O
-	O
active	O
recombinant	O
IKKbeta	S-PRGE
and	O
IKKalpha	S-PRGE
proteins	O
were	O
purchased	O
from	O
Active	O
Motif	O
and	O
Millipore	O
,	O
respectively	O
.	O

Bacterially	O
purified	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
,	O
GST	O
-	O
IkappaBalpha	O
(	O
1	O
-	O
54	O
)	O
,	O
wild	O
type	O
,	O
mutant	O
GST	B-PRGE
-	I-PRGE
RPS3	E-PRGE
,	O
or	O
RPS3	S-PRGE
proteins	O
were	O
used	O
as	O
substrates	O
.	O

The	O
in	O
vitro	O
kinase	O
assay	O
was	O
performed	O
as	O
previously	O
described29	O
.	O

Briefly	O
,	O
enzyme	O
(	O
100	O
ng	O
)	O
and	O
substrate	O
(	O
2	O
mug	O
)	O
were	O
co	O
-	O
incubated	O
in	O
IKK	O
reaction	O
buffer	O
(	O
25	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
8	O
.	O
0	O
]	O
,	O
50	O
mM	O
KCl	O
,	O
10	O
mM	O
MgCl2	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
Na3VO4	O
,	O
1	O
mM	O
ATP	O
)	O
or	O
NleH1	O
reaction	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
6	O
]	O
,	O
5	O
mM	O
MgCl2	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
ATP	O
)	O
with	O
0	O
.	O
5	O
muCi	O
32P	O
-	O
gamma	O
-	O
ATP	O
(	O
GE	O
Healthcare	O
)	O
added	O
at	O
37	O
degreesC	O
for	O
30	O
min	O
.	O

The	O
reactions	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
visualized	O
by	O
autoradiography	O
.	O

LC	O
-	O
MS	O
/	O
MS	O
Analysis	O

GST	O
or	O
GST	B-PRGE
-	I-PRGE
RPS3	E-PRGE
was	O
incubated	O
with	O
recombinant	O
IKKbeta	S-PRGE
protein	O
as	O
described	O
above	O
in	O
an	O
in	O
vitro	O
kinase	O
assay	O
reaction	O
conducted	O
without	O
32P	O
-	O
gamma	O
-	O
ATP	O
labeling	O
.	O

The	O
reaction	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
the	O
protein	O
gel	O
was	O
stained	O
with	O
Colloidal	O
Blue	O
(	O
Invitrogen	O
)	O
.	O

The	O
corresponding	O
protein	O
fragments	O
were	O
excised	O
and	O
subjected	O
to	O
trypsin	O
digestion	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
at	O
the	O
Yale	O
Cancer	O
Center	O
Mass	O
Spectrometry	O
Resource	O
(	O
New	O
Haven	O
,	O
CT	O
)	O
.	O

RNAi	O
and	O
Transfection	O

The	O
siRNA	O
(	O
sense	O
-	O
strand	O
sequence	O
)	O
IKKalpha	S-PRGE
,	O
5	O
'	O
-	O
AUGACAGAGAAUGAUCAUGUUCUGC	O
-	O
3	O
'	O
;	O
IKKbeta	S-PRGE
,	O
5	O
'	O
-	O
GCAGCAAGGAGAACAGAGGUUAAUA	O
-	O
3	O
'	O
;	O
IkappaBalpha	S-PRGE
,	O
5	O
'	O
-	O
GAGCUCCGAGACUUUCGAGGAAAUA	O
-	O
3	O
'	O
;	O
RPS3	S-PRGE
-	O
3	O
'	O
UTR	O
,	O
5	O
'	O
-	O
GGAUGUUGCUCUCUAAAGACC	O
-	O
3	O
'	O
(	O
Invitrogen	O
)	O
.	O

Transient	O
transfection	O
of	O
siRNA	O
and	O
DNA	O
constructs	O
into	O
Jurkat	O
cells	O
and	O
293T	O
cells	O
was	O
described	O
previously6	O
.	O

Subcellular	O
Fractionation	O

Subcellular	O
fractionation	O
was	O
performed	O
by	O
differential	O
centrifugation	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
resuspended	O
in	O
ice	O
-	O
cold	O
Buffer	O
A	O
(	O
10	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
0	O
.	O
4	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
,	O
complete	O
protease	O
inhibitor	O
cocktail	O
)	O
at	O
4	O
degreesC	O
for	O
5	O
min	O
.	O

Lysates	O
were	O
centrifuged	O
at	O
4	O
degreesC	O
,	O
500	O
x	O
g	O
for	O
3	O
min	O
,	O
and	O
supernatants	O
were	O
collected	O
as	O
cytosolic	O
fractions	O
.	O

Pellets	O
were	O
incubated	O
in	O
Buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
pH7	O
.	O
9	O
,	O
420	O
mM	O
NaCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
25	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
,	O
0	O
.	O
2	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
complete	O
protease	O
inhibitor	O
cocktail	O
)	O
at	O
4	O
degreesC	O
for	O
10	O
min	O
.	O

Supernatants	O
were	O
collected	O
as	O
nuclear	O
fractions	O
following	O
a	O
centrifuge	O
at	O
4	O
degreesC	O
,	O
13	O
,	O
800	O
x	O
g	O
for	O
10	O
min	O
.	O

Luciferase	O
Reporter	O
Gene	O
Assays	O

Luciferase	O
reporter	O
gene	O
assays	O
were	O
performed	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
cotransfected	O
at	O
a	O
ratio	O
of	O
10	O
:	O
1	O
with	O
various	O
promoter	O
-	O
driven	O
firefly	O
luciferase	S-PRGE
constructs	O
to	O
the	O
Renilla	O
luciferase	S-PRGE
pTKRL	O
plasmid	O
,	O
together	O
with	O
indicated	O
plasmids	O
.	O

Cells	O
were	O
cultured	O
for	O
1	O
-	O
2	O
days	O
and	O
then	O
stimulated	O
in	O
triplicate	O
before	O
harvest	O
.	O

Lysates	O
were	O
analyzed	O
using	O
the	O
Dual	O
-	O
Luciferase	O
Kit	O
(	O
Promega	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O
(	O
ChIP	O
)	O

ChIP	O
assays	O
was	O
performed	O
as	O
previously	O
described6	O
.	O

The	O
primers	O
used	O
to	O
amplify	O
the	O
promoter	O
region	O
adjacent	O
to	O
the	O
kappaB	O
sites	O
of	O
IL8	S-PRGE
and	O
NFKBIA	S-PRGE
,	O
as	O
well	O
as	O
ACTB	S-PRGE
have	O
been	O
described6	O
.	O

Immunofluorescence	O
Microscopy	O

Confocal	O
microscopy	O
was	O
performed	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
and	O
then	O
Cellspin	O
mounted	O
onto	O
slides	O
.	O

The	O
fixed	O
cells	O
were	O
then	O
permeabilized	O
with	O
0	O
.	O
05	O
%	O
Triton	O
X	O
-	O
100	O
in	O
PBS	O
and	O
stained	O
with	O
FITC	O
-	O
conjugated	O
rabbit	O
anti	O
-	O
RPS3	O
antibodies	O
(	O
Primm	O
Biotech	O
)	O
,	O
or	O
AlexaFluor	O
594	O
-	O
conjugated	O
rat	O
anti	O
-	O
Flag	O
antibodies	O
(	O
BD	O
)	O
for	O
40	O
min	O
together	O
with	O
1	O
mug	O
/	O
ml	O
of	O
Hoechst	O
33342	O
(	O
Sigma	O
)	O
for	O
5	O
min	O
at	O
25	O
degreesC	O
.	O

The	O
slides	O
were	O
then	O
rinsed	O
with	O
PBS	O
three	O
times	O
and	O
cover	O
mounted	O
for	O
fluorescence	O
microscopy	O
.	O

Immunoprecipitation	O
and	O
immunoblot	O

The	O
cells	O
were	O
harvested	O
and	O
lysed	O
on	O
ice	O
by	O
0	O
.	O
4	O
ml	O
of	O
the	O
modified	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
4	O
]	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
25	O
%	O
Na	O
-	O
deoxycholate	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
PMSF	O
,	O
1	O
mM	O
Na3VO4	O
,	O
1	O
mM	O
NaF	O
)	O
supplemented	O
with	O
1	O
x	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
)	O
and	O
1	O
x	O
phosphatase	O
inhibitor	O
cocktail	O
set	O
I	O
(	O
EMD	O
Biosciences	O
)	O
for	O
30	O
min	O
.	O

The	O
lysates	O
were	O
centrifuged	O
at	O
10	O
,	O
000	O
x	O
g	O
at	O
4	O
degreesC	O
for	O
10	O
min	O
to	O
remove	O
insoluble	O
material	O
.	O

After	O
normalizing	O
protein	O
concentrations	O
,	O
lysates	O
were	O
subjected	O
to	O
immunoprecipitation	O
by	O
adding	O
10	O
mg	O
/	O
ml	O
appropriate	O
antibody	O
plus	O
30	O
ml	O
of	O
protein	O
G	O
-	O
agarose	O
(	O
Roche	O
)	O
,	O
and	O
rotated	O
for	O
at	O
least	O
2	O
h	O
at	O
4degreesC	O
.	O

The	O
precipitates	O
were	O
washed	O
at	O
least	O
five	O
times	O
with	O
cold	O
lysis	O
buffer	O
followed	O
by	O
separation	O
by	O
SDS	O
-	O
PAGE	O
under	O
reduced	O
and	O
denaturing	O
conditions	O
.	O

Nitrocellulose	O
membranes	O
were	O
blocked	O
in	O
5	O
%	O
nonfat	O
milk	O
in	O
0	O
.	O
1	O
%	O
PBS	O
-	O
Tween	O
20	O
(	O
PBS	O
-	O
T	O
)	O
,	O
probed	O
with	O
specific	O
antibodies	O
as	O
described	O
previously6	O
.	O

For	O
immunoblotting	O
of	O
phosphorylated	O
proteins	O
,	O
gels	O
were	O
transferred	O
to	O
methanol	O
-	O
treated	O
polyvinylidene	O
chloride	O
membranes	O
,	O
retreated	O
with	O
methanol	O
,	O
and	O
dried	O
for	O
30	O
min	O
.	O

Blots	O
were	O
blocked	O
in	O
5	O
%	O
bovine	O
serum	O
albumin	S-PRGE
in	O
0	O
.	O
1	O
%	O
Tris	O
buffered	O
saline	O
-	O
Tween	O
20	O
(	O
TBS	O
-	O
T	O
)	O
,	O
and	O
probed	O
with	O
specific	O
antibodies	O
as	O
described	O
previously46	O
.	O

Bands	O
were	O
imaged	O
by	O
the	O
Super	O
Signaling	O
system	O
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

ELISA	O

The	O
amount	O
of	O
IL	B-PRGE
-	I-PRGE
8	E-PRGE
present	O
in	O
supernatants	O
collected	O
from	O
Jurkat	O
cell	O
culture	O
was	O
measured	O
using	O
a	O
Human	O
Interleukin	B-PRGE
-	I-PRGE
8	E-PRGE
ELISA	O
Ready	O
-	O
SET	O
-	O
Go	O
kit	S-PRGE
(	O
eBioscience	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cell	O
Infections	O

HeLa	O
cells	O
were	O
infected	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
or	O
C	O
.	O
rodentium	O
strains	O
as	O
described	O
previously9	O
.	O

Immunohistochemistry	O

Gnotobiotic	O
piglets	O
were	O
infected	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
strains	O
as	O
described	O
previously9	O
.	O

Spiral	O
colon	O
specimens	O
were	O
collected	O
at	O
necropsy	O
and	O
embedded	O
in	O
paraffin	O
.	O

Paraffin	O
sectioning	O
and	O
immunohistochemical	O
staining	O
using	O
phospho	O
-	O
RPS3	O
antibody	O
were	O
performed	O
by	O
Histoserv	O
Inc	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
1	O
Tat	S-PRGE
activates	O
NF	O
-	O
kappaB	O
via	O
physical	O
interaction	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
is	O
a	O
master	O
regulator	O
of	O
pro	O
-	O
inflammatory	O
genes	O
and	O
is	O
upregulated	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
.	O

Mechanisms	O
underlying	O
the	O
NF	O
-	O
kappaB	O
deregulation	O
by	O
HIV	O
-	O
1	O
are	O
relevant	O
for	O
immune	O
dysfunction	O
in	O
AIDS	O
.	O

We	O
report	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
,	O
or	O
single	O
-	O
pulse	O
PMA	O
stimulation	O
,	O
the	O
HIV	O
-	O
1	O
Tat	S-PRGE
transactivator	O
activated	O
NF	O
-	O
kappaB	O
by	O
hijacking	O
the	O
inhibitor	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
by	O
preventing	O
the	O
repressor	O
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

Moreover	O
,	O
Tat	S-PRGE
associated	O
with	O
the	O
p65	S-PRGE
subunit	O
of	O
NF	O
-	O
kappaB	O
and	O
increased	O
the	O
p65	S-PRGE
DNA	O
-	O
binding	O
affinity	O
and	O
transcriptional	O
activity	O
.	O

The	O
arginine	O
-	O
and	O
cysteine	O
-	O
rich	O
domains	O
of	O
Tat	S-PRGE
were	O
required	O
for	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
association	O
,	O
respectively	O
,	O
and	O
for	O
sustaining	O
the	O
NF	O
-	O
kappaB	O
activity	O
.	O

Among	O
an	O
array	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
Tat	S-PRGE
mostly	O
activated	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
in	O
a	O
p65	S-PRGE
-	O
dependent	O
manner	O
,	O
and	O
bound	O
to	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
NF	O
-	O
kappaB	O
enhancer	O
thus	O
promoting	O
the	O
recruitment	O
of	O
p65	S-PRGE
with	O
displacement	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
;	O
similar	O
findings	O
were	O
obtained	O
for	O
the	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
and	O
TLR2	S-PRGE
.	O

Our	O
results	O
support	O
a	O
novel	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
via	O
physical	O
interaction	O
of	O
Tat	S-PRGE
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
,	O
and	O
may	O
contribute	O
to	O
further	O
insights	O
into	O
the	O
deregulation	O
of	O
the	O
inflammatory	O
response	O
by	O
HIV	O
-	O
1	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
transcription	O
factors	O
regulate	O
the	O
transcription	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
response	O
(	O
1	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
family	O
includes	O
RelA	S-PRGE
/	O
p65	S-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	E-PRGE
,	O
RelB	S-PRGE
,	O
p50	S-PRGE
and	O
p52	S-PRGE
that	O
share	O
a	O
highly	O
conserved	O
300	O
-	O
amino	O
acid	O
Rel	O
homology	O
domain	O
(	O
RHD	O
)	O
for	O
homo	O
-	O
or	O
hetero	O
-	O
dimerization	O
and	O
DNA	O
-	O
binding	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
depends	O
on	O
dimer	O
composition	O
since	O
C	O
-	O
terminal	O
unrelated	O
transcriptional	O
activation	O
domains	O
are	O
present	O
exclusively	O
in	O
p65	S-PRGE
,	O
RelB	S-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	E-PRGE
(	O
2	O
)	O
.	O

Inhibitors	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
associate	O
with	O
the	O
NF	O
-	O
kappaB	O
complex	O
and	O
interfere	O
with	O
its	O
binding	O
to	O
DNA	O
(	O
3	O
)	O
.	O

In	O
the	O
canonical	O
pathway	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
the	O
activated	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
phosphorylates	O
IkappaB	O
at	O
specific	O
serine	O
residues	O
that	O
target	O
the	O
protein	O
to	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
,	O
which	O
releases	O
the	O
functional	O
NF	O
-	O
kappaB	O
complex	O
in	O
the	O
nucleus	O
.	O

IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
the	O
most	O
abundant	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
4	O
)	O
,	O
is	O
phosphorylated	O
by	O
IKK	O
at	O
Ser32	O
and	O
Ser36	O
(	O
5	O
)	O
,	O
and	O
subsequently	O
ubiquitylated	O
at	O
Lys21	O
and	O
Lys22	O
to	O
be	O
degraded	O
by	O
the	O
26S	O
proteasome	O
(	O
6	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
is	O
enhanced	O
by	O
phosphorylation	O
of	O
p65	S-PRGE
at	O
Ser276	O
by	O
PKA	O
and	O
MSK1	S-PRGE
(	O
7	O
,	O
8	O
)	O
,	O
Ser311	O
by	O
PKCzeta	S-PRGE
(	O
9	O
)	O
and	O
Ser536	O
by	O
IKKalpha	S-PRGE
(	O
10	O
,	O
11	O
)	O
.	O

Acetylation	O
of	O
p65	S-PRGE
at	O
Lys218	O
and	O
Lys221	O
increases	O
the	O
DNA	O
binding	O
and	O
impairs	O
the	O
association	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
and	O
acetylation	O
at	O
Lys310	O
enhances	O
the	O
p65	S-PRGE
transcriptional	O
activity	O
(	O
12	O
,	O
13	O
)	O
.	O

Post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
is	O
regulated	O
by	O
negative	O
feedback	O
loop	O
through	O
inhibitors	O
under	O
the	O
transcriptional	O
control	O
of	O
NF	O
-	O
kappaB	O
,	O
such	O
as	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
ubiquitin	O
-	O
editing	O
protein	O
A20	S-PRGE
(	O
14	O
-	O
20	O
)	O
.	O

Deacetylation	O
of	O
p65	S-PRGE
by	O
histone	B-PRGE
deacetylase	I-PRGE
-	I-PRGE
3	E-PRGE
or	O
SIRT1	S-PRGE
,	O
or	O
acetylation	O
of	O
p65	S-PRGE
at	O
Lys122	O
and	O
Lys123	O
down	O
-	O
regulate	O
the	O
NF	O
-	O
kappaB	O
activity	O
(	O
12	O
,	O
21	O
,	O
22	O
)	O
.	O

Persistent	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
monocytes	O
,	O
macrophages	O
and	O
microglia	O
,	O
and	O
enhances	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
including	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
cell	O
adhesion	O
molecules	O
and	O
chemokines	O
(	O
23	O
-	O
25	O
)	O
.	O

Chronic	O
inflammation	O
is	O
a	O
major	O
cause	O
of	O
immune	O
and	O
neuron	O
dysfunction	O
in	O
AIDS	O
(	O
26	O
,	O
27	O
)	O
.	O

Consistently	O
,	O
non	O
-	O
human	O
primate	O
hosts	O
for	O
simian	O
immunodeficiency	O
virus	O
,	O
such	O
as	O
African	O
green	O
monkeys	O
and	O
sooty	O
mangabey	O
,	O
lack	O
aberrant	O
immune	O
activation	O
and	O
do	O
not	O
develop	O
AIDS	O
despite	O
high	O
virus	O
replication	O
(	O
28	O
,	O
29	O
)	O
.	O

Thus	O
,	O
understanding	O
the	O
mechanisms	O
of	O
NF	O
-	O
kappaB	O
deregulation	O
by	O
HIV	O
-	O
1	O
may	O
provide	O
further	O
insights	O
into	O
AIDS	O
pathogenesis	O
.	O

In	O
HIV	O
-	O
1	O
entry	O
,	O
the	O
binding	O
of	O
the	O
gp120	S-PRGE
viral	O
envelope	O
to	O
CD4	S-PRGE
induces	O
the	O
NF	O
-	O
kappaB	O
activity	O
by	O
activation	O
of	O
IKK	O
(	O
30	O
)	O
and	O
procaspase	B-PRGE
8	E-PRGE
(	O
31	O
)	O
.	O

Following	O
viral	O
integration	O
,	O
the	O
early	O
encoded	O
HIV	O
-	O
1	O
Tat	S-PRGE
protein	O
interacts	O
with	O
the	O
HIV	O
-	O
1	O
RNA	O
and	O
host	O
cell	O
factors	O
to	O
sustain	O
the	O
viral	O
replication	O
.	O

Tat	S-PRGE
binds	O
to	O
RNA	O
stem	O
-	O
loop	O
structures	O
generated	O
by	O
the	O
5	O
'	O
end	O
of	O
target	O
transcripts	O
,	O
including	O
the	O
HIV	O
-	O
1	O
transactivation	O
-	O
responsive	O
element	O
(	O
TAR	O
)	O
(	O
32	O
)	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
beta	E-PRGE
(	O
TNFbeta	S-PRGE
)	O
(	O
33	O
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
)	O
(	O
34	O
)	O
to	O
activate	O
gene	O
transcription	O
.	O

Indeed	O
,	O
Tat	S-PRGE
promotes	O
the	O
transcriptional	O
initiation	O
and	O
elongation	O
by	O
interacting	O
with	O
transacting	O
factors	O
and	O
cofactors	O
,	O
such	O
as	O
Sp1	S-PRGE
(	O
35	O
)	O
,	O
TFIID	S-PRGE
(	O
36	O
)	O
,	O
E2F	B-PRGE
-	I-PRGE
4	E-PRGE
(	O
37	O
)	O
,	O
C	B-PRGE
/	I-PRGE
EBPbeta	E-PRGE
(	O
38	O
)	O
,	O
cyclin	B-PRGE
T1	E-PRGE
/	O
CDK9	S-PRGE
(	O
39	O
,	O
40	O
)	O
and	O
the	O
histone	O
acetyltransferases	O
p300	S-PRGE
/	O
CBP	S-PRGE
and	O
P	B-PRGE
/	I-PRGE
CAF	E-PRGE
(	O
41	O
-	O
43	O
)	O
.	O

When	O
released	O
from	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
,	O
Tat	S-PRGE
deregulates	O
the	O
cell	O
signaling	O
by	O
binding	O
to	O
cell	O
receptors	O
,	O
such	O
as	O
integrins	O
(	O
44	O
)	O
,	O
Flk1	B-PRGE
/	I-PRGE
KDR	I-PRGE
receptor	E-PRGE
(	O
45	O
)	O
and	O
chemokine	O
receptors	O
(	O
46	O
)	O
.	O

We	O
first	O
reported	O
that	O
NF	O
-	O
kappaB	O
was	O
constitutively	O
active	O
in	O
Jurkat	O
cells	O
that	O
stably	O
expressed	O
the	O
Tat	S-PRGE
gene	O
(	O
47	O
)	O
.	O

Following	O
gene	O
transfection	O
or	O
protein	O
transduction	O
,	O
Tat	S-PRGE
induced	O
the	O
IKK	O
activity	O
and	O
proteasomal	O
degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
48	O
)	O
,	O
and	O
increased	O
the	O
p65	S-PRGE
transcriptional	O
activity	O
by	O
inhibiting	O
the	O
SIRT	B-PRGE
-	I-PRGE
1	E-PRGE
-	O
mediated	O
deacetylation	O
of	O
p65	S-PRGE
Lys310	O
(	O
49	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
Tat	S-PRGE
modulates	O
crucial	O
enzymes	O
involved	O
in	O
NF	O
-	O
kappaB	O
signaling	O
;	O
however	O
,	O
it	O
was	O
unclear	O
how	O
Tat	S-PRGE
could	O
subvert	O
the	O
negative	O
feedback	O
of	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
mainly	O
dependent	O
on	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
15	O
,	O
17	O
)	O
.	O

We	O
previously	O
found	O
that	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
binds	O
to	O
Tat	S-PRGE
and	O
promotes	O
the	O
nuclear	O
export	O
of	O
the	O
viral	O
transactivator	O
(	O
50	O
,	O
51	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
Tat	S-PRGE
counteracts	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
through	O
direct	O
interaction	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
,	O
which	O
enhances	O
the	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

The	O
new	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
deregulation	O
here	O
described	O
may	O
provide	O
further	O
insights	O
into	O
the	O
chronic	O
immune	O
activation	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Plasmids	O

The	O
plasmids	O
pcDNA	O
-	O
3xHA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	S-PRGE
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
,	I-PRGE
52	I-PRGE
,	I-PRGE
53	I-PRGE
,	I-PRGE
55	I-PRGE
,	I-PRGE
56	I-PRGE
,	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
pGEX	O
-	O
2T	O
-	O
Tat	S-PRGE
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
pGEX	O
-	O
2T	O
-	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
,	I-PRGE
52	I-PRGE
,	I-PRGE
53	I-PRGE
,	I-PRGE
55	I-PRGE
,	I-PRGE
56	I-PRGE
,	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
were	O
previously	O
described	O
(	O
50	O
)	O
.	O

The	O
plasmids	O
pNL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
and	O
pHXB2	O
-	O
env	S-PRGE
were	O
obtained	O
from	O
the	O
AIDS	O
Research	O
&	O
Reference	O
Reagent	O
Program	O
,	O
Division	O
of	O
AIDS	O
,	O
NIAID	O
,	O
NIH	O
,	O
USA	O
;	O
pkappaBluc	O
and	O
pSV	O
-	O
beta	B-PRGE
-	I-PRGE
Gal	E-PRGE
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

The	O
plasmids	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65	E-PRGE
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65deltaC	E-PRGE
(	O
1	O
-	O
318	O
)	O
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65deltaN	E-PRGE
(	O
122	O
-	O
551	O
)	O
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
pNL4	O
-	O
3	O
.	O
FLAG	O
-	O
Tat	S-PRGE
.	O
R	O
-	O
E	O
-	O
were	O
generated	O
as	O
described	O
in	O
Supplementary	O
Data	O
.	O

Cells	O
,	O
transfection	O
,	O
treatments	O
and	O
luciferase	S-PRGE
assay	O

HeLa	O
,	O
p50	S-PRGE
-	O
/	O
-	O
p65	S-PRGE
-	O
/	O
-	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
(	O
52	O
)	O
and	O
293T	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
Jurkat	O
,	O
U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
cultured	O
in	O
RPMI	O
1640	O
.	O

PBMCs	O
were	O
isolated	O
as	O
previously	O
described	O
(	O
53	O
)	O
.	O

Media	O
were	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
and	O
2	O
mM	O
l	O
-	O
glutamine	O
(	O
Lonza	O
Cologne	O
AG	O
,	O
Germany	O
)	O
.	O

HeLa	O
,	O
p50	S-PRGE
-	O
/	O
-	O
p65	S-PRGE
-	O
/	O
-	O
MEFs	O
and	O
293T	O
were	O
transfected	O
with	O
DNA	O
by	O
using	O
FuGENE	O
HD	O
(	O
Roche	O
Diagnostic	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
;	O
total	O
DNA	O
amounts	O
were	O
equalized	O
by	O
transfection	O
of	O
pRc	O
/	O
CMV	O
empty	O
vector	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
pulse	O
-	O
stimulation	O
,	O
HeLa	O
cells	O
were	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
;	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
(	O
20	O
ng	O
/	O
ml	O
)	O
for	O
5	O
min	O
,	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
;	O
Sigma	O
-	O
Aldrich	O
)	O
(	O
20	O
ng	O
/	O
ml	O
)	O
for	O
30	O
min	O
,	O
washed	O
twice	O
in	O
complete	O
culture	O
medium	O
and	O
then	O
returned	O
to	O
culture	O
.	O

For	O
luciferase	S-PRGE
assays	O
,	O
pSV	O
-	O
beta	B-PRGE
-	I-PRGE
Gal	E-PRGE
was	O
co	O
-	O
transfected	O
with	O
pkappaBluc	O
to	O
monitor	O
the	O
transfection	O
efficiency	O
.	O

Forty	O
-	O
eight	O
-	O
hour	O
post	O
-	O
transfection	O
,	O
cells	O
were	O
lysed	O
in	O
lysis	O
buffer	O
of	O
Dual	O
Light	O
Luciferase	S-PRGE
System	O
(	O
Tropix	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
)	O
and	O
the	O
luciferase	S-PRGE
and	O
beta	B-PRGE
-	I-PRGE
galactosidase	E-PRGE
activities	O
were	O
evaluated	O
by	O
using	O
Dual	O
Light	O
Luciferase	O
System	O
(	O
Tropix	O
)	O
in	O
a	O
bioluminometer	O
(	O
Turner	O
Biosystem	O
,	O
Sunnyvale	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
ratio	O
of	O
firefly	O
luciferase	S-PRGE
activity	O
to	O
beta	B-PRGE
-	I-PRGE
galactosidase	E-PRGE
activity	O
was	O
expressed	O
as	O
relative	O
light	O
units	O
.	O

RNA	O
interference	O

Jurkat	O
or	O
U937	O
cells	O
were	O
transfected	O
by	O
electroporation	O
using	O
a	O
Bio	O
-	O
Rad	O
apparatus	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Briefly	O
,	O
aliquots	O
(	O
5	O
x	O
106	O
cells	O
)	O
were	O
suspended	O
in	O
0	O
.	O
3	O
ml	O
of	O
RPMI	O
1640	O
supplemented	O
with	O
20	O
%	O
fetal	O
calf	O
serum	O
and	O
subjected	O
to	O
a	O
double	O
electrical	O
pulse	O
(	O
0	O
.	O
22	O
V	O
,	O
960	O
microF	O
)	O
in	O
the	O
presence	O
of	O
annealed	O
siRNA	O
(	O
200	O
pmol	O
)	O
;	O
electroporated	O
cells	O
were	O
washed	O
and	O
cultured	O
in	O
complete	O
medium	O
.	O

RNA	O
interference	O
was	O
performed	O
with	O
:	O
siRNA	B-PRGE
Tat	I-PRGE
sense	E-PRGE
,	O
CUGCUUGUACCAAUUGCUAUU	O
and	O
siRNA	B-PRGE
Tat	I-PRGE
antisense	E-PRGE
,	O
UAGCAAUUGGUACAAGCAGUU	O
;	O
siRNA	O
control	O
sense	O
,	O
CUGCUUGUCACA	O
AUUGCUAUU	O
and	O
siRNA	O
control	O
antisense	O
,	O
UAGCAAUUGUGACAAGCAGUU	O
.	O

RNA	O
interference	O
of	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
performed	O
with	O
SMART	O
pool	O
siRNA	B-PRGE
p65	E-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
Dharmacon	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Pseudotyped	O
virions	O
and	O
single	O
round	O
infection	O

293T	O
cells	O
(	O
1	O
x	O
107	O
)	O
were	O
transfected	O
with	O
pNL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
or	O
pNL4	O
-	O
3	O
.	O
FLAG	O
-	O
Tat	S-PRGE
.	O
R	O
-	O
E	O
-	O
(	O
10	O
microg	O
)	O
together	O
with	O
pHXB2	O
Env	S-PRGE
(	O
10	O
microg	O
)	O
,	O
and	O
48	O
-	O
h	O
post	O
-	O
transfection	O
cell	O
supernatant	O
was	O
collected	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
anti	O
-	O
p24	O
antibody	O
measured	O
virion	O
concentration	O
.	O

PBMCs	O
,	O
Jurkat	O
or	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
infected	O
with	O
HXB2	O
Env	S-PRGE
-	O
pseudotyped	O
virions	O
(	O
500	O
ng	O
of	O
p24	S-PRGE
)	O
by	O
spinoculation	O
,	O
as	O
previously	O
described	O
(	O
50	O
)	O
.	O

Cell	O
extracts	O
,	O
western	O
blotting	O
,	O
IKK	O
activity	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O

Total	O
,	O
nuclear	O
and	O
cytosolic	O
extracts	O
were	O
performed	O
as	O
previously	O
described	O
(	O
54	O
)	O
;	O
details	O
are	O
reported	O
in	O
Supplementary	O
Data	O
.	O

Western	O
blotting	O
analysis	O
was	O
performed	O
by	O
resuspending	O
protein	O
aliquots	O
in	O
loading	O
buffer	O
(	O
125	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
6	O
.	O
8	O
,	O
5	O
%	O
SDS	O
,	O
1	O
%	O
bromophenol	O
blue	O
,	O
10	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
25	O
%	O
glycerol	O
)	O
,	O
resolved	O
on	O
12	O
%	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
polyvinylidene	O
difluoride	O
membrane	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
)	O
and	O
incubated	O
with	O
primary	O
antibodies	O
(	O
1	O
:	O
1000	O
)	O
followed	O
by	O
incubation	O
with	O
horseradish	O
-	O
peroxidase	O
-	O
linked	O
mouse	O
or	O
rabbit	O
IgG	O
(	O
1	O
:	O
2000	O
)	O
(	O
GE	O
Healthcare	O
Amersham	O
,	O
Little	O
Chalfont	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
in	O
PBS	O
containing	O
5	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Proteins	O
were	O
detected	O
by	O
chemiluminescence	O
using	O
the	O
ECL	O
System	O
(	O
GE	O
Healthcare	O
Amersham	O
)	O
.	O

Primary	O
antibodies	O
were	O
purchased	O
from	O
:	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
(	O
anti	O
-	O
HA	O
F7	O
,	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
C15	O
,	O
anti	O
-	O
Histone	O
H1	O
,	O
anti	O
-	O
Hexokinase	O
-	O
II	O
)	O
;	O
Sigma	O
-	O
Aldrich	O
(	O
anti	O
-	O
FLAG	O
M2	O
,	O
anti	O
-	O
gamma	O
-	O
Tubulin	O
)	O
;	O
Upstate	O
,	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
(	O
anti	O
-	O
p65	O
)	O
.	O

Densitometry	O
of	O
single	O
bands	O
was	O
analysed	O
by	O
ImageJ	O
software	O
package	O
(	O
NIH	O
,	O
USA	O
)	O
.	O

IKK	O
activity	O
was	O
evaluated	O
in	O
cytosolic	O
extracts	O
using	O
the	O
HTScan	O
IKK	O
kinase	O
assay	O
kit	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Binding	O
of	O
p65	S-PRGE
,	O
p50	S-PRGE
and	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
to	O
the	O
double	O
-	O
stranded	O
NF	O
-	O
kappaB	O
oligonucleotide	O
was	O
measured	O
using	O
NF	O
-	O
kappaB	O
Combo	O
Transcription	O
Factor	O
Assay	O
kit	O
(	O
Cayman	O
Chemical	O
Company	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O
was	O
performed	O
as	O
previously	O
described	O
(	O
55	O
)	O
;	O
details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O

In	O
vitro	O
translation	O

HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
p65	S-PRGE
and	O
Tat	S-PRGE
were	O
expressed	O
under	O
the	O
T7	O
promoter	O
and	O
in	O
vitro	O
translated	O
using	O
the	O
TnT	O
quick	O
coupled	O
transcription	O
/	O
translation	O
system	O
(	O
Promega	O
)	O
,	O
as	O
previously	O
reported	O
(	O
50	O
)	O
.	O

Details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O

Immunoprecipitation	O
assay	O
and	O
GST	S-PRGE
-	O
pull	O
down	O

Immunoprecipitation	O
,	O
GST	S-PRGE
-	O
pull	O
down	O
,	O
and	O
production	O
of	O
GST	S-PRGE
proteins	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
were	O
performed	O
as	O
previously	O
reported	O
(	O
50	O
)	O
.	O

Details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O

Real	O
-	O
time	O
PCR	O

Total	O
RNA	O
was	O
extracted	O
from	O
cells	O
by	O
using	O
the	O
TRIzol	O
reagent	O
(	O
Invitrogen	O
)	O
;	O
RNA	O
aliquots	O
(	O
200	O
ng	O
)	O
were	O
reverse	O
transcribed	O
using	O
Random	O
Examers	O
(	O
Roche	O
)	O
and	O
Superscript	O
III	O
Reverse	O
Transcriptase	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
the	O
iQ	O
Green	O
Super	O
mix	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
and	O
carried	O
out	O
with	O
the	O
iCycler	O
iQ	O
Real	O
-	O
Time	O
detection	O
system	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
under	O
the	O
following	O
conditions	O
:	O
95degreesC	O
,	O
1	O
min	O
;	O
(	O
94degreesC	O
,	O
10	O
s	O
;	O
60degreesC	O
,	O
30	O
s	O
)	O
x40	O
.	O

Primers	O
for	O
Tat	S-PRGE
and	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
are	O
listed	O
in	O
Supplementary	O
Data	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
,	O
TLR2	S-PRGE
,	O
GAPDH	S-PRGE
and	O
ACTB	S-PRGE
was	O
performed	O
using	O
the	O
RT2	O
profiler	O
PCR	O
Array	O
-	O
Human	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
(	O
QIAGEN	O
Sciences	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Reactions	O
were	O
carried	O
out	O
in	O
triplicate	O
,	O
and	O
gene	O
expression	O
levels	O
were	O
calculated	O
relative	O
to	O
GAPDH	S-PRGE
mRNA	O
levels	O
as	O
endogenous	O
control	O
.	O

Relative	O
expression	O
was	O
calculated	O
as	O
2	O
(	O
Ct	O
gene	O
under	O
investigation	O
-	O
Ct	O
GAPDH	S-PRGE
)	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O

Cells	O
were	O
fixed	O
by	O
adding	O
formaldehyde	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
at	O
the	O
final	O
concentration	O
of	O
1	O
%	O
.	O

After	O
10	O
min	O
,	O
ice	O
-	O
cold	O
PBS	O
plus	O
0	O
.	O
125	O
M	O
glycine	O
was	O
added	O
,	O
and	O
plates	O
were	O
transferred	O
on	O
ice	O
,	O
washed	O
extensively	O
with	O
PBS	O
,	O
and	O
scraped	O
.	O

After	O
centrifugation	O
,	O
cells	O
were	O
10	O
min	O
lysed	O
in	O
lysis	O
buffer	O
(	O
5	O
mM	O
PIPES	O
pH	O
8	O
.	O
0	O
,	O
85	O
mM	O
KCl	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
)	O
supplemented	O
with	O
1x	O
Complete	O
Protease	O
Inhibitor	O
(	O
Roche	O
Diagnostic	O
GmbH	O
)	O
.	O

Nuclei	O
were	O
pelletted	O
(	O
1000	O
x	O
g	O
,	O
5	O
min	O
)	O
,	O
and	O
resuspended	O
in	O
sonication	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
%	O
SDS	O
,	O
10	O
mM	O
EDTA	O
)	O
.	O

Chromatin	O
was	O
sonicated	O
using	O
Bandelin	O
Sonoplus	O
GM70	O
(	O
Bandelin	O
Electronic	O
,	O
Berlin	O
,	O
Germany	O
)	O
,	O
centrifuged	O
(	O
14	O
000	O
x	O
g	O
,	O
15	O
min	O
)	O
,	O
and	O
supernatant	O
was	O
10	O
-	O
fold	O
diluted	O
in	O
dilution	O
buffer	O
(	O
0	O
.	O
01	O
%	O
SDS	O
,	O
16	O
.	O
7	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
167	O
mM	O
NaCl	O
,	O
1	O
.	O
2	O
mM	O
EDTA	O
)	O
.	O

Samples	O
were	O
pre	O
-	O
cleared	O
by	O
3	O
-	O
h	O
incubation	O
with	O
20	O
microl	O
of	O
protein	B-PRGE
G	E-PRGE
agarose	O
beads	O
followed	O
by	O
incubation	O
with	O
antibodies	O
against	O
the	O
analysed	O
proteins	O
.	O

Primary	O
antibodies	O
were	O
:	O
anti	O
-	O
p65	O
(	O
sc	O
-	O
372	O
)	O
,	O
anti	O
-	O
IkappaBalpha	O
(	O
sc	O
-	O
203	O
)	O
and	O
rabbit	O
IgG	O
(	O
sc	O
-	O
2027	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
;	O
anti	O
-	O
FLAG	O
M2	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

Immunoprecipitations	O
were	O
carried	O
out	O
at	O
4degreesC	O
overnight	O
and	O
immune	O
complexes	O
were	O
collected	O
with	O
protein	B-PRGE
G	E-PRGE
agarose	O
beads	O
,	O
washed	O
five	O
times	O
with	O
low	O
salt	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
,	O
150	O
mM	O
NaCl	O
)	O
,	O
four	O
times	O
with	O
high	O
salt	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
,	O
500	O
mM	O
NaCl	O
)	O
,	O
once	O
with	O
TE	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
extracted	O
in	O
TE	O
buffer	O
containing	O
2	O
%	O
SDS	O
.	O

Protein	O
-	O
DNA	O
cross	O
-	O
links	O
were	O
reverted	O
by	O
heating	O
at	O
65degreesC	O
overnight	O
.	O

DNA	O
was	O
further	O
purified	O
by	O
QIAquick	O
PCR	O
purification	O
kit	O
(	O
QIAGEN	O
)	O
and	O
eluted	O
in	O
50	O
microl	O
sterile	O
distilled	O
water	O
.	O

Specific	O
enrichment	O
in	O
NF	O
-	O
kappaB	O
enhancer	O
sequences	O
was	O
measured	O
by	O
real	O
-	O
time	O
PCR	O
of	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
eluates	O
using	O
SYBR	O
GreenER	O
Master	O
Mix	O
(	O
Invitrogen	O
)	O
.	O

Reactions	O
were	O
carried	O
out	O
with	O
the	O
iCycler	O
iQ	O
Real	O
-	O
Time	O
detection	O
system	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
using	O
the	O
following	O
conditions	O
:	O
95degreesC	O
,	O
1	O
min	O
;	O
(	O
94degreesC	O
,	O
10	O
s	O
;	O
60degreesC	O
,	O
30	O
s	O
)	O
x40	O
.	O

Primers	O
used	O
for	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
GAPDH	S-PRGE
and	O
ACTB	S-PRGE
are	O
listed	O
in	O
Supplementary	O
Data	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
and	O
TLR2	S-PRGE
were	O
performed	O
using	O
the	O
Custom	O
ChIP	O
array	O
(	O
QIAGEN	O
)	O
.	O

For	O
each	O
sample	O
,	O
values	O
were	O
normalized	O
to	O
input	O
DNA	O
and	O
reported	O
as	O
%	O
of	O
input	O
over	O
the	O
rabbit	O
IgG	O
control	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
performed	O
by	O
two	O
-	O
tail	O
unpaired	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Data	O
were	O
reported	O
as	O
means	O
+	O
/	O
-	O
SE	O
.	O

Differences	O
between	O
the	O
means	O
were	O
considered	O
as	O
statistically	O
significant	O
at	O
the	O
95	O
%	O
level	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Tat	S-PRGE
enhances	O
the	O
NF	O
-	O
kappaB	O
activity	O
by	O
hijacking	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
inhibiting	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O

We	O
analysed	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
by	O
modulating	O
the	O
expression	O
of	O
Tat	S-PRGE
with	O
RNA	O
interference	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
,	O
siRNA	O
control	O
,	O
or	O
left	O
untransfected	O
,	O
and	O
24	O
h	O
later	O
cells	O
were	O
infected	O
with	O
HXB2	O
Env	S-PRGE
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
virions	O
.	O

By	O
cytofluorimetric	O
analysis	O
,	O
~	O
40	O
%	O
of	O
cells	O
was	O
siRNA	O
-	O
transfected	O
and	O
HIV	O
-	O
1	O
-	O
infected	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O

The	O
expression	O
of	O
Tat	S-PRGE
was	O
detected	O
at	O
1	O
-	O
h	O
post	O
-	O
infection	O
and	O
progressively	O
increased	O
up	O
to	O
12	O
h	O
in	O
untransfected	O
and	O
siRNA	O
control	O
-	O
transfected	O
cells	O
,	O
while	O
it	O
was	O
barely	O
detected	O
in	O
siRNA	B-PRGE
Tat	E-PRGE
-	O
transfected	O
cells	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
LTR	O
-	O
dependent	O
luciferase	S-PRGE
expression	O
was	O
also	O
progressively	O
induced	O
at	O
1	O
-	O
to	O
12	O
-	O
h	O
post	O
-	O
infection	O
in	O
untransfected	O
and	O
siRNA	O
control	O
-	O
transfected	O
cells	O
,	O
while	O
it	O
was	O
barely	O
observed	O
in	O
siRNA	B-PRGE
Tat	E-PRGE
-	O
transfected	O
cells	O
,	O
as	O
expected	O
for	O
the	O
Tat	S-PRGE
-	O
dependent	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
progressive	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
measured	O
by	O
p65	S-PRGE
-	O
p50	S-PRGE
binding	O
to	O
an	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotide	O
(	O
Figure	O
1B	O
)	O
and	O
nuclear	O
p65	S-PRGE
(	O
Figure	O
1C	O
,	O
nucleus	O
)	O
,	O
was	O
observed	O
at	O
1	O
-	O
to	O
3	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	S-PRGE
-	O
positive	O
(	O
no	O
siRNA	O
or	O
siRNA	O
control	O
)	O
and	O
Tat	S-PRGE
-	O
negative	O
(	O
siRNA	B-PRGE
Tat	E-PRGE
)	O
cells	O
;	O
however	O
,	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
,	O
the	O
p65	S-PRGE
DNA	O
binding	O
and	O
nuclear	O
p65	S-PRGE
persisted	O
elevated	O
in	O
presence	O
of	O
Tat	S-PRGE
(	O
no	O
siRNA	O
and	O
siRNA	O
control	O
)	O
,	O
while	O
they	O
dropped	O
in	O
absence	O
of	O
Tat	S-PRGE
(	O
siRNA	B-PRGE
Tat	E-PRGE
)	O
(	O
Figure	O
1B	O
and	O
C	O
)	O
.	O

IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
degraded	O
in	O
the	O
cytosol	O
within	O
3	O
-	O
h	O
post	O
-	O
infection	O
and	O
de	O
novo	O
synthesized	O
at	O
6	O
h	O
with	O
full	O
replenishment	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	S-PRGE
-	O
positive	O
and	O
Tat	S-PRGE
-	O
negative	O
cells	O
(	O
Figure	O
1C	O
,	O
cytosol	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activity	O
was	O
induced	O
at	O
1	O
-	O
h	O
post	O
-	O
infection	O
,	O
and	O
decreased	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
independently	O
of	O
the	O
presence	O
of	O
Tat	S-PRGE
(	O
Figure	O
1D	O
)	O
.	O

Similar	O
kinetics	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
IKK	O
activation	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
degradation	O
/	O
re	O
-	O
synthesis	O
were	O
observed	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
of	O
PBMCs	O
using	O
a	O
cocktail	O
of	O
Azidothymidine	O
(	O
AZT	O
)	O
and	O
Lamivudine	O
(	O
3TC	O
)	O
as	O
reverse	O
transcriptase	O
inhibitors	O
(	O
Supplementary	O
Figure	O
S2	O
)	O
.	O

These	O
results	O
indicated	O
that	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
the	O
NF	O
-	O
kappaB	O
activation	O
initially	O
correlated	O
with	O
the	O
IKK	O
activation	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
degradation	O
independently	O
of	O
the	O
presence	O
of	O
Tat	S-PRGE
,	O
and	O
it	O
was	O
kept	O
elevated	O
in	O
presence	O
of	O
Tat	S-PRGE
following	O
the	O
decay	O
of	O
the	O
IKK	O
activity	O
and	O
new	O
synthesis	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

Next	O
,	O
we	O
tested	O
the	O
single	O
action	O
of	O
Tat	S-PRGE
on	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activity	O
induced	O
by	O
PMA	O
.	O

To	O
this	O
end	O
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
p3x	O
-	O
FLAG	O
-	O
Tat	S-PRGE
,	O
or	O
empty	O
vector	O
,	O
stimulated	O
with	O
PMA	O
for	O
5	O
min	O
,	O
and	O
extensively	O
washed	O
to	O
avoid	O
the	O
oscillatory	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
17	O
,	O
18	O
)	O
.	O

In	O
un	O
-	O
stimulated	O
cells	O
,	O
the	O
p65	S-PRGE
DNA	O
binding	O
(	O
Figure	O
2A	O
)	O
and	O
nuclear	O
p65	S-PRGE
(	O
Figure	O
2B	O
,	O
nucleus	O
)	O
were	O
slightly	O
enhanced	O
by	O
Tat	S-PRGE
,	O
while	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
content	O
was	O
not	O
significantly	O
affected	O
(	O
Figure	O
2B	O
,	O
cytosol	O
)	O
.	O

Transient	O
stimulation	O
with	O
PMA	O
increased	O
the	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
nuclear	O
p65	S-PRGE
at	O
5	O
min	O
peaking	O
at	O
60	O
-	O
120	O
min	O
independently	O
of	O
the	O
presence	O
of	O
Tat	S-PRGE
(	O
Figure	O
2A	O
and	O
B	O
)	O
;	O
however	O
,	O
while	O
the	O
p65	S-PRGE
DNA	O
binding	O
and	O
nuclear	O
p65	S-PRGE
persisted	O
elevated	O
at	O
240	O
-	O
min	O
post	O
-	O
treatment	O
in	O
Tat	S-PRGE
-	O
positive	O
cells	O
,	O
they	O
dropped	O
in	O
Tat	S-PRGE
-	O
negative	O
cells	O
(	O
Figure	O
2A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
Tat	S-PRGE
bound	O
to	O
the	O
NF	O
-	O
kappaB	O
oligonucleotide	O
in	O
un	O
-	O
stimulated	O
cells	O
and	O
its	O
binding	O
increased	O
following	O
PMA	O
stimulation	O
(	O
Figure	O
2A	O
)	O
,	O
suggesting	O
that	O
the	O
viral	O
protein	O
was	O
a	O
component	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
bound	O
to	O
DNA	O
.	O

Degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
progressively	O
induced	O
at	O
5	O
-	O
30	O
min	O
,	O
followed	O
by	O
de	O
novo	O
synthesis	O
at	O
60	O
min	O
with	O
full	O
replenishment	O
at	O
240	O
min	O
in	O
both	O
Tat	S-PRGE
-	O
positive	O
and	O
negative	O
cells	O
(	O
Figure	O
2B	O
,	O
cytosol	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activation	O
started	O
at	O
5	O
min	O
,	O
and	O
turned	O
off	O
at	O
30	O
min	O
independently	O
of	O
the	O
presence	O
of	O
Tat	S-PRGE
(	O
Figure	O
2C	O
)	O
.	O

These	O
results	O
indicated	O
that	O
Tat	S-PRGE
enhanced	O
the	O
NF	O
-	O
kappaB	O
activity	O
in	O
un	O
-	O
stimulated	O
and	O
PMA	O
-	O
stimulated	O
cells	O
without	O
affecting	O
the	O
IKK	O
activity	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
content	O
.	O

As	O
we	O
previously	O
found	O
that	O
Tat	S-PRGE
binds	O
to	O
the	O
sixth	O
ankyrin	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
50	O
,	O
51	O
)	O
,	O
we	O
tested	O
whether	O
Tat	S-PRGE
counteracted	O
the	O
generation	O
of	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
/	O
NF	O
-	O
kappaB	O
complex	O
.	O

To	O
this	O
end	O
,	O
the	O
association	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
with	O
p65	S-PRGE
was	O
analysed	O
in	O
vivo	O
at	O
0	O
and	O
240	O
min	O
after	O
short	O
-	O
pulse	O
PMA	O
,	O
which	O
corresponded	O
to	O
the	O
time	O
of	O
un	O
-	O
stimulated	O
condition	O
and	O
post	O
-	O
activation	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
respectively	O
.	O

Coimmunoprecipitation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
with	O
p65	S-PRGE
was	O
detected	O
at	O
0	O
-	O
and	O
240	O
-	O
min	O
post	O
-	O
treatment	O
in	O
Tat	S-PRGE
-	O
negative	O
cells	O
(	O
Figure	O
2D	O
,	O
lanes	O
1	O
and	O
3	O
)	O
,	O
and	O
was	O
halved	O
in	O
Tat	S-PRGE
-	O
positive	O
cells	O
,	O
where	O
Tat	S-PRGE
coimmunoprecipitated	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
Figure	O
2D	O
,	O
lanes	O
2	O
and	O
4	O
)	O
,	O
indicating	O
that	O
Tat	S-PRGE
competed	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
binding	O
to	O
p65	S-PRGE
.	O

Tat	S-PRGE
counteracts	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
inhibition	O
of	O
p65	S-PRGE
by	O
competing	O
the	O
repressor	O
binding	O

We	O
further	O
investigated	O
the	O
physical	O
interaction	O
of	O
Tat	S-PRGE
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
using	O
in	O
vitro	O
translated	O
proteins	O
in	O
coimmunoprecipitation	O
assays	O
.	O

For	O
mapping	O
the	O
interaction	O
domains	O
,	O
we	O
used	O
the	O
following	O
Tat	S-PRGE
mutants	O
:	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
Figure	O
3A	O
)	O
.	O

IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
coimmunoprecipitated	O
with	O
all	O
Tat	S-PRGE
proteins	O
,	O
except	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
Figure	O
3B	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
arginine	O
-	O
rich	O
domain	O
of	O
Tat	S-PRGE
was	O
involved	O
in	O
the	O
binding	O
to	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
which	O
was	O
consistent	O
with	O
previous	O
observations	O
(	O
50	O
,	O
51	O
)	O
.	O

Moreover	O
,	O
Tat	S-PRGE
associating	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
competed	O
the	O
binding	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
to	O
p65	S-PRGE
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
3C	O
,	O
lanes	O
3	O
-	O
5	O
)	O
,	O
while	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
which	O
lacked	O
the	O
binding	O
site	O
for	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
did	O
not	O
associate	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
did	O
not	O
compete	O
the	O
binding	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
to	O
p65	S-PRGE
(	O
Figure	O
3C	O
,	O
lanes	O
6	O
-	O
8	O
)	O
.	O

Next	O
,	O
we	O
evaluated	O
whether	O
Tat	S-PRGE
counteracted	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
-	O
mediated	O
inhibition	O
of	O
p65	S-PRGE
binding	O
to	O
DNA	O
by	O
incubating	O
in	O
vitro	O
translated	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
proteins	O
with	O
the	O
NF	O
-	O
kappaB	O
probe	O
in	O
presence	O
or	O
absence	O
of	O
Tat	S-PRGE
followed	O
by	O
EMSA	O
.	O

The	O
p65	S-PRGE
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
restored	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
wild	O
-	O
type	O
Tat	S-PRGE
,	O
and	O
not	O
by	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	E-PRGE
(	O
Figure	O
3D	O
)	O
.	O

Further	O
,	O
we	O
analysed	O
the	O
Tat	S-PRGE
effect	O
on	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repression	O
of	O
p65	S-PRGE
transcriptional	O
activity	O
by	O
transfecting	O
p50	S-PRGE
-	O
/	O
-	O
p65	S-PRGE
-	O
/	O
-	O
MEFs	O
with	O
the	O
NF	O
-	O
kappaB	O
-	O
Luc	S-PRGE
reporter	O
together	O
with	O
expression	O
vectors	O
of	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
in	O
presence	O
or	O
absence	O
of	O
Tat	S-PRGE
.	O

IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
inhibited	O
the	O
p65	S-PRGE
-	O
dependent	O
expression	O
of	O
the	O
luciferase	S-PRGE
gene	O
,	O
which	O
was	O
restored	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
wild	O
-	O
type	O
Tat	S-PRGE
,	O
and	O
not	O
by	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
Figure	O
3E	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
Tat	S-PRGE
counteracts	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repression	O
of	O
the	O
p65	S-PRGE
DNA	O
-	O
binding	O
and	O
transcriptional	O
activity	O
by	O
associating	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
competing	O
the	O
repressor	O
binding	O
to	O
p65	S-PRGE
.	O

Tat	S-PRGE
increases	O
the	O
p65	S-PRGE
affinity	O
binding	O
to	O
DNA	O
through	O
association	O
with	O
p65	S-PRGE

We	O
tested	O
whether	O
Tat	S-PRGE
physically	O
interacted	O
with	O
p65	S-PRGE
.	O

HeLa	O
cells	O
were	O
transfected	O
with	O
the	O
expression	O
vectors	O
of	O
HA	B-PRGE
-	I-PRGE
p65	E-PRGE
and	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
,	O
and	O
24	O
h	O
later	O
Tat	S-PRGE
was	O
immunoprecipitated	O
from	O
cell	O
extracts	O
.	O

The	O
p65	S-PRGE
protein	O
was	O
coimmunoprecipitated	O
with	O
wild	O
-	O
type	O
Tat	S-PRGE
or	O
the	O
mutants	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
at	O
similar	O
levels	O
,	O
while	O
a	O
significant	O
decrease	O
in	O
coimmunoprecipitation	O
was	O
observed	O
for	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
Figure	O
4A	O
)	O
.	O

Consistently	O
,	O
GST	S-PRGE
-	O
pull	O
down	O
of	O
in	O
vitro	O
translated	O
proteins	O
showed	O
the	O
direct	O
binding	O
of	O
p65	S-PRGE
to	O
wild	O
-	O
type	O
Tat	S-PRGE
,	O
or	O
the	O
mutants	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
and	O
lack	O
of	O
binding	O
to	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
indicated	O
that	O
Tat	S-PRGE
associated	O
with	O
p65	S-PRGE
through	O
the	O
cysteine	O
-	O
rich	O
domain	O
and	O
ruled	O
-	O
out	O
the	O
requirement	O
of	O
bridging	O
proteins	O
to	O
mediate	O
such	O
interaction	O
.	O

To	O
identify	O
the	O
p65	S-PRGE
domain	O
required	O
for	O
binding	O
to	O
Tat	S-PRGE
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
together	O
with	O
HA	B-PRGE
-	I-PRGE
p65	E-PRGE
mutants	O
,	O
which	O
were	O
deleted	O
of	O
the	O
transactivation	O
domain	O
[	O
p65deltaC	B-PRGE
(	I-PRGE
1	I-PRGE
-	I-PRGE
318	I-PRGE
)	E-PRGE
]	O
,	O
or	O
the	O
RHD	O
[	O
p65deltaN	B-PRGE
(	I-PRGE
122	I-PRGE
-	I-PRGE
551	I-PRGE
)	E-PRGE
]	O
(	O
Figure	O
4C	O
)	O
.	O

Tat	S-PRGE
coimmunoprecipitated	O
with	O
p65deltaC	B-PRGE
(	I-PRGE
1	I-PRGE
-	I-PRGE
318	I-PRGE
)	E-PRGE
,	O
and	O
not	O
with	O
p65deltaN	B-PRGE
(	I-PRGE
122	I-PRGE
-	I-PRGE
551	I-PRGE
)	E-PRGE
(	O
Figure	O
4D	O
)	O
,	O
indicating	O
that	O
the	O
RHD	O
of	O
p65	S-PRGE
was	O
involved	O
in	O
the	O
physical	O
interaction	O
with	O
Tat	S-PRGE
.	O

To	O
address	O
the	O
effect	O
of	O
Tat	S-PRGE
on	O
the	O
p65	S-PRGE
DNA	O
-	O
binding	O
affinity	O
,	O
purified	O
recombinant	O
p65	S-PRGE
protein	O
was	O
incubated	O
with	O
32P	O
-	O
labeled	O
-	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
in	O
presence	O
or	O
absence	O
of	O
wild	O
-	O
type	O
Tat	S-PRGE
or	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
and	O
p65	S-PRGE
DNA	O
-	O
binding	O
was	O
analysed	O
by	O
EMSA	O
.	O

Whereas	O
wild	O
-	O
type	O
Tat	S-PRGE
significantly	O
increased	O
the	O
binding	O
of	O
p65	S-PRGE
to	O
DNA	O
,	O
the	O
mutant	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
lacking	O
the	O
binding	O
site	O
for	O
p65	S-PRGE
,	O
was	O
ineffective	O
(	O
Figure	O
4E	O
)	O
.	O

The	O
p65	S-PRGE
binding	O
to	O
DNA	O
was	O
evaluated	O
by	O
competition	O
with	O
increasing	O
amounts	O
of	O
cold	O
competitor	O
NF	O
-	O
kappaB	O
oligonucleotide	O
,	O
which	O
showed	O
that	O
Tat	S-PRGE
significantly	O
enhanced	O
the	O
p65	S-PRGE
affinity	O
binding	O
to	O
DNA	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

Tat	S-PRGE
activates	O
the	O
p65	S-PRGE
-	O
dependent	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
occupies	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
and	O
promotes	O
the	O
p65	S-PRGE
recruitment	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
displacement	O

We	O
analysed	O
the	O
action	O
of	O
Tat	S-PRGE
on	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
in	O
vivo	O
.	O

To	O
this	O
end	O
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
,	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
or	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
and	O
48	O
h	O
later	O
the	O
expression	O
of	O
a	O
number	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
was	O
analysed	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Tat	S-PRGE
significantly	O
increased	O
the	O
expression	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
and	O
TLR2	S-PRGE
,	O
while	O
the	O
mutants	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
and	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
were	O
ineffective	O
(	O
Figure	O
5A	O
-	O
E	O
)	O
.	O

The	O
Tat	S-PRGE
-	O
dependent	O
transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
was	O
abolished	O
when	O
cells	O
were	O
transfected	O
with	O
siRNA	B-PRGE
p65	E-PRGE
,	O
indicating	O
that	O
the	O
Tat	S-PRGE
transcriptional	O
activation	O
was	O
mediated	O
by	O
p65	S-PRGE
(	O
Figure	O
5A	O
-	O
E	O
)	O
.	O

Differently	O
,	O
the	O
expression	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
independent	O
genes	O
GAPDH	S-PRGE
and	O
ACTB	S-PRGE
was	O
unaffected	O
by	O
wild	O
-	O
type	O
and	O
Tat	S-PRGE
mutants	O
(	O
Figure	O
5F	O
and	O
G	O
)	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
requirement	O
of	O
both	O
the	O
cysteine	O
-	O
rich	O
and	O
arginine	O
-	O
rich	O
domains	O
of	O
Tat	S-PRGE
to	O
enhance	O
the	O
NF	O
-	O
kappaB	O
activity	O
,	O
suggesting	O
that	O
the	O
up	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
by	O
Tat	S-PRGE
might	O
occur	O
through	O
physical	O
interaction	O
of	O
the	O
viral	O
protein	O
with	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
which	O
was	O
the	O
mostly	O
activated	O
gene	O
by	O
Tat	S-PRGE
,	O
encodes	O
for	O
a	O
chemokine	O
that	O
promotes	O
the	O
recruitment	O
of	O
pro	O
-	O
inflammatory	O
cells	O
(	O
56	O
)	O
.	O

Consistently	O
with	O
our	O
findings	O
,	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
was	O
increased	O
in	O
glial	O
cells	O
and	O
lymph	O
nodes	O
of	O
AIDS	O
patients	O
(	O
57	O
,	O
58	O
)	O
;	O
moreover	O
,	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
production	O
was	O
induced	O
by	O
HIV	O
-	O
1	O
infection	O
(	O
59	O
,	O
60	O
)	O
and	O
Tat	S-PRGE
protein	O
(	O
57	O
,	O
61	O
,	O
62	O
)	O
.	O

The	O
transcriptional	O
regulation	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
has	O
been	O
poorly	O
characterized	O
.	O

Jaspar	O
-	O
based	O
analysis	O
(	O
http	O
:	O
/	O
/	O
jaspar	O
.	O
genereg	O
.	O
net	O
/	O
)	O
predicted	O
three	O
putative	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
the	O
proximal	O
promoter	O
region	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
gene	O
:	O
NF	O
-	O
kappaB1	O
,	O
-	O
1023	O
/	O
-	O
1014	O
nucleotides	O
;	O
NF	O
-	O
kappaB2	O
,	O
-	O
661	O
/	O
-	O
652	O
nucleotides	O
;	O
NF	O
-	O
kappaB3	O
,	O
+	O
370	O
/	O
+	O
379	O
nucleotides	O
(	O
Supplementary	O
Figure	O
S3A	O
)	O
.	O

To	O
validate	O
the	O
predicted	O
NF	O
-	O
kappaB	O
binding	O
sites	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
promoter	O
,	O
we	O
stimulated	O
HeLa	O
cells	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
a	O
well	O
-	O
known	O
NF	O
-	O
kappaB	O
inducer	O
,	O
and	O
measured	O
the	O
expression	O
levels	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
by	O
real	O
-	O
time	O
PCR	O
,	O
and	O
the	O
p65	S-PRGE
occupancy	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
by	O
ChIP	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
activated	O
the	O
expression	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
and	O
induced	O
the	O
p65	S-PRGE
recruitment	O
to	O
the	O
NF	O
-	O
kappaB1	O
site	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
without	O
affecting	O
the	O
occupancy	O
of	O
the	O
putative	O
NF	O
-	O
kappaB2	O
and	O
NF	O
-	O
kappaB3	O
sites	O
(	O
Supplementary	O
Figure	O
S3B	O
and	O
S3C	O
)	O
.	O

Tat	S-PRGE
also	O
promoted	O
the	O
recruitment	O
of	O
p65	S-PRGE
to	O
the	O
NF	O
-	O
kappaB1	O
site	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
while	O
it	O
did	O
not	O
affect	O
the	O
putative	O
NF	O
-	O
kappaB2	O
and	O
NF	O
-	O
kappaB3	O
sites	O
(	O
Supplementary	O
Figure	O
S3D	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
the	O
NF	O
-	O
kappaB1	O
site	O
was	O
the	O
only	O
effective	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
promoter	O
in	O
response	O
to	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
Tat	S-PRGE
.	O

Similarly	O
to	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
Tat	S-PRGE
increased	O
the	O
recruitment	O
of	O
p65	S-PRGE
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
of	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
and	O
TLR2	S-PRGE
,	O
while	O
it	O
was	O
ineffective	O
at	O
the	O
promoters	O
of	O
GAPDH	S-PRGE
and	O
ACTB	S-PRGE
(	O
Figure	O
5H	O
)	O
.	O

By	O
ChIP	O
,	O
Tat	S-PRGE
bound	O
to	O
the	O
NF	O
-	O
kappaB	O
-	O
responsive	O
promoters	O
,	O
and	O
not	O
to	O
the	O
GAPDH	S-PRGE
and	O
ACTB	S-PRGE
promoters	O
,	O
with	O
loss	O
of	O
binding	O
following	O
p65	S-PRGE
RNA	O
interference	O
(	O
Figure	O
5I	O
)	O
,	O
suggesting	O
that	O
Tat	S-PRGE
occupancy	O
occurred	O
via	O
p65	S-PRGE
interaction	O
.	O

As	O
additional	O
findings	O
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
chromatin	O
-	O
immunoprecipitated	O
at	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
absence	O
of	O
Tat	S-PRGE
,	O
and	O
it	O
was	O
significantly	O
removed	O
in	O
presence	O
of	O
Tat	S-PRGE
,	O
or	O
following	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
RNA	O
interference	O
(	O
Figure	O
5J	O
)	O
,	O
indicating	O
that	O
Tat	S-PRGE
displaced	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
from	O
promoters	O
.	O

In	O
HIV	O
-	O
1	O
-	O
infected	O
monocytes	O
Tat	S-PRGE
sustains	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
promotes	O
the	O
transcriptional	O
activation	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
by	O
interacting	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE

We	O
next	O
analysed	O
whether	O
Tat	S-PRGE
affected	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
the	O
expression	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
in	O
the	O
course	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

To	O
detect	O
the	O
Tat	S-PRGE
protein	O
,	O
we	O
produced	O
HXB2	O
Env	S-PRGE
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
which	O
were	O
used	O
in	O
single	O
-	O
round	O
infection	O
of	O
U937	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Cells	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
,	O
siRNA	O
control	O
or	O
left	O
untransfected	O
to	O
modulate	O
the	O
Tat	S-PRGE
expression	O
,	O
and	O
then	O
analysed	O
for	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
following	O
viral	O
infection	O
.	O

The	O
expression	O
of	O
Tat	S-PRGE
and	O
p24	S-PRGE
was	O
detected	O
at	O
3	O
-	O
to	O
12	O
-	O
h	O
post	O
-	O
infection	O
,	O
while	O
it	O
was	O
barely	O
detected	O
in	O
siRNA	B-PRGE
Tat	E-PRGE
-	O
transfected	O
cells	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
measured	O
by	O
p65	S-PRGE
DNA	O
binding	O
,	O
was	O
induced	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	S-PRGE
-	O
positive	O
(	O
no	O
siRNA	O
and	O
siRNA	O
control	O
)	O
and	O
Tat	S-PRGE
-	O
negative	O
cells	O
(	O
siRNA	B-PRGE
Tat	E-PRGE
)	O
,	O
and	O
increased	O
at	O
12	O
h	O
only	O
in	O
Tat	S-PRGE
-	O
positive	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

Degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
observed	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
,	O
and	O
was	O
followed	O
by	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
at	O
12	O
h	O
independently	O
of	O
the	O
Tat	S-PRGE
presence	O
(	O
Figure	O
6C	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activity	O
was	O
induced	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
and	O
turned	O
off	O
at	O
12	O
h	O
independently	O
of	O
the	O
Tat	S-PRGE
presence	O
(	O
Figure	O
6D	O
)	O
.	O

These	O
results	O
agreed	O
with	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
of	O
Jurkat	O
cells	O
(	O
Figure	O
1	O
)	O
,	O
and	O
further	O
supported	O
the	O
requirement	O
of	O
viral	O
expression	O
to	O
counteract	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
HIV	O
-	O
1	O
-	O
infected	O
U937	O
cells	O
,	O
the	O
endogenous	O
Tat	S-PRGE
was	O
coimmunoprecipitated	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
(	O
Figure	O
6E	O
)	O
,	O
and	O
activated	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
in	O
a	O
p65	S-PRGE
-	O
dependent	O
manner	O
,	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
following	O
RNA	O
interference	O
of	O
Tat	S-PRGE
or	O
p65	S-PRGE
(	O
Figure	O
6F	O
)	O
.	O

Moreover	O
,	O
Tat	S-PRGE
and	O
p65	S-PRGE
were	O
both	O
recruited	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
while	O
the	O
p65	S-PRGE
occupancy	O
was	O
abolished	O
by	O
siRNA	B-PRGE
Tat	E-PRGE
(	O
Figure	O
6G	O
and	O
H	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
Tat	S-PRGE
associated	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
,	O
and	O
induced	O
the	O
p65	S-PRGE
-	O
dependent	O
activation	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
through	O
occupancy	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
promoter	O
and	O
increased	O
recruitment	O
of	O
p65	S-PRGE
.	O

This	O
study	O
reports	O
a	O
novel	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
the	O
HIV	O
-	O
1	O
Tat	S-PRGE
transactivator	O
.	O

Based	O
on	O
the	O
evidence	O
that	O
Tat	S-PRGE
enhanced	O
the	O
transcriptional	O
activity	O
of	O
the	O
p65	S-PRGE
subunit	O
of	O
NF	O
-	O
kappaB	O
(	O
49	O
,	O
63	O
,	O
64	O
)	O
,	O
and	O
physically	O
interacted	O
with	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repressor	O
(	O
50	O
,	O
51	O
)	O
,	O
we	O
investigated	O
the	O
possibility	O
that	O
Tat	S-PRGE
could	O
activate	O
NF	O
-	O
kappaB	O
via	O
direct	O
interaction	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
.	O

To	O
this	O
end	O
,	O
the	O
NF	O
-	O
kappaB	O
activity	O
was	O
monitored	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
using	O
RNA	O
interference	O
to	O
silence	O
the	O
Tat	S-PRGE
expression	O
.	O

By	O
this	O
approach	O
,	O
we	O
avoided	O
the	O
perpetuation	O
of	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
due	O
to	O
subsequent	O
rounds	O
of	O
viral	O
entry	O
in	O
cell	O
culture	O
propagation	O
(	O
30	O
,	O
31	O
)	O
.	O

Upon	O
HIV	O
-	O
1	O
infection	O
,	O
the	O
early	O
NF	O
-	O
kappaB	O
activation	O
occurred	O
concomitantly	O
with	O
IKK	O
activation	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
degradation	O
in	O
the	O
absence	O
of	O
Tat	S-PRGE
.	O

Soon	O
after	O
the	O
shut	O
off	O
of	O
IKK	O
activity	O
and	O
new	O
synthesis	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
the	O
NF	O
-	O
kappaB	O
activity	O
was	O
kept	O
elevated	O
in	O
the	O
presence	O
of	O
Tat	S-PRGE
,	O
while	O
it	O
was	O
down	O
regulated	O
upon	O
silencing	O
of	O
the	O
Tat	S-PRGE
gene	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
,	O
Tat	S-PRGE
enhanced	O
the	O
NF	O
-	O
kappaB	O
activity	O
without	O
affecting	O
the	O
IKK	O
activity	O
and	O
the	O
half	O
-	O
life	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

Similar	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
occurred	O
upon	O
short	O
-	O
pulse	O
of	O
PMA	O
in	O
Tat	S-PRGE
-	O
transfected	O
HeLa	O
cells	O
,	O
where	O
Tat	S-PRGE
inhibited	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
in	O
presence	O
of	O
newly	O
synthesized	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

The	O
Tat	S-PRGE
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
association	O
of	O
the	O
viral	O
protein	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
,	O
which	O
interfered	O
with	O
the	O
generation	O
of	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
/	O
p65	S-PRGE
complex	O
.	O

This	O
evidence	O
demonstrated	O
that	O
Tat	S-PRGE
competed	O
for	O
the	O
binding	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
to	O
p65	S-PRGE
and	O
prevented	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repression	O
of	O
p65	S-PRGE
.	O

As	O
additional	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
Tat	S-PRGE
associated	O
with	O
p65	S-PRGE
and	O
increased	O
the	O
p65	S-PRGE
binding	O
affinity	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
;	O
this	O
evidence	O
was	O
obtained	O
with	O
recombinant	O
proteins	O
indicating	O
that	O
the	O
stronger	O
binding	O
of	O
p65	S-PRGE
to	O
DNA	O
was	O
a	O
consequence	O
of	O
direct	O
association	O
with	O
Tat	S-PRGE
,	O
which	O
likely	O
caused	O
a	O
conformational	O
change	O
of	O
p65	S-PRGE
.	O

We	O
also	O
demonstrated	O
that	O
the	O
Tat	S-PRGE
cysteine	O
-	O
rich	O
sequence	O
(	O
C22	O
,	O
25	O
,	O
27	O
)	O
was	O
involved	O
in	O
the	O
binding	O
to	O
the	O
RHD	O
of	O
p65	S-PRGE
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Differently	O
,	O
the	O
Tat	S-PRGE
arginine	O
-	O
rich	O
sequence	O
(	O
R49	O
,	O
52	O
,	O
53	O
,	O
55	O
,	O
56	O
,	O
57	O
)	O
was	O
required	O
for	O
the	O
binding	O
to	O
the	O
sixth	O
ankyrin	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
50	O
,	O
51	O
)	O
,	O
and	O
for	O
releasing	O
p65	S-PRGE
from	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
inhibition	O
.	O

Altogether	O
these	O
results	O
demonstrated	O
that	O
Tat	S-PRGE
abolished	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
by	O
hijacking	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repressor	O
,	O
shielding	O
p65	S-PRGE
from	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
embrace	O
,	O
and	O
enforcing	O
the	O
p65	S-PRGE
binding	O
to	O
DNA	O
.	O

Further	O
evidence	O
of	O
Tat	S-PRGE
activation	O
of	O
NF	O
-	O
kappaB	O
showed	O
that	O
wild	O
-	O
type	O
Tat	S-PRGE
,	O
and	O
not	O
the	O
Tat	B-PRGE
mutants	E-PRGE
lacking	O
the	O
arginine	O
-	O
or	O
cysteine	O
-	O
rich	O
domains	O
,	O
up	O
-	O
regulated	O
in	O
vivo	O
the	O
expression	O
of	O
a	O
number	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
including	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
,	O
CSF3	S-PRGE
,	O
LTA	S-PRGE
,	O
NFKBIA	S-PRGE
and	O
TLR2	S-PRGE
.	O

By	O
ChIP	O
analysis	O
,	O
we	O
observed	O
that	O
Tat	S-PRGE
increased	O
the	O
recruitment	O
of	O
p65	S-PRGE
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
of	O
the	O
activated	O
genes	O
,	O
and	O
was	O
recovered	O
at	O
the	O
same	O
sites	O
.	O

RNA	O
interference	O
of	O
p65	S-PRGE
abolished	O
the	O
Tat	S-PRGE
occupancy	O
of	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
indicating	O
that	O
the	O
Tat	S-PRGE
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
sites	O
was	O
mediated	O
by	O
p65	S-PRGE
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
evidence	O
that	O
Tat	S-PRGE
displaced	O
p65	S-PRGE
from	O
the	O
binding	O
to	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
Figures	O
2D	O
and	O
3C	O
)	O
,	O
and	O
increased	O
the	O
p65	S-PRGE
DNA	O
binding	O
affinity	O
through	O
association	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

Thus	O
,	O
Tat	S-PRGE
likely	O
increased	O
the	O
recruitment	O
of	O
p65	S-PRGE
to	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoters	O
by	O
associating	O
with	O
p65	S-PRGE
and	O
by	O
interfering	O
with	O
the	O
assembly	O
of	O
p65	S-PRGE
with	O
the	O
repressor	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

Of	O
interest	O
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
found	O
associated	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
absence	O
of	O
Tat	S-PRGE
,	O
where	O
it	O
was	O
displaced	O
in	O
presence	O
of	O
Tat	S-PRGE
.	O

These	O
results	O
suggest	O
a	O
negative	O
regulatory	O
role	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
in	O
gene	O
regulation	O
through	O
occupancy	O
of	O
specific	O
promoters	O
.	O

Indeed	O
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
found	O
associated	O
with	O
hystone	O
deacetylases	O
at	O
the	O
hes1	S-PRGE
promoter	O
,	O
from	O
where	O
it	O
was	O
removed	O
following	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
stimulation	O
causing	O
histone	O
acetylation	O
and	O
hes1	S-PRGE
transcriptional	O
activation	O
(	O
65	O
)	O
.	O

A	O
similar	O
mechanism	O
of	O
gene	O
regulation	O
could	O
apply	O
to	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
analysed	O
in	O
this	O
study	O
,	O
where	O
Tat	S-PRGE
could	O
activate	O
the	O
gene	O
expression	O
by	O
removing	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
promoting	O
the	O
p65	S-PRGE
loading	O
(	O
Figure	O
7	O
)	O
.	O

The	O
physiological	O
relevance	O
of	O
Tat	S-PRGE
cross	O
talk	O
with	O
NF	O
-	O
kappaB	O
was	O
demonstrated	O
in	O
the	O
HIV	O
-	O
1	O
infection	O
of	O
human	O
monocytes	O
,	O
where	O
HIV	O
-	O
1	O
-	O
encoded	O
Tat	S-PRGE
protein	O
counteracted	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
,	O
as	O
shown	O
by	O
:	O
(	O
i	O
)	O
sustained	O
NF	O
-	O
kappaB	O
activity	O
by	O
Tat	S-PRGE
in	O
presence	O
of	O
newly	O
synthesized	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
;	O
(	O
ii	O
)	O
coimmunoprecipitation	O
of	O
Tat	S-PRGE
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
;	O
(	O
iii	O
)	O
induction	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
dependent	O
on	O
Tat	S-PRGE
and	O
p65	S-PRGE
;	O
(	O
iv	O
)	O
Tat	S-PRGE
occupancy	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
NF	O
-	O
kappaB	O
enhancer	O
associated	O
with	O
increased	O
recruitment	O
of	O
p65	S-PRGE
.	O

This	O
study	O
supports	O
the	O
pro	O
-	O
inflammatory	O
action	O
of	O
Tat	S-PRGE
through	O
physical	O
interaction	O
with	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
.	O

Several	O
inflammatory	O
cytokines	O
under	O
the	O
transcriptional	O
control	O
of	O
NF	O
-	O
kappaB	O
are	O
hyper	O
-	O
expressed	O
in	O
HIV	O
-	O
1	O
infected	O
individuals	O
,	O
including	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
(	O
66	O
,	O
67	O
)	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
68	O
)	O
,	O
and	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
(	O
57	O
-	O
62	O
,	O
69	O
-	O
71	O
)	O
.	O

In	O
the	O
case	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
Tat	S-PRGE
activated	O
the	O
cytokine	O
expression	O
by	O
binding	O
to	O
the	O
TAR	O
-	O
like	O
stem	O
loop	O
of	O
the	O
5	O
'	O
transcript	O
,	O
thus	O
likely	O
promoting	O
the	O
transcriptional	O
elongation	O
(	O
33	O
,	O
37	O
,	O
47	O
)	O
.	O

Here	O
,	O
we	O
have	O
shown	O
that	O
the	O
Tat	S-PRGE
-	O
dependent	O
transcriptional	O
activation	O
of	O
a	O
number	O
of	O
pro	O
-	O
inflammatory	O
genes	O
required	O
the	O
assembly	O
of	O
Tat	S-PRGE
with	O
p65	S-PRGE
at	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
together	O
with	O
the	O
displacement	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
Figure	O
5	O
)	O
.	O

Thus	O
,	O
in	O
the	O
set	O
of	O
distinct	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
Tat	S-PRGE
acted	O
as	O
a	O
component	O
of	O
the	O
transcriptional	O
initiation	O
complex	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
on	O
Tat	S-PRGE
promoting	O
the	O
transcription	O
via	O
DNA	O
motifs	O
(	O
72	O
,	O
73	O
)	O
.	O

Overproduction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
is	O
considered	O
a	O
major	O
mechanism	O
of	O
immune	O
deregulation	O
(	O
26	O
)	O
and	O
neuron	O
dysfunction	O
in	O
AIDS	O
(	O
74	O
,	O
75	O
)	O
.	O

In	O
this	O
scenario	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
could	O
lead	O
to	O
a	O
therapeutic	O
strategy	O
for	O
counteracting	O
the	O
abnormal	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
HIV	O
-	O
1	O
infection	O
.	O

NF	O
-	O
kappaB	O
inhibitors	O
,	O
such	O
as	O
anti	O
-	O
oxidants	O
,	O
proteasome	O
and	O
IKK	O
inhibitors	O
,	O
significantly	O
reduced	O
the	O
HIV	O
-	O
1	O
replication	O
and	O
the	O
associated	O
inflammatory	O
response	O
(	O
76	O
,	O
77	O
)	O
;	O
however	O
,	O
these	O
NF	O
-	O
kappaB	O
inhibitors	O
acted	O
indiscriminately	O
in	O
both	O
HIV	O
-	O
1	O
-	O
infected	O
and	O
uninfected	O
cells	O
.	O

The	O
evidence	O
that	O
Tat	S-PRGE
activates	O
NF	O
-	O
kappaB	O
through	O
direct	O
interaction	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
may	O
lead	O
to	O
specific	O
inhibitors	O
to	O
counteract	O
the	O
Tat	S-PRGE
pro	O
-	O
inflammatory	O
action	O
.	O

Tat	S-PRGE
counteracts	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
in	O
single	O
round	O
HIV	O
-	O
1	O
-	O
infection	O
.	O

Jurkat	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
or	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
virions	O
(	O
500	O
ng	O
of	O
p24	S-PRGE
)	O
and	O
harvested	O
at	O
the	O
indicated	O
time	O
.	O

(	O
A	O
)	O
Tat	S-PRGE
expression	O
was	O
measured	O
in	O
total	O
RNA	O
by	O
real	O
-	O
time	O
PCR	O
,	O
while	O
the	O
luciferase	S-PRGE
activity	O
was	O
measured	O
in	O
whole	O
cell	O
extracts	O
.	O

(	O
B	O
)	O
Nuclear	O
extracts	O
(	O
10	O
microg	O
)	O
were	O
analysed	O
for	O
the	O
p65	S-PRGE
and	O
p50	S-PRGE
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
Assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
C	O
)	O
The	O
expression	O
of	O
p65	S-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
analysed	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
of	O
nuclear	O
or	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
using	O
anti	O
-	O
p65	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

Histone	O
H1	O
and	O
Hexokinase	B-PRGE
II	E-PRGE
were	O
detected	O
with	O
specific	O
antibodies	O
as	O
markers	O
of	O
nuclear	O
and	O
cytosolic	O
extracts	O
,	O
respectively	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
mock	O
)	O
.	O

(	O
D	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
extracts	O
(	O
100	O
microg	O
)	O
by	O
using	O
HTScan	O
IKK	O
Kinase	O
Assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

Tat	S-PRGE
enhances	O
the	O
NF	O
-	O
kappaB	O
activity	O
following	O
PMA	O
stimulation	O
by	O
associating	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
counteracting	O
the	O
NF	O
-	O
kappaB	O
repression	O
.	O

HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	S-PRGE
or	O
p3xFLAG	O
empty	O
vector	O
(	O
5	O
microg	O
)	O
,	O
and	O
48	O
h	O
later	O
were	O
stimulated	O
with	O
PMA	O
(	O
5	O
min	O
,	O
20	O
ng	O
/	O
ml	O
)	O
or	O
left	O
unstimulated	O
,	O
washed	O
twice	O
with	O
DMEM	O
and	O
harvested	O
at	O
the	O
indicated	O
times	O
.	O

Nuclear	O
and	O
cytosolic	O
extracts	O
were	O
prepared	O
for	O
further	O
analysis	O
.	O

(	O
A	O
)	O
Nuclear	O
extracts	O
were	O
analysed	O
for	O
the	O
p65	S-PRGE
,	O
p50	S-PRGE
and	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
B	O
)	O
Nuclear	O
and	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
using	O
the	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
,	O
anti	O
-	O
Histone	O
H1	O
,	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
and	O
anti	O
-	O
Hexokinase	O
-	O
II	O
antibodies	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

(	O
C	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
extracts	O
(	O
100	O
microg	O
)	O
by	O
using	O
HTScan	O
IKK	O
kinase	O
assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

(	O
D	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
or	O
without	O
p3xFLAG	O
-	O
Tat	S-PRGE
(	O
5	O
microg	O
)	O
;	O
48	O
h	O
later	O
,	O
cells	O
were	O
stimulated	O
with	O
PMA	O
(	O
5	O
min	O
,	O
20	O
ng	O
/	O
ml	O
)	O
or	O
left	O
unstimulated	O
,	O
washed	O
twice	O
with	O
DMEM	O
,	O
and	O
harvested	O
after	O
240	O
min	O
.	O

Whole	O
cell	O
extracts	O
(	O
1	O
mg	O
)	O
were	O
immunoprecipitated	O
with	O
protein	B-PRGE
G	E-PRGE
-	O
Sepharose	O
-	O
coupled	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O

Immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

Tat	S-PRGE
relieves	O
p65	S-PRGE
from	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
inhibition	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
Tat	S-PRGE
proteins	O
.	O

(	O
B	O
)	O
HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
5	O
microl	O
)	O
was	O
incubated	O
in	O
presence	O
or	O
absence	O
of	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
,	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
or	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
10	O
microl	O
)	O
using	O
in	O
vitro	O
translated	O
proteins	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
Tat	S-PRGE
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
FLAG	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
HA	O
and	O
anti	O
-	O
FLAG	O
antibodies	O
.	O

(	O
C	O
)	O
35S	O
-	O
methionine	O
-	O
labeled	O
p65	S-PRGE
(	O
5	O
microl	O
)	O
was	O
incubated	O
with	O
in	O
vitro	O
translated	O
HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
5	O
microl	O
)	O
in	O
presence	O
or	O
absence	O
of	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
or	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
5	O
,	O
10	O
or	O
20	O
microl	O
)	O
.	O

HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
was	O
immunoprecipitated	O
with	O
anti	O
-	O
HA	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
HA	O
and	O
anti	O
-	O
FLAG	O
antibodies	O
,	O
or	O
autoradiography	O
(	O
35S	O
-	O
Met	O
-	O
p65	S-PRGE
)	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

(	O
D	O
)	O
The	O
p65	S-PRGE
DNA	O
binding	O
activity	O
was	O
analysed	O
by	O
EMSA	O
using	O
in	O
vitro	O
translated	O
proteins	O
.	O

32P	O
-	O
labeled	O
-	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
was	O
incubated	O
with	O
p65	S-PRGE
(	O
0	O
.	O
5	O
microl	O
)	O
in	O
presence	O
or	O
absence	O
of	O
HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
1	O
microl	O
)	O
,	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
or	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
5	O
and	O
10	O
microl	O
)	O
;	O
competition	O
of	O
DNA	O
binding	O
was	O
performed	O
with	O
10	O
-	O
up	O
to	O
100	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
.	O

DNA	O
/	O
protein	O
complexes	O
were	O
run	O
on	O
6	O
%	O
PAGE	O
-	O
TBE	O
and	O
analysed	O
by	O
autoradiography	O
.	O

(	O
E	O
)	O
p50	S-PRGE
-	O
/	O
-	O
p65	S-PRGE
-	O
/	O
-	O
MEFs	O
(	O
3	O
x	O
105	O
cells	O
)	O
were	O
transfected	O
with	O
pkappaBLuc	O
(	O
0	O
.	O
5	O
microg	O
)	O
and	O
pSV	O
-	O
beta	B-PRGE
-	I-PRGE
Gal	E-PRGE
(	O
0	O
.	O
1	O
microg	O
)	O
with	O
or	O
without	O
pRc	O
/	O
CMV	O
-	O
p65	S-PRGE
(	O
0	O
.	O
5	O
microg	O
)	O
,	O
pCMV4	O
-	O
HA	B-PRGE
-	I-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
(	O
0	O
.	O
5	O
microg	O
)	O
,	O
p3xFLAG	O
-	O
Tat	S-PRGE
or	O
p3xFLAG	O
-	O
Tat	S-PRGE
R	O
(	O
49	O
-	O
57	O
)	O
A	O
(	O
0	O
.	O
5	O
,	O
1	O
and	O
2	O
microg	O
)	O
.	O

The	O
luciferase	S-PRGE
activity	O
was	O
measured	O
in	O
cell	O
extracts	O
48	O
-	O
h	O
post	O
-	O
transfection	O
and	O
normalized	O
to	O
beta	B-PRGE
-	I-PRGE
galactosidase	E-PRGE
activity	O
.	O

Fold	O
activation	O
was	O
calculated	O
relative	O
to	O
transfection	O
of	O
the	O
pkappaBLuc	O
plasmid	O
alone	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

As	O
control	O
of	O
protein	O
expression	O
,	O
aliquots	O
of	O
cell	O
extracts	O
(	O
20	O
microg	O
)	O
were	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
HA	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
gamma	O
-	O
tubulin	O
antibodies	O
.	O

Tat	S-PRGE
associates	O
with	O
p65	S-PRGE
increasing	O
its	O
DNA	O
-	O
affinity	O
binding	O
.	O

(	O
A	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65	E-PRGE
(	O
5	O
microg	O
)	O
in	O
presence	O
or	O
absence	O
of	O
p3xFLAG	O
-	O
Tat	S-PRGE
,	O
p3xFLAG	O
-	O
Tat	B-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
p3xFLAG	O
-	O
Tat	B-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
p3xFLAG	O
-	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
or	O
p3xFLAG	O
-	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
5	O
microg	O
)	O
.	O

FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
FLAG	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
FLAG	O
or	O
anti	O
-	O
HA	O
antibodies	O
.	O

(	O
B	O
)	O
In	O
vitro	O
translated	O
p65	S-PRGE
(	O
5	O
microl	O
)	O
was	O
incubated	O
with	O
GST	B-PRGE
-	I-PRGE
Tat	E-PRGE
,	O
GST	B-PRGE
-	I-PRGE
Tat	I-PRGE
T	I-PRGE
,	I-PRGE
N	I-PRGE
(	I-PRGE
23	I-PRGE
,	I-PRGE
24	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
GST	B-PRGE
-	I-PRGE
Tat	I-PRGE
K	I-PRGE
(	I-PRGE
50	I-PRGE
,	I-PRGE
51	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
GST	B-PRGE
-	I-PRGE
Tat	I-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
GST	B-PRGE
-	I-PRGE
Tat	I-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
,	O
or	O
GST	S-PRGE
(	O
5	O
microg	O
)	O
conjugated	O
with	O
Glutathione	O
-	O
Sepharose	O
.	O

Protein	O
complexes	O
were	O
recovered	O
by	O
GST	S-PRGE
-	O
pull	O
down	O
,	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
,	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
or	O
anti	O
-	O
GST	O
antibodies	O
.	O

(	O
C	O
)	O
Schematic	O
representation	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
p65	S-PRGE
proteins	O
.	O

(	O
D	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	S-PRGE
(	O
5	O
microg	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65	E-PRGE
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65deltaC	E-PRGE
(	O
1	O
-	O
318	O
)	O
,	O
or	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-PRGE
-	I-PRGE
p65deltaN	E-PRGE
(	O
122	O
-	O
551	O
)	O
(	O
5	O
microg	O
)	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
HA	B-PRGE
-	I-PRGE
p65	E-PRGE
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
HA	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
FLAG	O
or	O
anti	O
-	O
HA	O
antibodies	O
.	O

(	O
E	O
)	O
Recombinant	O
p65	S-PRGE
protein	O
(	O
100	O
ng	O
;	O
Active	O
Motif	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
was	O
20	O
min	O
incubated	O
with	O
32P	O
-	O
labeled	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
in	O
presence	O
or	O
absence	O
of	O
in	O
vitro	O
translated	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
or	O
FLAG	B-PRGE
-	I-PRGE
Tat	I-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	I-PRGE
A	E-PRGE
(	O
5	O
microl	O
)	O
;	O
competitions	O
were	O
performed	O
with	O
1	O
.	O
25	O
-	O
up	O
to	O
40	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
oligonucleotide	O
.	O

DNA	O
/	O
protein	O
complexes	O
were	O
separated	O
by	O
6	O
%	O
PAGE	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
and	O
analysed	O
by	O
autoradiography	O
.	O

(	O
F	O
)	O
Densitometry	O
of	O
band	O
-	O
shifts	O
shown	O
in	O
E	O
.	O

Tat	S-PRGE
activates	O
the	O
p65	S-PRGE
-	O
dependent	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
by	O
occupying	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
and	O
promoting	O
the	O
p65	S-PRGE
recruitment	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
displacement	O
.	O

HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	S-PRGE
,	O
p3xFLAG	O
-	O
Tat	B-PRGE
C	I-PRGE
(	I-PRGE
22	I-PRGE
,	I-PRGE
25	I-PRGE
,	I-PRGE
27	I-PRGE
)	E-PRGE
,	O
p3xFLAG	O
-	O
Tat	B-PRGE
R	I-PRGE
(	I-PRGE
49	I-PRGE
-	I-PRGE
57	I-PRGE
)	E-PRGE
or	O
empty	O
vector	O
(	O
10	O
microg	O
)	O
;	O
for	O
p65	S-PRGE
RNA	O
interference	O
,	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	S-PRGE
(	O
10	O
microg	O
)	O
and	O
siRNA	B-PRGE
p65	E-PRGE
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
.	O

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
transfection	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
analysed	O
by	O
real	O
-	O
time	O
PCR	O
to	O
evaluate	O
the	O
expression	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
(	O
A	O
)	O
,	O
CSF3	S-PRGE
(	O
B	O
)	O
,	O
LTA	S-PRGE
(	O
C	O
)	O
,	O
NFKBIA	S-PRGE
(	O
D	O
)	O
,	O
TLR2	S-PRGE
(	O
E	O
)	O
,	O
GAPDH	S-PRGE
(	O
F	O
)	O
,	O
ACTB	S-PRGE
(	O
G	O
)	O
genes	O
.	O

(	O
H	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	S-PRGE
,	O
or	O
empty	O
vector	O
(	O
10	O
microg	O
)	O
and	O
48	O
h	O
later	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
p65	O
antibody	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O

(	O
I	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
empty	O
vector	O
,	O
or	O
p3xFLAG	O
-	O
Tat	S-PRGE
(	O
10	O
microg	O
)	O
in	O
presence	O
or	O
absence	O
of	O
siRNA	B-PRGE
p65	E-PRGE
,	O
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
;	O
48	O
h	O
later	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
FLAG	O
antibody	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O

(	O
J	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
empty	O
vector	O
,	O
p3xFLAG	O
-	O
Tat	S-PRGE
(	O
10	O
microg	O
)	O
,	O
or	O
empty	O
vector	O
plus	O
siRNA	B-PRGE
IkappaB	I-PRGE
-	I-PRGE
alpha	E-PRGE
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
;	O
48	O
h	O
later	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

The	O
asterisks	O
indicate	O
statistically	O
significant	O
differences	O
compared	O
to	O
the	O
control	O
(	O
empty	O
vector	O
)	O
according	O
to	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
HIV	O
-	O
1	O
infection	O
Tat	S-PRGE
sustains	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
enhances	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
via	O
interaction	O
with	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
and	O
p65	S-PRGE
.	O

U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
,	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
.	O
R	O
-	O
E	O
-	O
virions	O
(	O
500	O
ng	O
of	O
p24	S-PRGE
)	O
and	O
harvested	O
at	O
the	O
indicated	O
time	O
.	O

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
of	O
total	O
RNA	O
measured	O
the	O
Tat	S-PRGE
expression	O
;	O
ELISA	O
measured	O
the	O
amount	O
of	O
p24	S-PRGE
in	O
whole	O
cell	O
extracts	O
.	O

(	O
B	O
)	O
The	O
binding	O
of	O
p65	S-PRGE
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
was	O
measured	O
in	O
nuclear	O
extracts	O
(	O
10	O
microg	O
)	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
C	O
)	O
The	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
content	O
was	O
analysed	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
of	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
using	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
mock	O
)	O
.	O

(	O
D	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
cell	O
extracts	O
(	O
100	O
microg	O
)	O
using	O
HTScan	O
IKK	O
Kinase	O
Assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

(	O
E	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
cell	O
extracts	O
(	O
1	O
mg	O
)	O
were	O
immunoprecipitated	O
with	O
protein	B-PRGE
G	E-PRGE
-	O
Sepharose	O
-	O
coupled	O
anti	O
-	O
FLAG	O
antibody	O
.	O

Immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

(	O
F	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
,	O
siRNA	B-PRGE
p65	E-PRGE
,	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
total	O
RNA	O
was	O
analysed	O
for	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
by	O
real	O
-	O
time	O
PCR	O
.	O

(	O
G	O
and	O
H	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-PRGE
Tat	E-PRGE
or	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-PRGE
-	I-PRGE
Tat	E-PRGE
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
p65	O
(	O
G	O
)	O
or	O
anti	O
-	O
FLAG	O
(	O
H	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
and	O
GAPDH	S-PRGE
promoters	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

The	O
asterisks	O
indicate	O
statistically	O
significant	O
differences	O
compared	O
to	O
the	O
control	O
(	O
mock	O
)	O
,	O
according	O
to	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Model	O
of	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
transcriptional	O
activation	O
by	O
HIV	O
-	O
1	O
Tat	S-PRGE
.	O

(	O
A	O
)	O
In	O
absence	O
of	O
Tat	S-PRGE
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
occupies	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
promoter	O
and	O
likely	O
interacts	O
with	O
transcriptional	O
repressors	O
,	O
such	O
as	O
HDACs	O
(	O
65	O
)	O
,	O
to	O
inhibit	O
gene	O
transcription	O
.	O

(	O
B	O
)	O
Tat	S-PRGE
activates	O
the	O
MIP	B-PRGE
-	I-PRGE
1alpha	E-PRGE
expression	O
by	O
removing	O
the	O
IkappaB	B-PRGE
-	I-PRGE
alpha	E-PRGE
repressor	O
from	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
,	O
and	O
by	O
increasing	O
the	O
binding	O
of	O
p65	O
NF	O
-	O
kappaB	O
complex	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
.	O

Inflammasome	O
-	O
Mediated	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
Production	O
in	O
Humans	O
with	O
Cystic	O
Fibrosis	O

Background	O

Inflammation	O
and	O
infection	O
are	O
major	O
determinants	O
of	O
disease	O
severity	O
and	O
consequently	O
,	O
the	O
quality	O
of	O
life	O
and	O
outcome	O
for	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
.	O

Interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
)	O
is	O
a	O
key	O
inflammatory	O
mediator	O
.	O

Secretion	O
of	O
biologically	O
active	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
involves	O
inflammasome	O
-	O
mediated	O
processing	O
.	O

Little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
the	O
inflammasomes	O
in	O
CF	O
inflammatory	O
disease	O
.	O

This	O
study	O
examines	O
inflammasome	O
-	O
mediated	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
CF	O
bronchial	O
epithelial	O
cell	O
lines	O
and	O
human	O
patients	O
with	O
CF	O
.	O

Results	O

Bronchial	O
epithelial	O
cell	O
lines	O
were	O
found	O
to	O
produce	O
negligible	O
amounts	O
of	O
basal	O
or	O
stimulated	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
compared	O
to	O
hematopoeitic	O
cells	O
and	O
they	O
did	O
not	O
significantly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O
.	O

In	O
contrast	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
both	O
CF	O
and	O
healthy	O
control	O
subjects	O
produced	O
large	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
strongly	O
upregulated	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O
.	O

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
displayed	O
similar	O
levels	O
of	O
caspase	O
-	O
1	O
activation	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
when	O
stimulated	O
with	O
inflammasome	O
activators	O
.	O

This	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
was	O
dependent	O
on	O
NF	O
-	O
kappaB	O
activity	O
and	O
could	O
be	O
enhanced	O
by	O
priming	O
with	O
LPS	O
.	O

Finally	O
,	O
chemical	O
inhibition	O
of	O
CFTR	O
activity	O
in	O
control	O
PBMCs	O
and	O
THP	O
-	O
1	O
cells	O
did	O
not	O
significantly	O
alter	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
or	O
IL	O
-	O
8	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

Conclusion	O

Hematopoeitic	O
cells	O
appear	O
to	O
be	O
the	O
predominant	O
source	O
of	O
inflammasome	O
-	O
induced	O
pro	O
-	O
inflammatory	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
in	O
CF	O
.	O

PBMCs	O
derived	O
from	O
CF	O
subjects	O
display	O
preserved	O
inflammasome	O
activation	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
in	O
response	O
to	O
the	O
major	O
CF	O
pathogen	O
Pseudomonas	O
aeruginosa	O
.	O

However	O
,	O
our	O
data	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
increased	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
CF	O
subjects	O
is	O
due	O
to	O
an	O
intrinsic	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
through	O
loss	O
of	O
CFTR	O
function	O
.	O

Cystic	O
fibrosis	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
)	O
,	O
which	O
functions	O
as	O
a	O
chloride	O
ion	O
channel	O
.	O

CF	O
remains	O
one	O
of	O
the	O
most	O
common	O
lethal	O
genetic	O
diseases	O
in	O
populations	O
of	O
European	O
descent	O
with	O
the	O
current	O
average	O
lifespan	O
of	O
CF	O
patients	O
approximately	O
40	O
years	O
of	O
age	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Recurrent	O
inflammatory	O
pulmonary	O
exacerbation	O
is	O
the	O
primary	O
cause	O
of	O
lung	O
disease	O
progression	O
and	O
ultimately	O
,	O
death	O
in	O
CF	O
.	O

Controlled	O
inflammation	O
is	O
important	O
for	O
fighting	O
infection	O
,	O
but	O
in	O
excess	O
,	O
it	O
becomes	O
destructive	O
to	O
host	O
cells	O
and	O
to	O
the	O
architecture	O
of	O
the	O
lungs	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

In	O
CF	O
,	O
airway	O
epithelial	O
cells	O
have	O
been	O
shown	O
to	O
produce	O
an	O
exaggerated	O
pro	O
-	O
inflammatory	O
cytokine	O
response	O
to	O
stimulation	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

It	O
is	O
unclear	O
whether	O
this	O
heightened	O
inflammatory	O
response	O
is	O
intrinsic	O
to	O
cells	O
lacking	O
CFTR	O
or	O
whether	O
it	O
is	O
a	O
result	O
of	O
chronic	O
polymicrobial	O
infection	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

Regardless	O
of	O
this	O
controversy	O
,	O
identifying	O
and	O
targeting	O
relevant	O
inflammatory	O
mediators	O
is	O
a	O
critical	O
step	O
in	O
developing	O
more	O
specific	O
therapeutic	O
approaches	O
to	O
control	O
inflammation	O
and	O
improve	O
health	O
outcomes	O
in	O
CF	O
[	O
8	O
]	O
.	O

Interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	E-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
)	O
is	O
a	O
major	O
inflammatory	O
mediator	O
.	O

Its	O
physiological	O
effects	O
are	O
diverse	O
and	O
potentially	O
important	O
to	O
the	O
pathogenesis	O
of	O
lung	O
exacerbations	O
in	O
CF	O
,	O
including	O
the	O
generation	O
of	O
fever	O
,	O
the	O
recruitment	O
of	O
inflammatory	O
effector	O
cells	O
,	O
the	O
induction	O
of	O
other	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
and	O
IL	O
-	O
8	O
,	O
and	O
the	O
shaping	O
of	O
T	O
cell	O
responses	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

Following	O
initiation	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
cascade	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
is	O
produced	O
in	O
the	O
cytosol	O
as	O
a	O
biologically	O
inactive	O
full	O
-	O
length	O
pro	O
-	O
IL	O
-	O
1beta	O
.	O

Pro	O
-	O
IL	O
-	O
1beta	O
is	O
subsequently	O
converted	O
into	O
its	O
active	O
form	O
by	O
cytosolic	O
protein	O
complexes	O
termed	O
"	O
inflammasomes	O
.	O
"	O
Inflammasomes	O
assemble	O
in	O
response	O
to	O
certain	O
cellular	O
danger	O
signals	O
and	O
mediate	O
the	O
auto	O
-	O
activation	O
of	O
caspase	O
-	O
1	O
[	O
9	O
]	O
,	O
[	O
11	O
]	O
,	O
which	O
cleaves	O
pro	O
-	O
IL	O
-	O
1beta	O
and	O
pro	O
-	O
IL	O
-	O
18	O
into	O
their	O
biologically	O
active	O
forms	O
for	O
secretion	O
.	O

Four	O
distinct	O
inflammasomes	O
have	O
been	O
recognized	O
.	O

These	O
are	O
the	O
NLRP1	O
[	O
12	O
]	O
,	O
NLRP3	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
NLRC4	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
,	O
and	O
AIM2	O
inflammasomes	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
which	O
respond	O
to	O
a	O
variety	O
of	O
different	O
microbial	O
signatures	O
and	O
danger	O
signals	O
[	O
11	O
]	O
.	O

P	O
.	O
aeruginosa	O
,	O
one	O
of	O
the	O
most	O
common	O
and	O
clinically	O
relevant	O
pathogens	O
among	O
CF	O
patients	O
,	O
activates	O
the	O
NLRC4	O
inflammasome	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

Infection	O
with	O
P	O
.	O
aeruginosa	O
triggers	O
an	O
increase	O
in	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
,	O
and	O
IL	O
-	O
8	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
from	O
patients	O
with	O
CF	O
[	O
21	O
]	O
.	O

Inflammasome	O
responses	O
depend	O
on	O
NF	O
-	O
kappaB	O
signaling	O
,	O
where	O
NF	O
-	O
kappaB	O
is	O
important	O
in	O
both	O
the	O
upregulation	O
of	O
specific	O
inflammasome	O
components	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
,	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
expression	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
.	O

Previous	O
studies	O
support	O
a	O
role	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
in	O
the	O
pathogenesis	O
of	O
CF	O
inflammatory	O
lung	O
disease	O
.	O

Levels	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
are	O
increased	O
in	O
BALF	O
from	O
CF	O
patients	O
with	O
infection	O
[	O
21	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
and	O
this	O
increase	O
has	O
been	O
temporally	O
associated	O
with	O
a	O
clinical	O
response	O
to	O
treatment	O
[	O
21	O
]	O
.	O

Polymorphisms	O
in	O
the	O
IL1B	S-PRGE
gene	O
have	O
also	O
been	O
associated	O
with	O
varying	O
degrees	O
of	O
disease	O
severity	O
in	O
CF	O
patients	O
[	O
29	O
]	O
.	O

Murine	O
models	O
of	O
CFTR	O
dysfunction	O
have	O
exhibited	O
significant	O
increases	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
expression	O
or	O
secretion	O
in	O
macrophages	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
the	O
loss	O
of	O
CFTR	O
increases	O
NF	O
-	O
kappaB	O
activation	O
under	O
basal	O
and	O
stimulatory	O
conditions	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

Finally	O
,	O
replacement	O
of	O
chloride	O
ions	O
with	O
glutamate	O
or	O
gluconate	O
in	O
cell	O
culture	O
media	O
increases	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
in	O
response	O
to	O
NLRP3	O
stimulation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
[	O
34	O
]	O
,	O
implying	O
an	O
inhibitory	O
role	O
for	O
extracellular	O
chloride	O
in	O
NLRP3	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
implicate	O
the	O
involvement	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
consequently	O
,	O
the	O
inflammasomes	O
,	O
in	O
CF	O
inflammatory	O
disease	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
produce	O
significant	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
in	O
response	O
to	O
inflammasome	O
stimulation	O

The	O
inflammasomes	O
and	O
their	O
respective	O
activators	O
examined	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Cells	O
were	O
stimulated	O
in	O
accordance	O
with	O
the	O
schedule	O
in	O
Figure	O
1	O
.	O

In	O
CF	O
,	O
airway	O
epithelial	O
cells	O
have	O
been	O
shown	O
to	O
possess	O
a	O
hyper	O
-	O
inflammatory	O
phenotype	O
and	O
produce	O
an	O
exaggerated	O
pro	O
-	O
inflammatory	O
cytokine	O
response	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

To	O
determine	O
if	O
airway	O
epithelial	O
cells	O
contribute	O
to	O
the	O
increased	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
patients	O
with	O
CF	O
,	O
CF	O
and	O
control	O
bronchial	O
epithelial	O
cell	O
lines	O
were	O
stimulated	O
with	O
the	O
inflammasome	O
inducers	O
P	O
.	O
aeruginosa	O
strain	O
PAO1	O
(	O
PAO1	O
)	O
and	O
LPS	O
followed	O
by	O
ATP	O
.	O

IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
levels	O
in	O
cell	O
culture	O
supernatants	O
were	O
not	O
greatly	O
increased	O
in	O
either	O
the	O
CF	O
or	O
control	O
cell	O
lines	O
(	O
Fig	O
.	O
2a	O
-	O
d	O
)	O
,	O
although	O
a	O
small	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
was	O
detected	O
in	O
NuLi	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
cells	O
,	O
but	O
not	O
in	O
S9	O
and	O
IB3	O
-	O
1	O
cells	O
,	O
by	O
24	O
hours	O
.	O

In	O
contrast	O
,	O
these	O
airway	O
cells	O
were	O
highly	O
responsive	O
to	O
other	O
inflammatory	O
stimuli	O
,	O
such	O
as	O
recombinant	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
,	O
producing	O
large	O
quantities	O
of	O
IL	O
-	O
8	O
(	O
Fig	O
.	O
2a	O
-	O
d	O
inserts	O
)	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
significantly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
in	O
response	O
to	O
inflammasome	O
stimulation	O

To	O
examine	O
if	O
inflammasome	O
activation	O
occurs	O
in	O
these	O
airway	O
cells	O
,	O
caspase	O
-	O
1	O
activity	O
was	O
quantified	O
by	O
flow	O
cytometry	O
.	O

There	O
was	O
no	O
significant	O
increase	O
upon	O
stimulation	O
with	O
live	O
PAO1	O
or	O
LPS	O
+	O
ATP	O
at	O
the	O
times	O
examined	O
(	O
Fig	O
.	O
3a	O
-	O
b	O
)	O
.	O

Because	O
previous	O
studies	O
have	O
indicated	O
a	O
role	O
for	O
caspase	O
-	O
1	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
through	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
signaling	O
[	O
35	O
]	O
,	O
we	O
examined	O
whether	O
chemical	O
inhibition	O
of	O
caspase	O
-	O
1	O
altered	O
NF	O
-	O
kappaB	O
-	O
dependent	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

However	O
,	O
treatment	O
with	O
the	O
caspase	O
-	O
1	O
inhibitor	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
YVAD	O
)	O
did	O
not	O
decrease	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
secretion	O
by	O
airway	O
epithelial	O
cells	O
(	O
Fig	O
.	O
3c	O
)	O
.	O

CD14	O
positive	O
monocytes	O
from	O
CF	O
patients	O
and	O
controls	O
show	O
similar	O
increases	O
in	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O

Monocytes	O
were	O
identified	O
in	O
PBMC	O
populations	O
using	O
CD14	S-PRGE
as	O
a	O
phenotyping	O
marker	O
.	O

CD14	O
positive	O
monocytes	O
from	O
CF	O
patients	O
and	O
healthy	O
controls	O
showed	O
a	O
significant	O
increase	O
in	O
caspase	O
-	O
1	O
activation	O
upon	O
stimulation	O
with	O
LPS	O
+	O
ATP	O
,	O
PAO1	O
,	O
and	O
LPS	O
+	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
Fig	O
.	O
4a	O
)	O
but	O
this	O
activation	O
was	O
not	O
different	O
between	O
CF	O
and	O
control	O
subjects	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
upon	O
inflammasome	O
stimulation	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
loss	O
of	O
CFTR	O
results	O
in	O
increased	O
NF	O
-	O
kappaB	O
activity	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
secretion	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

To	O
further	O
examine	O
this	O
relationship	O
,	O
PBMCs	O
from	O
CF	O
patients	O
and	O
healthy	O
adult	O
controls	O
were	O
stimulated	O
with	O
PAO1	O
,	O
LPS	O
+	O
ATP	O
,	O
and	O
LPS	O
+	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
,	O
to	O
activate	O
the	O
NLRC4	O
,	O
NLRP3	O
,	O
and	O
AIM2	O
inflammasomes	O
,	O
respectively	O
.	O

By	O
24	O
hours	O
of	O
stimulation	O
,	O
CF	O
PBMCs	O
did	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
(	O
Fig	O
.	O
5a	O
)	O
or	O
IL	O
-	O
8	O
(	O
Fig	O
.	O
5b	O
)	O
when	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
we	O
did	O
notice	O
a	O
transient	O
decrease	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
amount	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
produced	O
by	O
CF	O
cells	O
in	O
response	O
to	O
LPS	O
+	O
ATP	O
at	O
6	O
hours	O
(	O
data	O
not	O
shown	O
)	O
.	O

Stimulation	O
of	O
PBMCs	O
with	O
P	O
.	O
aeruginosa	O
that	O
lacks	O
exsA	S-PRGE
(	O
PAO1deltaexsA	O
)	O
,	O
a	O
key	O
regulator	O
of	O
type	O
III	O
secretion	O
,	O
produced	O
three	O
-	O
fold	O
less	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
compared	O
to	O
the	O
parental	O
PAO1	O
strain	O
by	O
24	O
hours	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

Inflammasome	O
stimulation	O
without	O
priming	O
did	O
not	O
result	O
in	O
any	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
either	O
CF	O
or	O
control	O
PBMCs	O
.	O

Contrary	O
to	O
our	O
hypothesis	O
,	O
these	O
results	O
indicate	O
that	O
PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
display	O
increased	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
or	O
IL	B-PRGE
-	I-PRGE
8	E-PRGE
with	O
inflammasome	O
activation	O
nor	O
do	O
they	O
suggest	O
any	O
increased	O
basal	O
or	O
induced	O
NF	O
-	O
kappaB	O
activity	O
.	O

These	O
results	O
are	O
consistent	O
with	O
our	O
observation	O
that	O
caspase	O
-	O
1	O
activity	O
is	O
not	O
different	O
between	O
CF	O
and	O
control	O
PBMCs	O
(	O
Fig	O
.	O
4	O
)	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
IL	O
-	O
8	O
responses	O
to	O
P	O
.	O
aeruginosa	O

We	O
confirmed	O
the	O
dependence	O
of	O
PAO1	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
IL	O
-	O
8	O
production	O
on	O
NF	O
-	O
kappaB	O
activation	O
using	O
THP	O
-	O
1	O
cells	O
expressing	O
a	O
reporter	O
driven	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
response	O
elements	O
.	O

We	O
found	O
that	O
stimulation	O
of	O
primed	O
THP	O
-	O
1	O
reporter	O
cells	O
with	O
heat	O
-	O
killed	O
PAO1	O
produced	O
the	O
highest	O
levels	O
of	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
Fig	O
.	O
6a	O
)	O
and	O
this	O
correlated	O
with	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
but	O
negligible	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
were	O
secreted	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Stimulation	O
of	O
primed	O
THP	O
-	O
1	O
reporter	O
cells	O
with	O
live	O
PAO1	O
did	O
not	O
significantly	O
increase	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
(	O
Fig	O
.	O
6a	O
)	O
or	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
over	O
priming	O
alone	O
.	O

However	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
was	O
greatly	O
augmented	O
over	O
primed	O
cells	O
stimulated	O
with	O
heat	O
-	O
killed	O
PAO1	O
or	O
unprimed	O
cells	O
stimulated	O
with	O
live	O
PAO1	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

This	O
confirmed	O
that	O
NF	O
-	O
kappaB	O
activation	O
alone	O
is	O
not	O
sufficient	O
for	O
maximal	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
,	O
but	O
increased	O
priming	O
of	O
NF	O
-	O
kappaB	O
is	O
capable	O
of	O
augmenting	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
and	O
secretion	O
upon	O
inflammasome	O
stimulation	O
.	O

Dependency	O
of	O
these	O
responses	O
on	O
NF	O
-	O
kappaB	O
was	O
confirmed	O
by	O
pharmacologic	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
using	O
the	O
Bay11	O
-	O
7082	O
inhibitor	O
of	O
IkappaBalpha	S-PRGE
phosphorylation	O
,	O
which	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6d	O
)	O
and	O
the	O
subsequent	O
production	O
of	O
IL	O
-	O
8	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6e	O
)	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6f	O
)	O
in	O
response	O
to	O
both	O
heat	O
-	O
killed	O
and	O
live	O
PAO1	O
.	O

These	O
results	O
were	O
also	O
verified	O
in	O
CF	O
and	O
control	O
PBMCs	O
for	O
each	O
inflammasome	O
examined	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6g	O
-	O
h	O
)	O
.	O

Overall	O
these	O
results	O
confirm	O
that	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
modulator	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
and	O
that	O
increased	O
activation	O
of	O
NF	O
-	O
kappaB	O
augments	O
inflammasome	O
-	O
mediated	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
.	O

Bay11	O
-	O
7082	O
inhibits	O
pro	O
-	O
IL	O
-	O
1beta	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O

In	O
addition	O
to	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
Bay11	O
-	O
7082	O
can	O
also	O
directly	O
inhibit	O
the	O
NLRP3	O
inflammasome	O
[	O
38	O
]	O
.	O

To	O
validate	O
its	O
use	O
in	O
this	O
study	O
as	O
an	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
western	O
blots	O
for	O
pro	O
-	O
IL	O
-	O
1beta	O
were	O
performed	O
alongside	O
inhibition	O
of	O
CFTR	O
activity	O
by	O
CFTRinh172	O
in	O
response	O
to	O
PAO1	O
at	O
4	O
hours	O
after	O
stimulation	O
(	O
Fig	O
.	O
7a	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
Bay11	O
-	O
7082	O
prevents	O
production	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
whereas	O
CFTRinh172	O
does	O
not	O
seem	O
to	O
affect	O
it	O
.	O

This	O
was	O
further	O
corroborated	O
by	O
the	O
ability	O
Bay11	O
-	O
7082	O
to	O
inhibit	O
IkappaBalpha	S-PRGE
degradation	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
1	O
.	O
5	O
hours	O
post	O
PAO1	O
stimulation	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

Disruption	O
of	O
CFTR	O
activity	O
does	O
not	O
increase	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
PBMCs	O
and	O
THP	O
-	O
1	O
cells	O

A	O
previous	O
study	O
has	O
indicated	O
a	O
role	O
for	O
chloride	O
ion	O
concentration	O
in	O
suppression	O
of	O
NLRP3	O
inflammasome	O
activation	O
[	O
34	O
]	O
.	O

To	O
determine	O
whether	O
CFTR	O
dysfunction	O
alters	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
,	O
THP	O
-	O
1	O
cells	O
and	O
PBMCs	O
from	O
CF	O
patients	O
and	O
healthy	O
controls	O
were	O
treated	O
with	O
the	O
CFTR	O
inhibitor	O
,	O
CFTRinh172	O
,	O
prior	O
to	O
simulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
.	O

Treatment	O
with	O
CFTRinh172	O
did	O
not	O
alter	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
or	O
IL	O
-	O
8	O
production	O
in	O
control	O
subjects	O
or	O
CF	O
patients	O
(	O
Fig	O
.	O
8a	O
-	O
b	O
)	O
.	O

Similarly	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
was	O
not	O
different	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
or	O
THP	O
-	O
1	O
reporter	O
cells	O
treated	O
with	O
CFTRinh172	O
(	O
Fig	O
.	O
8c	O
-	O
d	O
)	O
.	O

IL	O
-	O
8	O
(	O
Fig	O
.	O
8e	O
)	O
and	O
NF	O
-	O
kappaB	O
activity	O
(	O
Fig	O
.	O
8f	O
)	O
were	O
also	O
unchanged	O
in	O
CFTRinh172	O
-	O
treated	O
THP	O
-	O
1	O
reporter	O
cells	O
.	O

Levels	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
are	O
increased	O
in	O
the	O
BALF	O
of	O
CF	O
patients	O
but	O
the	O
cellular	O
source	O
of	O
this	O
cytokine	O
and	O
its	O
production	O
in	O
the	O
context	O
of	O
targeted	O
inflammasome	O
activation	O
are	O
still	O
unclear	O
.	O

We	O
first	O
studied	O
airway	O
epithelial	O
cells	O
due	O
to	O
their	O
role	O
in	O
barrier	O
function	O
,	O
proximity	O
to	O
infection	O
,	O
and	O
ability	O
to	O
produce	O
high	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

However	O
,	O
we	O
found	O
that	O
bronchial	O
epithelial	O
cells	O
do	O
not	O
produce	O
significant	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
do	O
not	O
show	O
a	O
significant	O
increase	O
in	O
caspase	O
-	O
1	O
activation	O
in	O
response	O
to	O
PAO1	O
and	O
LPS	O
+	O
ATP	O
,	O
in	O
comparison	O
to	O
hematopoeitic	O
mononuclear	O
cells	O
.	O

Hematopoeitically	O
-	O
derived	O
cells	O
,	O
such	O
as	O
monocytes	O
and	O
macrophages	O
,	O
appear	O
to	O
be	O
a	O
principal	O
source	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
.	O

CFTR	O
is	O
expressed	O
in	O
alveolar	O
macrophages	O
[	O
32	O
]	O
,	O
[	O
39	O
]	O
as	O
well	O
as	O
in	O
PBMCs	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
level	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
and	O
its	O
loss	O
is	O
frequently	O
associated	O
with	O
an	O
augmented	O
inflammatory	O
phenotype	O
.	O

Despite	O
our	O
findings	O
indicating	O
that	O
bronchial	O
epithelial	O
cells	O
when	O
grown	O
in	O
vitro	O
are	O
unlikely	O
to	O
be	O
significantly	O
involved	O
in	O
the	O
direct	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
(	O
Fig	O
.	O
2a	O
-	O
d	O
)	O
,	O
others	O
have	O
shown	O
their	O
capacity	O
to	O
respond	O
to	O
alveolar	O
macrophage	O
-	O
derived	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
to	O
amplify	O
the	O
inflammatory	O
response	O
through	O
the	O
induction	O
of	O
chemokines	O
and	O
recruitment	O
of	O
inflammatory	O
effector	O
cells	O
[	O
42	O
]	O
.	O

This	O
interaction	O
may	O
constitute	O
a	O
critical	O
component	O
to	O
effective	O
host	O
defense	O
and	O
diminishing	O
the	O
capacity	O
of	O
host	O
cells	O
to	O
respond	O
to	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
may	O
leave	O
the	O
host	O
susceptible	O
to	O
infections	O
by	O
pathogens	O
such	O
as	O
P	O
.	O
aeruginosa	O
[	O
43	O
]	O
.	O

Conversely	O
,	O
overproduction	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
can	O
also	O
play	O
a	O
key	O
role	O
in	O
chronic	O
inflammatory	O
responses	O
and	O
cause	O
damage	O
to	O
the	O
lung	O
parenchyma	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Although	O
we	O
hypothesized	O
that	O
CF	O
cells	O
would	O
secrete	O
increased	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
,	O
we	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
CF	O
PBMCs	O
was	O
not	O
increased	O
upon	O
inflammasome	O
stimulation	O
as	O
compared	O
to	O
controls	O
(	O
Fig	O
.	O
5a	O
-	O
b	O
)	O
.	O

This	O
was	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
from	O
our	O
group	O
,	O
which	O
showed	O
increased	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
by	O
CF	O
PBMCs	O
in	O
response	O
to	O
LPS	O
[	O
46	O
]	O
,	O
although	O
this	O
difference	O
may	O
be	O
accounted	O
for	O
by	O
technical	O
issues	O
in	O
stimulation	O
time	O
and	O
dose	O
.	O

Moreover	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
was	O
not	O
increased	O
in	O
CF	O
PBMCs	O
with	O
inflammasome	O
stimulation	O
alone	O
as	O
would	O
be	O
anticipated	O
if	O
there	O
were	O
basal	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Cells	O
deficient	O
in	O
CFTR	O
are	O
thought	O
to	O
exhibit	O
an	O
increased	O
basal	O
level	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
which	O
leads	O
to	O
increased	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
including	O
an	O
increased	O
availability	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
for	O
cleavage	O
and	O
secretion	O
.	O

This	O
amplification	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
was	O
shown	O
by	O
priming	O
THP	O
-	O
1	O
monocytes	O
and	O
PBMCs	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
or	O
LPS	O
prior	O
to	O
stimulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
.	O

This	O
dramatically	O
increased	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
over	O
stimulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
without	O
priming	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Similarly	O
,	O
if	O
CF	O
PBMCs	O
expressed	O
increased	O
basal	O
NF	O
-	O
kappaB	O
activity	O
,	O
there	O
would	O
be	O
an	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
in	O
the	O
absence	O
of	O
LPS	O
priming	O
.	O

However	O
,	O
no	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
was	O
observed	O
under	O
basal	O
or	O
primed	O
conditions	O
.	O

Studies	O
investigating	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
have	O
been	O
somewhat	O
inconsistent	O
.	O

A	O
study	O
by	O
Reininger	O
et	O
al	O
.	O

[	O
43	O
]	O
provided	O
evidence	O
that	O
human	O
bronchial	O
epithelial	O
cells	O
possessing	O
the	O
deltaF508	O
CFTR	O
mutation	O
had	O
a	O
slightly	O
reduced	O
capacity	O
to	O
produce	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
lacked	O
the	O
ability	O
to	O
induce	O
an	O
early	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

Conversely	O
,	O
a	O
study	O
by	O
Kotrange	O
et	O
al	O
.	O

[	O
31	O
]	O
found	O
that	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
expressing	O
deltaF508	O
-	O
CFTR	O
produced	O
increased	O
amounts	O
of	O
IL	O
-	O
1beta	O
when	O
compared	O
to	O
macrophages	O
expressing	O
normal	O
CFTR	O
in	O
response	O
to	O
Burkholderia	O
cenocepacia	O
K56	O
-	O
2	O
.	O

The	O
differentiation	O
of	O
monocytes	O
into	O
macrophages	O
may	O
partly	O
account	O
for	O
the	O
differences	O
observed	O
with	O
the	O
study	O
by	O
Kotrange	O
.	O

Inflammasome	O
-	O
mediated	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
by	O
monocytes	O
and	O
PBMCs	O
does	O
differ	O
from	O
macrophages	O
[	O
47	O
]	O
,	O
[	O
48	O
]	O
,	O
[	O
49	O
]	O
and	O
macrophages	O
are	O
found	O
to	O
have	O
higher	O
expression	O
of	O
CFTR	O
over	O
monocytes	O
[	O
50	O
]	O
.	O

However	O
,	O
as	O
monocytes	O
and	O
other	O
PBMCs	O
express	O
CFTR	O
[	O
50	O
]	O
,	O
[	O
51	O
]	O
and	O
produce	O
large	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
,	O
they	O
are	O
adequate	O
models	O
to	O
examine	O
the	O
effects	O
of	O
CFTR	O
function	O
on	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
.	O

Other	O
hematopoeitic	O
cells	O
may	O
also	O
contribute	O
to	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
.	O

For	O
example	O
,	O
neutrophil	O
counts	O
can	O
be	O
significantly	O
increased	O
in	O
the	O
lungs	O
of	O
CF	O
patients	O
[	O
52	O
]	O
,	O
[	O
53	O
]	O
,	O
[	O
54	O
]	O
and	O
may	O
produce	O
mature	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
through	O
caspase	O
-	O
1	O
independent	O
mechanisms	O
[	O
55	O
]	O
.	O

The	O
role	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
inflammasome	O
activation	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
is	O
not	O
straightforward	O
.	O

Studies	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
production	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
and	O
inflammasome	O
components	O
such	O
as	O
NLRP3	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
IKKbeta	O
,	O
a	O
kinase	O
essential	O
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
increases	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
in	O
murine	O
macrophages	O
[	O
56	O
]	O
,	O
[	O
57	O
]	O
and	O
demonstrates	O
a	O
dual	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
.	O

To	O
address	O
this	O
uncertainty	O
in	O
our	O
experiments	O
we	O
also	O
quantified	O
IL	O
-	O
8	O
,	O
an	O
important	O
CF	O
cytokine	O
and	O
marker	O
of	O
NF	O
-	O
kappaB	O
activation	O
[	O
58	O
]	O
,	O
and	O
found	O
no	O
differences	O
between	O
CF	O
and	O
control	O
subjects	O
.	O

Similarly	O
,	O
levels	O
of	O
intracellular	O
pro	O
-	O
IL	O
-	O
1beta	O
in	O
THP	O
-	O
1	O
cells	O
were	O
dependent	O
on	O
NF	O
-	O
kappaB	O
activity	O
and	O
did	O
not	O
increase	O
with	O
CFTRinh172	O
treatment	O
.	O

Subsequent	O
treatment	O
of	O
THP	O
-	O
1	O
cells	O
and	O
PBMCs	O
with	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
Bay11	O
-	O
7082	O
significantly	O
inhibited	O
both	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6d	O
-	O
h	O
)	O
.	O

Therefore	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
IL	O
-	O
8	O
responses	O
observed	O
were	O
both	O
dependent	O
upon	O
NF	O
-	O
kappaB	O
activation	O
.	O

Priming	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
,	O
like	O
LPS	O
,	O
is	O
unable	O
to	O
induce	O
a	O
strong	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
response	O
as	O
compared	O
to	O
live	O
P	O
.	O
aeruginosa	O
(	O
Fig	O
.	O
6c	O
)	O
,	O
but	O
generated	O
greater	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
Fig	O
.	O
6a	O
)	O
and	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
than	O
live	O
bacteria	O
despite	O
stimulation	O
at	O
equivalent	O
MOIs	O
.	O

This	O
may	O
be	O
indicative	O
of	O
the	O
different	O
degree	O
and	O
quality	O
of	O
the	O
inflammatory	O
response	O
generated	O
by	O
live	O
as	O
opposed	O
to	O
dead	O
bacteria	O
[	O
59	O
]	O
.	O

Potential	O
shortcomings	O
of	O
these	O
experiments	O
include	O
its	O
translatability	O
to	O
lung	O
disease	O
and	O
issues	O
related	O
to	O
the	O
hypermutability	O
of	O
P	O
.	O
aeruginosa	O
during	O
the	O
evolution	O
of	O
chronic	O
infection	O
.	O

Although	O
the	O
responses	O
measured	O
in	O
peripheral	O
blood	O
cells	O
may	O
not	O
completely	O
reflect	O
the	O
responses	O
occurring	O
in	O
the	O
CF	O
lung	O
,	O
PBMCs	O
have	O
a	O
number	O
of	O
useful	O
advantages	O
:	O
(	O
i	O
)	O
PBMCs	O
are	O
not	O
subject	O
to	O
alterations	O
that	O
may	O
emerge	O
from	O
long	O
-	O
term	O
cell	O
culture	O
,	O
cloning	O
and	O
immortalization	O
,	O
and	O
(	O
ii	O
)	O
PBMCs	O
express	O
a	O
large	O
repertoire	O
of	O
innate	O
immune	O
receptors	O
and	O
secrete	O
a	O
broad	O
array	O
of	O
cytokines	O
and	O
chemokines	O
allowing	O
comprehensive	O
analysis	O
of	O
the	O
modulation	O
of	O
inflammatory	O
responses	O
by	O
CFTR	O
.	O

Consideration	O
must	O
also	O
be	O
given	O
to	O
the	O
nature	O
of	O
P	O
.	O
aeruginosa	O
infection	O
and	O
genotypic	O
changes	O
in	O
P	O
.	O
aeruginosa	O
as	O
infection	O
progresses	O
.	O

P	O
.	O
aeruginosa	O
mediates	O
inflammasome	O
activation	O
through	O
its	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
and	O
the	O
NLRC4	O
inflammasome	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

However	O
,	O
clones	O
of	O
P	O
.	O
aeruginosa	O
established	O
during	O
chronic	O
infection	O
may	O
accumulate	O
mutations	O
in	O
virulence	O
factors	O
such	O
as	O
exsA	O
[	O
60	O
]	O
.	O

By	O
employing	O
a	O
deletion	O
mutant	O
in	O
exsA	S-PRGE
,	O
the	O
key	O
regulator	O
in	O
T3SS	O
transcription	O
,	O
we	O
confirmed	O
that	O
the	O
T3SS	O
is	O
important	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
(	O
Fig	O
.	O
5a	O
-	O
b	O
)	O
,	O
and	O
that	O
depending	O
on	O
the	O
adaptation	O
in	O
type	O
III	O
secretion	O
,	O
the	O
host	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
response	O
may	O
be	O
up	O
or	O
downregulated	O
[	O
19	O
]	O
,	O
[	O
60	O
]	O
,	O
[	O
61	O
]	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
role	O
for	O
hematopoietic	O
cells	O
,	O
not	O
airway	O
epithelial	O
cells	O
,	O
as	O
the	O
major	O
source	O
of	O
inflammasome	O
-	O
mediated	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
the	O
lungs	O
in	O
response	O
to	O
ATP	O
and	O
P	O
.	O
aeruginosa	O
.	O

Furthermore	O
,	O
we	O
find	O
little	O
evidence	O
to	O
support	O
an	O
increased	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
inflammatory	O
response	O
to	O
NF	O
-	O
kappaB	O
/	O
Inflammasome	O
stimulation	O
in	O
CF	O
patients	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
if	O
adaptations	O
of	O
P	O
.	O
aeruginosa	O
during	O
the	O
course	O
of	O
chronic	O
lung	O
infection	O
alters	O
inflammasome	O
activation	O
,	O
and	O
whether	O
this	O
can	O
be	O
correlated	O
with	O
disease	O
severity	O
in	O
CF	O
.	O

Ethics	O
Statement	O

Blood	O
samples	O
were	O
obtained	O
with	O
informed	O
written	O
consent	O
from	O
control	O
subjects	O
and	O
CF	O
patients	O
at	O
the	O
BC	O
Children	O
'	O
s	O
Hospital	O
.	O

Consent	O
was	O
obtained	O
for	O
children	O
by	O
their	O
parent	O
or	O
legal	O
guardian	O
.	O

Subjects	O
7	O
years	O
of	O
age	O
and	O
older	O
were	O
required	O
to	O
provide	O
informed	O
assent	O
as	O
well	O
.	O

Protocols	O
were	O
approved	O
by	O
the	O
Clinical	O
Research	O
Ethics	O
Board	O
(	O
H09	O
-	O
01192	O
)	O
.	O

Cell	O
Culture	O

CF	O
(	O
IB3	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
)	O
and	O
control	O
(	O
S9	O
and	O
NuLi	O
-	O
1	O
)	O
cells	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
.	O

IB3	O
-	O
1	O
cells	O
were	O
derived	O
from	O
a	O
patient	O
expressing	O
the	O
deltaF508	O
and	O
W1282X	O
mutations	O
and	O
CuFi	O
-	O
1	O
were	O
derived	O
from	O
a	O
deltaF508	O
homozygous	O
patient	O
.	O

S9	O
cells	O
are	O
IB3	O
-	O
1	O
cells	O
that	O
have	O
been	O
transfected	O
with	O
CFTR	O
using	O
an	O
adeno	O
-	O
associated	O
viral	O
vector	O
and	O
NuLi	O
-	O
1	O
cells	O
were	O
derived	O
from	O
a	O
patient	O
possessing	O
a	O
wild	O
-	O
type	O
CFTR	O
genotype	O
.	O

THP1	O
-	O
XBlue	O
cells	O
stably	O
express	O
a	O
secreted	O
embryonic	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
reporter	O
inducible	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
(	O
Invivogen	O
)	O
.	O

Cells	O
were	O
cultured	O
as	O
recommended	O
by	O
their	O
respective	O
suppliers	O
using	O
standard	O
protocols	O
.	O

S9	O
and	O
IB3	O
-	O
1	O
cells	O
were	O
cultured	O
in	O
basal	O
LHC	O
-	O
8	O
(	O
Invitrogen	O
)	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
.	O

NuLi	O
-	O
1	O
/	O
CuFi	O
-	O
1	O
cells	O
were	O
cultured	O
in	O
BEBM	O
serum	O
-	O
free	O
medium	O
(	O
Lonza	O
)	O
with	O
supplement	O
bullet	O
kit	O
(	O
EGF	O
,	O
hydrocortisone	O
,	O
bovine	O
pituitary	O
extract	O
,	O
transferrin	S-PRGE
,	O
bovine	O
insulin	S-PRGE
,	O
triiodothyronine	O
,	O
epinephrine	O
,	O
retinoic	O
acid	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
.	O

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
(	O
Hyclone	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
(	O
complete	O
RPMI	O
)	O
.	O

THP1	O
-	O
XBlue	O
cells	O
were	O
cultured	O
in	O
complete	O
RPMI	O
with	O
the	O
addition	O
of	O
zeocin	O
(	O
100	O
microg	O
/	O
ml	O
)	O
to	O
select	O
for	O
cells	O
expressing	O
the	O
SEAP	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
reporter	O
.	O

Prior	O
to	O
stimulation	O
,	O
bronchial	O
epithelial	O
cell	O
lines	O
were	O
plated	O
in	O
coated	O
[	O
62	O
]	O
96	O
-	O
well	O
plates	O
(	O
BD	O
Biosciences	O
)	O
at	O
3x104	O
cells	O
/	O
well	O
unless	O
indicated	O
,	O
and	O
allowed	O
to	O
adhere	O
overnight	O
.	O

Plates	O
for	O
S9	O
and	O
IB3	O
-	O
1	O
stimulations	O
were	O
coated	O
in	O
a	O
mixture	O
of	O
bovine	O
serum	B-PRGE
albumin	E-PRGE
(	O
100	O
microg	O
/	O
ml	O
)	O
,	O
fibronectin	O
(	O
10	O
microg	O
/	O
ml	O
)	O
,	O
and	O
bovine	O
collage	O
type	O
I	O
(	O
30	O
microg	O
/	O
ml	O
)	O
(	O
BD	O
Biosciences	O
)	O
.	O

Plates	O
for	O
NuLi	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
were	O
coated	O
with	O
collagen	O
type	O
IV	O
(	O
60	O
microg	O
/	O
ml	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
.	O

PBMCs	O
were	O
plated	O
in	O
96	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
1	O
.	O
5x105	O
cells	O
/	O
well	O
in	O
200	O
microl	O
(	O
7	O
.	O
5x105	O
cells	O
/	O
mL	O
)	O
.	O

THP	O
-	O
1	O
reporter	O
cells	O
were	O
differentiated	O
into	O
a	O
macrophage	O
-	O
like	O
phenotype	O
using	O
50	O
ng	O
/	O
ml	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
for	O
24	O
hours	O
at	O
a	O
density	O
of	O
1x105	O
cells	O
/	O
well	O
in	O
200	O
microl	O
(	O
5x105	O
cells	O
/	O
ml	O
)	O
.	O

Cells	O
were	O
washed	O
with	O
PBS	O
and	O
allowed	O
to	O
rest	O
a	O
further	O
42	O
hours	O
prior	O
to	O
stimulation	O
.	O

CF	O
and	O
control	O
subject	O
PBMCs	O

The	O
diagnosis	O
of	O
CF	O
was	O
established	O
by	O
typical	O
clinical	O
features	O
,	O
increased	O
sweat	O
chloride	O
concentrations	O
(	O
>	O
60	O
mmol	O
/	O
l	O
)	O
,	O
and	O
detection	O
of	O
CF	O
-	O
inducing	O
mutations	O
.	O

All	O
patients	O
with	O
CF	O
were	O
clinically	O
stable	O
at	O
the	O
time	O
of	O
blood	O
donation	O
,	O
and	O
we	O
excluded	O
any	O
subjects	O
who	O
were	O
receiving	O
systemic	O
corticosteroids	O
due	O
to	O
potential	O
immunomodulatory	O
activity	O
.	O

Control	O
samples	O
were	O
provided	O
by	O
healthy	O
adult	O
volunteers	O
.	O

In	O
previously	O
published	O
work	O
we	O
have	O
demonstrated	O
that	O
TLR	O
-	O
mediated	O
inflammatory	O
responses	O
are	O
stable	O
in	O
humans	O
from	O
birth	O
to	O
60	O
years	O
old	O
[	O
63	O
]	O
,	O
therefore	O
did	O
not	O
age	O
-	O
match	O
the	O
CF	O
patients	O
and	O
control	O
subjects	O
.	O

Peripheral	O
blood	O
was	O
collected	O
in	O
sodium	O
heparin	O
tubes	O
(	O
BD	O
Biosciences	O
)	O
and	O
PBMCs	O
were	O
isolated	O
using	O
density	O
gradient	O
centrifugation	O
on	O
Ficoll	O
-	O
Paque	O
(	O
TM	O
)	O
Plus	O
(	O
GE	O
Healthcare	O
)	O
.	O

The	O
layer	O
containing	O
PBMCs	O
was	O
isolated	O
,	O
washed	O
twice	O
in	O
PBS	O
and	O
resuspended	O
in	O
complete	O
RPMI	O
.	O

Cells	O
were	O
enumerated	O
by	O
trypan	O
blue	O
exclusion	O
using	O
the	O
Countess	O
automated	O
cell	O
counter	O
(	O
Invitrogen	O
)	O
.	O

For	O
derivation	O
of	O
macrophages	O
from	O
monocytes	O
,	O
monocytes	O
were	O
allowed	O
to	O
adhere	O
to	O
plastic	O
for	O
2	O
hours	O
in	O
RPMI	O
1640	O
after	O
which	O
non	O
-	O
adherent	O
cells	O
were	O
removed	O
.	O

Monocytes	O
were	O
allowed	O
to	O
differentiate	O
in	O
RPMI	O
1640	O
supplemented	O
with	O
10	O
%	O
human	O
AB	O
serum	O
for	O
10	O
days	O
.	O

Cell	O
stimulation	O
and	O
cytokine	O
quantification	O

Bronchial	O
epithelial	O
cells	O
were	O
plated	O
and	O
allowed	O
to	O
adhere	O
overnight	O
prior	O
to	O
stimulation	O
.	O

Bronchial	O
epithelial	O
cells	O
were	O
rested	O
or	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
stimulated	O
with	O
live	O
P	O
.	O
aeruginosa	O
PAO1	O
or	O
ATP	O
for	O
the	O
times	O
indicated	O
.	O

PBMCs	O
and	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
either	O
rested	O
or	O
primed	O
with	O
LPS	O
(	O
Invivogen	O
)	O
or	O
heat	O
-	O
killed	O
PAO1	O
overnight	O
(	O
16	O
hours	O
)	O
.	O

The	O
next	O
day	O
the	O
cells	O
were	O
challenged	O
with	O
live	O
PAO1	O
,	O
PAO1deltaexsA	O
,	O
ATP	O
(	O
Invivogen	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
for	O
the	O
times	O
indicated	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O

For	O
stimulations	O
with	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
,	O
lipofectamine	O
LTX	O
was	O
used	O
at	O
a	O
1	O
:	O
1	O
(	O
w	O
:	O
v	O
)	O
ratio	O
of	O
microg	O
of	O
DNA	O
to	O
microl	O
of	O
lipofectamine	O
and	O
was	O
mixed	O
30	O
minutes	O
prior	O
to	O
stimulation	O
.	O

The	O
NF	O
-	O
kappaB	O
inhibitor	O
Bay11	O
-	O
7082	O
(	O
Invivogen	O
)	O
was	O
added	O
to	O
cultures	O
1	O
hour	O
prior	O
to	O
priming	O
.	O

If	O
no	O
priming	O
was	O
involved	O
,	O
inhibitor	O
was	O
added	O
1	O
hour	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

The	O
CFTR	O
inhibitor	O
CFTRinh172	O
(	O
Sigma	O
Aldrich	O
)	O
was	O
added	O
to	O
cultures	O
18	O
hours	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

The	O
caspase	O
-	O
1	O
inhibitor	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
Biovision	O
)	O
was	O
added	O
to	O
cultures	O
1	O
hour	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

Supernatants	O
were	O
collected	O
and	O
stored	O
at	O
-	O
20degreesC	O
.	O

Cytokines	O
released	O
into	O
supernatants	O
from	O
PBMCs	O
stimulated	O
with	O
inflammasome	O
activators	O
were	O
quantified	O
using	O
sandwich	O
ELISA	O
(	O
eBioscience	O
)	O
.	O

Immunoblotting	O

1x106	O
cells	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
,	O
stimulated	O
as	O
indicated	O
,	O
and	O
lysed	O
in	O
RIPA	O
buffer	O
supplemented	O
with	O
Halt	O
protease	O
and	O
phosphatase	O
inhibitor	O
cocktail	O
(	O
Thermo	O
Scientific	O
)	O
.	O

Protein	O
concentrations	O
were	O
determined	O
by	O
Bradford	O
assay	O
(	O
Thermo	O
Scientific	O
)	O
.	O

Lysates	O
were	O
resolved	O
by	O
electrophoreses	O
on	O
10	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
and	O
transferred	O
onto	O
PVDF	O
membranes	O
(	O
Millipore	O
)	O
.	O

Blots	O
were	O
blocked	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
and	O
probed	O
overnight	O
at	O
4degreesC	O
for	O
pro	O
-	O
IL	O
-	O
1beta	O
(	O
Santa	O
Cruz	O
)	O
,	O
IkappaBalpha	S-PRGE
(	O
Cell	O
Signaling	O
)	O
,	O
or	O
beta	B-PRGE
-	I-PRGE
actin	E-PRGE
(	O
Cell	O
Signaling	O
)	O
.	O

Blots	O
were	O
subsequently	O
probed	O
with	O
fluorescently	O
-	O
labeled	O
secondary	O
antibodies	O
,	O
IRDye	O
(	O
R	O
)	O
680	O
or	O
800CW	O
(	O
LI	O
-	O
COR	O
Biosciences	O
)	O
for	O
1	O
hour	O
.	O

Both	O
blocking	O
and	O
probing	O
steps	O
were	O
carried	O
out	O
in	O
tris	O
-	O
buffered	O
saline	O
(	O
G	O
Biosciences	O
)	O
containing	O
5	O
%	O
bovine	O
serum	O
albumin	O
and	O
0	O
.	O
1	O
%	O
TWEEN	O
20	O
(	O
Calbiochem	O
)	O
.	O

Blots	O
were	O
imaged	O
on	O
a	O
LI	O
-	O
COR	O
Odyssey	O
infrared	O
imaging	O
system	O
(	O
LI	O
-	O
COR	O
Biosciences	O
)	O
and	O
quantified	O
using	O
the	O
included	O
analysis	O
software	O
.	O

Quantification	O
of	O
caspase	O
-	O
1	O
activity	O

Bronchial	O
epithelial	O
cells	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
at	O
5x105	O
cells	O
/	O
well	O
overnight	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
stimulated	O
with	O
ATP	O
for	O
1	O
hour	O
or	O
stimulated	O
with	O
live	O
PAO1	O
for	O
3	O
hours	O
.	O

PBMCs	O
were	O
stimulated	O
the	O
same	O
day	O
as	O
blood	O
donation	O
.	O

PBMCs	O
were	O
seeded	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
a	O
density	O
of	O
4	O
.	O
5x105	O
cells	O
/	O
well	O
(	O
2	O
.	O
5x106	O
cells	O
/	O
ml	O
)	O
,	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
then	O
stimulated	O
with	O
ATP	O
for	O
1	O
hour	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
for	O
3	O
hours	O
or	O
stimulated	O
with	O
live	O
PAO1	O
for	O
3	O
hours	O
.	O

Caspase	O
-	O
1	O
activity	O
was	O
measured	O
using	O
FLICA	O
(	O
Immunochemistry	O
Technologies	O
)	O
,	O
a	O
cell	O
-	O
permeable	O
fluorescent	O
probe	O
(	O
FAM	O
-	O
YVAD	O
-	O
fmk	O
)	O
that	O
binds	O
active	O
caspase	O
-	O
1	O
.	O

Cells	O
were	O
incubated	O
1	O
hour	O
with	O
FLICA	O
at	O
37degreesC	O
and	O
stained	O
with	O
PE	O
-	O
Cy7	O
-	O
conjugated	O
anti	O
-	O
CD14	O
antibodies	O
(	O
eBioscience	O
)	O
to	O
identify	O
monocytes	O
.	O

The	O
gating	O
strategy	O
consisted	O
of	O
including	O
live	O
cells	O
that	O
were	O
CD14	S-PRGE
positive	O
which	O
were	O
subsequently	O
analyzed	O
for	O
the	O
frequency	O
of	O
FLICA	O
positive	O
cells	O
.	O

NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
Activity	O
Assay	O

Supernatants	O
from	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
incubated	O
with	O
Quanti	O
-	O
Blue	O
substrate	O
(	O
Invivogen	O
)	O
at	O
37degreesC	O
and	O
allowed	O
to	O
develop	O
for	O
16	O
-	O
18	O
hours	O
.	O

Quanti	O
-	O
Blue	O
contains	O
a	O
substrate	O
for	O
alkaline	B-PRGE
phosphatase	E-PRGE
and	O
changes	O
in	O
the	O
amount	O
of	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
were	O
quantified	O
by	O
optical	O
density	O
(	O
lambda	O
=	O
655	O
)	O
measured	O
using	O
a	O
SpectraMax	O
384	O
Plus	O
plate	O
reader	O
and	O
SoftMax	O
Pro	O
software	O
(	O
Molecular	O
Devices	O
)	O
.	O

Bacterial	O
strains	O

P	O
.	O
aeruginosa	O
laboratory	O
strains	O
PAO1	O
and	O
the	O
PAO1deltaexsA	O
mutant	O
were	O
obtained	O
from	O
Dr	O
.	O
Robert	O
Hancock	O
.	O

P	O
.	O
aeruginosa	O
strains	O
PAO1	O
and	O
PAO1deltaexsA	O
were	O
grown	O
from	O
overnight	O
cultures	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
broth	O
and	O
LB	O
+	O
streptomycin	O
(	O
150	O
microg	O
/	O
ml	O
)	O
until	O
mid	O
-	O
logarithmic	O
phase	O
.	O

Cells	O
were	O
washed	O
once	O
in	O
PBS	O
and	O
resuspended	O
in	O
PBS	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
(	O
lambda	O
=	O
600	O
nm	O
)	O
.	O

To	O
prepare	O
heat	O
-	O
killed	O
bacteria	O
,	O
live	O
PAO1	O
was	O
resuspended	O
in	O
PBS	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
and	O
heated	O
at	O
60degreesC	O
for	O
1	O
hour	O
.	O

For	O
stimulations	O
,	O
live	O
PAO1	O
was	O
resuspended	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
in	O
PBS	O
and	O
further	O
diluted	O
in	O
culture	O
medium	O
prior	O
to	O
stimulation	O
to	O
achieve	O
the	O
desired	O
multiplicity	O
of	O
infection	O
.	O

Heat	O
-	O
killed	O
PAO1	O
was	O
added	O
in	O
a	O
volume	O
equivalent	O
to	O
that	O
used	O
to	O
achieve	O
an	O
MOI	O
of	O
1	O
for	O
live	O
PAO1	O
.	O

Statistics	O

All	O
graphs	O
display	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
and	O
were	O
generated	O
with	O
Prism	O
5	O
(	O
Graphpad	O
)	O
.	O

Statistical	O
significance	O
was	O
determined	O
by	O
performing	O
one	O
or	O
two	O
-	O
way	O
ANOVA	O
and	O
the	O
Bonferroni	O
post	O
-	O
test	O
where	O
applicable	O
.	O

Cell	O
stimulation	O
and	O
inhibitor	O
schedule	O
.	O

Schedule	O
outlines	O
the	O
timing	O
of	O
inhibitor	O
addition	O
and	O
priming	O
in	O
relation	O
to	O
inflammasome	O
stimulation	O
(	O
t	O
=	O
0	O
)	O
for	O
THP	O
-	O
1	O
reporter	O
and	O
PBMC	O
cytokine	O
quantification	O
experiments	O
.	O

Inhibitor	O
treatments	O
and	O
stimulations	O
were	O
carried	O
out	O
as	O
described	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
significantly	O
contribute	O
to	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
response	O
to	O
inflammasome	O
stimuli	O
.	O

Control	O
cell	O
lines	O
(	O
(	O
A	O
)	O
S9	O
,	O
(	O
C	O
)	O
NuLi	O
-	O
1	O
)	O
and	O
their	O
corresponding	O
CF	O
cell	O
lines	O
(	O
(	O
B	O
)	O
IB3	O
-	O
1	O
,	O
and	O
(	O
D	O
)	O
CuFi	O
-	O
1	O
)	O
cells	O
were	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
10	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
for	O
the	O
indicated	O
times	O
(	O
n	O
=	O
3	O
individual	O
experiments	O
)	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hours	O
where	O
appropriate	O
.	O

Cell	O
culture	O
supernatants	O
were	O
assayed	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
IL	O
-	O
8	O
production	O
by	O
ELISA	O
.	O

Insert	O
shows	O
IL	O
-	O
8	O
secretion	O
in	O
response	O
to	O
stimulation	O
with	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

Airway	O
cells	O
do	O
not	O
strongly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
in	O
response	O
to	O
inflammasome	O
stimuli	O
.	O

S9	O
and	O
IB3	O
-	O
1	O
cells	O
were	O
examined	O
for	O
caspase	O
-	O
1	O
activation	O
following	O
inflammasome	O
stimulation	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
10	O
)	O
and	O
ATP	O
(	O
5	O
mM	O
)	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
where	O
appropriate	O
.	O

A	O
representative	O
histogram	O
of	O
%	O
caspase	O
-	O
1	O
-	O
active	O
cells	O
is	O
shown	O
in	O
(	O
A	O
)	O
and	O
the	O
averaged	O
values	O
are	O
shown	O
in	O
(	O
B	O
)	O
(	O
n	O
=	O
3	O
separate	O
experiments	O
)	O
.	O

(	O
C	O
)	O
IB3	O
-	O
1	O
cells	O
(	O
5x104	O
cells	O
/	O
well	O
)	O
were	O
pre	O
-	O
treated	O
for	O
1	O
hour	O
with	O
increasing	O
concentrations	O
of	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
10	O
-	O
30	O
microM	O
)	O
prior	O
to	O
stimulation	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
50	O
)	O
.	O

Cell	O
culture	O
supernatants	O
were	O
collected	O
after	O
6	O
hours	O
and	O
assayed	O
for	O
IL	B-PRGE
-	I-PRGE
6	E-PRGE
by	O
ELISA	O
(	O
n	O
=	O
3	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
show	O
similar	O
increases	O
in	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
activation	O
.	O

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
6	O
)	O
were	O
primed	O
with	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
5	O
hours	O
prior	O
to	O
stimulation	O
with	O
ATP	O
(	O
5	O
mM	O
)	O
for	O
1	O
hour	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
for	O
3	O
hours	O
.	O

PBMCs	O
were	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
strain	O
PAO1	O
for	O
3	O
hours	O
.	O

A	O
representative	O
histogram	O
of	O
the	O
%	O
caspase	O
-	O
1	O
-	O
active	O
cells	O
is	O
shown	O
in	O
(	O
A	O
)	O
with	O
the	O
averaged	O
values	O
shown	O
in	O
(	O
B	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
.	O

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
17	O
-	O
20	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
15	O
-	O
19	O
)	O
were	O
primed	O
with	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
overnight	O
and	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
,	O
P	O
.	O
aeruginosa	O
PAO1	O
lacking	O
exsA	S-PRGE
(	O
MOI	O
=	O
1	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
for	O
24	O
hours	O
.	O

P	O
.	O
aeruginosa	O
lacking	O
exsA	S-PRGE
was	O
used	O
as	O
a	O
type	O
III	O
secretion	O
control	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
P	O
.	O
aeruginosa	O
.	O

Supernatants	O
were	O
assayed	O
for	O
(	O
A	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
(	O
B	O
)	O
IL	O
-	O
8	O
.	O

NF	O
-	O
kappaB	O
activation	O
potentiates	O
the	O
degree	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
and	O
secretion	O
upon	O
inflammasome	O
activation	O
.	O

THP	O
-	O
1	O
reporter	O
cells	O
were	O
primed	O
overnight	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
and	O
stimulated	O
the	O
next	O
day	O
with	O
live	O
P	O
.	O
aeruginosa	O
or	O
additional	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
for	O
the	O
times	O
indicated	O
.	O

Cell	O
culture	O
supernatants	O
were	O
assayed	O
for	O
(	O
A	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
,	O
(	O
B	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
C	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
(	O
n	O
=	O
3	O
-	O
6	O
experiments	O
)	O
.	O

Using	O
the	O
same	O
stimulation	O
method	O
,	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
treated	O
with	O
Bay11	O
-	O
7082	O
(	O
20	O
microM	O
)	O
for	O
1	O
hour	O
prior	O
to	O
priming	O
with	O
heat	O
-	O
killed	O
PAO1	O
or	O
live	O
PAO1	O
.	O

Supernatants	O
were	O
assayed	O
at	O
24	O
hours	O
for	O
(	O
D	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
,	O
(	O
E	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
F	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
(	O
n	O
=	O
3	O
-	O
5	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
11	O
-	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
10	O
-	O
13	O
)	O
were	O
treated	O
with	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
20	O
microM	O
)	O
or	O
Bay11	O
-	O
7082	O
(	O
10	O
microM	O
)	O
and	O
stimulated	O
with	O
live	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
according	O
to	O
the	O
schedule	O
in	O
Figure	O
1	O
.	O

(	O
G	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
(	O
H	O
)	O
IL	O
-	O
8	O
levels	O
were	O
measured	O
at	O
24	O
hours	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
two	O
way	O
ANOVA	O
with	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

*	O
,	O
*	O
*	O
,	O
and	O
*	O
*	O
*	O
signify	O
P	O
<	O
0	O
.	O
05	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
001	O
.	O

Bay11	O
-	O
7082	O
inhibits	O
pro	O
-	O
IL	O
-	O
1beta	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

PMA	O
-	O
differentiated	O
THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
10	O
microM	O
CFTRinh172	O
or	O
20	O
microM	O
Bay11	O
-	O
7082	O
and	O
harvested	O
after	O
(	O
A	O
)	O
4	O
hours	O
(	O
n	O
=	O
3	O
)	O
or	O
(	O
B	O
)	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
1	O
.	O
5	O
hours	O
(	O
n	O
=	O
3	O
)	O
stimulation	O
with	O
PAO1	O
.	O

One	O
representative	O
blot	O
is	O
shown	O
with	O
a	O
graph	O
of	O
the	O
averaged	O
fluorescence	O
intensity	O
values	O
over	O
3	O
experiments	O
.	O

Disruption	O
of	O
CFTR	O
activity	O
does	O
not	O
increase	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
in	O
PBMCs	O
or	O
macrophages	O
.	O

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
13	O
)	O
were	O
treated	O
with	O
CFTRinh172	O
(	O
10	O
microM	O
)	O
for	O
18	O
hours	O
prior	O
to	O
stimulation	O
with	O
live	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
.	O

(	O
A	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
and	O
(	O
B	O
)	O
IL	O
-	O
8	O
production	O
was	O
measured	O
at	O
24	O
hours	O
.	O

(	O
C	O
)	O
Monocytes	O
from	O
controls	O
(	O
n	O
=	O
3	O
)	O
were	O
differentiated	O
into	O
macrophages	O
.	O

Macrophages	O
were	O
treated	O
with	O
CFTRinh172	O
,	O
stimulated	O
as	O
per	O
monocytes	O
,	O
and	O
measured	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
production	O
at	O
24	O
hours	O
.	O

THP	O
-	O
1	O
reporter	O
cells	O
were	O
treated	O
with	O
CFTRinh172	O
24	O
hours	O
prior	O
to	O
stimulation	O
with	O
PAO1	O
and	O
measured	O
for	O
(	O
D	O
)	O
IL	B-PRGE
-	I-PRGE
1beta	E-PRGE
secretion	O
,	O
(	O
E	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
F	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
at	O
24	O
hours	O
(	O
n	O
=	O
4	O
)	O
.	O

Inflammasome	O
Activators	O
.	O
